[go: up one dir, main page]

US20190345133A1 - Cxcr3 receptor agonists - Google Patents

Cxcr3 receptor agonists Download PDF

Info

Publication number
US20190345133A1
US20190345133A1 US16/335,641 US201716335641A US2019345133A1 US 20190345133 A1 US20190345133 A1 US 20190345133A1 US 201716335641 A US201716335641 A US 201716335641A US 2019345133 A1 US2019345133 A1 US 2019345133A1
Authority
US
United States
Prior art keywords
compound
groups
substituted
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/335,641
Inventor
Adam YEAGER
Philip Turnbull
Lin Zhang
Junhua Fan
Junko Tamiya
Marcos Steinberg
Tom Fowler
Hanae Benelkebir
Raffaele Pasceri
Maria Ieva
Kevan Grant
Yang Tran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptos LLC
Original Assignee
Celgene International II SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene International II SARL filed Critical Celgene International II SARL
Priority to US16/335,641 priority Critical patent/US20190345133A1/en
Assigned to SYGNATURE DISCOVERY LIMITED reassignment SYGNATURE DISCOVERY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IEVA, Maria, GRANT, Kevan, BENELKEBIR, Hanae, FOWLER, TOM, PASCERI, Raffaele
Assigned to CELGENE INTERNATIONAL II SÀRL reassignment CELGENE INTERNATIONAL II SÀRL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SYGNATURE DISCOVERY LIMITED
Assigned to CELGENE INTERNATIONAL II SÀRL reassignment CELGENE INTERNATIONAL II SÀRL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FAN, JUNHUA, TRAN, Yang, ZHANG, LIN
Assigned to CELGENE INTERNATIONAL II SÀRL reassignment CELGENE INTERNATIONAL II SÀRL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TAMIYA, JUNKO, STEINBERG, MARCOS, YEAGER, Adam, TURNBULL, Philip
Publication of US20190345133A1 publication Critical patent/US20190345133A1/en
Priority to US16/872,161 priority patent/US11040954B1/en
Assigned to RECEPTOS LLC reassignment RECEPTOS LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CELGENE INTERNATIONAL II SÀRL
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This disclosure is directed to small molecule agonists of the chemokine receptor CXCR3, and product containing the same, as well as to methods related to the use of such small molecule agonists.
  • the chemokine receptor CXCR3 is a member of the seven transmembrane-spanning G protein-coupled receptor (GPCR) superfamily. CXCR3 is primarily expressed on activated T lymphocytes and NK cells. CXCL9/Mig, CXCL10/IP-10 and CXCL11/I-TAC, the natural chemokine ligands for CXCR3, are involved in directing activated T cells and other cells, such as NK cells, to sites of inflammation.
  • GPCR G protein-coupled receptor
  • CXCR3 has been implicated in Th1 cell-mediated inflammation, and upregulation of CXCR3 has been shown in a number of diseases involving T cells, such as inflammatory bowel disease (IBD), multiple sclerosis (MS), rheumatoid arthritis (RA) and diabetes, to name a few.
  • IBD inflammatory bowel disease
  • MS multiple sclerosis
  • RA rheumatoid arthritis
  • diabetes to name a few.
  • CXCR3 receptor agonists inhibit migration of activated T lymphocytes and NK cells.
  • O'Boyle et al (“Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation,” PNAS, 109(12):4598-4603, 2012)
  • generalized chemokine receptor desensitization can be induced by specific stimulation of a CXCR3 receptor on the surface of activated T cells, resulting in the inhibition of the inflammatory response that is normally produced.
  • CXCR3 receptor agonists may act as functional antagonists through chemokine receptor desensitization.
  • the present disclosure is generally directed to compounds which serve as agonists of the chemokine receptor CXCR3, as well as to composition containing the same, and to methods of their preparation and use.
  • compounds are provided having the structure of the following Formula I, including stereoisomers hydrates, solvates, isotopes, or pharmaceutically acceptable salts thereof:
  • R, R 1 , R 2 , R 3a and R 3b are as defined below.
  • a pharmaceutical composition comprising a compound of Formula I together with at least one pharmaceutically acceptable carrier, diluent or excipient is provided.
  • a method of use of a compound of Formula I comprising preparation of a medicament is provided.
  • a method of agonism of the CXCR3 receptor comprising contacting the receptor with a compound of Formula I, or a pharmaceutical composition comprising the same.
  • a method for treatment of a disease or condition in a subject for which agonism of the CXCR3 receptor is medically indicated comprising administering to the subject a compound of Formula I, or a pharmaceutical composition comprising the same.
  • a method for treating rheumatoid arthritis, multiple sclerosis, or inflammatory bowel disease in a subject in need thereof comprising administering to the subject a compound of Formula I, or a pharmaceutical composition comprising the same.
  • compounds are provided having the following Formula I, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • alkyl groups include straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons (C 1 -C 12 alkyl), or, in some embodiments, from 1 to 8 carbon atoms (C 1 -C 8 alkyl), or, in some embodiments, from 1 to 4 carbon atoms (C 1 -C 4 alkyl).
  • cycloalkyl groups such groups have from 3-20 carbon atoms as more specifically defined below.
  • straight chain alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
  • branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
  • alkenyl groups include straight and branched chain and cyclic alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Thus, alkenyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms.
  • Examples include, but are not limited to —CH ⁇ CH 2 , —CH ⁇ CH(CH 3 ), —CH ⁇ C(CH 3 ) 2 , —C(CH 3 ) ⁇ CH 2 , —C(CH 3 ) ⁇ CH(CH 3 ), —C(CH 2 CH 3 ) ⁇ CH 2 , —CH ⁇ CHCH 2 CH 3 , —CH ⁇ CH(CH 2 ) 2 CH 3 , —CH ⁇ CH(CH 2 ) 3 CH 3 , —CH ⁇ CH(CH 2 ) 4 CH 3 , vinyl, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others.
  • Alkynyl groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms. Thus, alkynyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to —C ⁇ CH, —C ⁇ C(CH 3 ), —C ⁇ C(CH 2 CH 3 ), —CH 2 C ⁇ CH, —CH 2 C ⁇ C(CH 3 ), and —CH 2 C ⁇ C(CH 2 CH 3 ), among others.
  • Cycloalkyl groups are alkyl groups forming a ring structure, which can be substituted or unsubstituted, wherein the ring is either completely saturated, partially unsaturated, or fully unsaturated, wherein if there is unsaturation, the conjugation of the pi-electrons in the ring do not give rise to aromaticity.
  • Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
  • the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7.
  • Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like.
  • (Cycloalkyl)alkyl groups, also referred to as “cycloalkylalkyl”, are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above.
  • cycloalkenyl alone or in combination denotes a cyclic alkenyl group wherein at least one double bond is present in the ring structure.
  • Cycloalkenyl groups include cycloalkyl groups having at least one double bond between two adjacent carbon atoms.
  • cycloalkenyl groups include but are not limited to cyclohexenyl, cyclopentenyl, and cyclohexadienyl groups, as well as polycyclic and/or bridging ring systems such as adamantine.
  • (Cycloalkenyl)alkyl groups, also referred to as “cycloalkylalkyl”, are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above.
  • Carbocyclic and “carbocyclyl” denote a ring structure wherein the atoms of the ring are carbon. In some embodiments, the carbocyclyl has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms is 4, 5, 6, or 7. Carbocyclyl includes, for example, cycloalkyl and cycloalkenyl.
  • (Carbocyclyl)alkyl groups, also referred to as “carbocyclylalkyls”, are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a carbocyclyl as defined above.
  • nonaromatic carbocyclyl or a “nonaromatic carbocyclylalkyl” is a group in which the carbocyclic ring of the carbocyclyl or carbocyclylalkyl is a completely saturated, a partially unsaturated, or a fully unsaturated carbocyclyl, wherein if there is unsaturation, the conjugation of the pi-electrons of the carbocyclic ring do not give rise to aromaticity.
  • Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms.
  • aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl groups.
  • aryl groups contain 6-14 carbons in the ring portions of the groups.
  • the phrase “aryl groups” includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like).
  • “Aralkyl” groups are alkyl, alkenyl or alkynyl groups as defined above in which a hydrogen atom of an alkyl, alkenyl or alkynyl group is replaced with an aryl group as defined above.
  • Representative aralkyl groups include benzyl (—CH 2 phenyl), phenylethyl (—CH 2 CH 2 phenyl) and phenylethylene (—CH ⁇ CHphenyl) groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl.
  • Aralky groups can be substituted on the aryl moiety, the alkyl, alkenyl or alkynyl moiety, or both.
  • Heterocyclyl or “heterocyclic” groups include aromatic and non-aromatic ring moieties containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, S, or P.
  • heterocyclyl groups include 3 to 20 ring members, whereas other such groups have 3 to 15 ring members, including for example single ring systems containing 5, 6 or 7 ring members. At least one ring contains a heteroatom, but every ring in a polycyclic system need not contain a heteroatom.
  • a dioxolanyl ring and a benzdioxolanyl ring system are both heterocyclyl groups within the meaning herein.
  • a heterocyclyl group designated as a C 2 -heterocyclyl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms, and so forth.
  • a C 4 -heterocyclyl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth.
  • the number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms.
  • heterocyclyl includes fused ring species including those having fused aromatic and non-aromatic groups.
  • the phrase also includes polycyclic and/or bridging ring systems containing a heteroatom such as, but not limited to, quinuclidyl and 7-azabicyclo[2.2.1]heptane.
  • a heterocyclyl group as defined herein can be a heteroaryl group or a partially or completely saturated cyclic group including at least one ring heteroatom.
  • Heterocyclyl groups include, but are not limited to, pyrazinyl, pyrimidinyl, pyridazinyl, thiadiazolyl, oxadiazolyl, imidazolinyl, hexahydropyrimidinyl, diazepanyl, triazinyl, imidazolyl, pyrrolidinyl, furanyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaind
  • Heteroaryl groups are aromatic ring moieties containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
  • a heteroaryl group designated as a C 2 -heteroaryl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth.
  • a C 4 -heteroaryl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms.
  • Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, pyrazinyl, pyrimidinyl, thiadiazolyl, imidazolyl, oxadiazolyl, thienyl, triazolyl, tetrazolyl, triazinyl, thiazolyl, thiophenyl, oxazolyl, isoxazolyl, benzothiophenyl, benzofuranyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xant
  • heteroaryl and “heteroaryl groups” include fused ring compounds such as wherein at least one ring, but not necessarily all rings, are aromatic, including tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl and 2,3-dihydro indolyl.
  • aryl and heteroaryl groups include but are not limited to phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl (1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl), thiadiazolyl (1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl), isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridiny
  • Heterocyclylalkyl groups are alkyl, alkenyl or alkynyl groups as defined above in which a hydrogen or carbon bond of an alkyl, alkenyl or alkynyl group is replaced with a bond to a heterocyclyl group as defined above.
  • Representative heterocyclyl alkyl groups include, but are not limited to, furan-2-yl methyl, furan-3-yl methyl, pyridine-2-yl methyl ( ⁇ -picolyl), pyridine-3-yl methyl ( ⁇ -picolyl), pyridine-4-yl methyl ( ⁇ -picolyl), tetrahydrofuran-2-yl ethyl, and indol-2-yl propyl.
  • Heterocyclylalkyl groups can be substituted on the heterocyclyl moiety, the alkyl, alkenyl or alkynyl moiety, or both.
  • Heteroarylalkyl groups are alkyl, alkenyl or alkynyl groups as defined above in which a hydrogen or carbon bond of an alkyl, alkenyl or alkynyl group is replaced with a bond to a heteroaryl group as defined above. Heteroarylalkyl groups can be substituted on the heteroaryl moiety, the alkyl, alkenyl or alkynyl moiety, or both.
  • heterocyclyl, heteroaryl, heterocyclylalkyl or heteroarylalkyl refers to a heterocyclyl, heteroaryl, heterocyclylalkyl or heteroarylalkyl as defined above having no additional substituents (i.e., unsubstituted) or have one or more substituents (i.e., substituted), wherein such substituents independently one or more R 4 groups as defined above, and in the case of a single carbon atom bearing two substituents includes oxo ( ⁇ O) and thioxo ( ⁇ S).
  • ring system as the term is used herein is meant a moiety comprising one, two, three or more rings, which can be substituted with non-ring groups or with other ring systems, or both, which can be fully saturated, partially unsaturated, fully unsaturated, or aromatic, and when the ring system includes more than a single ring, the rings can be fused, bridging, or spirocyclic.
  • spirocyclic is meant the class of structures wherein two rings are fused at a single tetrahedral carbon atom, as is well known in the art.
  • a “monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring” as the term is used herein refers to a ring system including an unsaturated ring possessing 4n+2 pi electrons, or a partially reduced (hydrogenated) form thereof.
  • the aromatic or partially aromatic ring can include additional fused, bridged, or spiro rings that are not themselves aromatic or partially aromatic.
  • naphthalene and tetrahydronaphthalene are both a “monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring” within the meaning herein.
  • a benzo-[2.2.2]-bicyclooctane is also a “monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring” within the meaning herein, containing a phenyl ring fused to a bridged bicyclic system.
  • a fully saturated ring has no double bonds therein, and is carbocyclic or heterocyclic depending on the presence of heteroatoms within the meaning herein.
  • R groups When two “R” groups are said to be joined together or taken together to form a ring, it is meant that together with the carbon atom or a non-carbon atom (e.g., nitrogen atom), to which they are bonded, they may form a ring system. In general, they are bonded to one another to form a 3- to 7-membered ring, or a 5- to 7-membered ring.
  • Non-limiting specific examples are the cyclopentyl, cyclohexyl, cycloheptyl, piperidinyl, piperazinyl, pyrolidinyl, pyrrolyl, pyridinyl.
  • alkoxy refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined above.
  • linear alkoxy groups include but are not limited to methoxy, ethoxy, n-propoxy, n-butoxy, n-pentyloxy, n-hexyloxy, n-heptyloxy, n-octyloxy n-nonyloxy, and the like.
  • branched alkoxy include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like.
  • cyclic alkoxy include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • aryloxy and arylalkoxy refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom at the alkyl moiety. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy.
  • acyl refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom.
  • the carbonyl carbon atom is also bonded to another carbon atom, which can be part of an alkyl, aryl, aralkyl cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl group or the like.
  • the group is a “formyl” group, an acyl group as the term is defined herein.
  • An acyl group can include 0 to about 12-20 additional carbon atoms bonded to the carbonyl group.
  • An acyl group can include double or triple bonds within the meaning herein.
  • An acryloyl group is an example of an acyl group.
  • An acyl group can also include heteroatoms within the meaning here.
  • a nicotinoyl group (pyridyl-3-carbonyl) group is an example of an acyl group within the meaning herein.
  • Other examples include acetyl, benzoyl, phenylacetyl, pyridylacetyl, cinnamoyl, and acryloyl groups and the like.
  • the group containing the carbon atom that is bonded to the carbonyl carbon atom contains a halogen, the group is termed a “haloacyl” group.
  • An example is a trifluoroacetyl group.
  • amine includes primary, secondary, and tertiary amines having, e.g., the formula N(group) 3 wherein each group can independently be H or non-H, such as alkyl, aryl, and the like.
  • Amines include but are not limited to R—NH 2 , for example, alkylamines, arylamines, alkylarylamines; R 2 NH wherein each R is independently selected, such as dialkylamines, diarylamines, aralkylamines, heterocyclylamines and the like; and R 3 N wherein each R is independently selected, such as trialkylamines, dialkylarylamines, alkyldiarylamines, triarylamines, and the like.
  • the term “amine” also includes ammonium ions as used herein.
  • amino group is a substituent of the form —NH 2 , —NHR, —NR 2 , —NR 3 + , wherein each R is independently selected, and protonated forms of each. Accordingly, any compound substituted with an amino group can be viewed as an amine.
  • ammonium ion includes the unsubstituted ammonium ion NH 4 + , but unless otherwise specified, it also includes any protonated or quaternarized forms of amines. Thus, trimethylammonium hydrochloride and tetramethylammonium chloride are both ammonium ions, and amines, within the meaning herein.
  • amide includes C- and N-amide groups, i.e., —C(O)NR 2 , and —NRC(O)R groups, respectively.
  • Amide groups therefore include but are not limited to carbamoyl groups (—C(O)NH 2 ) and formamide groups (—NHC(O)H).
  • a “carboxamido” group is a group of the formula C(O)NR 2 , wherein R can be H, alkyl, aryl, etc.
  • hydroxyl refers to an —OH group.
  • hydroxyalkyl refers to an -alkyl-OH group.
  • cyano refers to a —CN group.
  • carbonyl refers to a —C( ⁇ O)— group.
  • Halo “Halo,” “halogen,” and “halide” include fluorine, chlorine, bromine and iodine.
  • perhaloalkyl refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms. Perhaloalkyl groups include, but are not limited to, —CF 3 and —C(CF 3 ) 3 .
  • haloalkyl refers to an alkyl group where some but not necessarily all of the hydrogen atoms are replaced by halogen atoms. Haloalkyl groups include but are not limited to —CHF 2 and —CH 2 F.
  • perhaloalkoxy refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.
  • Perhaloalkoxy groups include, but are not limited to, —OCF 3 and —OC(CF 3 ) 3 .
  • haloalkoxy refers to an alkoxy group where some but not necessarily all of the hydrogen atoms are replaced by halogen atoms.
  • Haloalkoxy groups include but are not limited to —OCHF 2 and —OCH 2 F.
  • the compounds disclosed herein may be in the form of a neutral compound, or in the form of the free acid or free base. Alternatively, the compounds disclosed herein may be associated with a counter ion, and be in the form a salt. In one embodiment, the compound is in the form of a “pharmaceutically acceptable” salt, which refers to a salt possessing toxicity profiles within a range that affords utility in pharmaceutical applications.
  • a “hydrate” is a compound that exists in a composition with water molecules.
  • the composition can include water in stoichiometric quantities, such as a monohydrate or a dihydrate, or can include water in random amounts.
  • a “hydrate” refers to a solid form (i.e., a compound in water solution, while it may be hydrated, is not a hydrate as the term is used herein).
  • a “solvate” is a similar composition except that a solvent other that water replaces the water.
  • a solvent other that water replaces the water.
  • methanol or ethanol can form an “alcoholate”, which can again be stoichiometric or non-stoichiometric.
  • a “solvate” refers to a solid form (i.e., a compound in solution in a solvent, while it may be solvated, is not a solvate as the term is used herein).
  • a prodrug is a substance that can be administered to a patient where the substance is converted in vivo by the action of biochemicals within the patient's body, such as enzymes, to the active pharmaceutical ingredient.
  • prodrugs include esters of carboxylic acid groups, which can be hydrolyzed by endogenous esterases as are found in the bloodstream of humans and other mammals.
  • substances are provided that can be administered to a patient where the substance is converted in vivo by the action of biochemical within the patient's body, such as enzymes, to a compound having the structure of any one of Formulas (I)-(IV).
  • isotope refers to atoms with the same number of protons but a different number of neutrons
  • an isotope of a compound of Formula (I) includes any such compound wherein one or more atoms are replaced by an isotope of that atom.
  • carbon 12 the most common form of carbon, has six protons and six neutrons, whereas carbon 13 has six protons and seven neutrons, and carbon 14 has six protons and eight neutrons.
  • Hydrogen has two stable isotopes, deuterium (one proton and one neutron) and tritium (one proton and two neutrons). While fluorine has a number of isotopes, fluorine 19 is longest-lived.
  • an isotope of a compound having the structure of Formula (I) includes, but not limited to, compounds of Formula (I) wherein one or more carbon 12 atoms are replaced by carbon 13 and/or 14 atoms, wherein one or more hydrogen atoms are replaced with deuterium and/or tritium, and/or wherein one or more fluorine atoms are replaced by fluorine 19.
  • isolated optical isomer means a compound which has been substantially purified from the corresponding optical isomer(s) of the same formula.
  • the isolated isomer is at least about 80% pure by weight, or at least 80% pure by weight, or at least 85% pure by weight. In other embodiments, the isolated isomer is at least 90% pure by weight, or at least 98% pure by weight, or at least 99% pure by weight.
  • substantially enantiomerically or diastereomerically pure means a level of enantiomeric or diastereomeric enrichment of one enantiomer with respect to the other enantiomer or diastereomer of at least 80%, and in other embodiments means in excess of 80%, 85%, 90%, 95%, 98%, 99%, 99.5% or 99.9%.
  • Enantiomers are sometimes called optical isomers because a pure enantiomer rotates plane-polarized light in a particular direction. If the light rotates clockwise, then that enantiomer is labeled “(+)” or “d” for dextrorotatory, its counterpart will rotate the light counterclockwise and is labeled “( ⁇ )” or “1” for levorotatory.
  • racemate and “racemic mixture” are frequently used interchangeably.
  • a racemate is an equal mixture of two enantiomers.
  • a racemate is labeled “( ⁇ )” because it is not optically active (i.e., will not rotate plane-polarized light in either direction since its constituent enantiomers cancel each other out).
  • phrases such as “under conditions suitable to provide” or “under conditions sufficient to yield” or the like, in the context of methods of synthesis, as used herein refers to reaction conditions, such as time, temperature, solvent, reactant concentrations, and the like, that are within ordinary skill for an experimenter to vary, that provide a useful quantity or yield of a reaction product. It is not necessary that the desired reaction product be the only reaction product or that the starting materials be entirely consumed, provided the desired reaction product can be isolated or otherwise further used.
  • heteroatoms refers to non-carbon and non-hydrogen atoms, capable of forming covalent bonds with carbon, and is not otherwise limited. Typical heteroatoms are N, O, and S.
  • sulfur (S) When sulfur (S) is referred to, it is understood that the sulfur can be in any of the oxidation states in which it is found, thus including sulfoxides (R—S(O)—R′) and sulfones (R—S(O) 2 —R′), unless the oxidation state is specified; thus, the term “sulfone” encompasses only the sulfone form of sulfur; the term “sulfide” encompasses only the sulfide (R—S—R′) form of sulfur.
  • compounds are provided having the structure of the following Formula II, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • R, R 3a , R 3b , R 4 , and R 5 are as defined above.
  • compounds are provided having the structure of the following Formula III, including stereoisomers, hydrates, solvates, or pharmaceutically acceptable salts thereof:
  • R, R 3b , R 4 and R 5 are as defined above.
  • compounds are provided having the structure of the following Formula IV, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • R, R 3b and R 4 are as defined above.
  • compounds are provided having the structure of the following Formula V, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • R, R 1 , R 3a , R 3b , R 8 and R 9 are as defined above.
  • compounds are provided having the structure of the following Formula VI, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • R, R 1 , R 3a , R 3b and R 4 are as defined above.
  • compounds are provided having the structure of the following Formula VII, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • R, R 1 , R 3a , R 3b and R 4 are as defined above.
  • compounds are provided having the structure of the following Formula VIII, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • R, R 1 , R 3a , R 3b and R 4 are as defined above.
  • compounds are provided having the structure of the following Formula IX, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • R, R 1 , R 3a , R 3b and R 4 are as defined above.
  • compounds are provided having the structure of the following Formula X, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • R 14 is H or R 4 and R, R 1 , R 3a , R 3b and R 4 are as defined above.
  • R is intended to further limit the compounds of Formulas I, V and VI, but not Formulas II, III and IV (since R 1 has already been further limited in those structures).
  • R 3b would be applicable to each of Formulas I through VI since such structures list R 3a as a variable group.
  • R 1 is aryl
  • R 1 is aryl substituted with 1-4 R 4 groups.
  • R 1 is aryl substituted with 0 R 4 groups.
  • R 1 is heteroaryl
  • R 1 is heteroaryl substituted with 1-4 R 4 groups.
  • R 1 is heteroaryl substituted with 0 R 4 groups.
  • R 1 is substituted with at least one R 4 group. In another embodiment, R 1 is substituted with at least two R 4 groups. In another embodiment, R 1 is substituted with at least three R 4 groups.
  • R 4 is selected from halo and alkyl. In one embodiment, R 4 is halo. In another embodiment, R 4 is alkyl.
  • R 1 is substituted with at least three R 4 groups selected from halo and alkyl.
  • R 2 is aryl
  • R 2 is heteroaryl
  • R 2 is substituted with zero R 5 groups. In another embodiment, R 2 is substituted with at least one R 5 groups. In another embodiment, R 2 is substituted with at least two R 5 groups. In another embodiment, R 2 is substituted with three R 5 groups.
  • R 3a is hydrogen
  • R 3a is alkyl
  • R 3a is hydrogen and R 3b is a nitrogen or amine-containing moiety of carbon with at least one nitrogen atom and hydrogen.
  • R 3a is hydrogen and R 3b is alkyl substituted with —NR 10 R 11 , —N + R 10 R 11 R 12 , —NR 12 C( ⁇ O)NR 10 R 11 , —C( ⁇ O)NR 10 R 11 , —NR 12 C( ⁇ O)CH 2 NR 10 R 11 , —NR 12 N( ⁇ NR 13 )NR 10 R 11 , —NR 10 SO 2 R 11 , wherein R 10 , R 11 , R 12 and R 13 are independently hydrogen or R 4 .
  • R 10 , R 11 , R 12 and R 13 are independently hydrogen, alkyl or haloalkyl.
  • R 3a is hydrogen and R 3b is alkyl substituted with —NR 10 R 11 or —NR 10 R 11 R 12 .
  • R 3a is hydrogen and R 3b is —(CH 2 ) 2-4 NH 2 .
  • R 3a is hydrogen and R 3b is:
  • R 3a is hydrogen and R 3b is alkyl substituted with —NR 12 N( ⁇ NR 13 )NR 10 R 11 .
  • R 3a is hydrogen and R 3b is:
  • R 3a is hydrogen and R 3b is alkyl substituted with —C( ⁇ O)NR 10 R 11 , —NR 12 C( ⁇ O)NR 10 R 11 or —NR 12 C( ⁇ O)CH 2 NR 10 R 11 .
  • R 3a is hydrogen and R 3b is:
  • R 3a is hydrogen and R 3b is a nitrogen-containing heterocyclyl substituted with 0-4 R 4 groups.
  • R 3a is hydrogen and R 3b is:
  • R 3a is hydrogen and R 3b is alkyl substituted with a nitrogen-containing heterocyclyl substituted with 0-4 R 4 groups.
  • R 3a is hydrogen and R 3b is:
  • R 3a is hydrogen and R 3b is heteroaryl substituted with 0-4 R 4 groups.
  • R 3a is hydrogen and R 3b is alkyl substituted with heteroaryl substituted with 0-4 R 4 groups.
  • R 3a is hydrogen and R 3b is:
  • R 3a and R 3b are taken together with the carbon atom to which they are attached to form a cyclic nitrogen- or amine-containing moiety of carbon, at least one nitrogen atom and hydrogen.
  • R 3a and R 3b are taken together with the carbon atom to which they are attached to form a nitrogen-containing heterocyclyl substituted with 0-4 R 4 groups.
  • R 3a and R 3b are taken together with the carbon atom to which they are attached to form:
  • R 2 is —NR 8 R 9 , wherein R 8 is hydrogen or alkyl and R 9 is alkyl or aryl substituted with 0-4 R 4 groups.
  • —NR 8 R 9 is:
  • R 2 is —NR 8 R 9 and R 8 and R 9 taken together with the nitrogen atom to which they are attached form a heterocyclyl substituted with 0-4 R 4 groups and optionally substituted with oxo ( ⁇ O) or thioxo ( ⁇ S).
  • —NR 8 R 9 is:
  • compounds are provided having the structure of the following Formula XI, including hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • R, R 1 , R 2 and R 3b are as defined above.
  • compounds are provided having the structure of the following Formula XII, including hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • compounds are provided having the structure of the following Formula I, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • mammals include, for example, humans; non-human primates, e.g., apes and monkeys; cattle; horses; sheep; and goats.
  • Non-mammals include, for example, fish and birds.
  • a “receptor”, as is well known in the art, is a biomolecular entity usually comprising a protein that specifically binds a structural class of ligands or a single native ligand in a living organism, the binding of which causes the receptor to transduce the binding signal into another kind of biological action, such as signaling a cell that a binding event has occurred, which causes the cell to alter its function in some manner.
  • CXCR3 compound or “CXCR3 agonist” or “CXCR3 activator” or “CXCR3 modulator” or “CXCR3 antagonist” or “CXCR3 potentiator” or “CXCR3 modulator” as the terms are used herein refer to compounds that interact in some way with the CXCR3 receptor. They can be agonists, potentiators, or activators, or they can be antagonists or inhibitors, and can be selective for action of the CXCR3 receptor family.
  • disease or “disorder” or “malcondition” are used interchangeably, and are used to refer to diseases or conditions wherein a CXCR3 receptor plays a role in the biochemical mechanisms involved in the disease or malcondition or symptom(s) thereof such that a therapeutically beneficial effect can be achieved by acting on a CXCR3 receptor.
  • “Substantially” as the term is used herein means completely or almost completely; for example, a composition that is “substantially free” of a component either has none of the component or contains such a trace amount that any relevant functional property of the composition is unaffected by the presence of the trace amount, or a compound is “substantially pure” is there are only negligible traces of impurities present.
  • Treating” or “treatment” within the meaning herein refers to an alleviation of symptoms associated with a disorder or disease, or inhibition of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder.
  • the expression “effective amount”, when used to describe use of a compound of the invention in providing therapy to a patient suffering from a disorder or malcondition mediated by a CXCR3 receptor refers to the amount of a compound of the invention that is effective to bind to as an agonist or as an antagonist a CXCR3 receptor in the individual's tissues, wherein the CXCR3 is implicated in the disorder, wherein such binding occurs to an extent sufficient to produce a beneficial therapeutic effect on the patient.
  • an “effective amount” or a “therapeutically effective amount” of a compound of the invention refers to an amount of the compound that alleviates, in whole or in part, symptoms associated with the disorder or condition, or halts or slows further progression or worsening of those symptoms, or prevents or provides prophylaxis for the disorder or condition.
  • a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result by acting as an agonist of CXCR3 activity.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of compounds of the invention are outweighed by the therapeutically beneficial effects.
  • a therapeutically effective amount of a CXCR3 receptor antagonist of the invention is an amount sufficient to control the malcondition, to mitigate the progress of the malcondition, or to relieve the symptoms of the malcondition.
  • a pharmaceutical composition comprising a compound of Formula I together with at least one pharmaceutically acceptable carrier, diluent or excipient.
  • a method for activating, potentiating, or agonizing (i.e., to have an agonic effect, to act as an agonist) a CXCR3 receptor, with a compound of Formula I.
  • the method involves contacting the receptor with a suitable concentration of a compound of Formula I to bring about activation of the receptor.
  • the contacting can take place in vitro, for example in carrying out an assay to determine the CXCR3 receptor activation activity of a compound undergoing experimentation related to a submission for regulatory approval.
  • the method for activating a CXCR3 receptor can be carried out in vivo; that is, within the living body of a mammal, such as a human patient or a test animal.
  • the compound of Formula I can be supplied to the living organism via a suitable route (e.g., orally), or can be provided locally within the body tissues.
  • a method for treatment of a disease or condition in a subject or patient for which activation of a CXCR3 receptor is medically indicated, wherein the subject or patient is administered a therapeutically effective amount of a compound of Formula I.
  • a method for treating or preventing a disease or condition comprising administering a pharmaceutical composition comprising a compound of Formula I together with at least one pharmaceutically acceptable carrier, diluent or excipient to a subject or patient in need thereof.
  • the subject or patient is afflicted with, or at risk of developing, rheumatoid arthritis, multiple sclerosis, or inflammatory bowel disease.
  • use of a compound of Formula I is provided for preparation of a medicament.
  • methods are provided for synthesis of compounds of Formula I, including compounds of the invention as more fully illustrated herein.
  • the invention provides certain intermediate compounds associated with such methods of synthesis as illustrated herein.
  • LCMS Mass spectra
  • System 1 Agilent 1100 HPLC system equipped with a Agilent Eclipse XDB-C18, 3.5 ⁇ (4.6 ⁇ 150 mm) column using water with 0.05% TFA as the mobile phase A, and acetonitrile with 0.05% TFA as the mobile phase B with a flow rate of 1 mL/min.
  • Method 1 5% B (95% A) to 95% B over 12 min then held at 95% B for 3 min and to 5% B over 1 min.
  • Method 2 50% B (50% A) to 95% B over 4 min then held at 95% B for 4 min and to 50% B over 0.1 min.
  • System 2 Agilent 1100/6110 HPLC system equipped with a Agilent Poroshell 120 EC-C8, 2.7 ⁇ (50 ⁇ 3 mm) column using water with 5 mM ammonium acetate as the mobile phase C, and acetonitrile with 5 mM ammonium acetate as the mobile phase D with a flow rate of 1 mL/min.
  • Method 3 5% D (95% C) to 95% D over 12 min then held at 95% D for 2.8 min and then to 5% D over 0.2 min.
  • ammonia (NH 3 ), tetrahydrofuran (THF), hydrochloric acid (HCl), sodium bicarbonate (NaHCO 3 ), dichloroethane (DCE), trifluoroacetic acid (TFA), magnesium sulfate (MgSO 4 ), hydrogen (H 2 ), tetrabutylammonium fluoride (TBAF), diazabicycloundecene (DBU), methyl tert-butyl ether (MTBE), nitric acid (HNO 3 ), ethyl acetate (EA), 1-methy-2-pyrrolidinone (NMP), triethylamine (TEA), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), N-hydroxybenzotriazole (HOBt), 1-ethyl-3-(
  • Step 1A Ethyl (S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Intermediate 1A)
  • Step 1B (S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 1B)
  • Step 1C Methyl N 6 -(tert-butoxycarbonyl)-N 2 —((S)-2-(4-oxo-4-phenylbutanol)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-L-lysinate (Intermediate 1C)
  • Step 1D N 6 -(tert-butoxycarbonyl)-N 2 —((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-L-lysine (Intermediate 1D)
  • Step 1E Tert-butyl ((S)-6-((3,4-dichlorophenyl)amino)-6-oxo-5-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)hexyl)carbamate (Intermediate 1E)
  • Step 1F (S)—N—((S)-6-amino-1-((3,4-dichlorophenyl)amino)-1-oxohexan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 1-1)
  • Step 2A 2,5-dioxopyrrolidin-1-yl (S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetra hydro isoquinoline-3-carboxylate (Intermediate 2A)
  • Step 2B (S)-4-((tert-butoxycarbonyl)amino)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoic acid (Intermediate 2B)
  • Step 2C tert-butyl ((S)-4-((3,4-dichlorophenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)carbamate (Intermediate 2C)
  • Step 2D (S)—N—((S)-4-amino-1-((3,4-dichlorophenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 2-1)
  • Step 3A Synthesis of tert-butyl (S)-(1-((3,4-dichlorophenyl)amino)-1-oxo-5-ureidopentan-2-yl)carbamate (Intermediate 3A)
  • Step 3B Synthesis of (S)-2-amino-N-(3,4-dichlorophenyl)-5-ureidopentanamide, (Intermediate 3B)
  • Step 3C Synthesis of (S)—N—((S)-1-((3,4-dichlorophenyl)amino)-1-oxo-5-ureidopentan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 3-1)
  • Step 4A Synthesis of (9H-fluoren-9-yl)methyl tert-butyl (6-((4-chloro-3-methylphenyl)amino)-6-oxohexane-1,5-diyl)(S)-dicarbamate (Intermediate 4A)
  • Step 4B Synthesis of tert-butyl (S)-(5-amino-6-((4-chloro-3-methylphenyl)amino)-6-oxohexyl)carbamate (Intermediate 4B)
  • Step 4C Synthesis of tert-butyl ((S)-6-((4-chloro-3-methylphenyl)amino)-6-oxo-5-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) hexyl) carbamate. (Intermediate 4C)
  • Step 4D Synthesis of (S)—N—((S)-6-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxohexan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 4-2)
  • Step 5A Synthesis of (9H-fluoren-9-yl)methyl (S)-(1-((3,4-dichlorophenyl)amino)-5-(3,3-dimethylguanidino)-1-oxopentan-2-yl)carbamate (Intermediate 5A)
  • Step 5B Synthesis of (S)-2-amino-N-(3,4-dichlorophenyl)-5-(3,3-dimethylguanidino) pentanamide (Intermediate 5B)
  • Step 5C Synthesis of (S)—N—((S)-1-((3,4-dichlorophenyl) amino)-5-(3,3-dimethylguanidino)-1-oxopentan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide. (Compound 5-1)
  • Step 7A Synthesis of 2-(4-(4-fluorophenyl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 7A)
  • Step 7B Synthesis of 2-(4-(4-fluorophenyl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 7B)
  • Step 7C Synthesis of (9H-fluoren-9-yl)methyl tert-butyl (6-((4-chloro-3-methylphenyl)amino)-6-oxohexane-1,5-diyl)(S)-dicarbamate (Intermediate 7C)
  • Step 7D Synthesis of tert-butyl (S)-(5-amino-6-((4-chloro-3-methylphenyl)amino)-6-oxohexyl)carbamate (Intermediate 7D)
  • Step 7E Synthesis of tert-butyl ((5S)-6-((4-chloro-3-methylphenyl)amino)-5-(2-(4-(4-fluorophenyl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-6-oxohexyl) carbamate (Intermediate 7E)
  • Step 7F Synthesis of N—((S)-6-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxohexan-2-yl)-2-(4-(4-fluorophenyl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 7-1)
  • Step 8A Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(isobutylamino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 8-1)
  • Step 9A Synthesis of (2S)-3-guanidino-2-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)propanoic acid (Intermediate 9A)
  • Step 9B Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-3-guanidino-1-oxopropan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 9-1)
  • Step 10A Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 10A)
  • Step 10B Synthesis of tert-butyl ((S)-4-((4-chloro-3-methylphenyl)amino)-4-oxo-3-((S)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)carbamate (Intermediate 10B)
  • Step 10C Synthesis of tert-butyl ((S)-4-((4-chloro-3-methylphenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-(piperidin-1-yl)butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) butyl) carbamate (Intermediate 10C)
  • Step 10D Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl) butanoyl)-1,2,3,4-tetrahydro isoquino line-3-carboxamide (Compound 10-1)
  • Step 11A Synthesis of tert-butyl 4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((2-chloro-3-methylphenyl)carbamoyl)piperidine-1-carboxylate (Intermediate 11A)
  • Step 11B Synthesis of tert-butyl 4-amino-4-((2-chloro-3-methylphenyl) carbamoyl) piperidine-1-carboxylate (Intermediate 11B)
  • Step 11C Synthesis of tert-butyl (S)-4-((2-chloro-3-methylphenyl)carbamoyl)-4-(1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1-carboxylate (Intermediate 11C)
  • Step 11D Synthesis of tert-butyl (S)-4-((2-chloro-3-methylphenyl)carbamoyl)-4-(1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1-carboxylate (Intermediate 11D
  • Step 11E Synthesis of tert-butyl (S)-4-((2-chloro-3-methylphenyl)carbamoyl)-4-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1-carboxylate (Intermediate 11E)
  • Step 11F Synthesis of (S)—N-(4-((2-chloro-3-methylphenyl)carbamoyl)piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 11-1)
  • Step 12A Synthesis of 4-((S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Intermediate 12A)
  • Step 12B Synthesis of tert-butyl ((S)-4-((4-chloro-3-methylphenyl)amino)-3-((S)-2-(4-((2R,6S)-2,6-dimethylmorpholino)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)carbamate (Intermediate 12B)
  • Step 13A Synthesis of 1-(tert-butyl) 4-methyl (S)-4-(2-(((9H-fluoren-9-yl)methoxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) piperidine-1,4-dicarboxylate (Intermediate 13A)
  • Step 13B Synthesis of 1-(tert-butyl) 4-methyl (S)-4-(1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1,4-dicarboxylate (Intermediate 13B)
  • Step 13C Synthesis of (S)-1-tert-butyl 4-methyl 4-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1,4-dicarboxylate (Intermediate 13C)
  • Step 13D Synthesis of (S)-1-(tert-butoxycarbonyl)-4-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetra hydro isoquinoline-3-carboxamido) piperidine-4-carboxylic acid (Intermediate 13D)
  • Step 13E Synthesis of tert-butyl (S)-4-((2,3-dihydro-1H-inden-5-yl)carbamoyl)-4-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1-carboxylate (Intermediate 13E)
  • Step 13F Synthesis of ((S)—N-(4-((2,3-dihydro-1H-inden-5-yl)carbamoyl) piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 13-1)
  • Step 14A Synthesis of (9H-fluoren-9-yl) methyl (S)-(4-azido-1-((2-chloro-5-fluoro phenyl) amino)-1-oxo butan-2-yl)carbamate (Intermediate 14A)
  • Step 14C Synthesis of (S)—N—((S)-4-azido-1-((2-chloro-5-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,34-tetrahydroisoquinoline-3-carboxamide (Intermediate 14C)
  • Step 14D Synthesis of (S)—N—((S)-4-amino-1-((2-chloro-5-fluorophenyl) amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 14-1)
  • Step 15A Synthesis of tert-butyl (S)-3-(((S)-4-azido-1-((3,4-dichloro-2-fluorophenyl) amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 15A)
  • Step 15B Synthesis of (S)—N—((S)-4-azido-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Intermediate 15B)
  • Step 15C Synthesis of 4-((S)-3-(((S)-4-azido-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl) carbamoyl)-3,4-dihydroisoquinolin-2 (1H)-yl)-4-oxobutanoic acid (Intermediate 15C)
  • Step 15D Synthesis of (S)—N—((S)-4-azido-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-(4,4-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Intermediate 15D)
  • Step 15E Synthesis of (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-(4,4-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydro iso quinoline-3-carboxamide (Compound 15-1)
  • Step 16A Synthesis of tert-butyl (S)-(4-(benzyloxy)-1-((4-chloro-3-methylphenyl) amino)-1-oxobutan-2-yl) carbamate (Intermediate 16A)
  • DIEA (5.63 mL, 32.3 mmol) was added to a solution of O-benzyl-N-(tert-butoxycarbonyl)-L-homoserine (2.5 g, 8.1 mmol) and 4-chloro-3-methylaniline (1.3 g, 8.9 mmol) in DCM (15 mL) at 0° C., followed by HATU (6.2 g, 16.6 mmol). After 2 h, the reaction was partitioned between DCM (50 mL) and H 2 O (40 mL). The layers were separated using a phase separator and the aqueous layer was re-extracted with DCM (50 mL).
  • Step 16B Synthesis of tert-butyl (S)-(1-((4-chloro-3-methylphenyl)amino)-4-hydroxy-1-oxobutan-2-yl)carbamate (Intermediate 16B)
  • Step 16C Synthesis of tert-butyl (S)-(1-((4-chloro-3-methylphenyl)amino)-1,4-dioxo butan-2-yl) carbamate (Intermediate 16C)
  • Oxalyl dichloride (199 ⁇ L, 2.35 mmol) was added dropwise to a solution of DMSO (332 ⁇ L, 4.67 mmol) in DCM (6 mL) at ⁇ 78° C. After 15 min, a solution of Intermediate 16B (450 mg, 1.313 mmol) in DCM (4 mL) was added slowly. After 45 min at ⁇ 78° C., NEt 3 (951 ⁇ L, 6.83 mmol) was added dropwise. After 1 h, the mixture was warmed to 0° C. then quenched with NaHCO 3 (20 mL), split through a hydrophobic frit, and washed with DCM. The solvent was removed to afford 447 mg (100%, assumed) of Intermediate 16C as a white solid which was used without further purification or analysis.
  • Step 16D Synthesis of tert-butyl (S)-(1-((4-chloro-3-methylphenyl)amino)-4-(cyclopropylamino)-1-oxobutan-2-yl)carbamate (Intermediate 16D)
  • Step 16E Synthesis (S)-2-amino-N-(4-chloro-3-methylphenyl)-4-(cyclopropylamino) butanamide (Intermediate 16E)
  • Step 16F Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(cyclopropylamino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 16-1)
  • Step 17A Synthesis of tert-butyl (S)-3-((((9H-fluoren-9-yl)methoxy) carbonyl)amino)-4-((4-chloro-3-methylphenyl)amino)-4-oxobutanoate (Compound 17A)
  • Step 17B Synthesis of tert-butyl (S)-3-amino-4-((4-chloro-3-methylphenyl) amino)-4-oxobutanoate (Compound 17B)
  • Step 17C Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-4-(tert-butoxy)-1-((4-chloro-3-methylphenyl) amino)-1,4-dioxobutan-2-yl) carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17C)
  • Step 17D Synthesis of (S)-3-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-((4-chloro-3-methylphenyl)amino)-4-oxobutanoic acid (Compound 17D)
  • Step 17E Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-hydroxy-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17E)
  • Step 17F Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-hydroxy-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17F)
  • Step 17G Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17G)
  • Step 17H Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17H)
  • Step 171 Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 17-1)
  • Step 18A Synthesis of (S)-4-(3-(tert-butoxycarbonyl)-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Compound 18A)
  • Step 18B Synthesis of tert-butyl (S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Compound 18B)
  • Step 18C Synthesis of (S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Compound 18C)
  • Step 18D Synthesis of (S)—N—((S)-4-azido-1-((4-chloro-2-iodo-5-methylphenyl) amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 18D)
  • Step 18E Synthesis of (S)—N—((S)-4-azido-1-((4-chloro-2-cyano-5-methyl phenyl) amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethyl piperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 18E)
  • Step 18F Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-2-cyano-5-methyl phenyl) amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethyl piperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 18-1)
  • Step 19A Synthesis of (S)-4-(3-(tert-butoxycarbonyl)-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Compound 19-1)
  • Step 20A Synthesis of (S)—N-(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-((4-chloro-3-methyl phenyl) carbamoyl)piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydro isoquinoline-3-carboxamide (Compound 20A)
  • Step 20B Synthesis of (S)—N-(4-((4-chloro-3-methyl phenyl) carbamoyl)-1-(2-hydroxyethyl) piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydro isoquinoline-3-carboxamide (Compound 20-1)
  • Step 21A Synthesis of methyl (E)-2-((tert-butoxycarbonyl)amino)-4-(3-(dimethylamino)oxetan-3-yl)but-2-enoate (Intermediate 21A)
  • Step 21B Synthesis of methyl 2-((tert-butoxycarbonyl)amino)-4-(3-(dimethylamino) oxetan-3-yl)butanoate (Intermediate 21B)
  • Step 21C Synthesis of 2-((tert-butoxycarbonyl)amino)-4-(3-(dimethylamino) oxetan-3-yl) butanoic acid (Intermediate 21C)
  • Step 21D Synthesis of tert-butyl (1-((4-chloro-3-methylphenyl)amino)-4-(3-(dimethylamino)oxetan-3-yl)-1-oxobutan-2-yl)carbamate (Intermediate 21D)
  • Step 21E Synthesis of 2-amino-N-(4-chloro-3-methyl phenyl)-4-(3-(dimethyl amino) oxetan-3-yl) butanamide (Intermediate 21E)
  • Step 21F Synthesis of (3S)—N-(1-((4-chloro-3-methylphenyl)amino)-4-(3-(dimethylamino)oxetan-3-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 21-1)
  • Step 22A Synthesis of (E)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(3-((tert-butoxycarbonyl)amino)bicycle[1.1.1]pentan-1-yl)acrylate (Intermediate 22A)
  • Step 22B Synthesis of methyl 2-amino-3-(3-((tert-butoxycarbonyl) amino) bicyclo[1.1.1]pentan-1-yl) propanoate (Intermediate 22B)
  • Step 22C Synthesis of (3-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)propanoic acid (Intermediate 22C)
  • Step 22D Synthesis of 3-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-1)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) propanoic acid (Intermediate 22D)
  • Step 22E Synthesis of tert-butyl (3-(3-((4-chloro-3-methylphenyl)amino)-3-oxo-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,34-tetrahydroisoquinoline-3-carboxamido)propyl)bicyclo[1.1.1]pentan-1-yl)carbamate (Intermediate 22E)
  • Step 22F Synthesis of (S)—N—((S)-3-(3-aminobicyclo[1.1.1]pentan-1-yl)-1-((4-chloro-3-methylphenyl)amino)-1-oxopropan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 22-1) and (S)—N—((R)-3-(3-aminobicyclo[1.1.1]pentan-1-yl)-1-((4-chloro-3-methylphenyl)amino)-1-oxopropan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 22-2)
  • Step 23A Synthesis of tert-butyl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-homoserinate (Intermediate 23A)
  • Step 23B Synthesis of tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-oxobutanoate (Intermediate 23B)
  • Step 23C Synthesis of tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-fluoropiperidin-1-yl)butanoate (Intermediate 23C)
  • Step 23D Synthesis of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-fluoropiperidin-1-yl)butanoic acid (Intermediate 23D)
  • Step 23E Synthesis of (9H-fluoren-9-yl)methyl (S)-(1-((2,3-dihydro-1H-inden-5-yl)amino)-4-(4-fluoropiperidin-1-yl)-1-oxobutan-2-yl)carbamate (Intermediate 23E)
  • Step 23F Synthesis of (S)-2-amino-N-(2,3-dihydro-1H-inden-5-yl)-4-(4-fluoropiperidin-1-yl)butanamide (Intermediate 23F)
  • Step 23G Synthesis of N-(1-((2,3-dihydro-1H-inden-5-yl)amino)-4-(4-fluoropiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 23-1)
  • Step 24A Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-iodo-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 24A)
  • Step 24B Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-methoxypiperidin-1-yl)-1-oxobutan-2-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Intermediate 24B)
  • Step 24C Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-methoxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Intermediate 24-1)
  • Step 25A Synthesis of (9H-fluoren-9-yl)methyl (3S)-3-((1-(tert-butoxy)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 25A)
  • Step 25B Synthesis of (9H-fluoren-9-yl)methyl (3S)-3-((4-(4-acetoxypiperidin-1-yl)-1-(tert-butoxy)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 25B)
  • Step 25C Synthesis of tert-butyl 4-(4-acetoxypiperidin-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoate (Intermediate 25C)
  • Step 25D Synthesis of 4-(4-acetoxypiperidin-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoic acid (Intermediate 25D)
  • Step 25E Synthesis of 1-(4-((2,4-dichloro-3-methylphenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)piperidin-4-yl acetate (Compound 25-E)
  • Step 25F Synthesis of (3S)—N-(1-((2,4-dichloro-3-methylphenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 25-1)
  • Step 26A Synthesis of tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-acetoxypiperidin-1-yl)butanoate (Intermediate 26A)
  • Step 26B Synthesis of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-acetoxypiperidin-1-yl)butanoic acid (Intermediate 26B)
  • Step 26C Synthesis of (S)-1-(3-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((3,4-dichloro-2-fluorophenyl)amino)-4-oxobutyl)piperidin-4-yl acetate (Intermediate 26C)
  • Step 26D Synthesis of (S)-1-(3-amino-4-((3,4-dichloro-2-fluorophenyl)amino)-4-oxobutyl)piperidin-4-yl acetate (Intermediate 26D)
  • Step 26E Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-4-(4-acetoxypiperidin-1-yl)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 26E)
  • Step 26F Synthesis of 1-((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-4-oxo-3-((S)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)piperidin-4-yl acetate (Intermediate 26F)
  • Step 26G Synthesis of 4-((S)-3-(((S)-4-(4-acetoxypiperidin-1-yl)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Intermediate 26G)
  • Step 26H Synthesis of 1-((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-3-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)piperidin-4-yl acetate (Intermediate 26H)
  • Step 261 Synthesis of (S)—N—((S)-1-((3,4-dichloro-2-fluorophenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 26-1)
  • Step 27A Synthesis of tert-butyl ((S)-4-((4-chloro-5-methylpyridin-2-yl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)carbamate (Intermediate 27A)
  • Step 27B Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-5-methylpyridin-2-yl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,34-tetrahydroisoquinoline-3-carboxamide (Compound 27-1)
  • Step 28A Synthesis of tert-butyl (S)-4-(4-hydroxypiperidin-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoate (Intermediate 28A)
  • Step 28B Synthesis of (S)-4-(4-hydroxypiperidin-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoic acid (Intermediate 28B)
  • Step 28C Synthesis of (S)—N—((S)-1-((2,3-dihydro-1H-inden-5-yl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 28-1)
  • Step 29A Synthesis of (S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-2-(4-oxo-4-phenylbutanol)-1,2,3,4-tetrahydroisoquinolin-7-yl methanesulfonate (Intermediate 29A)
  • Step 29B Synthesis of (S)-3-(((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl methanesulfonate (Compound 29-1)
  • Step 30A Synthesis of tert-butyl ((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-7-((trifluoromethyl)sulfonyl)-1,2,3,4-tetra hydro isoquinoline-3-carboxamido)butyl)carbamate (Intermediate 30A)
  • Step 30B Synthesis of tert-butyl ((S)-3-((S)-7-cyano-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-((3,4-dichloro-2-fluorophenyl) amino)-4-oxobutyl)carbamate (Intermediate 30B)
  • Pd(Ph 3 P) 4 (8.86 mg, 7.7 ⁇ mol) was added to a solution of Intermediate 30A (0.065 g, 0.08 mmol) and Zinc cyanide (0.012 g, 0.1 mmol) in degassed DMF (0.7 mL). The reaction mixture was degassed for another 10 min and heated to 80° C. for 2.5 h under N 2 . Additional Pd(Ph 3 P) 4 (8.86 mg, 7.7 ⁇ mol) was added and the temperature increased to 120° C. and stirred for 6 h. The reaction mixture was cooled to rt, diluted with EA (5 mL), washed with NaHCO 3 solution (2 ⁇ 3 mL) and brine (3 mL).
  • Step 30C Synthesis of (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-7-cyano-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 30-1)
  • Step 31A Synthesis of tert-butyl (2-(((S)-4-((4-chloro-3-methylphenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-(piperidin-1-yl) butanoyl)-1,2,3,4 tetrahydroisoquinoline-3-carboxamido) butyl)amino)-2-oxoethyl)carbamate (Intermediate 31A)
  • Step 31B Synthesis of (S)—N—((S)-4-(2-aminoacetamido)-1-((4-chloro-3-methylphenyl) amino)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl) butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 31-1)
  • Step 32A Synthesis of (S)—N—((S)-1-((3,4-dichloro-2-fluorophenyl)amino)-4-(methylsulfonamido)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl)butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 32-1)
  • Step 33A Synthesis of methyl 3-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1] pentan-1-yl)-2-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetra hydro isoquinoline-3-carboxamido) propanoate (Intermediate 33A)
  • Step 33B Synthesis of 3-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)-2-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)propanoic acid (Intermediate 33-B)
  • Step 33C Synthesis of tert-butyl (3-(3-((3,4-dichloro-2-fluorophenyl)amino)-2-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-3-oxopropyl)bicyclo[1.1.1]pentan-1-yl)carbamate (Intermediate 33-C)
  • Step 33D Synthesis of (3S)—N-(3-(3-aminobicyclo[1.1.1]pentan-1-yl)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxopropan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 33-1)
  • Step 34A Synthesis of (S)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 34A)
  • Step 34B Synthesis of (S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 34B)
  • Step 34C Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-6-fluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 34C)
  • Step 34D Synthesis of tert-butyl ((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-3-((S)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)carbamate (Intermediate 34D)
  • Step 34E Synthesis of 4-((S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Intermediate 34E)
  • Step 34F Synthesis of tert-butyl ((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-3-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)carbamate (Intermediate 34F)
  • Step 34G Synthesis of (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 34-1)
  • Step 35A Synthesis of tert-butyl ((S)-4-((4-cyano-2,3-dihydro-1H-inden-5-yl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) butyl)carbamate (Intermediate 35A)
  • Step 35B Synthesis of (S)—N—((S)-4-amino-1-((4-cyano-2,3-dihydro-1H-inden-5-yl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 35-1)
  • Step 36A Synthesis of 7-bromo-2,3-dihydro-1H-inden-4-ol (Intermediate 36A)
  • Step 36B Synthesis of 7-bromo-5-nitro-2,3-dihydro-1H-inden-4-ol (Intermediate 36B)
  • Step 36C Synthesis of 7-bromo-4-methoxy-5-nitro-2,3-dihydro-1H-indenene (Intermediate 36C)
  • Step 36D Synthesis of 4-methoxy-2,3-dihydro-1H-inden-5-amine (Intermediate 36-1)
  • Step 37A Synthesis of 2,3-dimethylphenol (Intermediate 37A)
  • Step 37B Synthesis of 1-bromo-4-methoxy-2,3-dimethylbenzene (Intermediate 37B)
  • Step 37C Synthesis of 1-bromo-4-methoxy-2,3-dimethylbenzene (Intermediate 37C)
  • Step 37D Synthesis of 2-methoxy-3,4-dimethylaniline (Intermediate 37-1)
  • Step 38A Synthesis of 5-methoxy-1,2,3,4-tetrahydronaphthalene (Intermediate 38A)
  • Step 38B Synthesis of 5-bromo-8-methoxy-1,2,3,4-tetrahydronaphthalene (Intermediate 38B)
  • Step 38C Synthesis of 8-bromo-5-methoxy-6-nitro-1,2,3,4-tetrahydronaphthalene (Intermediate 38C)
  • Step 38D Synthesis of 1-methoxy-5,6,7,8-tetrahydronaphthalen-2-amine (Intermediate 38-1)
  • Step 39A Synthesis of 1-fluoro-4-methoxy-2-methyl-5-nitrobenzene (Intermediate 39A)
  • Step 39B Synthesis of 1-fluoro-4-methoxy-2-methyl-5-nitrobenzene (Intermediate 39-1)
  • Step 40A Synthesis of 1,1-dimethyl-2,3-dihydro-1H-inden-5-amine (Intermediate 40-1)
  • Step 41A Synthesis of 2,2-dimethyl-2,3-dihydro-1H-inden-5-amine (Intermediate 41A)
  • Step 41B Synthesis of 2,2-dimethyl-6-nitro-2,3-dihydro-1H-inden-1-one (Intermediate 41B)
  • Step 41C Synthesis of 2,2-dimethyl-2,3-dihydro-1H-inden-5-amine (Intermediate 41-1)
  • Step 42A Synthesis of 2-methoxy-1-nitro-3-vinylbenzene (Intermediate 42A)
  • Step 42B Synthesis of 3-ethyl-2-methoxyaniline (Intermediate 42-1)
  • Step 43A Synthesis of tert-butyl (3,4-dichloro-2-hydroxyphenyl)carbamate (Intermediate 43A)
  • Step 43B Synthesis of tert-butyl (3,4-dichloro-2-methoxyphenyl)carbamate (Intermediate 43B)
  • Step 43C Synthesis of 3,4-dichloro-2-methoxyaniline (Intermediate 43-1)
  • Step 44A Synthesis of 5-methyl-2-(trifluoromethoxy)aniline (Intermediate 44A)
  • Step 44B Synthesis of 4-bromo-5-methyl-2-(trifluoromethoxy)aniline (Intermediate 44B)
  • Step 44C Synthesis of 4,5-dimethyl-2-(trifluoromethoxy)aniline (Intermediate 44-1)
  • Step 45A Synthesis of 5-fluoro-6-nitro-2,3-dihydro-1H-inden-1-one (Intermediate 45A)
  • Step 45B Synthesis of 6-fluoro-2,3-dihydro-1H-inden-5-amine (Intermediate 45-1)
  • Step 46A Synthesis of 4,6-dibromo-2,3-dihydro-1H-inden-5-amine (Intermediate 46A)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.

Description

    FIELD OF THE INVENTION
  • This disclosure is directed to small molecule agonists of the chemokine receptor CXCR3, and product containing the same, as well as to methods related to the use of such small molecule agonists.
    • BACKGROUND
  • The chemokine receptor CXCR3 is a member of the seven transmembrane-spanning G protein-coupled receptor (GPCR) superfamily. CXCR3 is primarily expressed on activated T lymphocytes and NK cells. CXCL9/Mig, CXCL10/IP-10 and CXCL11/I-TAC, the natural chemokine ligands for CXCR3, are involved in directing activated T cells and other cells, such as NK cells, to sites of inflammation. CXCR3 has been implicated in Th1 cell-mediated inflammation, and upregulation of CXCR3 has been shown in a number of diseases involving T cells, such as inflammatory bowel disease (IBD), multiple sclerosis (MS), rheumatoid arthritis (RA) and diabetes, to name a few.
  • CXCR3 receptor agonists inhibit migration of activated T lymphocytes and NK cells. As described by O'Boyle et al (“Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation,” PNAS, 109(12):4598-4603, 2012), generalized chemokine receptor desensitization can be induced by specific stimulation of a CXCR3 receptor on the surface of activated T cells, resulting in the inhibition of the inflammatory response that is normally produced. In effect, CXCR3 receptor agonists may act as functional antagonists through chemokine receptor desensitization.
  • Prior efforts directed to the identification of small molecule agonists of CXCR3 have been undertaken, resulting in the identification of several compounds. As described by Stroke et al (“Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries,” Biochemical and Biophysical Research Communication, 349:221-228, 2006), high-throughput screening of encoded combinatorial libraries have identified two classes of receptor agonists. In one class, compounds A and B have been identified, while the other class includes compound C:
  • Figure US20190345133A1-20191114-C00001
  • While advances have been made in this field, there remains a significant need for small molecule agonists of CXCR3, as well as for products and methods related to the same. The present disclosure fulfills these and other needs, as described in more detail in the following detailed description.
    • SUMMARY OF THE INVENTION
  • The present disclosure is generally directed to compounds which serve as agonists of the chemokine receptor CXCR3, as well as to composition containing the same, and to methods of their preparation and use.
  • In one embodiment, compounds are provided having the structure of the following Formula I, including stereoisomers hydrates, solvates, isotopes, or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00002
  • wherein R, R1, R2, R3a and R3b are as defined below.
  • In one embodiment, a pharmaceutical composition comprising a compound of Formula I together with at least one pharmaceutically acceptable carrier, diluent or excipient is provided.
  • In one embodiment, a method of use of a compound of Formula I comprising preparation of a medicament is provided.
  • In one embodiment, a method of agonism of the CXCR3 receptor is provided comprising contacting the receptor with a compound of Formula I, or a pharmaceutical composition comprising the same.
  • In one embodiment, a method is provided for treatment of a disease or condition in a subject for which agonism of the CXCR3 receptor is medically indicated, comprising administering to the subject a compound of Formula I, or a pharmaceutical composition comprising the same.
  • In one embodiment, a method is provided for treating rheumatoid arthritis, multiple sclerosis, or inflammatory bowel disease in a subject in need thereof, comprising administering to the subject a compound of Formula I, or a pharmaceutical composition comprising the same.
    • DETAILED DESCRIPTION OF THE INVENTION
  • As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.
  • In one embodiment, compounds are provided having the following Formula I, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00003
  • wherein:
      • R is hydrogen, hydroxy, cyano, halo or —OS(═O)2R6;
      • R1 is aryl or heteroaryl and substituted with 0-4 R4 groups;
      • R2 is aryl or heteroaryl and substituted with 0-3 R5 groups, or R2 is —NR8R9;
      • R3a is hydrogen or alkyl and R3b is a nitrogen- or amine-containing moiety of carbon, at least one nitrogen atom and hydrogen,
      • or R3a and R3b taken together with the carbon to which they are attached form a cyclic nitrogen- or amine-containing moiety of carbon, at least one nitrogen atom and hydrogen;
      • R4 and R5 are, at each occurrence, cyano, halo, alkyl, haloalkyl, aminoalkyl, hydroxyalkyl, hydroxy, alkoxy, phenyl, heterocyclyl, —S(═O)2R6, —C(═O)R6, —C(═O)OR6, —C(═O)NR6N7 or —NR6R7;
      • R6 and R7 are, at each occurrence, hydrogen or alkyl; and
      • R8 is hydrogen or alkyl and R9 is alkyl or aryl substituted with 0-4 R4 groups,
      • or R8 and R9 taken together with the nitrogen atom to which they are attached form a heterocyclyl substituted with 0-4 R4 groups and optionally substituted with oxo (═O) or thioxo (═S).
  • As used herein, “alkyl” groups include straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons (C1-C12 alkyl), or, in some embodiments, from 1 to 8 carbon atoms (C1-C8 alkyl), or, in some embodiments, from 1 to 4 carbon atoms (C1-C4 alkyl). In the case of cycloalkyl groups, such groups have from 3-20 carbon atoms as more specifically defined below. Examples of straight chain alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
  • “Alkenyl” groups include straight and branched chain and cyclic alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Thus, alkenyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to —CH═CH2, —CH═CH(CH3), —CH═C(CH3)2, —C(CH3)═CH2, —C(CH3)═CH(CH3), —C(CH2CH3)═CH2, —CH═CHCH2CH3, —CH═CH(CH2)2CH3, —CH═CH(CH2)3CH3, —CH═CH(CH2)4CH3, vinyl, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others.
  • “Alkynyl” groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms. Thus, alkynyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to —C≡CH, —C≡C(CH3), —C≡C(CH2CH3), —CH2C≡CH, —CH2C≡C(CH3), and —CH2C≡C(CH2CH3), among others.
  • “Cycloalkyl” groups are alkyl groups forming a ring structure, which can be substituted or unsubstituted, wherein the ring is either completely saturated, partially unsaturated, or fully unsaturated, wherein if there is unsaturation, the conjugation of the pi-electrons in the ring do not give rise to aromaticity. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7. Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like.
  • “(Cycloalkyl)alkyl” groups, also referred to as “cycloalkylalkyl”, are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above.
  • The term “cycloalkenyl” alone or in combination denotes a cyclic alkenyl group wherein at least one double bond is present in the ring structure. Cycloalkenyl groups include cycloalkyl groups having at least one double bond between two adjacent carbon atoms. Thus for example, cycloalkenyl groups include but are not limited to cyclohexenyl, cyclopentenyl, and cyclohexadienyl groups, as well as polycyclic and/or bridging ring systems such as adamantine.
  • “(Cycloalkenyl)alkyl” groups, also referred to as “cycloalkylalkyl”, are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above.
  • The terms “carbocyclic” and “carbocyclyl” denote a ring structure wherein the atoms of the ring are carbon. In some embodiments, the carbocyclyl has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms is 4, 5, 6, or 7. Carbocyclyl includes, for example, cycloalkyl and cycloalkenyl.
  • “(Carbocyclyl)alkyl” groups, also referred to as “carbocyclylalkyls”, are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a carbocyclyl as defined above.
  • A “nonaromatic carbocyclyl” or a “nonaromatic carbocyclylalkyl” is a group in which the carbocyclic ring of the carbocyclyl or carbocyclylalkyl is a completely saturated, a partially unsaturated, or a fully unsaturated carbocyclyl, wherein if there is unsaturation, the conjugation of the pi-electrons of the carbocyclic ring do not give rise to aromaticity.
  • “Aryl” groups are cyclic aromatic hydrocarbons that do not contain heteroatoms. Thus aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl groups. In some embodiments, aryl groups contain 6-14 carbons in the ring portions of the groups. The phrase “aryl groups” includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like).
  • “Aralkyl” groups are alkyl, alkenyl or alkynyl groups as defined above in which a hydrogen atom of an alkyl, alkenyl or alkynyl group is replaced with an aryl group as defined above. Representative aralkyl groups include benzyl (—CH2phenyl), phenylethyl (—CH2CH2phenyl) and phenylethylene (—CH═CHphenyl) groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl. Aralky groups can be substituted on the aryl moiety, the alkyl, alkenyl or alkynyl moiety, or both.
  • “Heterocyclyl” or “heterocyclic” groups include aromatic and non-aromatic ring moieties containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, S, or P. In some embodiments, heterocyclyl groups include 3 to 20 ring members, whereas other such groups have 3 to 15 ring members, including for example single ring systems containing 5, 6 or 7 ring members. At least one ring contains a heteroatom, but every ring in a polycyclic system need not contain a heteroatom. For example, a dioxolanyl ring and a benzdioxolanyl ring system (methylenedioxyphenyl ring system) are both heterocyclyl groups within the meaning herein. A heterocyclyl group designated as a C2-heterocyclyl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms, and so forth. Likewise a C4-heterocyclyl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms.
  • The term “heterocyclyl” includes fused ring species including those having fused aromatic and non-aromatic groups. The phrase also includes polycyclic and/or bridging ring systems containing a heteroatom such as, but not limited to, quinuclidyl and 7-azabicyclo[2.2.1]heptane. A heterocyclyl group as defined herein can be a heteroaryl group or a partially or completely saturated cyclic group including at least one ring heteroatom. Heterocyclyl groups include, but are not limited to, pyrazinyl, pyrimidinyl, pyridazinyl, thiadiazolyl, oxadiazolyl, imidazolinyl, hexahydropyrimidinyl, diazepanyl, triazinyl, imidazolyl, pyrrolidinyl, furanyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups.
  • “Heteroaryl” groups are aromatic ring moieties containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. A heteroaryl group designated as a C2-heteroaryl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth. Likewise a C4-heteroaryl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms. Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, pyrazinyl, pyrimidinyl, thiadiazolyl, imidazolyl, oxadiazolyl, thienyl, triazolyl, tetrazolyl, triazinyl, thiazolyl, thiophenyl, oxazolyl, isoxazolyl, benzothiophenyl, benzofuranyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, and quinazolinyl groups. The terms “heteroaryl” and “heteroaryl groups” include fused ring compounds such as wherein at least one ring, but not necessarily all rings, are aromatic, including tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl and 2,3-dihydro indolyl.
  • Additional examples of aryl and heteroaryl groups include but are not limited to phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl (1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl), thiadiazolyl (1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl), isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3-triazol-1-yl, 1,2,3-triazol-2-yl, 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), prazolo[1,5-a]pyridinyl, quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), isobenzofuranyl, 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3-dihydro-benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydro-benzo[b]thiophenyl, (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro-benzo[b]thiophenyl), 4-(2,3-dihydro-benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazole (1-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1-benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), benzo[d]isoxazolyl, carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H-dibenz[b,f]azepine (5H-dibenz[b,f]azepin-1-yl, 5H-dibenz[b,f]azepine-2-yl, 5H-dibenz[b,f]azepine-3-yl, 5H-dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl), 10,11-dihydro-5H-dibenz[b,f]azepine (10,11-dihydro-5H-dibenz[b,f]azepine-1-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-2-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-3-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-4-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-5-yl), and the like.
  • “Heterocyclylalkyl” groups are alkyl, alkenyl or alkynyl groups as defined above in which a hydrogen or carbon bond of an alkyl, alkenyl or alkynyl group is replaced with a bond to a heterocyclyl group as defined above. Representative heterocyclyl alkyl groups include, but are not limited to, furan-2-yl methyl, furan-3-yl methyl, pyridine-2-yl methyl (α-picolyl), pyridine-3-yl methyl (β-picolyl), pyridine-4-yl methyl (γ-picolyl), tetrahydrofuran-2-yl ethyl, and indol-2-yl propyl. Heterocyclylalkyl groups can be substituted on the heterocyclyl moiety, the alkyl, alkenyl or alkynyl moiety, or both.
  • “Heteroarylalkyl” groups are alkyl, alkenyl or alkynyl groups as defined above in which a hydrogen or carbon bond of an alkyl, alkenyl or alkynyl group is replaced with a bond to a heteroaryl group as defined above. Heteroarylalkyl groups can be substituted on the heteroaryl moiety, the alkyl, alkenyl or alkynyl moiety, or both.
  • An “optionally substituted” heterocyclyl, heteroaryl, heterocyclylalkyl or heteroarylalkyl refers to a heterocyclyl, heteroaryl, heterocyclylalkyl or heteroarylalkyl as defined above having no additional substituents (i.e., unsubstituted) or have one or more substituents (i.e., substituted), wherein such substituents independently one or more R4 groups as defined above, and in the case of a single carbon atom bearing two substituents includes oxo (═O) and thioxo (═S).
  • By a “ring system” as the term is used herein is meant a moiety comprising one, two, three or more rings, which can be substituted with non-ring groups or with other ring systems, or both, which can be fully saturated, partially unsaturated, fully unsaturated, or aromatic, and when the ring system includes more than a single ring, the rings can be fused, bridging, or spirocyclic. By “spirocyclic” is meant the class of structures wherein two rings are fused at a single tetrahedral carbon atom, as is well known in the art.
  • A “monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring” as the term is used herein refers to a ring system including an unsaturated ring possessing 4n+2 pi electrons, or a partially reduced (hydrogenated) form thereof. The aromatic or partially aromatic ring can include additional fused, bridged, or spiro rings that are not themselves aromatic or partially aromatic. For example, naphthalene and tetrahydronaphthalene are both a “monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring” within the meaning herein. Also, for example, a benzo-[2.2.2]-bicyclooctane is also a “monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring” within the meaning herein, containing a phenyl ring fused to a bridged bicyclic system. A fully saturated ring has no double bonds therein, and is carbocyclic or heterocyclic depending on the presence of heteroatoms within the meaning herein.
  • When two “R” groups are said to be joined together or taken together to form a ring, it is meant that together with the carbon atom or a non-carbon atom (e.g., nitrogen atom), to which they are bonded, they may form a ring system. In general, they are bonded to one another to form a 3- to 7-membered ring, or a 5- to 7-membered ring. Non-limiting specific examples are the cyclopentyl, cyclohexyl, cycloheptyl, piperidinyl, piperazinyl, pyrolidinyl, pyrrolyl, pyridinyl.
  • The term “alkoxy” refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined above. Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, n-propoxy, n-butoxy, n-pentyloxy, n-hexyloxy, n-heptyloxy, n-octyloxy n-nonyloxy, and the like. Examples of branched alkoxy include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like. Examples of cyclic alkoxy include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
  • The terms “aryloxy” and “arylalkoxy” refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom at the alkyl moiety. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy.
  • An “acyl” group as the term is used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom is also bonded to another carbon atom, which can be part of an alkyl, aryl, aralkyl cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl group or the like. In the special case wherein the carbonyl carbon atom is bonded to hydrogen, the group is a “formyl” group, an acyl group as the term is defined herein. An acyl group can include 0 to about 12-20 additional carbon atoms bonded to the carbonyl group. An acyl group can include double or triple bonds within the meaning herein. An acryloyl group is an example of an acyl group. An acyl group can also include heteroatoms within the meaning here. A nicotinoyl group (pyridyl-3-carbonyl) group is an example of an acyl group within the meaning herein. Other examples include acetyl, benzoyl, phenylacetyl, pyridylacetyl, cinnamoyl, and acryloyl groups and the like. When the group containing the carbon atom that is bonded to the carbonyl carbon atom contains a halogen, the group is termed a “haloacyl” group. An example is a trifluoroacetyl group.
  • The term “amine” includes primary, secondary, and tertiary amines having, e.g., the formula N(group)3 wherein each group can independently be H or non-H, such as alkyl, aryl, and the like. Amines include but are not limited to R—NH2, for example, alkylamines, arylamines, alkylarylamines; R2NH wherein each R is independently selected, such as dialkylamines, diarylamines, aralkylamines, heterocyclylamines and the like; and R3N wherein each R is independently selected, such as trialkylamines, dialkylarylamines, alkyldiarylamines, triarylamines, and the like. The term “amine” also includes ammonium ions as used herein.
  • An “amino” group is a substituent of the form —NH2, —NHR, —NR2, —NR3 +, wherein each R is independently selected, and protonated forms of each. Accordingly, any compound substituted with an amino group can be viewed as an amine.
  • An “ammonium” ion includes the unsubstituted ammonium ion NH4 +, but unless otherwise specified, it also includes any protonated or quaternarized forms of amines. Thus, trimethylammonium hydrochloride and tetramethylammonium chloride are both ammonium ions, and amines, within the meaning herein.
  • The term “amide” (or “amido”) includes C- and N-amide groups, i.e., —C(O)NR2, and —NRC(O)R groups, respectively. Amide groups therefore include but are not limited to carbamoyl groups (—C(O)NH2) and formamide groups (—NHC(O)H). A “carboxamido” group is a group of the formula C(O)NR2, wherein R can be H, alkyl, aryl, etc.
  • The term “hydroxyl” refers to an —OH group.
  • The term “hydroxyalkyl” refers to an -alkyl-OH group.
  • The term “cyano” refers to a —CN group.
  • The term “carbonyl,” refers to a —C(═O)— group.
  • “Halo,” “halogen,” and “halide” include fluorine, chlorine, bromine and iodine.
  • The term “perhaloalkyl” refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms. Perhaloalkyl groups include, but are not limited to, —CF3 and —C(CF3)3. The term “haloalkyl” refers to an alkyl group where some but not necessarily all of the hydrogen atoms are replaced by halogen atoms. Haloalkyl groups include but are not limited to —CHF2 and —CH2F.
  • The term “perhaloalkoxy” refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms. Perhaloalkoxy groups include, but are not limited to, —OCF3 and —OC(CF3)3. The term “haloalkoxy” refers to an alkoxy group where some but not necessarily all of the hydrogen atoms are replaced by halogen atoms. Haloalkoxy groups include but are not limited to —OCHF2 and —OCH2F.
  • The compounds disclosed herein may be in the form of a neutral compound, or in the form of the free acid or free base. Alternatively, the compounds disclosed herein may be associated with a counter ion, and be in the form a salt. In one embodiment, the compound is in the form of a “pharmaceutically acceptable” salt, which refers to a salt possessing toxicity profiles within a range that affords utility in pharmaceutical applications.
  • A “hydrate” is a compound that exists in a composition with water molecules. The composition can include water in stoichiometric quantities, such as a monohydrate or a dihydrate, or can include water in random amounts. As the term is used herein a “hydrate” refers to a solid form (i.e., a compound in water solution, while it may be hydrated, is not a hydrate as the term is used herein).
  • A “solvate” is a similar composition except that a solvent other that water replaces the water. For example, methanol or ethanol can form an “alcoholate”, which can again be stoichiometric or non-stoichiometric. As the term is used herein a “solvate” refers to a solid form (i.e., a compound in solution in a solvent, while it may be solvated, is not a solvate as the term is used herein).
  • A prodrug is a substance that can be administered to a patient where the substance is converted in vivo by the action of biochemicals within the patient's body, such as enzymes, to the active pharmaceutical ingredient. Examples of prodrugs include esters of carboxylic acid groups, which can be hydrolyzed by endogenous esterases as are found in the bloodstream of humans and other mammals. In one embodiment of the present invention, substances are provided that can be administered to a patient where the substance is converted in vivo by the action of biochemical within the patient's body, such as enzymes, to a compound having the structure of any one of Formulas (I)-(IV).
  • The term “isotope” refers to atoms with the same number of protons but a different number of neutrons, and an isotope of a compound of Formula (I) includes any such compound wherein one or more atoms are replaced by an isotope of that atom. For example, carbon 12, the most common form of carbon, has six protons and six neutrons, whereas carbon 13 has six protons and seven neutrons, and carbon 14 has six protons and eight neutrons. Hydrogen has two stable isotopes, deuterium (one proton and one neutron) and tritium (one proton and two neutrons). While fluorine has a number of isotopes, fluorine 19 is longest-lived. Thus, an isotope of a compound having the structure of Formula (I) includes, but not limited to, compounds of Formula (I) wherein one or more carbon 12 atoms are replaced by carbon 13 and/or 14 atoms, wherein one or more hydrogen atoms are replaced with deuterium and/or tritium, and/or wherein one or more fluorine atoms are replaced by fluorine 19.
  • In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described. Moreover, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any combination of individual members or subgroups of members of Markush groups. Thus, for example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, and Y is described as selected from the group consisting of methyl, ethyl, and propyl, claims for X being bromine and Y being methyl are fully described.
  • All chiral, diastereomeric, racemic forms of a structure are intended, unless a particular stereochemistry or isomeric form is specifically indicated. Compounds of the present invention include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions, at any degree of enrichment. Both racemic and diastereomeric mixtures, as well as the individual optical isomers can be synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these are all within the scope of certain embodiments of the invention.
  • “Isolated optical isomer” means a compound which has been substantially purified from the corresponding optical isomer(s) of the same formula. In an embodiment, the isolated isomer is at least about 80% pure by weight, or at least 80% pure by weight, or at least 85% pure by weight. In other embodiments, the isolated isomer is at least 90% pure by weight, or at least 98% pure by weight, or at least 99% pure by weight.
  • “Substantially enantiomerically or diastereomerically” pure means a level of enantiomeric or diastereomeric enrichment of one enantiomer with respect to the other enantiomer or diastereomer of at least 80%, and in other embodiments means in excess of 80%, 85%, 90%, 95%, 98%, 99%, 99.5% or 99.9%.
  • Enantiomers are sometimes called optical isomers because a pure enantiomer rotates plane-polarized light in a particular direction. If the light rotates clockwise, then that enantiomer is labeled “(+)” or “d” for dextrorotatory, its counterpart will rotate the light counterclockwise and is labeled “(−)” or “1” for levorotatory.
  • The terms “racemate” and “racemic mixture” are frequently used interchangeably. A racemate is an equal mixture of two enantiomers. A racemate is labeled “(±)” because it is not optically active (i.e., will not rotate plane-polarized light in either direction since its constituent enantiomers cancel each other out).
  • All structures encompassed within a claim are “chemically feasible,” by which is meant that the structure depicted by any combination or subcombination of optional substituents meant to be recited by the claim is physically capable of existence with at least some stability as can be determined by the laws of structural chemistry and by experimentation. Structures that are not chemically feasible are not within a claimed set of compounds. Further, isotopes of the atoms depicted (such as deuterium and tritium in the case of hydrogen) are encompassed within the scope of this invention.
  • Phrases such as “under conditions suitable to provide” or “under conditions sufficient to yield” or the like, in the context of methods of synthesis, as used herein refers to reaction conditions, such as time, temperature, solvent, reactant concentrations, and the like, that are within ordinary skill for an experimenter to vary, that provide a useful quantity or yield of a reaction product. It is not necessary that the desired reaction product be the only reaction product or that the starting materials be entirely consumed, provided the desired reaction product can be isolated or otherwise further used.
  • The term “heteroatoms” as used herein refers to non-carbon and non-hydrogen atoms, capable of forming covalent bonds with carbon, and is not otherwise limited. Typical heteroatoms are N, O, and S. When sulfur (S) is referred to, it is understood that the sulfur can be in any of the oxidation states in which it is found, thus including sulfoxides (R—S(O)—R′) and sulfones (R—S(O)2—R′), unless the oxidation state is specified; thus, the term “sulfone” encompasses only the sulfone form of sulfur; the term “sulfide” encompasses only the sulfide (R—S—R′) form of sulfur.
  • In one embodiment, compounds are provided having the structure of the following Formula II, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00004
  • wherein R, R3a, R3b, R4, and R5 are as defined above.
  • In one embodiment, compounds are provided having the structure of the following Formula III, including stereoisomers, hydrates, solvates, or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00005
  • wherein R, R3b, R4 and R5 are as defined above.
  • In one embodiment, compounds are provided having the structure of the following Formula IV, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00006
  • wherein R, R3b and R4 are as defined above.
  • In one embodiment, compounds are provided having the structure of the following Formula V, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00007
  • wherein R, R1, R3a, R3b, R8 and R9 are as defined above.
  • In one embodiment, compounds are provided having the structure of the following Formula VI, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00008
  • wherein R, R1, R3a, R3b and R4 are as defined above.
  • In one embodiment, compounds are provided having the structure of the following Formula VII, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00009
  • wherein R, R1, R3a, R3b and R4 are as defined above.
  • In one embodiment, compounds are provided having the structure of the following Formula VIII, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00010
  • wherein R, R1, R3a, R3b and R4 are as defined above.
  • In one embodiment, compounds are provided having the structure of the following Formula IX, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00011
  • wherein R, R1, R3a, R3b and R4 are as defined above.
  • In one embodiment, compounds are provided having the structure of the following Formula X, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00012
  • wherein R14 is H or R4 and R, R1, R3a, R3b and R4 are as defined above.
  • In the following more specific embodiments, the various “R” groups are set forth in more detail with respect to the compounds of each of Formulas I through V, as applicable to the R group being further defined. For example, reference to R1 below is intended to further limit the compounds of Formulas I, V and VI, but not Formulas II, III and IV (since R1 has already been further limited in those structures). Similarly, reference to R3b below would be applicable to each of Formulas I through VI since such structures list R3a as a variable group.
  • In one embodiment, R1 is aryl.
  • In one embodiment, R1 is aryl substituted with 1-4 R4 groups.
  • In one embodiment, R1 is aryl substituted with 0 R4 groups.
  • In one embodiment, R1 is heteroaryl.
  • In one embodiment, R1 is heteroaryl substituted with 1-4 R4 groups.
  • In one embodiment, R1 is heteroaryl substituted with 0 R4 groups.
  • In one embodiment, R1 is substituted with at least one R4 group. In another embodiment, R1 is substituted with at least two R4 groups. In another embodiment, R1 is substituted with at least three R4 groups.
  • In one embodiment, R4 is selected from halo and alkyl. In one embodiment, R4 is halo. In another embodiment, R4 is alkyl.
  • In one embodiment, R1 is substituted with at least three R4 groups selected from halo and alkyl.
  • In one embodiment, R2 is aryl.
  • In one embodiment, R2 is heteroaryl.
  • In one embodiment, R2 is substituted with zero R5 groups. In another embodiment, R2 is substituted with at least one R5 groups. In another embodiment, R2 is substituted with at least two R5 groups. In another embodiment, R2 is substituted with three R5 groups.
  • In one embodiment, R3a is hydrogen.
  • In another embodiment, R3a is alkyl.
  • In one embodiment, R3a is hydrogen and R3b is a nitrogen or amine-containing moiety of carbon with at least one nitrogen atom and hydrogen.
  • In one embodiment, R3a is hydrogen and R3b is alkyl substituted with —NR10R11, —N+R10R11R12, —NR12C(═O)NR10R11, —C(═O)NR10R11, —NR12C(═O)CH2NR10R11, —NR12N(═NR13)NR10R11, —NR10SO2R11, wherein R10, R11, R12 and R13 are independently hydrogen or R4. In another embodiment, R10, R11, R12 and R13 are independently hydrogen, alkyl or haloalkyl.
  • In another embodiment, R3a is hydrogen and R3b is alkyl substituted with —NR10R11 or —NR10R11R12.
  • In another embodiment, R3a is hydrogen and R3b is —(CH2)2-4NH2.
  • In one embodiment, R3a is hydrogen and R3b is:
  • Figure US20190345133A1-20191114-C00013
  • In another embodiment, R3a is hydrogen and R3b is alkyl substituted with —NR12N(═NR13)NR10R11.
  • In one embodiment, R3a is hydrogen and R3b is:
  • Figure US20190345133A1-20191114-C00014
  • In another embodiment, R3a is hydrogen and R3b is alkyl substituted with —C(═O)NR10R11, —NR12C(═O)NR10R11 or —NR12C(═O)CH2NR10R11.
  • In one embodiment, R3a is hydrogen and R3b is:
  • Figure US20190345133A1-20191114-C00015
  • In one embodiment, R3a is hydrogen and R3b is a nitrogen-containing heterocyclyl substituted with 0-4 R4 groups.
  • In one embodiment, R3a is hydrogen and R3b is:
  • Figure US20190345133A1-20191114-C00016
  • In one embodiment, R3a is hydrogen and R3b is alkyl substituted with a nitrogen-containing heterocyclyl substituted with 0-4 R4 groups.
  • In one embodiment, R3a is hydrogen and R3b is:
  • Figure US20190345133A1-20191114-C00017
  • In one embodiment, R3a is hydrogen and R3b is heteroaryl substituted with 0-4 R4 groups.
  • In one embodiment, R3a is hydrogen and R3b is alkyl substituted with heteroaryl substituted with 0-4 R4 groups.
  • In one embodiment, R3a is hydrogen and R3b is:
  • Figure US20190345133A1-20191114-C00018
  • In one embodiment, R3a and R3b are taken together with the carbon atom to which they are attached to form a cyclic nitrogen- or amine-containing moiety of carbon, at least one nitrogen atom and hydrogen.
  • In one embodiment, R3a and R3b are taken together with the carbon atom to which they are attached to form a nitrogen-containing heterocyclyl substituted with 0-4 R4 groups.
  • In one embodiment, R3a and R3b are taken together with the carbon atom to which they are attached to form:
  • Figure US20190345133A1-20191114-C00019
  • In one embodiment, R2 is —NR8R9, wherein R8 is hydrogen or alkyl and R9 is alkyl or aryl substituted with 0-4 R4 groups.
  • In one embodiment, —NR8R9 is:
  • Figure US20190345133A1-20191114-C00020
    Figure US20190345133A1-20191114-C00021
  • In one embodiment, R2 is —NR8R9 and R8 and R9 taken together with the nitrogen atom to which they are attached form a heterocyclyl substituted with 0-4 R4 groups and optionally substituted with oxo (═O) or thioxo (═S).
  • In one embodiment, —NR8R9 is:
  • Figure US20190345133A1-20191114-C00022
    Figure US20190345133A1-20191114-C00023
    Figure US20190345133A1-20191114-C00024
    Figure US20190345133A1-20191114-C00025
    Figure US20190345133A1-20191114-C00026
  • In one embodiment, compounds are provided having the structure of the following Formula XI, including hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00027
  • wherein R, R1, R2 and R3b are as defined above.
  • In one embodiment, compounds are provided having the structure of the following Formula XII, including hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00028
  • wherein
      • R, R1 and R2 are as defined above; and
      • R3a and R3b taken together with the carbon to which they are attached form a cyclic nitrogen- or amine-containing moiety of carbon.
  • In another embodiment, a compound is provided having the structure as shown in the following Table A.
  • TABLE A
    REPRESENTATIVE COMPOUNDS
    Structure Cpd. No.
    Figure US20190345133A1-20191114-C00029
         		1-1
    Figure US20190345133A1-20191114-C00030
         		1-2
    Figure US20190345133A1-20191114-C00031
         		1-3
    Figure US20190345133A1-20191114-C00032
         		1-5
    Figure US20190345133A1-20191114-C00033
         		1-6
    Figure US20190345133A1-20191114-C00034
         		1-7
    Figure US20190345133A1-20191114-C00035
         		1-8
    Figure US20190345133A1-20191114-C00036
         		1-9
    Figure US20190345133A1-20191114-C00037
         		1-10
    Figure US20190345133A1-20191114-C00038
         		1-11
    Figure US20190345133A1-20191114-C00039
         		1-12
    Figure US20190345133A1-20191114-C00040
         		1-13
    Figure US20190345133A1-20191114-C00041
         		1-14
    Figure US20190345133A1-20191114-C00042
         		1-15
    Figure US20190345133A1-20191114-C00043
         		1-16
    Figure US20190345133A1-20191114-C00044
         		1-17
    Figure US20190345133A1-20191114-C00045
         		1-18
    Figure US20190345133A1-20191114-C00046
         		1-19
    Figure US20190345133A1-20191114-C00047
         		1-20
    Figure US20190345133A1-20191114-C00048
         		1-21
    Figure US20190345133A1-20191114-C00049
         		1-22
    Figure US20190345133A1-20191114-C00050
         		1-23
    Figure US20190345133A1-20191114-C00051
         		1-24
    Figure US20190345133A1-20191114-C00052
         		1-25
    Figure US20190345133A1-20191114-C00053
         		1-26
    Figure US20190345133A1-20191114-C00054
         		1-27
    Figure US20190345133A1-20191114-C00055
         		1-28
    Figure US20190345133A1-20191114-C00056
         		1-29
    Figure US20190345133A1-20191114-C00057
         		1-30
    Figure US20190345133A1-20191114-C00058
         		1-31
    Figure US20190345133A1-20191114-C00059
         		1-32
    Figure US20190345133A1-20191114-C00060
         		1-33
    Figure US20190345133A1-20191114-C00061
         		1-34
    Figure US20190345133A1-20191114-C00062
         		1-35
    Figure US20190345133A1-20191114-C00063
         		1-36
    Figure US20190345133A1-20191114-C00064
         		1-37
    Figure US20190345133A1-20191114-C00065
         		1-38
    Figure US20190345133A1-20191114-C00066
         		1-39
    Figure US20190345133A1-20191114-C00067
         		2-1
    Figure US20190345133A1-20191114-C00068
         		2-2
    Figure US20190345133A1-20191114-C00069
         		2-3
    Figure US20190345133A1-20191114-C00070
         		2-4
    Figure US20190345133A1-20191114-C00071
         		2-5
    Figure US20190345133A1-20191114-C00072
         		2-6
    Figure US20190345133A1-20191114-C00073
         		2-7
    Figure US20190345133A1-20191114-C00074
         		2-8
    Figure US20190345133A1-20191114-C00075
         		2-9
    Figure US20190345133A1-20191114-C00076
         		2-10
    Figure US20190345133A1-20191114-C00077
         		2-11
    Figure US20190345133A1-20191114-C00078
         		2-12
    Figure US20190345133A1-20191114-C00079
         		2-13
    Figure US20190345133A1-20191114-C00080
         		2-14
    Figure US20190345133A1-20191114-C00081
         		2-15
    Figure US20190345133A1-20191114-C00082
         		2-16
    Figure US20190345133A1-20191114-C00083
         		2-17
    Figure US20190345133A1-20191114-C00084
         		2-18
    Figure US20190345133A1-20191114-C00085
         		2-19
    Figure US20190345133A1-20191114-C00086
         		2-20
    Figure US20190345133A1-20191114-C00087
         		2-21
    Figure US20190345133A1-20191114-C00088
         		2-22
    Figure US20190345133A1-20191114-C00089
         		2-23
    Figure US20190345133A1-20191114-C00090
         		2-24
    Figure US20190345133A1-20191114-C00091
         		2-25
    Figure US20190345133A1-20191114-C00092
         		2-26
    Figure US20190345133A1-20191114-C00093
         		2-27
    Figure US20190345133A1-20191114-C00094
         		2-28
    Figure US20190345133A1-20191114-C00095
         		2-29
    Figure US20190345133A1-20191114-C00096
         		2-30
    Figure US20190345133A1-20191114-C00097
         		2-31
    Figure US20190345133A1-20191114-C00098
         		2-32
    Figure US20190345133A1-20191114-C00099
         		2-33
    Figure US20190345133A1-20191114-C00100
         		2-34
    Figure US20190345133A1-20191114-C00101
         		2-35
    Figure US20190345133A1-20191114-C00102
         		2-36
    Figure US20190345133A1-20191114-C00103
         		2-37
    Figure US20190345133A1-20191114-C00104
         		2-38
    Figure US20190345133A1-20191114-C00105
         		2-39
    Figure US20190345133A1-20191114-C00106
         		2-40
    Figure US20190345133A1-20191114-C00107
         		2-41
    Figure US20190345133A1-20191114-C00108
         		2-42
    Figure US20190345133A1-20191114-C00109
         		2-43
    Figure US20190345133A1-20191114-C00110
         		2-44
    Figure US20190345133A1-20191114-C00111
         		2-45
    Figure US20190345133A1-20191114-C00112
         		2-46
    Figure US20190345133A1-20191114-C00113
         		2-47
    Figure US20190345133A1-20191114-C00114
         		2-48
    Figure US20190345133A1-20191114-C00115
         		2-49
    Figure US20190345133A1-20191114-C00116
         		2-50
    Figure US20190345133A1-20191114-C00117
         		2-51
    Figure US20190345133A1-20191114-C00118
         		2-52
    Figure US20190345133A1-20191114-C00119
         		2-53
    Figure US20190345133A1-20191114-C00120
         		2-54
    Figure US20190345133A1-20191114-C00121
         		2-55
    Figure US20190345133A1-20191114-C00122
         		2-56
    Figure US20190345133A1-20191114-C00123
         		2-57
    Figure US20190345133A1-20191114-C00124
         		2-58
    Figure US20190345133A1-20191114-C00125
         		2-59
    Figure US20190345133A1-20191114-C00126
         		2-60
    Figure US20190345133A1-20191114-C00127
         		2-61
    Figure US20190345133A1-20191114-C00128
         		2-62
    Figure US20190345133A1-20191114-C00129
         		2-63
    Figure US20190345133A1-20191114-C00130
         		2-64
    Figure US20190345133A1-20191114-C00131
         		2-65
    Figure US20190345133A1-20191114-C00132
         		2-66
    Figure US20190345133A1-20191114-C00133
         		2-67
    Figure US20190345133A1-20191114-C00134
         		2-68
    Figure US20190345133A1-20191114-C00135
         		2-69
    Figure US20190345133A1-20191114-C00136
         		2-70
    Figure US20190345133A1-20191114-C00137
         		2-71
    Figure US20190345133A1-20191114-C00138
         		2-72
    Figure US20190345133A1-20191114-C00139
         		2-73
    Figure US20190345133A1-20191114-C00140
         		2-74
    Figure US20190345133A1-20191114-C00141
         		2-75
    Figure US20190345133A1-20191114-C00142
         		2-76
    Figure US20190345133A1-20191114-C00143
         		2-77
    Figure US20190345133A1-20191114-C00144
         		2-78
    Figure US20190345133A1-20191114-C00145
         		2-79
    Figure US20190345133A1-20191114-C00146
         		2-80
    Figure US20190345133A1-20191114-C00147
         		2-81
    Figure US20190345133A1-20191114-C00148
         		2-82
    Figure US20190345133A1-20191114-C00149
         		3-1
    Figure US20190345133A1-20191114-C00150
         		3-2
    Figure US20190345133A1-20191114-C00151
         		3-3
    Figure US20190345133A1-20191114-C00152
         		3-4
    Figure US20190345133A1-20191114-C00153
         		3-5
    Figure US20190345133A1-20191114-C00154
         		3-6
    Figure US20190345133A1-20191114-C00155
         		3-7
    Figure US20190345133A1-20191114-C00156
         		3-8
    Figure US20190345133A1-20191114-C00157
         		3-9
    Figure US20190345133A1-20191114-C00158
         		3-10
    Figure US20190345133A1-20191114-C00159
         		3-11
    Figure US20190345133A1-20191114-C00160
         		3-12
    Figure US20190345133A1-20191114-C00161
         		3-13
    Figure US20190345133A1-20191114-C00162
         		3-14
    Figure US20190345133A1-20191114-C00163
         		4-2
    Figure US20190345133A1-20191114-C00164
         		4-3
    Figure US20190345133A1-20191114-C00165
         		4-4
    Figure US20190345133A1-20191114-C00166
         		4-5
    Figure US20190345133A1-20191114-C00167
         		4-6
    Figure US20190345133A1-20191114-C00168
         		4-7
    Figure US20190345133A1-20191114-C00169
         		4-8
    Figure US20190345133A1-20191114-C00170
         		4-9
    Figure US20190345133A1-20191114-C00171
         		4-10
    Figure US20190345133A1-20191114-C00172
         		4-11
    Figure US20190345133A1-20191114-C00173
         		4-12
    Figure US20190345133A1-20191114-C00174
         		4-13
    Figure US20190345133A1-20191114-C00175
         		4-14
    Figure US20190345133A1-20191114-C00176
         		4-15
    Figure US20190345133A1-20191114-C00177
         		4-16
    Figure US20190345133A1-20191114-C00178
         		4-17
    Figure US20190345133A1-20191114-C00179
         		4-18
    Figure US20190345133A1-20191114-C00180
         		4-19
    Figure US20190345133A1-20191114-C00181
         		4-20
    Figure US20190345133A1-20191114-C00182
         		5-1
    Figure US20190345133A1-20191114-C00183
         		5-2
    Figure US20190345133A1-20191114-C00184
         		5-3
    Figure US20190345133A1-20191114-C00185
         		5-4
    Figure US20190345133A1-20191114-C00186
         		6-1
    Figure US20190345133A1-20191114-C00187
         		6-2
    Figure US20190345133A1-20191114-C00188
         		6-3
    Figure US20190345133A1-20191114-C00189
         		6-4
    Figure US20190345133A1-20191114-C00190
         		6-5
    Figure US20190345133A1-20191114-C00191
         		6-6
    Figure US20190345133A1-20191114-C00192
         		6-7
    Figure US20190345133A1-20191114-C00193
         		7-1
    Figure US20190345133A1-20191114-C00194
         		7-2
    Figure US20190345133A1-20191114-C00195
         		7-3
    Figure US20190345133A1-20191114-C00196
         		7-4
    Figure US20190345133A1-20191114-C00197
         		7-5
    Figure US20190345133A1-20191114-C00198
         		7-6
    Figure US20190345133A1-20191114-C00199
         		7-7
    Figure US20190345133A1-20191114-C00200
         		7-8
    Figure US20190345133A1-20191114-C00201
         		7-9
    Figure US20190345133A1-20191114-C00202
         		8-1
    Figure US20190345133A1-20191114-C00203
         		8-2
    Figure US20190345133A1-20191114-C00204
         		8-3
    Figure US20190345133A1-20191114-C00205
         		8-4
    Figure US20190345133A1-20191114-C00206
         		8-5
    Figure US20190345133A1-20191114-C00207
         		8-6
    Figure US20190345133A1-20191114-C00208
         		8-7
    Figure US20190345133A1-20191114-C00209
         		9-1
    Figure US20190345133A1-20191114-C00210
         		10-1
    Figure US20190345133A1-20191114-C00211
         		10-2
    Figure US20190345133A1-20191114-C00212
         		10-3
    Figure US20190345133A1-20191114-C00213
         		10-4
    Figure US20190345133A1-20191114-C00214
         		10-5
    Figure US20190345133A1-20191114-C00215
         		10-6
    Figure US20190345133A1-20191114-C00216
         		10-7
    Figure US20190345133A1-20191114-C00217
         		10-8
    Figure US20190345133A1-20191114-C00218
         		10-9
    Figure US20190345133A1-20191114-C00219
         		10-10
    Figure US20190345133A1-20191114-C00220
         		10-11
    Figure US20190345133A1-20191114-C00221
         		10-12
    Figure US20190345133A1-20191114-C00222
         		11-1
    Figure US20190345133A1-20191114-C00223
         		11-2
    Figure US20190345133A1-20191114-C00224
         		11-3
    Figure US20190345133A1-20191114-C00225
         		11-4
    Figure US20190345133A1-20191114-C00226
         		11-5
    Figure US20190345133A1-20191114-C00227
         		11-6
    Figure US20190345133A1-20191114-C00228
         		12-1
    Figure US20190345133A1-20191114-C00229
         		12-2
    Figure US20190345133A1-20191114-C00230
         		12-3
    Figure US20190345133A1-20191114-C00231
         		12-4
    Figure US20190345133A1-20191114-C00232
         		12-5
    Figure US20190345133A1-20191114-C00233
         		12-6
    Figure US20190345133A1-20191114-C00234
         		12-7
    Figure US20190345133A1-20191114-C00235
         		12-8
    Figure US20190345133A1-20191114-C00236
         		12-9
    Figure US20190345133A1-20191114-C00237
         		12-10
    Figure US20190345133A1-20191114-C00238
         		12-11
    Figure US20190345133A1-20191114-C00239
         		12-12
    Figure US20190345133A1-20191114-C00240
         		12-13
    Figure US20190345133A1-20191114-C00241
         		12-14
    Figure US20190345133A1-20191114-C00242
         		12-15
    Figure US20190345133A1-20191114-C00243
         		12-16
    Figure US20190345133A1-20191114-C00244
         		12-17
    Figure US20190345133A1-20191114-C00245
         		12-18
    Figure US20190345133A1-20191114-C00246
         		12-19
    Figure US20190345133A1-20191114-C00247
         		12-20
    Figure US20190345133A1-20191114-C00248
         		12-21
    Figure US20190345133A1-20191114-C00249
         		12-22
    Figure US20190345133A1-20191114-C00250
         		12-23
    Figure US20190345133A1-20191114-C00251
         		12-24
    Figure US20190345133A1-20191114-C00252
         		12-25
    Figure US20190345133A1-20191114-C00253
         		12-26
    Figure US20190345133A1-20191114-C00254
         		12-27
    Figure US20190345133A1-20191114-C00255
         		12-28
    Figure US20190345133A1-20191114-C00256
         		12-29
    Figure US20190345133A1-20191114-C00257
         		12-30
    Figure US20190345133A1-20191114-C00258
         		12-31
    Figure US20190345133A1-20191114-C00259
         		12-32
    Figure US20190345133A1-20191114-C00260
         		12-33
    Figure US20190345133A1-20191114-C00261
         		12-34
    Figure US20190345133A1-20191114-C00262
         		12-35
    Figure US20190345133A1-20191114-C00263
         		12-36
    Figure US20190345133A1-20191114-C00264
         		12-37
    Figure US20190345133A1-20191114-C00265
         		12-38
    Figure US20190345133A1-20191114-C00266
         		12-39
    Figure US20190345133A1-20191114-C00267
         		12-40
    Figure US20190345133A1-20191114-C00268
         		12-41
    Figure US20190345133A1-20191114-C00269
         		12-42
    Figure US20190345133A1-20191114-C00270
         		12-43
    Figure US20190345133A1-20191114-C00271
         		12-44
    Figure US20190345133A1-20191114-C00272
         		12-45
    Figure US20190345133A1-20191114-C00273
         		12-46
    Figure US20190345133A1-20191114-C00274
         		12-47
    Figure US20190345133A1-20191114-C00275
         		12-48
    Figure US20190345133A1-20191114-C00276
         		12-49
    Figure US20190345133A1-20191114-C00277
         		12-50
    Figure US20190345133A1-20191114-C00278
         		12-51
    Figure US20190345133A1-20191114-C00279
         		12-52
    Figure US20190345133A1-20191114-C00280
         		12-53
    Figure US20190345133A1-20191114-C00281
         		12-54
    Figure US20190345133A1-20191114-C00282
         		12-55
    Figure US20190345133A1-20191114-C00283
         		12-56
    Figure US20190345133A1-20191114-C00284
         		12-57
    Figure US20190345133A1-20191114-C00285
         		12-58
    Figure US20190345133A1-20191114-C00286
         		12-59
    Figure US20190345133A1-20191114-C00287
         		12-60
    Figure US20190345133A1-20191114-C00288
         		12-61
    Figure US20190345133A1-20191114-C00289
         		12-62
    Figure US20190345133A1-20191114-C00290
         		12-63
    Figure US20190345133A1-20191114-C00291
         		12-64
    Figure US20190345133A1-20191114-C00292
         		12-65
    Figure US20190345133A1-20191114-C00293
         		12-66
    Figure US20190345133A1-20191114-C00294
         		12-67
    Figure US20190345133A1-20191114-C00295
         		12-68
    Figure US20190345133A1-20191114-C00296
         		12-69
    Figure US20190345133A1-20191114-C00297
         		12-70
    Figure US20190345133A1-20191114-C00298
         		12-71
    Figure US20190345133A1-20191114-C00299
         		12-72
    Figure US20190345133A1-20191114-C00300
         		12-73
    Figure US20190345133A1-20191114-C00301
         		12-74
    Figure US20190345133A1-20191114-C00302
         		12-75
    Figure US20190345133A1-20191114-C00303
         		12-76
    Figure US20190345133A1-20191114-C00304
         		12-77
    Figure US20190345133A1-20191114-C00305
         		12-78
    Figure US20190345133A1-20191114-C00306
         		12-79
    Figure US20190345133A1-20191114-C00307
         		12-80
    Figure US20190345133A1-20191114-C00308
         		12-81
    Figure US20190345133A1-20191114-C00309
         		12-82
    Figure US20190345133A1-20191114-C00310
         		12-83
    Figure US20190345133A1-20191114-C00311
         		12-84
    Figure US20190345133A1-20191114-C00312
         		12-85
    Figure US20190345133A1-20191114-C00313
         		12-86
    Figure US20190345133A1-20191114-C00314
         		12-87
    Figure US20190345133A1-20191114-C00315
         		12-88
    Figure US20190345133A1-20191114-C00316
         		12-89
    Figure US20190345133A1-20191114-C00317
         		12-90
    Figure US20190345133A1-20191114-C00318
         		12-91
    Figure US20190345133A1-20191114-C00319
         		12-92
    Figure US20190345133A1-20191114-C00320
         		12-93
    Figure US20190345133A1-20191114-C00321
         		12-94
    Figure US20190345133A1-20191114-C00322
         		12-95
    Figure US20190345133A1-20191114-C00323
         		12-96
    Figure US20190345133A1-20191114-C00324
         		12-97
    Figure US20190345133A1-20191114-C00325
         		12-98
    Figure US20190345133A1-20191114-C00326
         		12-99
    Figure US20190345133A1-20191114-C00327
         		12-100
    Figure US20190345133A1-20191114-C00328
         		12-101
    Figure US20190345133A1-20191114-C00329
         		12-102
    Figure US20190345133A1-20191114-C00330
         		12-103
    Figure US20190345133A1-20191114-C00331
         		12-104
    Figure US20190345133A1-20191114-C00332
         		12-105
    Figure US20190345133A1-20191114-C00333
         		12-106
    Figure US20190345133A1-20191114-C00334
         		12-107
    Figure US20190345133A1-20191114-C00335
         		12-108
    Figure US20190345133A1-20191114-C00336
         		12-109
    Figure US20190345133A1-20191114-C00337
         		12-110
    Figure US20190345133A1-20191114-C00338
         		12-111
    Figure US20190345133A1-20191114-C00339
         		12-112
    Figure US20190345133A1-20191114-C00340
         		12-113
    Figure US20190345133A1-20191114-C00341
         		12-114
    Figure US20190345133A1-20191114-C00342
         		12-115
    Figure US20190345133A1-20191114-C00343
         		12-116
    Figure US20190345133A1-20191114-C00344
         		12-117
    Figure US20190345133A1-20191114-C00345
         		12-118
    Figure US20190345133A1-20191114-C00346
         		12-119
    Figure US20190345133A1-20191114-C00347
         		12-120
    Figure US20190345133A1-20191114-C00348
         		12-121
    Figure US20190345133A1-20191114-C00349
         		12-122
    Figure US20190345133A1-20191114-C00350
         		12-123
    Figure US20190345133A1-20191114-C00351
         		12-124
    Figure US20190345133A1-20191114-C00352
         		12-125
    Figure US20190345133A1-20191114-C00353
         		12-126
    Figure US20190345133A1-20191114-C00354
         		12-127
    Figure US20190345133A1-20191114-C00355
         		12-128
    Figure US20190345133A1-20191114-C00356
         		12-129
    Figure US20190345133A1-20191114-C00357
         		12-130
    Figure US20190345133A1-20191114-C00358
         		12-131
    Figure US20190345133A1-20191114-C00359
         		12-132
    Figure US20190345133A1-20191114-C00360
         		12-133
    Figure US20190345133A1-20191114-C00361
         		12-134
    Figure US20190345133A1-20191114-C00362
         		12-135
    Figure US20190345133A1-20191114-C00363
         		12-136
    Figure US20190345133A1-20191114-C00364
         		12-137
    Figure US20190345133A1-20191114-C00365
         		12-138
    Figure US20190345133A1-20191114-C00366
         		12-139
    Figure US20190345133A1-20191114-C00367
         		12-140
    Figure US20190345133A1-20191114-C00368
         		12-141
    Figure US20190345133A1-20191114-C00369
         		12-142
    Figure US20190345133A1-20191114-C00370
         		12-143
    Figure US20190345133A1-20191114-C00371
         		12-144
    Figure US20190345133A1-20191114-C00372
         		12-145
    Figure US20190345133A1-20191114-C00373
         		12-146
    Figure US20190345133A1-20191114-C00374
         		12-147
    Figure US20190345133A1-20191114-C00375
         		12-148
    Figure US20190345133A1-20191114-C00376
         		12-149
    Figure US20190345133A1-20191114-C00377
         		12-150
    Figure US20190345133A1-20191114-C00378
         		12-151
    Figure US20190345133A1-20191114-C00379
         		12-152
    Figure US20190345133A1-20191114-C00380
         		12-153
    Figure US20190345133A1-20191114-C00381
         		12-154
    Figure US20190345133A1-20191114-C00382
         		12-155
    Figure US20190345133A1-20191114-C00383
         		12-156
    Figure US20190345133A1-20191114-C00384
         		12-157
    Figure US20190345133A1-20191114-C00385
         		12-158
    Figure US20190345133A1-20191114-C00386
         		12-159
    Figure US20190345133A1-20191114-C00387
         		13-1
    Figure US20190345133A1-20191114-C00388
         		13-2
    Figure US20190345133A1-20191114-C00389
         		13-3
    Figure US20190345133A1-20191114-C00390
         		13-4
    Figure US20190345133A1-20191114-C00391
         		13-5
    Figure US20190345133A1-20191114-C00392
         		13-6
    Figure US20190345133A1-20191114-C00393
         		13-7
    Figure US20190345133A1-20191114-C00394
         		14-1
    Figure US20190345133A1-20191114-C00395
         		14-2
    Figure US20190345133A1-20191114-C00396
         		14-3
    Figure US20190345133A1-20191114-C00397
         		14-4
    Figure US20190345133A1-20191114-C00398
         		14-5
    Figure US20190345133A1-20191114-C00399
         		14-6
    Figure US20190345133A1-20191114-C00400
         		14-7
    Figure US20190345133A1-20191114-C00401
         		14-8
    Figure US20190345133A1-20191114-C00402
         		14-9
    Figure US20190345133A1-20191114-C00403
         		14-10
    Figure US20190345133A1-20191114-C00404
         		14-11
    Figure US20190345133A1-20191114-C00405
         		14-12
    Figure US20190345133A1-20191114-C00406
         		14-13
    Figure US20190345133A1-20191114-C00407
         		14-14
    Figure US20190345133A1-20191114-C00408
         		14-15
    Figure US20190345133A1-20191114-C00409
         		14-16
    Figure US20190345133A1-20191114-C00410
         		14-17
    Figure US20190345133A1-20191114-C00411
         		14-18
    Figure US20190345133A1-20191114-C00412
         		14-19
    Figure US20190345133A1-20191114-C00413
         		14-20
    Figure US20190345133A1-20191114-C00414
         		14-21
    Figure US20190345133A1-20191114-C00415
         		14-23
    Figure US20190345133A1-20191114-C00416
         		14-24
    Figure US20190345133A1-20191114-C00417
         		14-25
    Figure US20190345133A1-20191114-C00418
         		14-26
    Figure US20190345133A1-20191114-C00419
         		14-27
    Figure US20190345133A1-20191114-C00420
         		14-28
    Figure US20190345133A1-20191114-C00421
         		14-29
    Figure US20190345133A1-20191114-C00422
         		15-1
    Figure US20190345133A1-20191114-C00423
         		15-2
    Figure US20190345133A1-20191114-C00424
         		15-3
    Figure US20190345133A1-20191114-C00425
         		15-4
    Figure US20190345133A1-20191114-C00426
         		15-5
    Figure US20190345133A1-20191114-C00427
         		15-6
    Figure US20190345133A1-20191114-C00428
         		15-7
    Figure US20190345133A1-20191114-C00429
         		15-8
    Figure US20190345133A1-20191114-C00430
         		15-9
    Figure US20190345133A1-20191114-C00431
         		15-10
    Figure US20190345133A1-20191114-C00432
         		15-11
    Figure US20190345133A1-20191114-C00433
         		15-12
    Figure US20190345133A1-20191114-C00434
         		15-13
    Figure US20190345133A1-20191114-C00435
         		15-14
    Figure US20190345133A1-20191114-C00436
         		15-15
    Figure US20190345133A1-20191114-C00437
         		15-16
    Figure US20190345133A1-20191114-C00438
         		15-17
    Figure US20190345133A1-20191114-C00439
         		15-18
    Figure US20190345133A1-20191114-C00440
         		15-19
    Figure US20190345133A1-20191114-C00441
         		15-20
    Figure US20190345133A1-20191114-C00442
         		15-21
    Figure US20190345133A1-20191114-C00443
         		15-22
    Figure US20190345133A1-20191114-C00444
         		15-23
    Figure US20190345133A1-20191114-C00445
         		15-24
    Figure US20190345133A1-20191114-C00446
         		15-25
    Figure US20190345133A1-20191114-C00447
         		15-26
    Figure US20190345133A1-20191114-C00448
         		15-27
    Figure US20190345133A1-20191114-C00449
         		15-28
    Figure US20190345133A1-20191114-C00450
         		15-29
    Figure US20190345133A1-20191114-C00451
         		15-30
    Figure US20190345133A1-20191114-C00452
         		15-31
    Figure US20190345133A1-20191114-C00453
         		15-32
    Figure US20190345133A1-20191114-C00454
         		15-33
    Figure US20190345133A1-20191114-C00455
         		15-34
    Figure US20190345133A1-20191114-C00456
         		15-35
    Figure US20190345133A1-20191114-C00457
         		15-36
    Figure US20190345133A1-20191114-C00458
         		15-37
    Figure US20190345133A1-20191114-C00459
         		15-38
    Figure US20190345133A1-20191114-C00460
         		15-39
    Figure US20190345133A1-20191114-C00461
         		15-40
    Figure US20190345133A1-20191114-C00462
         		15-41
    Figure US20190345133A1-20191114-C00463
         		15-42
    Figure US20190345133A1-20191114-C00464
         		15-43
    Figure US20190345133A1-20191114-C00465
         		15-44
    Figure US20190345133A1-20191114-C00466
         		15-45
    Figure US20190345133A1-20191114-C00467
         		15-46
    Figure US20190345133A1-20191114-C00468
         		15-47
    Figure US20190345133A1-20191114-C00469
         		15-48
    Figure US20190345133A1-20191114-C00470
         		15-49
    Figure US20190345133A1-20191114-C00471
         		15-50
    Figure US20190345133A1-20191114-C00472
         		15-51
    Figure US20190345133A1-20191114-C00473
         		15-52
    Figure US20190345133A1-20191114-C00474
         		15-53
    Figure US20190345133A1-20191114-C00475
         		15-54
    Figure US20190345133A1-20191114-C00476
         		15-55
    Figure US20190345133A1-20191114-C00477
         		15-56
    Figure US20190345133A1-20191114-C00478
         		15-57
    Figure US20190345133A1-20191114-C00479
         		15-58
    Figure US20190345133A1-20191114-C00480
         		15-59
    Figure US20190345133A1-20191114-C00481
         		15-60
    Figure US20190345133A1-20191114-C00482
         		15-61
    Figure US20190345133A1-20191114-C00483
         		15-62
    Figure US20190345133A1-20191114-C00484
         		15-63
    Figure US20190345133A1-20191114-C00485
         		15-64
    Figure US20190345133A1-20191114-C00486
         		16-1
    Figure US20190345133A1-20191114-C00487
         		17-1
    Figure US20190345133A1-20191114-C00488
         		17-2
    Figure US20190345133A1-20191114-C00489
         		17-3
    Figure US20190345133A1-20191114-C00490
         		17-4
    Figure US20190345133A1-20191114-C00491
         		18-1
    Figure US20190345133A1-20191114-C00492
         		19-1
    Figure US20190345133A1-20191114-C00493
         		20-1
    Figure US20190345133A1-20191114-C00494
         		21-1
    Figure US20190345133A1-20191114-C00495
         		22-1
    Figure US20190345133A1-20191114-C00496
         		22-2
    Figure US20190345133A1-20191114-C00497
         		22-3
    Figure US20190345133A1-20191114-C00498
         		23-1
    Figure US20190345133A1-20191114-C00499
         		23-2
    Figure US20190345133A1-20191114-C00500
         		23-3
    Figure US20190345133A1-20191114-C00501
         		23-4
    Figure US20190345133A1-20191114-C00502
         		23-5
    Figure US20190345133A1-20191114-C00503
         		23-6
    Figure US20190345133A1-20191114-C00504
         		23-7
    Figure US20190345133A1-20191114-C00505
         		23-8
    Figure US20190345133A1-20191114-C00506
         		23-9
    Figure US20190345133A1-20191114-C00507
         		24-1
    Figure US20190345133A1-20191114-C00508
         		24-2
    Figure US20190345133A1-20191114-C00509
         		25-1
    Figure US20190345133A1-20191114-C00510
         		25-2
    Figure US20190345133A1-20191114-C00511
         		25-3
    Figure US20190345133A1-20191114-C00512
         		26-1
    Figure US20190345133A1-20191114-C00513
         		26-2
    Figure US20190345133A1-20191114-C00514
         		26-3
    Figure US20190345133A1-20191114-C00515
         		27-1
    Figure US20190345133A1-20191114-C00516
         		27-2
    Figure US20190345133A1-20191114-C00517
         		27-3
    Figure US20190345133A1-20191114-C00518
         		27-4
    Figure US20190345133A1-20191114-C00519
         		27-5
    Figure US20190345133A1-20191114-C00520
         		27-6
    Figure US20190345133A1-20191114-C00521
         		27-7
    Figure US20190345133A1-20191114-C00522
         		28-1
    Figure US20190345133A1-20191114-C00523
         		28-2
    Figure US20190345133A1-20191114-C00524
         		28-3
    Figure US20190345133A1-20191114-C00525
         		29-1
    Figure US20190345133A1-20191114-C00526
         		30-1
    Figure US20190345133A1-20191114-C00527
         		31-1
    Figure US20190345133A1-20191114-C00528
         		32-1
    Figure US20190345133A1-20191114-C00529
         		32-2
    Figure US20190345133A1-20191114-C00530
         		33-1
    Figure US20190345133A1-20191114-C00531
         		34-1
    Figure US20190345133A1-20191114-C00532
         		35-2
    Figure US20190345133A1-20191114-C00533
         		35-1
  • In one embodiment, compounds are provided having the structure of the following Formula I, including stereoisomers, hydrates, solvates, isotopes or pharmaceutically acceptable salts thereof:
  • Figure US20190345133A1-20191114-C00534
  • wherein:
      • R is H;
      • R1 is
  • Figure US20190345133A1-20191114-C00535
    Figure US20190345133A1-20191114-C00536
      • R2 is
  • Figure US20190345133A1-20191114-C00537
  • and
      • R3a is hydrogen and R3b is
  • Figure US20190345133A1-20191114-C00538
      • or R3a and R3b taken together with the carbon to which they are attached is
  • Figure US20190345133A1-20191114-C00539
  • In another embodiment, a compound is provided as listed in the following Table B.
  • TABLE B
    REPRESENTATIVE COMPOUNDS
    1-14 1-18 1-29 1-35 1-36
    1-37 1-38 1-39 2-2  2-15
    2-22 2-24 2-25 2-39 2-57
    4-12 4-14 8-4  10-3  12-73 
    12-88  12-104 12-131 12-136 13-1 
    14-3  14-6  14-18  15-3  15-6 
    18-1 
  • As used herein, “individual” (as in the subject or patient of the treatment) means both mammals and non-mammals. Mammals include, for example, humans; non-human primates, e.g., apes and monkeys; cattle; horses; sheep; and goats. Non-mammals include, for example, fish and birds.
  • A “receptor”, as is well known in the art, is a biomolecular entity usually comprising a protein that specifically binds a structural class of ligands or a single native ligand in a living organism, the binding of which causes the receptor to transduce the binding signal into another kind of biological action, such as signaling a cell that a binding event has occurred, which causes the cell to alter its function in some manner. Any molecule, naturally occurring or not, that binds to a receptor and activates it for signal transduction, is referred to as an “agonist” or “activator.” Any molecule, naturally occurring or not, that binds to a receptor, but does not cause signal transduction to occur, and which can block the binding of an agonist and its consequent signal transduction, is referred to as an “antagonist.” Certain molecules bind to receptors at locations other than the binding sites of their natural ligands and such allosteric binding molecules may potentiate, activate or agonize the receptor and may enhance the effect of a natural ligand or a co-administered ligand.
  • A “CXCR3 compound” or “CXCR3 agonist” or “CXCR3 activator” or “CXCR3 modulator” or “CXCR3 antagonist” or “CXCR3 potentiator” or “CXCR3 modulator” as the terms are used herein refer to compounds that interact in some way with the CXCR3 receptor. They can be agonists, potentiators, or activators, or they can be antagonists or inhibitors, and can be selective for action of the CXCR3 receptor family.
  • The term “disease” or “disorder” or “malcondition” are used interchangeably, and are used to refer to diseases or conditions wherein a CXCR3 receptor plays a role in the biochemical mechanisms involved in the disease or malcondition or symptom(s) thereof such that a therapeutically beneficial effect can be achieved by acting on a CXCR3 receptor.
  • “Substantially” as the term is used herein means completely or almost completely; for example, a composition that is “substantially free” of a component either has none of the component or contains such a trace amount that any relevant functional property of the composition is unaffected by the presence of the trace amount, or a compound is “substantially pure” is there are only negligible traces of impurities present.
  • “Treating” or “treatment” within the meaning herein refers to an alleviation of symptoms associated with a disorder or disease, or inhibition of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder.
  • The expression “effective amount”, when used to describe use of a compound of the invention in providing therapy to a patient suffering from a disorder or malcondition mediated by a CXCR3 receptor refers to the amount of a compound of the invention that is effective to bind to as an agonist or as an antagonist a CXCR3 receptor in the individual's tissues, wherein the CXCR3 is implicated in the disorder, wherein such binding occurs to an extent sufficient to produce a beneficial therapeutic effect on the patient. Similarly, as used herein, an “effective amount” or a “therapeutically effective amount” of a compound of the invention refers to an amount of the compound that alleviates, in whole or in part, symptoms associated with the disorder or condition, or halts or slows further progression or worsening of those symptoms, or prevents or provides prophylaxis for the disorder or condition. In particular, a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result by acting as an agonist of CXCR3 activity. A therapeutically effective amount is also one in which any toxic or detrimental effects of compounds of the invention are outweighed by the therapeutically beneficial effects. For example, in the context of treating a malcondition mediated by activation of a CXCR3 receptor, a therapeutically effective amount of a CXCR3 receptor antagonist of the invention is an amount sufficient to control the malcondition, to mitigate the progress of the malcondition, or to relieve the symptoms of the malcondition.
  • In the following disclosure, reference to “a compound of Formula I” is intended to include the more specific embodiment of Formulas II-XII, as well as the compounds listed in the above Tables A and B.
  • In certain embodiments, a pharmaceutical composition is provided comprising a compound of Formula I together with at least one pharmaceutically acceptable carrier, diluent or excipient.
  • In certain embodiments, a method is provided for activating, potentiating, or agonizing (i.e., to have an agonic effect, to act as an agonist) a CXCR3 receptor, with a compound of Formula I. The method involves contacting the receptor with a suitable concentration of a compound of Formula I to bring about activation of the receptor. The contacting can take place in vitro, for example in carrying out an assay to determine the CXCR3 receptor activation activity of a compound undergoing experimentation related to a submission for regulatory approval.
  • In certain embodiments, the method for activating a CXCR3 receptor can be carried out in vivo; that is, within the living body of a mammal, such as a human patient or a test animal. The compound of Formula I can be supplied to the living organism via a suitable route (e.g., orally), or can be provided locally within the body tissues.
  • In one embodiment, a method is provided for treatment of a disease or condition in a subject or patient for which activation of a CXCR3 receptor is medically indicated, wherein the subject or patient is administered a therapeutically effective amount of a compound of Formula I.
  • In one embodiment, a method is provided for treating or preventing a disease or condition comprising administering a pharmaceutical composition comprising a compound of Formula I together with at least one pharmaceutically acceptable carrier, diluent or excipient to a subject or patient in need thereof.
  • In more specific embodiments, the subject or patient is afflicted with, or at risk of developing, rheumatoid arthritis, multiple sclerosis, or inflammatory bowel disease.
  • In certain embodiments, use of a compound of Formula I is provided for preparation of a medicament.
  • In certain embodiments, methods are provided for synthesis of compounds of Formula I, including compounds of the invention as more fully illustrated herein. In certain other embodiments, the invention provides certain intermediate compounds associated with such methods of synthesis as illustrated herein.
    • EXAMPLES
  • The invention is further illustrated by the following examples. The examples below are non-limiting and are merely representative of various aspects of the invention. Solid and dotted wedges within the structures herein disclosed illustrate relative stereochemistry, with absolute stereochemistry depicted only when specifically stated or delineated.
    • General Methods
  • NMR Spectra
  • 1H NMR (400 MHz) and 13C NMR (100 MHz) were obtained in solution of deuterochloroform (CDCl3) or dimethyl sulfoxide (d6-DMSO). NMR spectra were processed using MestReNova 6.0.3-5604.
  • LCMS Data
  • Mass spectra (LCMS) were obtained using one of 2 systems. System 1: Agilent 1100 HPLC system equipped with a Agilent Eclipse XDB-C18, 3.5μ (4.6×150 mm) column using water with 0.05% TFA as the mobile phase A, and acetonitrile with 0.05% TFA as the mobile phase B with a flow rate of 1 mL/min. Method 1: 5% B (95% A) to 95% B over 12 min then held at 95% B for 3 min and to 5% B over 1 min. Method 2: 50% B (50% A) to 95% B over 4 min then held at 95% B for 4 min and to 50% B over 0.1 min. System 2: Agilent 1100/6110 HPLC system equipped with a Agilent Poroshell 120 EC-C8, 2.7μ (50×3 mm) column using water with 5 mM ammonium acetate as the mobile phase C, and acetonitrile with 5 mM ammonium acetate as the mobile phase D with a flow rate of 1 mL/min. Method 3: 5% D (95% C) to 95% D over 12 min then held at 95% D for 2.8 min and then to 5% D over 0.2 min. Agilent 1260 LCMS equipped with a Waters Sect CSH C18 3.5 μm (4.6×50 mm) column using water with 0.1% formic acid as mobile phase A and acetonitrile with 0.1% formic acid as mobile phase B. Method 4: The gradient was 5-95% mobile phase B over 3.0 min with a flow rate of 2.5 mL/min, then held at 95% for 0.6 min with an flow rate of 4.5 mL/min. Method 5: The gradient was 5-95% mobile phase B over 13.0 min with a flow rate of 2.5 mL/min, then held at 95% for 1.0 min with a flow rate of 4.5 mL/min.
    • Reaction Conditions and Abbreviations
  • Pyridine, dichloromethane (DCM), tetrahydrofuran (THF), and toluene used in the procedures were from Aldrich Sure-Seal bottles or Acros AcroSeal dry solvent and kept under nitrogen (N2). All reactions were stirred magnetically and temperatures are external reaction temperatures. The following abbreviations are used: ammonia (NH3), tetrahydrofuran (THF), hydrochloric acid (HCl), sodium bicarbonate (NaHCO3), dichloroethane (DCE), trifluoroacetic acid (TFA), magnesium sulfate (MgSO4), hydrogen (H2), tetrabutylammonium fluoride (TBAF), diazabicycloundecene (DBU), methyl tert-butyl ether (MTBE), nitric acid (HNO3), ethyl acetate (EA), 1-methy-2-pyrrolidinone (NMP), triethylamine (TEA), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), N-hydroxybenzotriazole (HOBt), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), N,N-dimethylformamide (DMF), dimethyl acetamide (DMA), di-tert-butyl dicarbonate (Boc2O), N,N-diisopropylethylamine (DIEA), acetic acid (AcOH), hydrochloric acid (HCl), O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), 4-dimethylaminopyridine (DMAP), tert-butanol (t-BuOH), sodium hydride (NaH), sodium triacetoxyborohydride (Na(OAc)3BH), ethanol (EtOH), methanol (MeOH), sodium sulfate (Na2SO4), dichloromethane (DCM), acetonitrile (ACN), water (H2O), room temperature (rt), hour (h), minute (min) and silica gel (SiO2).
  • Purifications
  • Chromatographies were carried out using a Combiflash Rf flash purification system (Teledyne Isco) equipped with Redisep (Teledyne Isco), Telos (Kinesis) or GraceResolv (Grace Davison Discovery Sciences) silica gel (SiO2) or RediSep Rf Gold C18 column. Preparative HPLC purifications were performed using one of two systems. System 1: Dionex Ultimate 3000 system equipped with an Waters-Sunfire Prep-C18, OBD, 5 m (30×150 mm) column using water containing 0.1% formic acid as mobile phase A and methanol with 0.1% formic acid as mobile phase B. The gradient was 10% mobile phase B held for 2 min, then, 10-95% mobile phase B over 13 min, held at 95% for 7 min, and then returned to 10% over 0.1 min with a flow rate of 10 mL/min. Fractions were collected by UV detection at 254 nm. System 2: Waters X-Select CSH C18, 5 m, 19×50 mm or Waters X-Bridge BEH C18, 5 rim, 19×50 mm column using either a gradient of 0.1% formic acid in MeCN and 0.1% aqueous formic acid, or a gradient of MeCN and 10 mM ammonium bicarbonate (aq). Fractions were collected following detection by either UV at a single wavelength measured by a variable wavelength detector on a Gilson 215 or by mass ion and UV detection at a single wavelength measured by a ZQ single quadropole mass spectrometer, with positive and negative ion electrospray, and dual wavelength detection on a Waters FractionLynx LCMS. System 3: Waters Fractionlynx system equipped with an Agilent Prep-C18, 5 m (21.2×50 mm) column using water containing 0.1% formic acid as mobile phase A, and acetonitrile with 0.1% formic acid as mobile phase B. The gradient was 20-95% mobile phase B over 12 min, held at 95% for 4 min, and then returned to 20% over 1.5 min with a flow rate of 28 mL/min. Fractions were collected by UV detection at 254 nm or by mass and concentrated using a Genevac EZ-2.
    • Synthetic Methods for Preparing Compounds
  • Molecular embodiments of the present invention can be synthesized using standard synthetic techniques known to those of skill in the art. Compounds of the present invention can be synthesized using the general synthetic procedures set forth in Schemes 1-22.
  • Figure US20190345133A1-20191114-C00540
    • Example 1 Synthesis of (S)—N—((S)-6-amino-1-((3,4-dichlorophenyl)amino)-1-oxohexan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 1-1)
  • Figure US20190345133A1-20191114-C00541
    • Step 1A: Ethyl (S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Intermediate 1A)
  • Figure US20190345133A1-20191114-C00542
  • A stirring solution of THF (100 mL) and DMF (20 mL) containing ethyl (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate HCl (4.5 g, 18.5 mmol), 4-oxo-4-phenylbutanoic acid (3.0 g, 16.8 mmol) and DIEA (20.3 mmol, 58.9 mmol) in THF (100 mL) and DMF (20 mL) was cooled to 0° C. HATU (6.7 g, 17.7 mmol) was added over 5 min and the reaction mixture was warmed to rt and stirred for 2 h. The mixture was diluted with EA and washed with NaHCO3 (sat. aqueous). The aqueous fraction was back-extracted with EA and the combined organic fractions were dried over Na2SO4 and purified by column chromatography (EA/Hexane) to provide Intermediate 1A. Yield 4.9 g (81%). LCMS (m/z) calculated for C22H23NO4: 365.2; found 366 [M+H]+, tR=6.43 min (Method 1).
    • Step 1B: (S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 1B)
  • Figure US20190345133A1-20191114-C00543
  • Into a mixture of Intermediate 1A (7.7 g, 20.5 mmol) in THF (40 mL) and water (10 mL) was added 1.0M LiOH (24.6 mL, 24.6 mmol). The reaction mixture was stirred overnight at rt, then diluted with water. The THF was removed in vacuo. The aqueous layer was washed with ether, acidified with 1N HCl and extracted with EA. The EA layers were dried (Na2SO4) and concentrated to provide Intermediate 1B (5.8 g, 82%). LCMS (m/z) calculated for C20H19NO4: 337.1; found 338.0 [M+H]+, tR=10.78 min (Method 1).
    • Step 1C: Methyl N6-(tert-butoxycarbonyl)-N2—((S)-2-(4-oxo-4-phenylbutanol)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-L-lysinate (Intermediate 1C)
  • Figure US20190345133A1-20191114-C00544
  • A stirring solution of Intermediate 1B (1.2 g, 3.6 mmol), H-lys(Boc)OMe HCl (1.0 g, 3.4 mmol) and DIEA (2.05 mL, 11.8 mmol) in THF (30 mL) was cooled to 0° C. A solution of HATU (1.3 g, 3.5 mmol) in THF (8 mL) was added dropwise over 5 min. The reaction mixture was warmed to rt and stirred for 2 h then diluted with EA and washed with NaHCO3 (sat. aqueous) The aqueous fraction was back-extracted with EA. The combined organic fractions were dried (Na2SO4) then concentrated and purified by column chromatography (EA/hexane then MeOH/DCM) to provide Intermediate 1C (1.5 g, 76%). LCMS (m/z) calculated for C32H41N3O7: 579.3; found 580.0 [M+H]+, tR=17 min (Method 1).
    • Step 1D: N6-(tert-butoxycarbonyl)-N2—((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-L-lysine (Intermediate 1D)
  • Figure US20190345133A1-20191114-C00545
  • Into a mixture of Intermediate 1C (1.5 g, 2.6 mmol) in THF (25 mL) and H2O (5 mL) was added 1.0M LiOH (3.1 mL, 3.1 mmol). The reaction mixture was stirred overnight at rt, then diluted with H2O. The THF was removed in vacuo. The aqueous layer was washed with ether, acidified with 1N HCl and extracted with EA. The EA layers were dried (Na2SO4) and concentrated to provide Intermediate 1D (1.2 g, 79%). LCMS (m/z) calculated for C31H39N3O7: 565.3; found 566.0 [M+H]+, tR=11.72 min (Method 1).
    • Step 1E: Tert-butyl ((S)-6-((3,4-dichlorophenyl)amino)-6-oxo-5-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)hexyl)carbamate (Intermediate 1E)
  • Figure US20190345133A1-20191114-C00546
  • A stirring solution of Intermediate 1D (30 mg, 0.053 mmol), 3,4-dichloroaniline (8.2 mg, 0.05 mmol) and DIEA (0.023 mL, 0.13 mmol) in THF (5 mL) was cooled to 0° C. A solution of HATU (20 mg, 0.05 mmol) in THF (1 mL) was added dropwise over 5 min. The reaction mixture was warmed to rt, stirred for 2 h, then diluted with EA and washed with NaHCO3 (sat.) The aqueous fraction was back-extracted with EA. The combined organic fractions were dried (Na2SO4) then purified by column chromatography (EA/hexane then MeOH/DCM) to provide Intermediate 1E (28 mg, 78%). LCMS (m/z) calculated for C37H42Cl2N4O6: 708.3; found 609.0 [M-Boc]+, tR=13.25 min (Method 1).
    • Step 1F: (S)—N—((S)-6-amino-1-((3,4-dichlorophenyl)amino)-1-oxohexan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 1-1)
  • Figure US20190345133A1-20191114-C00547
  • A solution of 4N HCl in dioxane (0.03 mL, 0.1 mmol) was added to Intermediate 1E (28 mg, 0.04 mmol) in DCM (0.5 mL). The reaction mixture was allowed to stir for 2 h at rt, then concentrated in vacuo and suspended in diethyl ether. The resulting precipitate was filtered, washed with diethyl ether, and dried to give Compound 1-1. LCMS (m/z) calculated for C32H34Cl2N4O4: 608.2; found 609.2 [M+H]+, tR=11.31 min (Method 1).
  • Following the procedures as set forth in Scheme 1 above, the compounds of the following Table 1 were prepared using the appropriate R1, R3a and R3b reagents.
  • TABLE 1
    Figure US20190345133A1-20191114-C00548
    R3a, R3b MS LCMS
    Cpd. Stereo- MS Obs Ret. Purity
    No. R1 R3a R3b chem. Calc (MH)+ (min) Method
    1-1 
    Figure US20190345133A1-20191114-C00549
    Figure US20190345133A1-20191114-C00550
    Figure US20190345133A1-20191114-C00551
         		S 608.2 609.2 11.31 1
    1-2 
    Figure US20190345133A1-20191114-C00552
    Figure US20190345133A1-20191114-C00553
    Figure US20190345133A1-20191114-C00554
         		S 574.2 575.0 10.70 1
    1-3 
    Figure US20190345133A1-20191114-C00555
    Figure US20190345133A1-20191114-C00556
    Figure US20190345133A1-20191114-C00557
         		S 554.3 555.5 10.42 1
    1-5 
    Figure US20190345133A1-20191114-C00558
    Figure US20190345133A1-20191114-C00559
    Figure US20190345133A1-20191114-C00560
         		S 616.3 617.3 11.28 1
    1-6 
    Figure US20190345133A1-20191114-C00561
    Figure US20190345133A1-20191114-C00562
    Figure US20190345133A1-20191114-C00563
         		S 570.3 571.9 10.15 1
    1-7 
    Figure US20190345133A1-20191114-C00564
    Figure US20190345133A1-20191114-C00565
    Figure US20190345133A1-20191114-C00566
         		S 582.3 583.3 11.38 1
    1-8 
    Figure US20190345133A1-20191114-C00567
    Figure US20190345133A1-20191114-C00568
    Figure US20190345133A1-20191114-C00569
         		S 558.3 559.3 10.29 1
    1-9 
    Figure US20190345133A1-20191114-C00570
    Figure US20190345133A1-20191114-C00571
    Figure US20190345133A1-20191114-C00572
         		S 574.2 576.0 10.73 1
    1-10
    Figure US20190345133A1-20191114-C00573
    Figure US20190345133A1-20191114-C00574
    Figure US20190345133A1-20191114-C00575
         		S 554.3 555.2 10.41 1
    1-11
    Figure US20190345133A1-20191114-C00576
    Figure US20190345133A1-20191114-C00577
    Figure US20190345133A1-20191114-C00578
         		S 570.3 571.3 10.27 1
    1-12
    Figure US20190345133A1-20191114-C00579
    Figure US20190345133A1-20191114-C00580
    Figure US20190345133A1-20191114-C00581
         		S 554.3 555.1 10.14 1
    1-13
    Figure US20190345133A1-20191114-C00582
    Figure US20190345133A1-20191114-C00583
    Figure US20190345133A1-20191114-C00584
         		S 608.3 609.2 10.83 1
    1-14
    Figure US20190345133A1-20191114-C00585
    Figure US20190345133A1-20191114-C00586
    Figure US20190345133A1-20191114-C00587
         		S 588.3 589.2 10.95 1
    1-15
    Figure US20190345133A1-20191114-C00588
    Figure US20190345133A1-20191114-C00589
    Figure US20190345133A1-20191114-C00590
         		S 558.3 559.1 9.78 1
    1-16
    Figure US20190345133A1-20191114-C00591
    Figure US20190345133A1-20191114-C00592
    Figure US20190345133A1-20191114-C00593
         		S 596.3 597.3 11.65 1
    1-17
    Figure US20190345133A1-20191114-C00594
    Figure US20190345133A1-20191114-C00595
    Figure US20190345133A1-20191114-C00596
         		S 608.2 609.2 10.36 1
    1-18
    Figure US20190345133A1-20191114-C00597
    Figure US20190345133A1-20191114-C00598
    Figure US20190345133A1-20191114-C00599
         		S 642.2 643.3 12.42 1
    1-19
    Figure US20190345133A1-20191114-C00600
    Figure US20190345133A1-20191114-C00601
    Figure US20190345133A1-20191114-C00602
         		S 626.3 627.0 11.03 1
    1-20
    Figure US20190345133A1-20191114-C00603
    Figure US20190345133A1-20191114-C00604
    Figure US20190345133A1-20191114-C00605
         		S 592.2 593.0 11.88 1
    1-21
    Figure US20190345133A1-20191114-C00606
    Figure US20190345133A1-20191114-C00607
    Figure US20190345133A1-20191114-C00608
         		S 576.3 577.5 10.22 1
    1-22
    Figure US20190345133A1-20191114-C00609
    Figure US20190345133A1-20191114-C00610
    Figure US20190345133A1-20191114-C00611
         		S 642.2 643.2 11.39 1
    1-23
    Figure US20190345133A1-20191114-C00612
    Figure US20190345133A1-20191114-C00613
    Figure US20190345133A1-20191114-C00614
         		S 592.2 593.2 11.86 1
    1-24
    Figure US20190345133A1-20191114-C00615
    Figure US20190345133A1-20191114-C00616
    Figure US20190345133A1-20191114-C00617
         		S 588.3 588.9 12.03 1
    1-25
    Figure US20190345133A1-20191114-C00618
    Figure US20190345133A1-20191114-C00619
    Figure US20190345133A1-20191114-C00620
         		S 622.2 623.2 12.43 1
    1-26
    Figure US20190345133A1-20191114-C00621
    Figure US20190345133A1-20191114-C00622
    Figure US20190345133A1-20191114-C00623
         		S 626.3 627.4 10.82 1
    1-27
    Figure US20190345133A1-20191114-C00624
    Figure US20190345133A1-20191114-C00625
    Figure US20190345133A1-20191114-C00626
         		S 588.3 589.3 12.21 1
    1-28
    Figure US20190345133A1-20191114-C00627
    Figure US20190345133A1-20191114-C00628
    Figure US20190345133A1-20191114-C00629
         		S 622.2 623.0 11.12 1
    1-29
    Figure US20190345133A1-20191114-C00630
    Figure US20190345133A1-20191114-C00631
    Figure US20190345133A1-20191114-C00632
         		S 568.3 569.3 10.51 1
    1-30
    Figure US20190345133A1-20191114-C00633
    Figure US20190345133A1-20191114-C00634
    Figure US20190345133A1-20191114-C00635
         		S 622.3 623.3 11.10 1
    1-31
    Figure US20190345133A1-20191114-C00636
    Figure US20190345133A1-20191114-C00637
    Figure US20190345133A1-20191114-C00638
         		S 636.2 637.3 10.42 1
    1-32
    Figure US20190345133A1-20191114-C00639
    Figure US20190345133A1-20191114-C00640
    Figure US20190345133A1-20191114-C00641
         		S 616.3 617.0 12.27 1
    1-33
    Figure US20190345133A1-20191114-C00642
    Figure US20190345133A1-20191114-C00643
    Figure US20190345133A1-20191114-C00644
         		S 596.3 596.0 11.95 1
    1-34
    Figure US20190345133A1-20191114-C00645
    Figure US20190345133A1-20191114-C00646
    Figure US20190345133A1-20191114-C00647
         		S 569.3 570.3 9.02 1
    1-35
    Figure US20190345133A1-20191114-C00648
    Figure US20190345133A1-20191114-C00649
    Figure US20190345133A1-20191114-C00650
         		S 542.3 543.1 11.23 1
    1-36
    Figure US20190345133A1-20191114-C00651
    Figure US20190345133A1-20191114-C00652
    Figure US20190345133A1-20191114-C00653
         		S 590.2 592.0 11.9 1
    1-37
    Figure US20190345133A1-20191114-C00654
    Figure US20190345133A1-20191114-C00655
    Figure US20190345133A1-20191114-C00656
         		S 556.3 557.0 11.67 1
    1-38
    Figure US20190345133A1-20191114-C00657
    Figure US20190345133A1-20191114-C00658
    Figure US20190345133A1-20191114-C00659
         		S 556.3 557.2 11.78 1
    1-39
    Figure US20190345133A1-20191114-C00660
    Figure US20190345133A1-20191114-C00661
    Figure US20190345133A1-20191114-C00662
         		S 582.3 583.4 12.26 1
  • Figure US20190345133A1-20191114-C00663
    • Example 2 Synthesis of (S)—N—((S)-4-amino-1-((3,4-dichlorophenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 2-1)
  • Figure US20190345133A1-20191114-C00664
    • Step 2A: 2,5-dioxopyrrolidin-1-yl (S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetra hydro isoquinoline-3-carboxylate (Intermediate 2A)
  • Figure US20190345133A1-20191114-C00665
  • EDCI (4.9 g, 26 mmol) was added to a solution of N-hydroxysuccinimide (2.96 g, 26 mmol) and (S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 1B) (6.2 g, 18 mmol) in DCM (25 mL). After stirring overnight, the reaction mixture was concentrated and purified over SiO2 (EA/Hexane) to provide Intermediate 2A (5.6 g, 70%). LCMS (m/z) calculated for C24H22N2O6: 434.2; found 434.9 [M+H]+, tR=3.99 min (Method 2).
    • Step 2B: (S)-4-((tert-butoxycarbonyl)amino)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoic acid (Intermediate 2B)
  • Figure US20190345133A1-20191114-C00666
  • DIEA (0.5 mL, 2.8 mmol) was added to a solution of (S)-2-amino-4-((tert-butoxycarbonyl)amino)butanoic acid (0.27 g, 1.23 mmol) and Intermediate 2A (0.5 g, 1.15 mmol) in DCM (2.5 mL) and stirred overnight. The reaction mixture was diluted with EA and washed with 1N HCl and water. The organic layer was dried (Na2SO4), concentrated and purified over SiO2 (MeOH/DCM). The resulting material was recrystallized from THF/Et2O to provide Intermediate 2B (0.3 g, 49%). LCMS (m/z) calculated for C29H35N3O7: 537.3; found 537.9 [M+H]+, tR=4.67 min (Method 2).
    • Step 2C: tert-butyl ((S)-4-((3,4-dichlorophenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)carbamate (Intermediate 2C)
  • Figure US20190345133A1-20191114-C00667
  • HATU (233 mg, 0.61 mmol) and DIEA (0.25 mL, 1.4 mmol) were added to a solution of Intermediate 2B (0.3 g, 0.6 mmol) and 3,4-dichloroaniline (99 mg, 0.61 mmol) in THF (15 mL). After stirring overnight, the reaction mixture was concentrated, diluted with EA and washed with 0.1 M HCl, 0.1 M NaOH, saturated NaHCO3, water and brine. The resulting material (Intermediate 2C) was used without further purification. LCMS (m/z) calculated for C35H38Cl2N4O6: 680.2; found 681.1 [M+H]+, tR=13.28 min (Method 1).
    • Step 2D: (S)—N—((S)-4-amino-1-((3,4-dichlorophenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 2-1)
  • Figure US20190345133A1-20191114-C00668
  • A solution of 4M HCl (4.4 mL, 17.6 mmol) in dioxane was added to a solution of Intermediate 2C (0.3 g, 0.44 mmol) in THF (5 mL) at 0° C. DCM (5 mL) was added to dissolve the resulting precipitate. After 4 h, the reaction mixture was concentrated and purified by RP-Prep HPLC to provide Compound 2-1 (31 mg, 12%). LCMS (m/z) calculated for C30H30Cl2N4O4: 580.2; found 582.0 [M+H]+, tR=12.42 min (Method 1).
  • Following the procedures as set forth in Example 2 above, the compounds of the following Table 2 were prepared using the appropriate R1 reagents:
  • TABLE 2
    Figure US20190345133A1-20191114-C00669
    Com- MS LCMS
    pound MS Obs Retention Purity
    Number R1 Calc (MH)+ (min) Method
    2-1 
    Figure US20190345133A1-20191114-C00670
         		580.2 582.0 12.42 1
    2-2 
    Figure US20190345133A1-20191114-C00671
         		560.2 561.2 12.23 1
    2-3 
    Figure US20190345133A1-20191114-C00672
         		540.3 541.0 10.43 1
    2-4 
    Figure US20190345133A1-20191114-C00673
         		614.2 615.0 10.09 1
    2-5 
    Figure US20190345133A1-20191114-C00674
         		526.3 527.1 11.50 1
    2-6 
    Figure US20190345133A1-20191114-C00675
         		580.2 581.0 11.48 1
    2-7 
    Figure US20190345133A1-20191114-C00676
         		594.3 595.0 12.19 1
    2-8 
    Figure US20190345133A1-20191114-C00677
         		548.2 549.0 11.6 1
    2-9 
    Figure US20190345133A1-20191114-C00678
         		564.2 565.3 11.81 1
    2-10
    Figure US20190345133A1-20191114-C00679
         		560.2 561.3 12.03 1
    2-11
    Figure US20190345133A1-20191114-C00680
         		598.2 599.0 12.06 1
    2-12
    Figure US20190345133A1-20191114-C00681
         		564.2 565.0 11.96 1
    2-13
    Figure US20190345133A1-20191114-C00682
         		614.2 615.0 12.4 1
    2-14
    Figure US20190345133A1-20191114-C00683
         		598.2 599.0 12.67 1
    2-15
    Figure US20190345133A1-20191114-C00684
         		594.2 595.0 12.38 1
    2-16
    Figure US20190345133A1-20191114-C00685
         		560.2 561.0 12.16 1
    2-17
    Figure US20190345133A1-20191114-C00686
         		580.2 581.0 12.59 1
    2-18
    Figure US20190345133A1-20191114-C00687
         		578.2 579.0 12.07 1
    2-19
    Figure US20190345133A1-20191114-C00688
         		574.2 575.1 12.28 1
    2-20
    Figure US20190345133A1-20191114-C00689
         		598.2 598.9 12.22 1
    2-21
    Figure US20190345133A1-20191114-C00690
         		594.2 595.0 12.3 1
    2-22
    Figure US20190345133A1-20191114-C00691
         		594.2 595.2 12.49 1
    2-23
    Figure US20190345133A1-20191114-C00692
         		610.2 611.0 12.22 1
    2-24
    Figure US20190345133A1-20191114-C00693
         		598.2 599.0 12.35 1
    2-25
    Figure US20190345133A1-20191114-C00694
         		590.2 591.3 12.22 1
    2-26
    Figure US20190345133A1-20191114-C00695
         		574.2 575.0 12.14 1
    2-27
    Figure US20190345133A1-20191114-C00696
         		594.2 595 12.32 1
    2-28
    Figure US20190345133A1-20191114-C00697
         		562.3 563.4 11.98 1
    2-29
    Figure US20190345133A1-20191114-C00698
         		588.3 589.2 12.38 1
    2-30
    Figure US20190345133A1-20191114-C00699
         		608.2 609.5 12.74 1
    2-31
    Figure US20190345133A1-20191114-C00700
         		544.3 545.4 11.5 1
    2-32
    Figure US20190345133A1-20191114-C00701
         		544.3 544.6 11.54 1
    2-33
    Figure US20190345133A1-20191114-C00702
         		544.3 545.0 11.5 1
    2-34
    Figure US20190345133A1-20191114-C00703
         		564.2 565.0 11.69 1
    2-35
    Figure US20190345133A1-20191114-C00704
         		560.2 561.0 11.79 1
    2-36
    Figure US20190345133A1-20191114-C00705
         		560.2 561.0 11.83 1
    2-37
    Figure US20190345133A1-20191114-C00706
         		564.2 565.0 11.72 1
    2-38
    Figure US20190345133A1-20191114-C00707
         		686.1 687.0 12.6 1
    2-39
    Figure US20190345133A1-20191114-C00708
         		574.2 575.0 11.55 1
    2-40
    Figure US20190345133A1-20191114-C00709
         		638.1 640.0 12.77 1
    2-41
    Figure US20190345133A1-20191114-C00710
         		588.3 589.0 12.51 1
    2-42
    Figure US20190345133A1-20191114-C00711
         		563.3 564.0 8.89 1
    2-43
    Figure US20190345133A1-20191114-C00712
         		563.3 564.0 8.69 1
    2-44
    Figure US20190345133A1-20191114-C00713
         		563.3 564.0 8.75 1
    2-45
    Figure US20190345133A1-20191114-C00714
         		563.3 564.0 8.75 1
    2-46
    Figure US20190345133A1-20191114-C00715
         		566.3 566.7 12.3 1
    2-47
    Figure US20190345133A1-20191114-C00716
         		552.3 553.0 12.07 1
    2-48
    Figure US20190345133A1-20191114-C00717
         		608.2 609.0 12.52 1
    2-49
    Figure US20190345133A1-20191114-C00718
         		540.3 541.0 11.42 1
    2-50
    Figure US20190345133A1-20191114-C00719
         		542.3 543.0 11.42 1
    2-51
    Figure US20190345133A1-20191114-C00720
         		556.3 557.0 11.64 1
    2-52
    Figure US20190345133A1-20191114-C00721
         		580.2 581.2 12.23 1
    2-53
    Figure US20190345133A1-20191114-C00722
         		554.3 555.4 11.72 1
    2-54
    Figure US20190345133A1-20191114-C00723
         		588.3 589.0 12.42 1
    2-55
    Figure US20190345133A1-20191114-C00724
         		574.2 575.0 12.38 1
    2-56
    Figure US20190345133A1-20191114-C00725
         		558.3 559.0 11.77 1
    2-57
    Figure US20190345133A1-20191114-C00726
         		577.3 578.0 11.52 1
    2-58
    Figure US20190345133A1-20191114-C00727
         		582.3 583.2 12.12 1
    2-59
    Figure US20190345133A1-20191114-C00728
         		596.3 597.3 12.57 1
    2-60
    Figure US20190345133A1-20191114-C00729
         		574.3 575.5 11.86 1
    2-61
    Figure US20190345133A1-20191114-C00730
         		570.3 571.2 11.92 1
    2-62
    Figure US20190345133A1-20191114-C00731
         		596.3 597.3 12.48 1
    2-63
    Figure US20190345133A1-20191114-C00732
         		556.2 557.2 10.76 1
    2-64
    Figure US20190345133A1-20191114-C00733
         		583.2 584.2 12.43 1
    2-65
    Figure US20190345133A1-20191114-C00734
         		569.2 570.4 10.48 1
    2-66
    Figure US20190345133A1-20191114-C00735
         		552.3 553.3 11.85 1
    2-67
    Figure US20190345133A1-20191114-C00736
         		552.3 553.3 11.97 1
    2-68
    Figure US20190345133A1-20191114-C00737
         		566.3 567.5 10.42 1
    2-69
    Figure US20190345133A1-20191114-C00738
         		566.3 567.3 10.34 1
    2-70
    Figure US20190345133A1-20191114-C00739
         		578.2 579.3 11.53 1
    2-71
    Figure US20190345133A1-20191114-C00740
         		574.3 575.3 11.61 1
    2-72
    Figure US20190345133A1-20191114-C00741
         		580.3 581.2 12.71 1
    2-73
    Figure US20190345133A1-20191114-C00742
         		586.2 587.2 12.03 1
    2-74
    Figure US20190345133A1-20191114-C00743
         		568.3 569.1 11.61 1
    2-75
    Figure US20190345133A1-20191114-C00744
         		580.3 581.2 12.77 1
    2-76
    Figure US20190345133A1-20191114-C00745
         		624.3 625.5 12.09 1
    2-77
    Figure US20190345133A1-20191114-C00746
         		586.2 587.2 12.09 1
    2-78
    Figure US20190345133A1-20191114-C00747
         		570.3 571.2 11.84 1
    2-79
    Figure US20190345133A1-20191114-C00748
         		570.3 571.2 12.00 1
    2-80
    Figure US20190345133A1-20191114-C00749
         		569.2 570.2 10.67 1
    2-81
    Figure US20190345133A1-20191114-C00750
         		566.3 567.5 12.06 1
    2-82
    Figure US20190345133A1-20191114-C00751
         		567.3 568.1 8.89 1
  • Figure US20190345133A1-20191114-C00752
    • Example 3 Synthesis of (S)—N—((S)-1-((3,4-dichlorophenyl)amino)-1-oxo-5-ureidopentan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 3-1)
  • Figure US20190345133A1-20191114-C00753
    • Step 3A: Synthesis of tert-butyl (S)-(1-((3,4-dichlorophenyl)amino)-1-oxo-5-ureidopentan-2-yl)carbamate (Intermediate 3A)
  • Figure US20190345133A1-20191114-C00754
  • A stirring solution of (S)-2-((tert-butoxycarbonyl)amino)-5-ureidopentanoic acid (1.0 g, 3.6 mmol), 3,4-dichloroaniline (0.56 g, 3.5 mmol) and DIEA (1.5 mL, 8.7 mmol) in 10 mL of THF was cooled to 0° C. A solution of HATU (1.4 g, 3.6 mmol) in 1 mL of THF was added dropwise over 5 min. The reaction mixture was allowed to warm to rt and stirred for 2 h. The mixture was diluted with EA and washed with NaHCO3 (sat. aqueous). The organic solvent was concentrated water was added. The resulting solid was filtered and dried to provide Intermediate 3A. LCMS (m/z) calculated for C17H24Cl2N4O4: 418.1; found 419 [M+H]+, tR=4.73 min (Method 2).
    • Step 3B: Synthesis of (S)-2-amino-N-(3,4-dichlorophenyl)-5-ureidopentanamide, (Intermediate 3B)
  • Figure US20190345133A1-20191114-C00755
  • A solution of 4N HCl in dioxane (3.3 mL, 13.1 mmol) was added to Intermediate 3A (1.1 g, 2.6 mmol) in DCM (10 mL). The mixture was stirred overnight and then concentrated. Diethyl ether was added and the resulting solid was collected by filtration to provide Intermediate 3B. LCMS (m/z) calculated for C12H16Cl2N4O2: 318.1; found 319 [M+H]+, tR=3.08 min (Method 2).
    • Step 3C: Synthesis of (S)—N—((S)-1-((3,4-dichlorophenyl)amino)-1-oxo-5-ureidopentan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 3-1)
  • Figure US20190345133A1-20191114-C00756
  • A stirring solution of Intermediate 1B (50 mg, 0.15 mmol), Intermediate 3B (50 mg, 0.14 mmol) and DIEA (0.09 mL, 0.5 mmol) in THF (3 mL) was cooled to 0° C. A solution of HATU (56 mg, 0.15 mmol) in THF (2 mL) was added dropwise over 5 min. The reaction mixture was allowed to warm to rt, stirred for 2h, then diluted with EA and washed with NaHCO3 (sat.). The aqueous fraction was back-extracted with EA. The combined organic fractions were dried (Na2SO4) then concentrated and purified by prep-HPLC to provide Compound 3-1. LCMS (m/z) calculated for C32H33Cl2N5O5: 637.2; found 638.0 [M+H]+, tR=11.94 min (Method 1).
  • Following the procedures as set forth in Example 3 above, the compounds of the following Table 3 were prepared using the appropriate R1, R3a and R3b reagents:
  • TABLE 3
    Figure US20190345133A1-20191114-C00757
    R3a,R3b MS LCMS
    Cmpd Stereo- MS Obs Ret. Purity
    Number R1 R3a R3b chem. Calc (MH)+ (min) Method
    3-1
    Figure US20190345133A1-20191114-C00758
    Figure US20190345133A1-20191114-C00759
    Figure US20190345133A1-20191114-C00760
         		S 637.2 638.0 11.94 1
    3-2
    Figure US20190345133A1-20191114-C00761
    Figure US20190345133A1-20191114-C00762
    Figure US20190345133A1-20191114-C00763
         		S 602.2 603.3 12.24 1
    3-3
    Figure US20190345133A1-20191114-C00764
    Figure US20190345133A1-20191114-C00765
    Figure US20190345133A1-20191114-C00766
         		Racemic 608.2 609.0 12.37 1
    3-4
    Figure US20190345133A1-20191114-C00767
    Figure US20190345133A1-20191114-C00768
    Figure US20190345133A1-20191114-C00769
         		S 608.2 609.0 12.22 1
    3-5
    Figure US20190345133A1-20191114-C00770
    Figure US20190345133A1-20191114-C00771
    Figure US20190345133A1-20191114-C00772
         		S 608.2 609.0 12.58 1
    3-6
    Figure US20190345133A1-20191114-C00773
    Figure US20190345133A1-20191114-C00774
    Figure US20190345133A1-20191114-C00775
         		S 651.2 652.5 12.01 1
    3-7
    Figure US20190345133A1-20191114-C00776
    Figure US20190345133A1-20191114-C00777
    Figure US20190345133A1-20191114-C00778
         		S 644.3 645.4 4.88 5
    3-8
    Figure US20190345133A1-20191114-C00779
    Figure US20190345133A1-20191114-C00780
    Figure US20190345133A1-20191114-C00781
         		S 614.3 615.3 4.55 5
    3-9
    Figure US20190345133A1-20191114-C00782
    Figure US20190345133A1-20191114-C00783
    Figure US20190345133A1-20191114-C00784
         		S 628.3 629.3 4.71 5
    3-10
    Figure US20190345133A1-20191114-C00785
    Figure US20190345133A1-20191114-C00786
    Figure US20190345133A1-20191114-C00787
         		S 623.2 624.2 4.61 5
    3-11
    Figure US20190345133A1-20191114-C00788
    Figure US20190345133A1-20191114-C00789
    Figure US20190345133A1-20191114-C00790
         		S 639.2 640.3 7.03 5
    3-12
    Figure US20190345133A1-20191114-C00791
    Figure US20190345133A1-20191114-C00792
    Figure US20190345133A1-20191114-C00793
         		S 574.2 575.2 6.24 5
    3-13
    Figure US20190345133A1-20191114-C00794
    Figure US20190345133A1-20191114-C00795
    Figure US20190345133A1-20191114-C00796
         		S 588.2 589.2 6.36 5
    3-14
    Figure US20190345133A1-20191114-C00797
    Figure US20190345133A1-20191114-C00798
    Figure US20190345133A1-20191114-C00799
         		S 624.2 625.0 5.35 5
  • Figure US20190345133A1-20191114-C00800
    • Example 4 Synthesis of (S)—N—((S)-6-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxohexan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 4-2)
  • Figure US20190345133A1-20191114-C00801
    • Step 4A: Synthesis of (9H-fluoren-9-yl)methyl tert-butyl (6-((4-chloro-3-methylphenyl)amino)-6-oxohexane-1,5-diyl)(S)-dicarbamate (Intermediate 4A)
  • Figure US20190345133A1-20191114-C00802
  • A stirring solution ofN-(((9H-fluoren-9-yl)methoxy)carbonyl)-N-(tert-butoxycarbonyl)-L-lysine (2.0 g, 4.3 mmol), 4-chloro-3-methylaniline (0.58 g, 4.1 mmol) and DIEA (1.77 mL, 10.2 mmol) in THF (15 mL) was cooled to 0° C. A solution of HATU (1.62 g, 4.3 mmol) in THF (1 mL) was added dropwise over 5 min. The reaction mixture was allowed to warm to rt and stirred for 2 h, then diluted with EA and washed with NaHCO3 (sat. aqueous) The aqueous fraction was back-extracted with EA. The combined organic fractions were dried (Na2SO4) then concentrated to provide 2 g (83%) of crude Intermediate 4A. LCMS (m/z) calculated for C33H38ClN3O5: 591.3; found 592.0 [M+H]+, tR=6.4 min (Method 2).
    • Step 4B: Synthesis of tert-butyl (S)-(5-amino-6-((4-chloro-3-methylphenyl)amino)-6-oxohexyl)carbamate (Intermediate 4B)
  • Figure US20190345133A1-20191114-C00803
  • A solution of 50% piperidine in DMF (1 mL) was added to a solution of Intermediate 4A (2.0 g, 3.4 mmol) DCM (25 mL) and the mixture was stirred for 30 min at rt. The reaction mixture was concentrated in vacuo and the residue (Intermediate 4B) was directly used for the next step without purification. LCMS (m/z) calculated for C18H27ClN3O3: 369.2; found 370.0 [M+H]+, tR=4.5 min (Method 2).
    • Step 4C: Synthesis of tert-butyl ((S)-6-((4-chloro-3-methylphenyl)amino)-6-oxo-5-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) hexyl) carbamate. (Intermediate 4C)
  • Figure US20190345133A1-20191114-C00804
  • A stirring solution of Intermediate 1B (80 mg, 0.24 mmol), Intermediate 4B (88 mg, 0.24 mmol) and DIEA (0.87 mL, 0.6 mmol) in THF (5 mL) was cooled to 0° C. A solution of HATU (90 mg, 0.24 mmol) in THF (1 mL) was added dropwise over 5 min. The reaction mixture was allowed to warm to rt and stirred for 2 h, then diluted with EA and washed with NaHCO3 (sat. aqueous). The aqueous fraction was back-extracted with EA. The combined organic fractions were dried (Na2SO4) then concentrated to provide crude Intermediate 4C. LCMS (m/z) calculated for C38H45ClN4O6: 688.3; found 689.0 [M+H]+, tR=4.5 min (Method 2).
    • Step 4D: Synthesis of (S)—N—((S)-6-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxohexan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 4-2)
  • Figure US20190345133A1-20191114-C00805
  • A solution of 4N HCl in dioxane (0.5 mL, 2 mmol) was added to a solution of Intermediate 4C (100 mg, 0.15 mmol) in DCM (2 mL). After stirring overnight at rt, the reaction mixture was concentrated in vacuo and purified by RP-prep HPLC to provide Compound 4-2. LCMS [m/z] calculated for C33H37ClN4O4: 588.3; found: 589.0 [M+H]+, tR=11.05 min (Method 1).
  • Following the procedures as set forth in Example 4 above, the compounds of the following Table 4 were prepared using the appropriate R1, R3a and R3b reagents.
  • TABLE 4
    Figure US20190345133A1-20191114-C00806
    *2
    *1 Core R3a/R3b MS LCMS
    Cmpd Stereo- Stereo- MS Obs Ret. Purity
    No. R1 R3a R3b chem. chem. Calc (MH)+ (min) Method
    4-2
    Figure US20190345133A1-20191114-C00807
    Figure US20190345133A1-20191114-C00808
    Figure US20190345133A1-20191114-C00809
         		R R 588.3 589.0 11.05 1
    4-3
    Figure US20190345133A1-20191114-C00810
    Figure US20190345133A1-20191114-C00811
    Figure US20190345133A1-20191114-C00812
         		S S 574.2 575.0 10.97 1
    4-4
    Figure US20190345133A1-20191114-C00813
    Figure US20190345133A1-20191114-C00814
    Figure US20190345133A1-20191114-C00815
         		S S 602.3 603.0 12.28 1
    4-5
    Figure US20190345133A1-20191114-C00816
    Figure US20190345133A1-20191114-C00817
    Figure US20190345133A1-20191114-C00818
         		S R 646.2 647.0 11.13 1
    4-6
    Figure US20190345133A1-20191114-C00819
    Figure US20190345133A1-20191114-C00820
    Figure US20190345133A1-20191114-C00821
         		S S 630.3 631.0 12.43 1
    4-7
    Figure US20190345133A1-20191114-C00822
    Figure US20190345133A1-20191114-C00823
    Figure US20190345133A1-20191114-C00824
         		S Racemic 600.3 601.3 12.66 1
    4-8
    Figure US20190345133A1-20191114-C00825
    Figure US20190345133A1-20191114-C00826
    Figure US20190345133A1-20191114-C00827
         		S S 597.2 598.0 12.3 1
    4-9
    Figure US20190345133A1-20191114-C00828
    Figure US20190345133A1-20191114-C00829
         		Me S R 602.3 604.0 12.52 1
    4-10
    Figure US20190345133A1-20191114-C00830
         		Me
    Figure US20190345133A1-20191114-C00831
         		S S 602.3 604.0 12.32 1
    4-11
    Figure US20190345133A1-20191114-C00832
    Figure US20190345133A1-20191114-C00833
    Figure US20190345133A1-20191114-C00834
         		S Racemic 614.3 615.0 12.22 1
    4-12
    Figure US20190345133A1-20191114-C00835
    Figure US20190345133A1-20191114-C00836
    Figure US20190345133A1-20191114-C00837
         		S NA 586.2 587.2 12.21 1
    4-13
    Figure US20190345133A1-20191114-C00838
    Figure US20190345133A1-20191114-C00839
    Figure US20190345133A1-20191114-C00840
         		S Racemic 596.2 599 6.04 4
    4-14
    Figure US20190345133A1-20191114-C00841
    Figure US20190345133A1-20191114-C00842
    Figure US20190345133A1-20191114-C00843
         		S NA 624.2 626.9 6.59 4
    4-15
    Figure US20190345133A1-20191114-C00844
    Figure US20190345133A1-20191114-C00845
    Figure US20190345133A1-20191114-C00846
         		S S 581.2 582 3.98 5
    4-16
    Figure US20190345133A1-20191114-C00847
    Figure US20190345133A1-20191114-C00848
    Figure US20190345133A1-20191114-C00849
         		S S 561.2 562 3.78 5
    4-17
    Figure US20190345133A1-20191114-C00850
    Figure US20190345133A1-20191114-C00851
    Figure US20190345133A1-20191114-C00852
         		R S 561.2 562.1 4.12 5
    4-18
    Figure US20190345133A1-20191114-C00853
    Figure US20190345133A1-20191114-C00854
    Figure US20190345133A1-20191114-C00855
         		S S 594.2 595.3 4.76 5
    4-19
    Figure US20190345133A1-20191114-C00856
    Figure US20190345133A1-20191114-C00857
    Figure US20190345133A1-20191114-C00858
         		S S 578.2 579.3 4.61 5
    4-20
    Figure US20190345133A1-20191114-C00859
    Figure US20190345133A1-20191114-C00860
    Figure US20190345133A1-20191114-C00861
         		S S 614.2 615.2 3.99 5
  • Figure US20190345133A1-20191114-C00862
    • Example 5 Synthesis of (S)—N—((S)-1-((3,4-dichlorophenyl)amino)-5-(3,3-dimethylguanidino)-1-oxopentan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 5-1)
  • Figure US20190345133A1-20191114-C00863
    • Step 5A. Synthesis of (9H-fluoren-9-yl)methyl (S)-(1-((3,4-dichlorophenyl)amino)-5-(3,3-dimethylguanidino)-1-oxopentan-2-yl)carbamate (Intermediate 5A)
  • Figure US20190345133A1-20191114-C00864
  • A stirring solution of N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-Nω,Nω-dimethyl-L-arginine (0.20 g, 0.47 mmol), 3,4-dichloroaniline (0.076 g, 0.47 mmol) and DIEA (0.2 mL, 1.2 mmol) in THF (8 mL) was cooled to 0° C. A solution of HATU (0.18 g, 0.47 mmol) in THF (1 mL) was added dropwise over 5 min. The reaction mixture was allowed to warm to rt and stirred for 2h, then diluted with EA and washed with NaHCO3 (sat. aqueous) The aqueous fraction was back-extracted with EA. The combined organic fractions were dried (Na2SO4) then concentrated to provide crude Intermediate 5A. LCMS (m/z) calculated for C29H31Cl2N5O3: 567.2; found 568.0 [M+H]+, tR=5.2 (Method 2).
    • Step 5B. Synthesis of (S)-2-amino-N-(3,4-dichlorophenyl)-5-(3,3-dimethylguanidino) pentanamide (Intermediate 5B)
  • Figure US20190345133A1-20191114-C00865
  • A solution of 50% piperidine in DMF (10 mL) was added to a solution of Intermediate 5A (70 mg, 0.12 mmol) in DCM (5 mL) and the mixture was stirred for 30 min at rt. The reaction mixture was concentrated in vacuo and the residue (Intermediate 5B) was directly used for next step without purification. LCMS (m/z) calculated for C14H21Cl2N5O: 345.1; found 346.0 [M+H]+, tR=2.7 min (Method 2).
    • Step 5C. Synthesis of (S)—N—((S)-1-((3,4-dichlorophenyl) amino)-5-(3,3-dimethylguanidino)-1-oxopentan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide. (Compound 5-1)
  • Figure US20190345133A1-20191114-C00866
  • A stirring solution of Intermediate 1D (30 mg, 0.09 mmol), Intermediate 5B (31 mg, 0.09 mmol) and DIEA (0.054 mL, 0.31 mmol) in THF (10 mL) was cooled to 0° C. A solution of HATU (36 mg, 0.09 mmol) in THF (8 mL) was added dropwise over 5 min. The reaction mixture was allowed to warm to rt and stirred for 2 h, then diluted with EA and washed with NaHCO3 (sat. aqueous) The aqueous fraction was back-extracted with EA. The combined organic fractions were dried (Na2SO4) then concentrated to provide crude material which was purified by RP-Prep HPLC to provide product Compound 5-1. LCMS [m/z] calculated for C34H38Cl2N6O4: 665.6; found 666.9[M+H]+, tR=11.56 min (Method 1).
  • Following the procedures as set forth in Example 5 above, the compounds of the following Table 5 were prepared using the appropriate R1, R3a and R3b reagents.
  • TABLE 5
    Figure US20190345133A1-20191114-C00867
    *2
    *1 Core R3a/R3b MS LCMS
    Cmpd Stereo- Stereo- MS Obs Ret. Purity
    # R1 R3a R3b chem. chem. Calc (MH)+ (min) Method
    5-1
    Figure US20190345133A1-20191114-C00868
    Figure US20190345133A1-20191114-C00869
    Figure US20190345133A1-20191114-C00870
         		S S 664.2 666.9 11.56 1
    5-2
    Figure US20190345133A1-20191114-C00871
    Figure US20190345133A1-20191114-C00872
    Figure US20190345133A1-20191114-C00873
         		S S 611.2 612 12.45 1
    5-3
    Figure US20190345133A1-20191114-C00874
    Figure US20190345133A1-20191114-C00875
    Figure US20190345133A1-20191114-C00876
         		S S 614.2 615 13.6 1
    5-4
    Figure US20190345133A1-20191114-C00877
    Figure US20190345133A1-20191114-C00878
    Figure US20190345133A1-20191114-C00879
         		S S 630.3 631 4.5 5
  • Figure US20190345133A1-20191114-C00880
    • Example 6 Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-3-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 6-1) and 4-((S)-3-((4-chloro-3-methylphenyl)amino)-3-oxo-2-((s)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)propyl)-1,1-dimethylpiperidin-1-ium iodide (Compound 6-2)
  • Figure US20190345133A1-20191114-C00881
  • Compound 4-11 (15 mg, 0.024 mmol) was dissolved in DMF (1 mL). Cs2CO3 (20 mg, 0.06 mmol) was added and the mixture was degassed (N2 bubbling). MeI (3.5 mg, 0.024 mmol) was added and the reaction mixture was stirred for 1 h, protected from light. The reaction mixture was concentrated and purified by RP-HPLC to provide both Compound 6-1, LCMS [m/z] calculated for C36H41ClN4O4: 628.3; found 629.0 [M+H]+, tR=12.33 min (Method 1) and Compound 6-2 LCMS [m/z] calculated for C37H44ClN4O4: 643.3; found 643.0 [M+H]+, tR=12.34 min (Method 1).
  • Following the procedures as set forth in Example 6 above, the compounds of the following Table 6 were prepared from the appropriate amine starting material.
  • TABLE 6
    Figure US20190345133A1-20191114-C00882
    R3a/R3b LCMS
    Compound Stereo- MS Obs Ret. Purity
    Number R3a R3b chemistry MS Calc (MH)+ (min) Method
    6-1
    Figure US20190345133A1-20191114-C00883
    Figure US20190345133A1-20191114-C00884
         		Racemic 628.3 629.0 12.33 1
    6-2
    Figure US20190345133A1-20191114-C00885
    Figure US20190345133A1-20191114-C00886
         		Racemic 643.3 643.0 12.34 1
    6-3
    Figure US20190345133A1-20191114-C00887
    Figure US20190345133A1-20191114-C00888
         		S 631.3 631.0 12.17 1
    6-4
    Figure US20190345133A1-20191114-C00889
    Figure US20190345133A1-20191114-C00890
         		No stereo- center 600.3 600.8 12.14 1
    6-5
    Figure US20190345133A1-20191114-C00891
    Figure US20190345133A1-20191114-C00892
         		Racemic 614.3 615.0 12.63 1
    6-6
    Figure US20190345133A1-20191114-C00893
    Figure US20190345133A1-20191114-C00894
         		Racemic 629.3 629.0 12.38 1
    6-7
    Figure US20190345133A1-20191114-C00895
    Figure US20190345133A1-20191114-C00896
         		S 603.3 603.3 12.11 1
  • Figure US20190345133A1-20191114-C00897
    • Example 7 Synthesis of N—((S)-6-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxohexan-2-yl)-2-(4-(4-fluorophenyl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 7-1)
  • Figure US20190345133A1-20191114-C00898
    • Step 7A. Synthesis of 2-(4-(4-fluorophenyl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 7A)
  • Figure US20190345133A1-20191114-C00899
  • A stirring solution of ethyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate HCl (680 mg, 2.8 mmol), 4-(4-fluorophenyl)-4-oxobutanoic acid (500 mg, 2.55 mmol) and DIEA (1.6 ml, 8.9 mmol) in THF (8 mL) and DMF (2 mL) was cooled to 0° C. HATU (1.0 g, 2.7 mmol) was added over 5 min and the reaction mixture was allowed to warm to rt and stirred for 2 h. The reaction mixture was diluted with EA and washed with NaHCO3 (sat. aqueous). The aqueous fraction was back-extracted with EA and the combined organic fractions were dried (Na2SO4), then concentrated onto celite and purified by column chromatography (EA/Hexane) to provide Intermediate 7A (980 mg, 46%). LCMS [m/z] calculated for C22H22FNO4: 383.2; found 384.0 [M+H]+, tR=4.96 min (Method 2).
    • Step 7B. Synthesis of 2-(4-(4-fluorophenyl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 7B)
  • Figure US20190345133A1-20191114-C00900
  • A solution of 1.0M LiOH (10.9 mL, 10.9 mmol) was added to a solution of Intermediate 7A (400 mg, 1.1 mmol) in THF (16 mL) and H2O (3 ml). The reaction mixture was stirred overnight at rt and was diluted with H2O and the THF was removed in vacuo. The aqueous layer was washed with diethyl ether, made acidic with 1N HCl, and extracted with EA. The organic layer was dried (Na2SO4) then concentrated and purified by column chromatography to provide Intermediate 7B (250 mg, 66%). LCMS [m/z] calculated for C20H18FNO4: 355.1; found 338.0 [M+H]+, tR=4.4 min (Method 2).
    • Step 7C. Synthesis of (9H-fluoren-9-yl)methyl tert-butyl (6-((4-chloro-3-methylphenyl)amino)-6-oxohexane-1,5-diyl)(S)-dicarbamate (Intermediate 7C)
  • Figure US20190345133A1-20191114-C00901
  • A stirring solution of N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-(tert-butoxycarbonyl)-L-lysine (4.0 g, 8.52 mmol), 4-chloro-3-methylaniline (1.2 g, 8.2 mmol) and DIEA (3.5 mL, 20.3 mmol) THF (20 mL) was cooled to 0° C. A solution of HATU (3.2 g, 8.5 mmol) in THF (2 mL) was added dropwise over 5 min and the mixture was allowed to warm to rt, stirred for 2 h, then diluted with EA and washed with NaHCO3 (sat. aqueous). The aqueous fraction was back-extracted with EA and the combined organic fractions were dried (Na2SO4), concentrated and purified by column chromatography to provide 5 g of Intermediate 7C. LCMS (m/z) calculated for C33H38ClN3O5: 591.3; found 492.0 [M-Boc]+, tR=6.5 min (Method 2).
    • Step 7D. Synthesis of tert-butyl (S)-(5-amino-6-((4-chloro-3-methylphenyl)amino)-6-oxohexyl)carbamate (Intermediate 7D)
  • Figure US20190345133A1-20191114-C00902
  • A solution of piperidine (1.8 g, 84.4 mmol) in DMF (1 mL) was added to a solution of Intermediate 7C (5 g, 8.44 mmol) in DCM (50 mL). The mixture is stirred for 30 min at rt then was concentrated in vacuo. The residue, Intermediate 7D, was directly used for next step without purification. LCMS (m/z) calculated for C18H28ClN3O3: 369.2; found 370.0 [M+H]+, tR=11.23 min (Method 1).
    • Step 7E. Synthesis of tert-butyl ((5S)-6-((4-chloro-3-methylphenyl)amino)-5-(2-(4-(4-fluorophenyl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-6-oxohexyl) carbamate (Intermediate 7E)
  • Figure US20190345133A1-20191114-C00903
  • A stirring solution of Intermediate 7B (70 mg, 0.2 mmol), Intermediate 7D (70 mg, 0.2 mmol) and DIEA (0.083 mL, 0.47 mmol) in THF (2.5 mL) was cooled to 0° C. A solution of HATU (75 mg, 0.2 mmol) in THF (1 mL) was added dropwise over 5 min. The reaction mixture was allowed to warm to rt, stirred for 2 h, then diluted with EA and washed with NaHCO3 (sat.). The aqueous fraction was back-extracted with EA. The combined organic fractions were dried (Na2SO4), concentrated and purified by column chromatography to provide Intermediate 7E (20 mg, 15%). LCMS [m/z] calculated for C38H44ClFN4O4: 706.3; found 707 [M+H]+, tR=12.3 min (Method 2).
    • Step 7F. Synthesis of N—((S)-6-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxohexan-2-yl)-2-(4-(4-fluorophenyl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 7-1)
  • Figure US20190345133A1-20191114-C00904
  • A solution of 4N HCl in dioxane (0.5 ml, 2 mmol) was added to a solution of Intermediate 7E (20 mg, 0.03 mmol) in DCM (0.5 mL). The reaction mixture was allowed stirred for 2 h at rt then concentrated and purified by prep-HPLC to give Compound 7-1 (6 mg, 30%). LCMS [m/z] calculated for C33H36ClFN4O4: 606.2; found 607.0 [M+H]+, tR=11.20 min. (Method 1).
  • Following the procedures as set forth in Example 7 above, the compounds of the following Table 7 were prepared using the appropriate R2 reagents.
  • TABLE 7
    Figure US20190345133A1-20191114-C00905
    LCMS
    Compound MS Obs Retention Purity
    Number R2 MS Calc (MH)+ (min) Method
    7-1
    Figure US20190345133A1-20191114-C00906
         		606.2 607.0 11.20 1
    7-2
    Figure US20190345133A1-20191114-C00907
         		622.2 623.0 11.47 1
    7-3
    Figure US20190345133A1-20191114-C00908
         		620.3 621.0 11.49 1
    7-4
    Figure US20190345133A1-20191114-C00909
         		624.2 625.0 11.2 1
    7-5
    Figure US20190345133A1-20191114-C00910
         		620.3 621.0 11.55 1
    7-6
    Figure US20190345133A1-20191114-C00911
         		631.3 632.0 10.73 1
    7-7
    Figure US20190345133A1-20191114-C00912
         		632.3 633.1 Not recorded 1
    7-8
    Figure US20190345133A1-20191114-C00913
         		656.2 657.0 11.29 1
    7-9
    Figure US20190345133A1-20191114-C00914
         		636.3 638.3 10.81 1
  • Figure US20190345133A1-20191114-C00915
    • Example 8 Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(isobutylamino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 8-1)
  • Figure US20190345133A1-20191114-C00916
    • Step 8A. Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(isobutylamino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 8-1)
  • Figure US20190345133A1-20191114-C00917
  • To a solution of Compound 2-2 (180 mg, 0.32 mmol) in DCE (5 mL) were added isobutyraldehyde (38.5 μL, 0.422 mmol) and AcOH (46.4 μL, 0.811 mmol). The reaction mixture was stirred at rt for 1 h. Sodium triacetoxyborohydride (172 mg, 0.811 mmol) was added and the reaction mixture was stirred at rt overnight. The reaction mixture was quenched with a saturated aqueous solution of NaHCO3 (5 mL) and stirred for 20 min. DCM (10 mL) was added and the layers were separated using a phase sep-cartridge. The aqueous layer was re-extracted with DCM (10 mL). The combined organic phases were concentrated in vacuo. The crude product was purified by chromatography (MeOH/DCM with NH3) to afford Compound 8-1 (25 mg, 0.04 mmol, 12% yield) as a white foam. LCMS [m/z] calculated for C35H41ClN4O4: 616.3; found 617.3 [M+H]+, tR=4.94 min (Method 3).
  • Following the procedures as set forth in Example 8 above, the following the compounds of the following Table 8 were made using the appropriate amine and aldehyde building blocks.
  • TABLE 8
    Figure US20190345133A1-20191114-C00918
    R3a/R3b LCMS
    Compound Stereo- MS Obs Retention Purity
    Number R3a R3b chemistry MS Calc (MH)+ (min) Method
    8-1
    Figure US20190345133A1-20191114-C00919
    Figure US20190345133A1-20191114-C00920
         		S 616.3 617.3 4.94 3
    8-2
    Figure US20190345133A1-20191114-C00921
    Figure US20190345133A1-20191114-C00922
         		S 642.3 643.4 4.63 3
    8-3
    Figure US20190345133A1-20191114-C00923
    Figure US20190345133A1-20191114-C00924
         		S 602.3 604.3 7.5 4
    8-4
    Figure US20190345133A1-20191114-C00925
    Figure US20190345133A1-20191114-C00926
         		S 588.3 589.3 4.49 5
    8-5
    Figure US20190345133A1-20191114-C00927
    Figure US20190345133A1-20191114-C00928
         		S 616.3 617.4 4.53 5
    8-6
    Figure US20190345133A1-20191114-C00929
    Figure US20190345133A1-20191114-C00930
         		S 642.2 643.0 6.3 5
    8-7
    Figure US20190345133A1-20191114-C00931
    Figure US20190345133A1-20191114-C00932
         		S 640.2 642 7.3 3
  • Figure US20190345133A1-20191114-C00933
    • Example 9 Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-3-guanidino-1-oxopropan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 9-1)
  • Figure US20190345133A1-20191114-C00934
    • Step 9A. Synthesis of (2S)-3-guanidino-2-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)propanoic acid (Intermediate 9A)
  • Figure US20190345133A1-20191114-C00935
  • A solution of Intermediate 2A (400 mg, 1.19 mmol), N-hydroxysuccinimide (191 mg, 1.66 mmol) and HATU (450 mg, 1.19 mmol) were stirred at rt for 2 h. H-guanidine (DAP)-OH (238 mg, 1.3 mmol) and DIEA (460 μL, 3.6 mmol) were added. After 2 h, the reaction mixture was quenched with 0.5 M HCl (aq), and extracted with DCM. The organic layer was washed with H2O and brine, then dried (Na2SO4), filtered and concentrated to provide Intermediate 9A which was used without further purification.
    • Step 9B. Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-3-guanidino-1-oxopropan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 9-1)
  • Figure US20190345133A1-20191114-C00936
  • Intermediate 9A (250 mg, 0.54 mmol), 4-chloro-3-methylaniline (106 mg, 0.75 mmol) and DIEA (277 μL, 0.21 mmol) were stirred in DMF (1.25 mL). HATU (265 mg, 0.7 mmol) was added and the mixture was stirred overnight. The mixture was diluted with EA, washed with H2O, NaHCO3 and brine, then dried (Na2SO4), filtered, and concentrated. The resulting material was purified by RP-chromatography to provide 4.8 mg (1.5%) of Compound 9-1. LCMS [m/z] calculated for C35H41ClN4O4: 589.1; found 589.3 [M+H]+, tR=12.43 min (Method 2).
  • Figure US20190345133A1-20191114-C00937
    • Example 10 Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl)butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 10-1)
  • Figure US20190345133A1-20191114-C00938
    • Step 10A. Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 10A)
  • Figure US20190345133A1-20191114-C00939
  • Into a solution of (S)-tert-butyl (3-amino-4-((4-chloro-3-methylphenyl)amino)-4-oxobutyl)carbamate (2.06 g, 6.03 mmol) in DMF (20 mL) at 0° C. were added (S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (2.19 g, 5.48 mmol) and N-ethyl-N-isopropylpropan-2-amine (2.86 mL, 16.44 mmol). After 5 min, HATU (3.12 g, 8.22 mmol) was added portionwise and the mixture was stirred at 0° C. for 2 h. Water (20 mL) was added and the resulting white precipitate was collected by filtration. The solid was dissolved in DCM, dried (MgSO4), filtered and concentrated to afford an orange oil. The crude product was purified by chromatography (EA/isohexane) to afford 3.2 g (77%) of Intermediate 10A as a white solid. 1H NMR (400 MHz, DMSO-d6, 363 K) δ 9.49 (s, 1H), 7.92-7.81 (m, 2H), 7.75 (d, J=8.0 Hz, 1H), 7.68-7.56 (m, 2H), 7.47-7.37 (m, 3H), 7.37-7.28 (m, 3H), 7.26 (d, J=8.6 Hz, 1H), 7.23-7.09 (m, 4H), 6.15 (s, 1H), 4.75 (t, J=5.6 Hz, 1H), 4.64 (d, J=15.7 Hz, 1H), 4.53 (d, J=15.7 Hz, 1H), 4.48-4.20 (m, 4H), 3.22-3.09 (m, 2H), 2.95-2.77 (m, 2H), 2.27 (s, 3H), 1.93-1.78 (m, 1H), 1.71 (dtd, J=13.9, 8.0, 6.1 Hz, 1H), 1.36 (s, 9H).
    • Step 10B. Synthesis of tert-butyl ((S)-4-((4-chloro-3-methylphenyl)amino)-4-oxo-3-((S)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)carbamate (Intermediate 10B)
  • Figure US20190345133A1-20191114-C00940
  • A solution of Intermediate 10A (3.2 g, 4.4 mmol) in DCM (15 mL) was treated with diethylamine (15 mL). After 1 h, the reaction mixture was concentrated, resuspended in toluene and concentrated (2×). The resulting crude product was purified by chromatography (MeOH, 0.3% NH3/DCM) to afford 1.66 g (75%) of Intermediate 10B as a white solid. LCMS [m/z] calculated for C26H33ClN4O4: 500.2; found 501.3 [M+H]+, tR=1.72 min (Method 4). 1H NMR (400 MHz, DMSO-d6) δ 10.15 (s, 1H), 8.14 (d, J=8.0 Hz, 1H), 7.63-7.54 (m, 1H), 7.45 (dd, J=8.6, 2.6 Hz, 1H), 7.35 (d, J=8.7 Hz, 1H), 7.11 (d, J=2.8 Hz, 3H), 7.08-7.01 (m, 1H), 6.75 (t, J=5.5 Hz, 1H), 4.45 (q, J=7.6 Hz, 1H), 3.99-3.81 (m, 2H), 3.49 (dd, J=10.0, 4.7 Hz, 1H), 3.06-2.86 (m, 3H), 2.82-2.58 (m, 2H), 2.30 (s, 3H), 1.96-1.66 (m, 2H), 1.36 (s, 9H).
    • Step 10C. Synthesis of tert-butyl ((S)-4-((4-chloro-3-methylphenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-(piperidin-1-yl)butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) butyl) carbamate (Intermediate 10C)
  • Figure US20190345133A1-20191114-C00941
  • A solution of Intermediate 10B (60 mg, 0.12 mmol) and 4-oxo-4-(piperidin-1-yl)butanoic acid (33 mg, 0.18 mmol) in DCM (4 mL) was treated with DIEA (83 μL, 0.48 mmol) and HATU (91 mg, 0.24 mmol). After 12 h, the reaction mixture was partitioned between DCM (5 mL) and 1 M aqueous HCl solution (5 mL). The layers were separated using a phase sep-cartridge then re-extracted with DCM (5 mL). The combined organic layers were concentrated in vacuo to afford the Boc protected intermediate 10C. LCMS [m/z] calculated for C35H46ClN5O6: 667.3; found 668.1 [M+H]+, tR=2.65 min (Method 4).
    • Step 10D. Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl) butanoyl)-1,2,3,4-tetrahydro isoquino line-3-carboxamide (Compound 10-1)
  • Figure US20190345133A1-20191114-C00942
  • Crude intermediate 10C was dissolved in DCM (5 mL) and TFA (1 mL). After 4 h, the solvents were removed under vacuum and the resulting crude products were purified by chromatography (0.7 M NH3/MeOH/DCM) to provide 43 mg (63%) of Compound 10-1. LCMS [m/z] calculated for C30H38ClN5O4: 567.3; found 568.3 [M+H]+, tR=4.11 min (Method 4). 1H NMR (400 MHz, DMSO-d6, 363 K) δ 7.61 (br s, 1H), 7.48 (br s, 1H), 7.37-6.79 (m, 6H), 5.21-4.50 (m, 3H), 4.43-4.23 (m, 1H), 3.28-3.11 (m, 4H), 2.96 (br s, 2H), 2.75-2.63 (m, 2H), 2.58 (dt, J=15.4, 5.6 Hz, 1H), 2.51-2.39 (m, 3H), 2.32 (s, 3H), 2.08-2.00 (m, 1H), 1.81-1.72 (d, J=5.7 Hz, 1H), 1.51 (br s, 2H), 1.37 (br s, 4H), NH2, NHAr not observed.
  • The procedures as set forth in Example 10 above, the compounds of the following Table 10 were prepared using the appropriate R1, R8 and R9 reagents.
  • TABLE 10
    Figure US20190345133A1-20191114-C00943
        Compound Number
    Figure US20190345133A1-20191114-C00944
         		      R1       MS Calc     MS Obs (MH)+   LCMS Retention (min)     Purity Method
    10-1
    Figure US20190345133A1-20191114-C00945
    Figure US20190345133A1-20191114-C00946
         		567.3 568.3 4.11 5
    10-2
    Figure US20190345133A1-20191114-C00947
    Figure US20190345133A1-20191114-C00948
         		569.2 570.3 3.29 5
    10-3
    Figure US20190345133A1-20191114-C00949
    Figure US20190345133A1-20191114-C00950
         		582.3 583.4 1.92 5
    10-4
    Figure US20190345133A1-20191114-C00951
    Figure US20190345133A1-20191114-C00952
         		620.2 621 1.95 5
    10-5
    Figure US20190345133A1-20191114-C00953
    Figure US20190345133A1-20191114-C00954
         		613.4 614.1 7.49 5
    10-6
    Figure US20190345133A1-20191114-C00955
    Figure US20190345133A1-20191114-C00956
         		585.3 586.1 5.94 5
    10-7
    Figure US20190345133A1-20191114-C00957
    Figure US20190345133A1-20191114-C00958
         		587.4 588.1 6.18 5
    10-8
    Figure US20190345133A1-20191114-C00959
    Figure US20190345133A1-20191114-C00960
         		599.4 600.1 6.49 5
    10-9
    Figure US20190345133A1-20191114-C00961
    Figure US20190345133A1-20191114-C00962
         		609.3 611 7.19 5
    10-10
    Figure US20190345133A1-20191114-C00963
    Figure US20190345133A1-20191114-C00964
         		607.3 609 7.15 5
    10-11
    Figure US20190345133A1-20191114-C00965
    Figure US20190345133A1-20191114-C00966
         		621.3 623 7.51 5
    10-12
    Figure US20190345133A1-20191114-C00967
    Figure US20190345133A1-20191114-C00968
         		609.3 611 7.57 5
  • Figure US20190345133A1-20191114-C00969
    • Example 11 Synthesis of (S)—N-(4-((2-chloro-3-methylphenyl)carbamoyl)piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 11-1)
  • Figure US20190345133A1-20191114-C00970
    • Step 11A. Synthesis of tert-butyl 4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((2-chloro-3-methylphenyl)carbamoyl)piperidine-1-carboxylate (Intermediate 11A)
  • Figure US20190345133A1-20191114-C00971
  • A solution of 4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (130 mg, 0.28 mmol) in DCM (3 mL) was treated with 1-chloro-N,N,2-trimethylprop-1-en-1-amine (74 μL, 0.56 mmol). After 1 h, 2-chloro-3-methylaniline (79 mg, 0.56 mmol) in pyridine (1 mL) was added. After stirring overnight, the reaction mixture was partitioned between DCM and 1 M aqueous solution of HCl (5 mL each). The phases were passed through phase sep cartridge and the solvent was removed under vacuum. The crude products were purified by chromatography (EA/isohexane) to afford 144 mg (87%) of Intermediate 11A. LCMS [m/z] calculated for C33H36ClN3O5: 589.2; found 612.0 [M+Na]+, tR=3.04 min (Method 4).
    • Step 11B. Synthesis of tert-butyl 4-amino-4-((2-chloro-3-methylphenyl) carbamoyl) piperidine-1-carboxylate (Intermediate 11B)
  • Figure US20190345133A1-20191114-C00972
  • A solution of Intermediate 11A (144 mg, 0.24 mmol) in DCM (4 mL) was treated with diethylamine (1 mL). After 6 h the reaction mixture was concentrated and the crude product co-evaporated with DCM/toluene and purified by chromatography (MeOH (0.7N NH3)/DCM) to afford 96 mg (50%) of Intermediate 11B. LCMS [m/z] calculated for C18H26ClN3O3: 367.2; found 268.1 [M+H-Boc]+, tR=1.51 min (Method 4).
    • Step 11C. Synthesis of tert-butyl (S)-4-((2-chloro-3-methylphenyl)carbamoyl)-4-(1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1-carboxylate (Intermediate 11C)
  • Figure US20190345133A1-20191114-C00973
  • A solution of Intermediate 11B (95 mg, 0.26 mmol) and (S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (155 mg, 0.39 mmol) in DCM (4 mL) was treated with DIEA (225 μL, 0.26 mmol) and HATU (295 mg, 0.8 mmol). After stirring overnight, the reaction mixture was partitioned between DCM and 1 M aqueous solution of HCl (5 mL each). The aqueous layer was re-extracted with DCM (5 mL). The combined organic layers were dried (MgSO4), filtered and concentrated and the crude product was purified by chromatography (EA/hexane) to afford 208 mg (38%) of Intermediate 11C. LCMS [m/z] calculated for C43H45ClN4O6: 748.3; found 771.0 [M+Na]+, tR=2.85 min (Method 4).
    • Step 11D. Synthesis of tert-butyl (S)-4-((2-chloro-3-methylphenyl)carbamoyl)-4-(1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1-carboxylate (Intermediate 11D
  • Figure US20190345133A1-20191114-C00974
  • A solution of Intermediate 11C (206 mg, 0.28 mmol) in DCM (3 mL) was treated with diethylamine (1 mL). After 6 h the reaction mixture was concentrated and the crude product was purified by chromatography (MeOH (0.7 N NH3)/DCM) to afford 75 mg (35%) of Intermediate 11D. LCMS [m/z] calculated for C28H35ClN4O4: 526.2; found 527.1 [M+H]+, tR=1.63 min (Method 4).
    • Step 11E. Synthesis of tert-butyl (S)-4-((2-chloro-3-methylphenyl)carbamoyl)-4-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1-carboxylate (Intermediate 11E)
  • Figure US20190345133A1-20191114-C00975
  • A solution of Intermediate 11D (75 mg, 0.14 mmol) and 4-oxo-4-phenylbutanoic acid (51 mg, 0.29 mmol) in DCM (4 mL) was treated with N-ethyl-N-isopropylpropan-2-amine (120 μl, 0.71 mmol) and HATU (162 mg, 0.43 mmol). The reaction mixture was stirred at rt for 4 h. The reaction mixture was partitioned between DCM (5 mL) and 1 M aq HCl solution. The layers were separated using a phase sep-cartridge then re-extracted with DCM (5 mL). The combined organic layers were concentrated and the crude product was purified by chromatography (EA/isohexane) to afford 56 mg (57%) of Intermediate 11E. LCMS [m/z] calculated for C38H43ClN4O6: 686.3; found 709 [M+Na]+, tR=2.72 min (Method 4).
    • Step 11F. Synthesis of (S)—N-(4-((2-chloro-3-methylphenyl)carbamoyl)piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 11-1)
  • Figure US20190345133A1-20191114-C00976
  • Into a solution of Intermediate 11E (56 mg, 0.08 mmol) in DCM (4 mL) was added TFA (1 mL) and the reaction mixture was stirred at rt. The solvent was removed and the crude products were purified by chromatography (0.7 M NH3/MeOH)/DCM) to afford 34 mg (39%) of Compound 11-1. LCMS [m/z] calculated for C33H35ClN4O4: 586.2; found 587.1 [M+H]+, tR=3.99 min (Method 4).
  • Following the procedures as set forth in Example 11 above, the compounds of the following Table 11 were prepared using the appropriate R1 reagents.
  • TABLE 11
    Figure US20190345133A1-20191114-C00977
    Cmpd MS Obs
    Number R1 MS Calc (MH)+ LCMS Ret. (min) Purity Method
    11-1
    Figure US20190345133A1-20191114-C00978
         		586.2 587.1 3.99 5
    11-2
    Figure US20190345133A1-20191114-C00979
         		620.2 621 4.58 5
    11-3
    Figure US20190345133A1-20191114-C00980
         		604.2 605.1 4.33 5
    11-4
    Figure US20190345133A1-20191114-C00981
         		600.3 601.1 4.44 5
    11-5
    Figure US20190345133A1-20191114-C00982
         		606.2 607 4.12 5
    11-6
    Figure US20190345133A1-20191114-C00983
         		620.2 621 4.51 5
  • Figure US20190345133A1-20191114-C00984
    • Example 12 Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)-2-(4-((2R,6S)-2,6-dimethylmorpholino)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 12-1)
  • Figure US20190345133A1-20191114-C00985
    • Step 12A. Synthesis of 4-((S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Intermediate 12A)
  • Figure US20190345133A1-20191114-C00986
  • Succinic anhydride (0.23 g, 2.26 mmol) in DCM (10 mL) was added dropwise to a solution of Intermediate 10B (1.13 g, 2.3 mmol) in DCM (40 mL) under N2. After 36 h, the solvent was removed in vacuo and the crude product purified by chromatography (MeOH (+0.1% AcOH)/DCM) to provide 1.22 g (85%) of Intermediate 12A as a white solid. LCMS [m/z] calculated for C30H37ClN4O7: 600.2; found 501.1 [M-Boc]+, tR=2.35 min (Method 4). 1H NMR (400 MHz, DMSO-d6, 363K) δ 11.68 (br s, 1H), 9.30 (br s, 1H), 7.52 (br s, 1H), 7.46-7.36 (m, 1H), 7.29 (d, J=8.7 Hz, 1H), 7.26-7.15 (m, 4H), 6.16 (br s, 1H), 4.92 (t, J=5.4 Hz, 1H), 4.83-4.74 (m, 1H), 4.66 (br s, 1H), 4.35-4.25 (m, 1H), 3.23-3.07 (m, 2H), 2.90-2.66 (m, 4H), 2.55 (t, J=6.3 Hz, 2H), 2.32 (s, 3H), 1.86 (dq, J=13.5, 6.9 Hz, 1H), 1.68 (dq, J=14.9, 8.1 Hz, 1H), 1.39 (s, 9H), NH not observed.
    • Step 12B. Synthesis of tert-butyl ((S)-4-((4-chloro-3-methylphenyl)amino)-3-((S)-2-(4-((2R,6S)-2,6-dimethylmorpholino)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)carbamate (Intermediate 12B)
  • Figure US20190345133A1-20191114-C00987
  • Intermediate 12A (50 mg, 0.083 mmol) and (2S, 6R)-2,6-dimethylmorpholine (0.03 mL, 0.21 mmol), were dissolved in DCM (3 mL). DIEA (0.07 mL, 0.42 mmol) was added, followed after 10 min by HATU (95 mg, 0.25 mmol). After 2h, the reaction mixture was partitioned between DCM (5 mL) and 1 M aqueous solution of HCl (5 mL). The layers were separated using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (5 mL). The combined organic phases were concentrated in vacuo to afford Intermediate 12B, which was used directly without further purification.
    • Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)-2-(4-((2R,6S)-2,6-dimethylmorpholino)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 12-1)
  • Figure US20190345133A1-20191114-C00988
  • Intermediate 12B was stirred in a solution of DCM (4 mL) and TFA (1 mL) for 2 h. The solvents were evaporated and the resulting crude material was purified by chromatography (0.7 M Ammonia/MeOH)/DCM) to afford 46 mg (88%) of Compound 12-1 as a white solid. LCMS [m/z] calculated for C31H40ClN5O5: 597.3; found 598.1 [M+H]+, tR=3.79 min (Method 4). 1H NMR (400 MHz, DMSO-d6, 363 K) δ 7.61 (br s, 1H), 7.47 (br s, 1H), 7.38-7.06 (m, 6H), 5.10-4.65 (m, 3H), 4.39 (t, J=7.1 Hz, 1H), 3.91 (br s, 1H), 3.39-3.13 (m, 3H), 2.99 (br s, 4H), 2.78-2.70 (m, 2H), 2.60 (dt, J=15.4, 5.7 Hz, 1H), 2.50-2.40 (m, 2H), 2.33 (s, 3H), 2.30-2.15 (br s, 1H), 2.09-2.00 (m, 1H), 1.78 (br s, 1H), 1.06 (s, 3H), 1.04 (s, 3H), NH2, NHAr not observed.
  • Following the procedures as set forth in Example 12 above, the compounds of the following Table 12 were prepared using the appropriate R1, R3a, R3b, R8 and R9 reagents.
  • TABLE 12
    Figure US20190345133A1-20191114-C00989
        Cmpd #       R1       R3a       R3b *1 R3a/R3b Stereo- chem
    Figure US20190345133A1-20191114-C00990
         		    MS Calc     MS (MH)+     Purity RT     Purity Method
    12-1
    Figure US20190345133A1-20191114-C00991
         		H
    Figure US20190345133A1-20191114-C00992
         		S
    Figure US20190345133A1-20191114-C00993
         		597.3 598.1 3.79 5
    12-2
    Figure US20190345133A1-20191114-C00994
         		H
    Figure US20190345133A1-20191114-C00995
         		S
    Figure US20190345133A1-20191114-C00996
         		583.3 584.1 4.56 5
    12-3
    Figure US20190345133A1-20191114-C00997
         		H
    Figure US20190345133A1-20191114-C00998
         		S
    Figure US20190345133A1-20191114-C00999
         		595.3 596.1 4.68 5
    12-4
    Figure US20190345133A1-20191114-C01000
         		H
    Figure US20190345133A1-20191114-C01001
         		S
    Figure US20190345133A1-20191114-C01002
         		603.2 604.1 4.08 5
    12-5
    Figure US20190345133A1-20191114-C01003
         		H
    Figure US20190345133A1-20191114-C01004
         		S
    Figure US20190345133A1-20191114-C01005
         		553.3 554.1 3.77 5
    12-6
    Figure US20190345133A1-20191114-C01006
         		H
    Figure US20190345133A1-20191114-C01007
         		S
    Figure US20190345133A1-20191114-C01008
         		583.3 584.1 3.15 5
    12-7
    Figure US20190345133A1-20191114-C01009
         		H
    Figure US20190345133A1-20191114-C01010
         		S
    Figure US20190345133A1-20191114-C01011
         		607.3 608.1 4.94 5
    12-8
    Figure US20190345133A1-20191114-C01012
         		H
    Figure US20190345133A1-20191114-C01013
         		S
    Figure US20190345133A1-20191114-C01014
         		589.2 590.1 3.86 5
    12-9
    Figure US20190345133A1-20191114-C01015
         		H
    Figure US20190345133A1-20191114-C01016
         		S
    Figure US20190345133A1-20191114-C01017
         		581.2 582.1 3.24 5
    12-10
    Figure US20190345133A1-20191114-C01018
         		H
    Figure US20190345133A1-20191114-C01019
         		S
    Figure US20190345133A1-20191114-C01020
         		581.3 582.1 4.4 5
    12-11
    Figure US20190345133A1-20191114-C01021
         		H
    Figure US20190345133A1-20191114-C01022
         		S
    Figure US20190345133A1-20191114-C01023
         		629.3 630.1 4.87 5
    12-12
    Figure US20190345133A1-20191114-C01024
         		H
    Figure US20190345133A1-20191114-C01025
         		S
    Figure US20190345133A1-20191114-C01026
         		597.3 598.1 3.4 5
    12-13
    Figure US20190345133A1-20191114-C01027
         		H
    Figure US20190345133A1-20191114-C01028
         		S
    Figure US20190345133A1-20191114-C01029
         		581.3 582.1 4.41 5
    12-14
    Figure US20190345133A1-20191114-C01030
         		H
    Figure US20190345133A1-20191114-C01031
         		S
    Figure US20190345133A1-20191114-C01032
         		555.3 556.1 4.04 5
    12-15
    Figure US20190345133A1-20191114-C01033
         		H
    Figure US20190345133A1-20191114-C01034
         		S
    Figure US20190345133A1-20191114-C01035
         		646.2 647 3.41 5
    12-16
    Figure US20190345133A1-20191114-C01036
         		H
    Figure US20190345133A1-20191114-C01037
         		S
    Figure US20190345133A1-20191114-C01038
         		603.3 604.1 4.58 5
    12-17
    Figure US20190345133A1-20191114-C01039
         		H
    Figure US20190345133A1-20191114-C01040
         		S
    Figure US20190345133A1-20191114-C01041
         		617.2 618 3.17 5
    12-18
    Figure US20190345133A1-20191114-C01042
         		H
    Figure US20190345133A1-20191114-C01043
         		S
    Figure US20190345133A1-20191114-C01044
         		589.2 590 4.15 5
    12-19
    Figure US20190345133A1-20191114-C01045
         		H
    Figure US20190345133A1-20191114-C01046
         		S
    Figure US20190345133A1-20191114-C01047
         		557.2 558 3.44 5
    12-20
    Figure US20190345133A1-20191114-C01048
         		H
    Figure US20190345133A1-20191114-C01049
         		S
    Figure US20190345133A1-20191114-C01050
         		583.3 584.1 3.39 5
    12-21
    Figure US20190345133A1-20191114-C01051
         		H
    Figure US20190345133A1-20191114-C01052
         		R
    Figure US20190345133A1-20191114-C01053
         		583.3 584.1 3.39 5
    12-22
    Figure US20190345133A1-20191114-C01054
         		H
    Figure US20190345133A1-20191114-C01055
         		S
    Figure US20190345133A1-20191114-C01056
         		597.3 598.1 3.47 5
    12-23
    Figure US20190345133A1-20191114-C01057
         		H
    Figure US20190345133A1-20191114-C01058
         		S
    Figure US20190345133A1-20191114-C01059
         		597.3 598.1 3.79 5
    12-24
    Figure US20190345133A1-20191114-C01060
         		H
    Figure US20190345133A1-20191114-C01061
         		S
    Figure US20190345133A1-20191114-C01062
         		609.3 610.1 3.51 5
    12-25
    Figure US20190345133A1-20191114-C01063
         		H
    Figure US20190345133A1-20191114-C01064
         		S
    Figure US20190345133A1-20191114-C01065
         		581.3 582.1 4.27 5
    12-26
    Figure US20190345133A1-20191114-C01066
         		H
    Figure US20190345133A1-20191114-C01067
         		S
    Figure US20190345133A1-20191114-C01068
         		595.3 596.1 4.69 5
    12-27
    Figure US20190345133A1-20191114-C01069
         		H
    Figure US20190345133A1-20191114-C01070
         		S
    Figure US20190345133A1-20191114-C01071
         		583.3 584.1 3.4 5
    12-28
    Figure US20190345133A1-20191114-C01072
         		H
    Figure US20190345133A1-20191114-C01073
         		S
    Figure US20190345133A1-20191114-C01074
         		595.3 596.1 4.65 5
    12-29
    Figure US20190345133A1-20191114-C01075
         		H
    Figure US20190345133A1-20191114-C01076
         		S
    Figure US20190345133A1-20191114-C01077
         		581.3 582.1 4.34 5
    12-30
    Figure US20190345133A1-20191114-C01078
         		H
    Figure US20190345133A1-20191114-C01079
         		S
    Figure US20190345133A1-20191114-C01080
         		539.2 540 3.36 5
    12-31
    Figure US20190345133A1-20191114-C01081
         		H
    Figure US20190345133A1-20191114-C01082
         		S
    Figure US20190345133A1-20191114-C01083
         		581.3 582.1 4.26 5
    12-32
    Figure US20190345133A1-20191114-C01084
         		H
    Figure US20190345133A1-20191114-C01085
         		S
    Figure US20190345133A1-20191114-C01086
         		579.3 580.1 4.1 5
    12-33
    Figure US20190345133A1-20191114-C01087
         		H
    Figure US20190345133A1-20191114-C01088
         		S
    Figure US20190345133A1-20191114-C01089
         		608.3 609.1 1.97 5
    12-34
    Figure US20190345133A1-20191114-C01090
         		H
    Figure US20190345133A1-20191114-C01091
         		S
    Figure US20190345133A1-20191114-C01092
         		596.3 597.1 1.71 5
    12-35
    Figure US20190345133A1-20191114-C01093
         		H
    Figure US20190345133A1-20191114-C01094
         		S
    Figure US20190345133A1-20191114-C01095
         		596.3 597.1 1.68 5
    12-36
    Figure US20190345133A1-20191114-C01096
         		H
    Figure US20190345133A1-20191114-C01097
         		S
    Figure US20190345133A1-20191114-C01098
         		596.3 597.1 1.93 5
    12-37
    Figure US20190345133A1-20191114-C01099
         		H
    Figure US20190345133A1-20191114-C01100
         		S
    Figure US20190345133A1-20191114-C01101
         		596.3 597.1 2.9 5
    12-38
    Figure US20190345133A1-20191114-C01102
         		H
    Figure US20190345133A1-20191114-C01103
         		S
    Figure US20190345133A1-20191114-C01104
         		629.3 630.1 4.74 5
    12-39
    Figure US20190345133A1-20191114-C01105
         		H
    Figure US20190345133A1-20191114-C01106
         		S
    Figure US20190345133A1-20191114-C01107
         		595.3 596.1 4.67 5
    12-40
    Figure US20190345133A1-20191114-C01108
         		H
    Figure US20190345133A1-20191114-C01109
         		S
    Figure US20190345133A1-20191114-C01110
         		595.3 596.1 4.6 5
    12-41
    Figure US20190345133A1-20191114-C01111
         		H
    Figure US20190345133A1-20191114-C01112
         		S
    Figure US20190345133A1-20191114-C01113
         		595.3 596.1 4.61 5
    12-42
    Figure US20190345133A1-20191114-C01114
         		H
    Figure US20190345133A1-20191114-C01115
         		S
    Figure US20190345133A1-20191114-C01116
         		597.3 598.1 3.66 5
    12-43
    Figure US20190345133A1-20191114-C01117
         		H
    Figure US20190345133A1-20191114-C01118
         		S
    Figure US20190345133A1-20191114-C01119
         		595.3 596.1 4.62 5
    12-44
    Figure US20190345133A1-20191114-C01120
         		H
    Figure US20190345133A1-20191114-C01121
         		S
    Figure US20190345133A1-20191114-C01122
         		592.3 593.1 3.51 5
    12-45
    Figure US20190345133A1-20191114-C01123
         		H
    Figure US20190345133A1-20191114-C01124
         		S
    Figure US20190345133A1-20191114-C01125
         		567.3 568.1 3.89 5
    12-46
    Figure US20190345133A1-20191114-C01126
         		H
    Figure US20190345133A1-20191114-C01127
         		S
    Figure US20190345133A1-20191114-C01128
         		567.3 568.1 3.94 5
    12-47
    Figure US20190345133A1-20191114-C01129
         		H
    Figure US20190345133A1-20191114-C01130
         		S
    Figure US20190345133A1-20191114-C01131
         		581.3 582.1 4.01 5
    12-48
    Figure US20190345133A1-20191114-C01132
         		H
    Figure US20190345133A1-20191114-C01133
         		S
    Figure US20190345133A1-20191114-C01134
         		569.2 570.1 3.07 5
    12-49
    Figure US20190345133A1-20191114-C01135
         		H
    Figure US20190345133A1-20191114-C01136
         		S
    Figure US20190345133A1-20191114-C01137
         		596.3 597.1 2 5
    12-50
    Figure US20190345133A1-20191114-C01138
         		H
    Figure US20190345133A1-20191114-C01139
         		S
    Figure US20190345133A1-20191114-C01140
         		596.3 597.1 1.91 5
    12-51
    Figure US20190345133A1-20191114-C01141
         		H
    Figure US20190345133A1-20191114-C01142
         		S
    Figure US20190345133A1-20191114-C01143
         		621.2 622.1 4.26 5
    12-52
    Figure US20190345133A1-20191114-C01144
         		H
    Figure US20190345133A1-20191114-C01145
         		S
    Figure US20190345133A1-20191114-C01146
         		621.2 622.1 4.18 5
    12-53
    Figure US20190345133A1-20191114-C01147
         		H
    Figure US20190345133A1-20191114-C01148
         		S
    Figure US20190345133A1-20191114-C01149
         		629.3 630.1 1.77 5
    12-54
    Figure US20190345133A1-20191114-C01150
         		H
    Figure US20190345133A1-20191114-C01151
         		S
    Figure US20190345133A1-20191114-C01152
         		629.3 630.1 4.84 5
    12-55
    Figure US20190345133A1-20191114-C01153
         		H
    Figure US20190345133A1-20191114-C01154
         		S
    Figure US20190345133A1-20191114-C01155
         		607.3 608.1 4.67 5
    12-56
    Figure US20190345133A1-20191114-C01156
         		H
    Figure US20190345133A1-20191114-C01157
         		S
    Figure US20190345133A1-20191114-C01158
         		581.3 582.1 4.22 5
    12-57
    Figure US20190345133A1-20191114-C01159
         		H
    Figure US20190345133A1-20191114-C01160
         		S
    Figure US20190345133A1-20191114-C01161
         		581.3 582.1 4.31 5
    12-58
    Figure US20190345133A1-20191114-C01162
         		H
    Figure US20190345133A1-20191114-C01163
         		S
    Figure US20190345133A1-20191114-C01164
         		581.3 582.1 4.29 5
    12-59
    Figure US20190345133A1-20191114-C01165
         		H
    Figure US20190345133A1-20191114-C01166
         		S
    Figure US20190345133A1-20191114-C01167
         		607.3 608.1 4.74 5
    12-60
    Figure US20190345133A1-20191114-C01168
         		H
    Figure US20190345133A1-20191114-C01169
         		S
    Figure US20190345133A1-20191114-C01170
         		609.3 610.1 4.92 5
    12-61
    Figure US20190345133A1-20191114-C01171
         		H
    Figure US20190345133A1-20191114-C01172
         		S
    Figure US20190345133A1-20191114-C01173
         		595.3 596.1 4.67 5
    12-62
    Figure US20190345133A1-20191114-C01174
         		H
    Figure US20190345133A1-20191114-C01175
         		S
    Figure US20190345133A1-20191114-C01176
         		583.3 584.1 3.21 5
    12-63
    Figure US20190345133A1-20191114-C01177
         		H
    Figure US20190345133A1-20191114-C01178
         		S
    Figure US20190345133A1-20191114-C01179
         		585.3 586.1 3.64 5
    12-64
    Figure US20190345133A1-20191114-C01180
         		H
    Figure US20190345133A1-20191114-C01181
         		S
    Figure US20190345133A1-20191114-C01182
         		583.3 584.1 3.41 5
    12-65
    Figure US20190345133A1-20191114-C01183
         		H
    Figure US20190345133A1-20191114-C01184
         		S
    Figure US20190345133A1-20191114-C01185
         		581.3 582.1 4.15 5
    12-66
    Figure US20190345133A1-20191114-C01186
         		H
    Figure US20190345133A1-20191114-C01187
         		S
    Figure US20190345133A1-20191114-C01188
         		579.3 580 4.08 5
    12-67
    Figure US20190345133A1-20191114-C01189
         		H
    Figure US20190345133A1-20191114-C01190
         		S
    Figure US20190345133A1-20191114-C01191
         		585.3 586.1 3.62 5
    12-68
    Figure US20190345133A1-20191114-C01192
         		H
    Figure US20190345133A1-20191114-C01193
         		S
    Figure US20190345133A1-20191114-C01194
         		581.3 582.1 3.97 5
    12-69
    Figure US20190345133A1-20191114-C01195
         		H
    Figure US20190345133A1-20191114-C01196
         		S
    Figure US20190345133A1-20191114-C01197
         		579.3 580.1 4.11 5
    12-70
    Figure US20190345133A1-20191114-C01198
         		H
    Figure US20190345133A1-20191114-C01199
         		S
    Figure US20190345133A1-20191114-C01200
         		578.2 579 3.27 5
    12-71
    Figure US20190345133A1-20191114-C01201
         		H
    Figure US20190345133A1-20191114-C01202
         		S
    Figure US20190345133A1-20191114-C01203
         		595.3 596.1 4.2 5
    12-72
    Figure US20190345133A1-20191114-C01204
         		H
    Figure US20190345133A1-20191114-C01205
         		S
    Figure US20190345133A1-20191114-C01206
         		607.3 608.1 4.7 5
    12-73
    Figure US20190345133A1-20191114-C01207
         		H
    Figure US20190345133A1-20191114-C01208
         		S
    Figure US20190345133A1-20191114-C01209
         		593.3 594.1 4.44 5
    12-74
    Figure US20190345133A1-20191114-C01210
         		H
    Figure US20190345133A1-20191114-C01211
         		S
    Figure US20190345133A1-20191114-C01212
         		595.3 596.1 4.7 5
    12-75
    Figure US20190345133A1-20191114-C01213
         		H
    Figure US20190345133A1-20191114-C01214
         		S
    Figure US20190345133A1-20191114-C01215
         		609.3 610.1 4.88 5
    12-76
    Figure US20190345133A1-20191114-C01216
         		H
    Figure US20190345133A1-20191114-C01217
         		S
    Figure US20190345133A1-20191114-C01218
         		615.3 616.3 4.17 5
    12-77
    Figure US20190345133A1-20191114-C01219
         		H
    Figure US20190345133A1-20191114-C01220
         		S
    Figure US20190345133A1-20191114-C01221
         		578.2 579.1 3.31 5
    12-78
    Figure US20190345133A1-20191114-C01222
         		H
    Figure US20190345133A1-20191114-C01223
         		S 607.3 608.1 4.39 5
    12-79
    Figure US20190345133A1-20191114-C01224
         		H
    Figure US20190345133A1-20191114-C01225
         		S
    Figure US20190345133A1-20191114-C01226
         		603.2 604.1 3.87 5
    12-80
    Figure US20190345133A1-20191114-C01227
         		H
    Figure US20190345133A1-20191114-C01228
         		S
    Figure US20190345133A1-20191114-C01229
         		569.3 570.1 5.02 5
    12-81
    Figure US20190345133A1-20191114-C01230
         		H
    Figure US20190345133A1-20191114-C01231
         		S
    Figure US20190345133A1-20191114-C01232
         		575.2 576.1 4.76 5
    12-82
    Figure US20190345133A1-20191114-C01233
         		H
    Figure US20190345133A1-20191114-C01234
         		S
    Figure US20190345133A1-20191114-C01235
         		575.2 576 4.33 5
    12-83
    Figure US20190345133A1-20191114-C01236
         		H
    Figure US20190345133A1-20191114-C01237
         		S
    Figure US20190345133A1-20191114-C01238
         		555.3 556.1 4.7 5
    12-84
    Figure US20190345133A1-20191114-C01239
         		H
    Figure US20190345133A1-20191114-C01240
         		S
    Figure US20190345133A1-20191114-C01241
         		592.3 593.1 3.6 5
    12-85
    Figure US20190345133A1-20191114-C01242
         		H
    Figure US20190345133A1-20191114-C01243
         		S
    Figure US20190345133A1-20191114-C01244
         		607.2 608 3.61 5
    12-86
    Figure US20190345133A1-20191114-C01245
         		H
    Figure US20190345133A1-20191114-C01246
         		S
    Figure US20190345133A1-20191114-C01247
         		581.2 582.1 2.89 5
    12-87
    Figure US20190345133A1-20191114-C01248
         		H
    Figure US20190345133A1-20191114-C01249
         		S
    Figure US20190345133A1-20191114-C01250
         		623.3 624.1 5.22 5
    12-88
    Figure US20190345133A1-20191114-C01251
         		H
    Figure US20190345133A1-20191114-C01252
         		S
    Figure US20190345133A1-20191114-C01253
         		595.3 596.1 4.61 5
    12-89
    Figure US20190345133A1-20191114-C01254
         		H
    Figure US20190345133A1-20191114-C01255
         		S
    Figure US20190345133A1-20191114-C01256
         		585.3 586.1 3.64 5
    12-90
    Figure US20190345133A1-20191114-C01257
         		H
    Figure US20190345133A1-20191114-C01258
         		S
    Figure US20190345133A1-20191114-C01259
         		595.2 596 3.74 5
    12-91
    Figure US20190345133A1-20191114-C01260
         		H
    Figure US20190345133A1-20191114-C01261
         		S
    Figure US20190345133A1-20191114-C01262
         		569.3 570.1 4.09 5
    12-92
    Figure US20190345133A1-20191114-C01263
         		H
    Figure US20190345133A1-20191114-C01264
         		S 569.3 570.1 4.11 5
    12-93
    Figure US20190345133A1-20191114-C01265
         		H
    Figure US20190345133A1-20191114-C01266
         		S
    Figure US20190345133A1-20191114-C01267
         		569.3 570.1 4.23 5
    12-94
    Figure US20190345133A1-20191114-C01268
         		H
    Figure US20190345133A1-20191114-C01269
         		S
    Figure US20190345133A1-20191114-C01270
         		593.3 594.1 4.45 5
    12-95
    Figure US20190345133A1-20191114-C01271
         		H
    Figure US20190345133A1-20191114-C01272
         		S
    Figure US20190345133A1-20191114-C01273
         		607.3 608.1 4.61 5
    12-96
    Figure US20190345133A1-20191114-C01274
         		H
    Figure US20190345133A1-20191114-C01275
         		S
    Figure US20190345133A1-20191114-C01276
         		609.3 610.1 4.93 5
    12-97
    Figure US20190345133A1-20191114-C01277
         		H
    Figure US20190345133A1-20191114-C01278
         		S
    Figure US20190345133A1-20191114-C01279
         		595.3 596.1 4.53 5
    12-98
    Figure US20190345133A1-20191114-C01280
         		H
    Figure US20190345133A1-20191114-C01281
         		S
    Figure US20190345133A1-20191114-C01282
         		597.3 598.1 4.98 5
    12-99
    Figure US20190345133A1-20191114-C01283
         		H
    Figure US20190345133A1-20191114-C01284
         		S
    Figure US20190345133A1-20191114-C01285
         		596.3 597.1 1.85 5
    12- 100
    Figure US20190345133A1-20191114-C01286
         		H
    Figure US20190345133A1-20191114-C01287
         		S
    Figure US20190345133A1-20191114-C01288
         		596.3 597.1 1.9 5
    12- 101
    Figure US20190345133A1-20191114-C01289
         		H
    Figure US20190345133A1-20191114-C01290
         		S
    Figure US20190345133A1-20191114-C01291
         		644.3 645.1 4.46 5
    12- 102
    Figure US20190345133A1-20191114-C01292
         		H
    Figure US20190345133A1-20191114-C01293
         		S
    Figure US20190345133A1-20191114-C01294
         		624.3 625.1 2.05 5
    12- 103
    Figure US20190345133A1-20191114-C01295
         		H
    Figure US20190345133A1-20191114-C01296
         		S
    Figure US20190345133A1-20191114-C01297
         		610.3 611.1 2.18 5
    12- 104
    Figure US20190345133A1-20191114-C01298
         		H
    Figure US20190345133A1-20191114-C01299
         		S
    Figure US20190345133A1-20191114-C01300
         		610.3 611.1 2.02 5
    12- 105
    Figure US20190345133A1-20191114-C01301
         		H
    Figure US20190345133A1-20191114-C01302
         		S
    Figure US20190345133A1-20191114-C01303
         		608.3 609.1 2.01 5
    12- 106
    Figure US20190345133A1-20191114-C01304
         		H
    Figure US20190345133A1-20191114-C01305
         		S
    Figure US20190345133A1-20191114-C01306
         		610.3 611.1 3.02 5
    12- 107
    Figure US20190345133A1-20191114-C01307
         		H
    Figure US20190345133A1-20191114-C01308
         		S
    Figure US20190345133A1-20191114-C01309
         		646.3 647.1 3.72 5
    12- 108
    Figure US20190345133A1-20191114-C01310
         		H
    Figure US20190345133A1-20191114-C01311
         		S
    Figure US20190345133A1-20191114-C01312
         		651.2 652 3.31 5
    12- 109
    Figure US20190345133A1-20191114-C01313
         		H
    Figure US20190345133A1-20191114-C01314
         		S
    Figure US20190345133A1-20191114-C01315
         		639.3 640.1 3.39 5
    12- 110
    Figure US20190345133A1-20191114-C01316
         		H
    Figure US20190345133A1-20191114-C01317
         		S
    Figure US20190345133A1-20191114-C01318
         		608.3 609.1 2 5
    12- 111
    Figure US20190345133A1-20191114-C01319
         		H
    Figure US20190345133A1-20191114-C01320
         		S
    Figure US20190345133A1-20191114-C01321
         		581.3 582.1 4.2 5
    12- 112
    Figure US20190345133A1-20191114-C01322
         		H
    Figure US20190345133A1-20191114-C01323
         		S
    Figure US20190345133A1-20191114-C01324
         		595.3 596.1 4.51 5
    12- 113
    Figure US20190345133A1-20191114-C01325
         		H
    Figure US20190345133A1-20191114-C01326
         		S
    Figure US20190345133A1-20191114-C01327
         		571.3 572.1 3.45 5
    12- 114
    Figure US20190345133A1-20191114-C01328
         		H
    Figure US20190345133A1-20191114-C01329
         		S
    Figure US20190345133A1-20191114-C01330
         		583.3 584.1 4.5 5
    12- 115
    Figure US20190345133A1-20191114-C01331
         		H
    Figure US20190345133A1-20191114-C01332
         		S
    Figure US20190345133A1-20191114-C01333
         		568.3 569.1 1.78 5
    12- 116
    Figure US20190345133A1-20191114-C01334
         		H
    Figure US20190345133A1-20191114-C01335
         		S
    Figure US20190345133A1-20191114-C01336
         		596.3 597.1 1.86 5
    12- 117
    Figure US20190345133A1-20191114-C01337
         		H
    Figure US20190345133A1-20191114-C01338
         		S
    Figure US20190345133A1-20191114-C01339
         		607.3 608.1 3.33 5
    12- 118
    Figure US20190345133A1-20191114-C01340
         		H
    Figure US20190345133A1-20191114-C01341
         		S
    Figure US20190345133A1-20191114-C01342
         		585.3 586.1 1.83 5
    12- 119
    Figure US20190345133A1-20191114-C01343
         		H
    Figure US20190345133A1-20191114-C01344
         		S
    Figure US20190345133A1-20191114-C01345
         		595.2 596 3.96 5
    12- 120
    Figure US20190345133A1-20191114-C01346
         		H
    Figure US20190345133A1-20191114-C01347
         		S
    Figure US20190345133A1-20191114-C01348
         		595.3 596.1 4.31 5
    12- 121
    Figure US20190345133A1-20191114-C01349
         		H
    Figure US20190345133A1-20191114-C01350
         		S
    Figure US20190345133A1-20191114-C01351
         		609.3 610.1 4.87 5
    12- 122
    Figure US20190345133A1-20191114-C01352
         		H
    Figure US20190345133A1-20191114-C01353
         		S
    Figure US20190345133A1-20191114-C01354
         		567.3 568.1 4.04 5
    12- 123
    Figure US20190345133A1-20191114-C01355
         		H
    Figure US20190345133A1-20191114-C01356
         		S
    Figure US20190345133A1-20191114-C01357
         		567.3 568.1 4.05 5
    12- 124
    Figure US20190345133A1-20191114-C01358
         		H
    Figure US20190345133A1-20191114-C01359
         		S
    Figure US20190345133A1-20191114-C01360
         		589.3 590 4.43 5
    12- 125
    Figure US20190345133A1-20191114-C01361
         		NA
    Figure US20190345133A1-20191114-C01362
         		633.2 636 4.41 5
    12- 126
    Figure US20190345133A1-20191114-C01363
         		H
    Figure US20190345133A1-20191114-C01364
         		S
    Figure US20190345133A1-20191114-C01365
         		624.3 625.1 2.34 5
    12- 127
    Figure US20190345133A1-20191114-C01366
         		NA
    Figure US20190345133A1-20191114-C01367
         		661.2 664 3.89 5
    12- 128
    Figure US20190345133A1-20191114-C01368
         		NA
    Figure US20190345133A1-20191114-C01369
         		671.2 674 4.51 5
    12- 129
    Figure US20190345133A1-20191114-C01370
         		NA
    Figure US20190345133A1-20191114-C01371
         		633.2 636 4.34 5
    12- 130
    Figure US20190345133A1-20191114-C01372
         		NA
    Figure US20190345133A1-20191114-C01373
         		659.2 662.1 4.74 5
    12- 131
    Figure US20190345133A1-20191114-C01374
         		H
    Figure US20190345133A1-20191114-C01375
         		S
    Figure US20190345133A1-20191114-C01376
         		610.3 611.1 1.52 5
    12- 132
    Figure US20190345133A1-20191114-C01377
         		H
    Figure US20190345133A1-20191114-C01378
         		S
    Figure US20190345133A1-20191114-C01379
         		629.3 630.1 4.6 5
    12- 133
    Figure US20190345133A1-20191114-C01380
         		H
    Figure US20190345133A1-20191114-C01381
         		S
    Figure US20190345133A1-20191114-C01382
         		582.3 583.1 1.86 5
    12- 134
    Figure US20190345133A1-20191114-C01383
         		H
    Figure US20190345133A1-20191114-C01384
         		S
    Figure US20190345133A1-20191114-C01385
         		597.3 598.1 3.77 5
    12- 135
    Figure US20190345133A1-20191114-C01386
    Figure US20190345133A1-20191114-C01387
         		NA
    Figure US20190345133A1-20191114-C01388
         		659.2 662.1 4.42 5
    12- 136
    Figure US20190345133A1-20191114-C01389
    Figure US20190345133A1-20191114-C01390
         		NA
    Figure US20190345133A1-20191114-C01391
         		657.2 660 4.32 5
    12- 137
    Figure US20190345133A1-20191114-C01392
    Figure US20190345133A1-20191114-C01393
         		NA 647.2 650 4.29 5
    12- 138
    Figure US20190345133A1-20191114-C01394
    Figure US20190345133A1-20191114-C01395
         		NA
    Figure US20190345133A1-20191114-C01396
         		646.2 649 2.15 5
    12- 139
    Figure US20190345133A1-20191114-C01397
         		H
    Figure US20190345133A1-20191114-C01398
         		S
    Figure US20190345133A1-20191114-C01399
         		585.3 586.1 3.88 5
    12- 140
    Figure US20190345133A1-20191114-C01400
         		H
    Figure US20190345133A1-20191114-C01401
         		S
    Figure US20190345133A1-20191114-C01402
         		630.3 631.1 4.7 5
    12- 141
    Figure US20190345133A1-20191114-C01403
         		H
    Figure US20190345133A1-20191114-C01404
         		S
    Figure US20190345133A1-20191114-C01405
         		595.3 596.1 4.53 5
    12- 142
    Figure US20190345133A1-20191114-C01406
         		H
    Figure US20190345133A1-20191114-C01407
         		S
    Figure US20190345133A1-20191114-C01408
         		595.3 596.1 4.59 5
    12- 143
    Figure US20190345133A1-20191114-C01409
         		H
    Figure US20190345133A1-20191114-C01410
         		S
    Figure US20190345133A1-20191114-C01411
         		603.2 604.1 4.04 5
    12- 144
    Figure US20190345133A1-20191114-C01412
         		H
    Figure US20190345133A1-20191114-C01413
         		S
    Figure US20190345133A1-20191114-C01414
         		585.3 586.1 3.94 5
    12- 145
    Figure US20190345133A1-20191114-C01415
         		H
    Figure US20190345133A1-20191114-C01416
         		S
    Figure US20190345133A1-20191114-C01417
         		568.3 569.1 1.91 5
    12- 146
    Figure US20190345133A1-20191114-C01418
         		H
    Figure US20190345133A1-20191114-C01419
         		S
    Figure US20190345133A1-20191114-C01420
         		608.3 609.1 2.00 5
    12- 147
    Figure US20190345133A1-20191114-C01421
         		H
    Figure US20190345133A1-20191114-C01422
         		S
    Figure US20190345133A1-20191114-C01423
         		629.3 631.1 4.87 5
    12- 148
    Figure US20190345133A1-20191114-C01424
         		H
    Figure US20190345133A1-20191114-C01425
         		S
    Figure US20190345133A1-20191114-C01426
         		667.2 668 4.65 5
    12- 149
    Figure US20190345133A1-20191114-C01427
         		H
    Figure US20190345133A1-20191114-C01428
         		S
    Figure US20190345133A1-20191114-C01429
         		667.2 668 4.75 5
    12- 150
    Figure US20190345133A1-20191114-C01430
         		H
    Figure US20190345133A1-20191114-C01431
         		S
    Figure US20190345133A1-20191114-C01432
         		610.3 611.1 4.49 5
    12- 151
    Figure US20190345133A1-20191114-C01433
         		H
    Figure US20190345133A1-20191114-C01434
         		S
    Figure US20190345133A1-20191114-C01435
         		610.3 611.1 4.32 5
    12- 152
    Figure US20190345133A1-20191114-C01436
         		H
    Figure US20190345133A1-20191114-C01437
         		S
    Figure US20190345133A1-20191114-C01438
         		631.2 632 4.5 5
    12- 153
    Figure US20190345133A1-20191114-C01439
         		H
    Figure US20190345133A1-20191114-C01440
         		S
    Figure US20190345133A1-20191114-C01441
         		581.3 582.1 4.45 5
    12- 154
    Figure US20190345133A1-20191114-C01442
         		H
    Figure US20190345133A1-20191114-C01443
         		S
    Figure US20190345133A1-20191114-C01444
         		581.3 582.1 4.38 5
    12- 155
    Figure US20190345133A1-20191114-C01445
         		H
    Figure US20190345133A1-20191114-C01446
         		S
    Figure US20190345133A1-20191114-C01447
         		596.3 597.3 3.94 5
    12- 156
    Figure US20190345133A1-20191114-C01448
         		H
    Figure US20190345133A1-20191114-C01449
         		S
    Figure US20190345133A1-20191114-C01450
         		594.3 595.3 3.82 5
    12- 157
    Figure US20190345133A1-20191114-C01451
         		H
    Figure US20190345133A1-20191114-C01452
         		S
    Figure US20190345133A1-20191114-C01453
         		582.3 583.4 3.79 5
    12- 158
    Figure US20190345133A1-20191114-C01454
         		H
    Figure US20190345133A1-20191114-C01455
         		S
    Figure US20190345133A1-20191114-C01456
         		608.3 609.4 4.24 5
  • Figure US20190345133A1-20191114-C01457
    • Example 13 Synthesis of ((S)—N-(4-((2,3-dihydro-1H-inden-5-yl)carbamoyl)piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 13-1)
  • Figure US20190345133A1-20191114-C01458
    • Step 13A. Synthesis of 1-(tert-butyl) 4-methyl (S)-4-(2-(((9H-fluoren-9-yl)methoxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) piperidine-1,4-dicarboxylate (Intermediate 13A)
  • Figure US20190345133A1-20191114-C01459
  • Into a solution of (S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (1.7 g, 4.3 mmol) and 1-tert-butyl 4-methyl 4-aminopiperidine-1,4-dicarboxylate (1.0 g, 3.9 mmol) in DCM (100 mL) were added DIEA (3.0 mL, 19.4 mmol) and, after 20 min, HATU (4.4 g, 11.6 mmol). After 2 h, the reaction mixture was partitioned between DCM (5 mL) and al M aqueous solution of HCl (100 mL). The layers were separated using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (100 mL). The combined organic phases were concentrated. The crude product was purified by chromatography (EA/isohexane) to afford 2.6 g (93%) of Intermediate 13 as a white foaming solid. LCMS [m/z] calculated for C37H41N3O7: 639.3; found 662.1 [M+Na]+, tR=2.85 min (Method 4).
    • Step 13B. Synthesis of 1-(tert-butyl) 4-methyl (S)-4-(1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1,4-dicarboxylate (Intermediate 13B)
  • Figure US20190345133A1-20191114-C01460
  • Diethylamine (5 mL, 38.7 mmol) was added to a solution of Intermediate 13A (2.6 g, 4.06 mmol) in DCM (8 mL, 4.06 mmol). After 30 min, the reaction mixture was concentrated in vacuo and dissolved in toluene/DCM and re-concentrated (2×). The crude product was purified by chromatography (MeOH (+1% NH3)/DCM) to afford 1.6 g (94%) of Intermediate 13 as a white sticky solid. LCMS [m/z] calculated for C22H31N3O5: 417.2; found 418.2 [M+H]+, tR=1.36 min (Method 4).
    • Step 13C. Synthesis of (S)-1-tert-butyl 4-methyl 4-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1,4-dicarboxylate (Intermediate 13C)
  • Figure US20190345133A1-20191114-C01461
  • Into a solution of Intermediate 13B (1.5 g, 3.6 mmol) and 4-oxo-4-phenylbutanoic acid (1.3 g, 7.2 mmol) in DCM (15 mL) was added N-ethyl-N-isopropylpropan-2-amine (3.13 mL, 17.96 mmol). After 10 min, HATU (4.10 g, 10.78 mmol) was added. After 2 h, the reaction mixture was partitioned between DCM (20 mL) and 1 M aqueous solution of HCl (20 mL). The layers were separated using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (20 mL). The combined organic phases were concentrated and the crude product was purified by chromatography (EA/isohexane) to afford 1 g (43%) of Intermediate 13C as a sticky yellow gum. LCMS [m/z] calculated for C32H39N3O7: 577.7; found 600.1 [M+Na]+, tR=2.34 min (Method 4).
    • Step 13D. Synthesis of (S)-1-(tert-butoxycarbonyl)-4-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetra hydro isoquinoline-3-carboxamido) piperidine-4-carboxylic acid (Intermediate 13D)
  • Figure US20190345133A1-20191114-C01462
  • To a solution of Intermediate 13C (1.06 g, 1.835 mmol) in a mixture of H2O/THF (3/1, 12 mL) was added LiOH (0.439 g, 18.35 mmol). The reaction mixture was stirred for 36 h then diluted with DCM (20 mL). The aqueous layer was acidified with aq. 1 M HCl (15 mL). The layers were separated and the aqueous layer was re-extracted with DCM (20 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated. The resulting crude product was purified by chromatography (EA(+1% AcOH)/isohexane) to afford 1.1 g (97%) of Intermediate 13D as a white solid. LCMS [m/z] calculated for C31H37N3O7: 563.3; found 586.1 [M+Na]+, tR=2.21 min (Method 4). 1H NMR (400 MHz, DMSO-d6) δ 12.36 (br s, 1H), 8.14 (br s, 0.5H), 8.03-7.95 (m, 2H), 7.78 (br s, 0.5H), 7.69-7.60 (m, 1H), 7.59-7.48 (m, 2H), 7.31-7.11 (m, 4H), 5.06 (app t, J=5.2 Hz, 0.5H), 4.99-4.83 (m, 1H), 4.79-4.65 (m, 1H), 4.43 (d, J=16.3 Hz, 0.5H), 3.60 (br s, 2H), 3.48-2.99 (m, 5H), 2.97-2.66 (m, 3H), 2.05-1.77 (m, 2H), 1.76-1.49 (m, 2H), 1.39 (d, J=4.6 Hz, 9H).
    • Step 13E. Synthesis of tert-butyl (S)-4-((2,3-dihydro-1H-inden-5-yl)carbamoyl)-4-(2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)piperidine-1-carboxylate (Intermediate 13E)
  • Figure US20190345133A1-20191114-C01463
  • Into a solution of Intermediate 13D (50 mg, 0.09 mmol) and 2,3-dihydro-1H-inden-5-amine (35.4 mg, 0.27 mmol) in DMF (3 mL) was added DIEA (0.08 mL, 0.44 mmol). The reaction mixture was heated at 50° C. for 10 min and HATU (101 mg, 0.266 mmol) was added. The reaction mixture was stirred at 50° C. overnight then partitioned between DCM (5 mL) and 1 M aqueous solution of HCl (5 mL). The layers were separated using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (5 mL). The combined organic phases were concentrated in vacuo and the resulting crude material was purified by chromatography (MeOH/DCM) to afford unclean Intermediate 13E, which was used without further purification.
    • Step 13F. Synthesis of ((S)—N-(4-((2,3-dihydro-1H-inden-5-yl)carbamoyl) piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 13-1)
  • Figure US20190345133A1-20191114-C01464
  • Intermediate 13E was dissolved in DCM (5 mL) and TFA (1 mL). After 4 h, the solvents were removed and the crude product was purified by chromatography (0.7 M NH3/MeOH)/DCM) to afford 16 mg (30%) of Compound 13-1 as a white solid. LCMS [m/z] calculated for C35H38N4O4: 578.3; found 579.1 [M+H]+, tR=4.31 min (Method 5). 1H NMR (400 MHz, DMSO-d6, 363 K) δ 8.68 (br s, 1H), 8.00-7.83 (m, 2H), 7.62 (t, J=7.4 Hz, 1H), 7.49 (t, J=7.6 Hz, 2H), 7.35 (br s, 2H), 7.25-7.18 (m, 4H), 6.97 (d, J=8.2 Hz, 1H), 4.85-4.74 (m, 3H), 3.34 (br s, 2H), 3.21 (br s, 2H), 2.97-2.82 (m, 4H), 2.79-2.73 (m, 4H), 2.68-2.64 (m, 1H), 2.62-2.55 (m, 1H), 2.18-1.74 (m, 6H), CH2NH, NHAr not observed.
  • Following the procedures as set forth in Example 13 above, the compounds of the following Table 13 were prepared using the appropriate R1 reagents.
  • TABLE 13
    Figure US20190345133A1-20191114-C01465
    LCMS
    Compound MS MS Retention Purity
    Number R1 Calc (MH)+ (min) Method
    13-1
    Figure US20190345133A1-20191114-C01466
         		578.7 579.1 4.31 5
    13-2
    Figure US20190345133A1-20191114-C01467
         		570.6 571.1 3.87 5
    13-3
    Figure US20190345133A1-20191114-C01468
         		570.6 571.1 3.79 5
    13-4
    Figure US20190345133A1-20191114-C01469
         		576.2 577.3 12.01 2
    13-5
    Figure US20190345133A1-20191114-C01470
         		570.3 571.1 12.19 2
    13-6
    Figure US20190345133A1-20191114-C01471
         		560.2 561.1 11.22 2
    13-7
    Figure US20190345133A1-20191114-C01472
         		610.2 611.1 11.89 2
  • Figure US20190345133A1-20191114-C01473
    • Example 14 Synthesis of (S)—N—((S)-4-amino-1-((2-chloro-5-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 14-1)
  • Figure US20190345133A1-20191114-C01474
    • Step 14A. Synthesis of (9H-fluoren-9-yl) methyl (S)-(4-azido-1-((2-chloro-5-fluoro phenyl) amino)-1-oxo butan-2-yl)carbamate (Intermediate 14A)
  • Figure US20190345133A1-20191114-C01475
  • A solution of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-azidobutanoic acid (300 mg, 0.81 mmol) in anhydrous DCM (15 mL) in a flame-dried round-bottom flask under N2 was cooled to 0° C. 1-Chloro-N, N-2-trimethylprop-1-en-1-amine (0.18 mL, 1.5 mmol) was added. After 10 min, a solution of 2-chloro-5-fluoroaniline (108 mg, 0.75 mmol) in 2 mL of 1:1 DCM: pyridine was added. After 10 min, the reaction was diluted with DCM and washed with brine (2×). The organic layer was dried (Na2SO4) and concentrated to provide crude Intermediate 14A, which was used without further purification. LCMS [m/z] calculated for C25H21ClFN5O3: 493.1; found 494.3 [M+H]+, tR=5.9 min (Method 1).
    • Step 14B. Synthesis of (S)-2-amino-4-azido-N-(2-chloro-5-fluorophenyl)butanamide (Intermediate 14B)
  • Figure US20190345133A1-20191114-C01476
  • Pyrrolidine (1 mL) was added to a solution of Intermediate 14A in DCM (2 mL). After 30 min, the reaction mixture was concentrated in vacuo. The resulting crude material was purified by chromatography (EA/hexanes) to provide 201 mg (75%) of Intermediate B. LCMS [m/z] calculated for C25H21ClFN5O3: 271.1; found 272.4 [M+H]+, tR=2.8 min (Method 1).
    • Step 14C. Synthesis of (S)—N—((S)-4-azido-1-((2-chloro-5-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,34-tetrahydroisoquinoline-3-carboxamide (Intermediate 14C)
  • Figure US20190345133A1-20191114-C01477
  • Into a solution of Intermediate 14B (150 mg, 0.55 mmol) and Intermediate 1B (170 mg, 0.5 mmol) in DMF (2 mL) and THF (2 mL) was added DIEA (0.22 mL, 1.26 mmol). The reaction mixture was cooled to 0° C. and HATU (191 mg, 0.5 mmol) was added. The reaction mixture was stirred for 6 h then diluted with EA and washed with water (3×), NaHCO3, and dried (MgSO4). The resulting crude material was purified by chromatography (MeOH/DCM) to afford 150 mg (51%) Intermediate 14C. LCMS [m/z] calculated for C30H28ClFN6O4: 590.2; found 591.3 [M+H]+, tR=5.41 min (Method 1).
    • Synthesis of (S)—N—((S)-4-azido-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 14-22)
  • Figure US20190345133A1-20191114-C01478
  • Compound 14-22 was synthesized from (S)-2-amino-4-azido-N-(3,4-dichloro-2-fluorophenyl)butanamide according to Step 14C. LCMS [m/z] calculated for C30H27C12FN6O4: 625.5; found 627.9 [M+H]+, tR=8.33 min (Method 3).
    • Step 14D. Synthesis of (S)—N—((S)-4-amino-1-((2-chloro-5-fluorophenyl) amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 14-1)
  • Figure US20190345133A1-20191114-C01479
  • Into a solution of Intermediate 14C (150 mg, 0.25 mmol) in THF (5 mL) were added H2O (0.2 mL) and PS-PPh3 resin (250 mg, 0.5 mmol equiv). After shaking for 24 h, the resin was removed via filtration through celite. The resulting solution was concentrated and purified by RP-HPLC (MeOH/H2O) to afford 22.4 mg (16%) Compound 14-1. LCMS [m/z] calculated for C30H30ClFN4O4: 564.2; found 565.2 [M+H]+, tR=11.33 min (Method 1).
  • Following the procedures as set forth in Example 14 above, the compounds of the following Table 14 were prepared using the appropriate R1 reagents.
  • TABLE 14
    Figure US20190345133A1-20191114-C01480
    LCMS
    Compound *2 R3a/R3b MS Retention Purity
    Number R1 Stereochemistry MS Calc (MH)+ (min) Method
    14-1 
    Figure US20190345133A1-20191114-C01481
         		S 564.2 565 11.33 1
    14-2 
    Figure US20190345133A1-20191114-C01482
         		S 648.2 649.5 12.56 1
    14-3 
    Figure US20190345133A1-20191114-C01483
         		S 594.2 596.9 12.38 1
    14-4 
    Figure US20190345133A1-20191114-C01484
         		S 614.1 615 11.68 1
    14-5 
    Figure US20190345133A1-20191114-C01485
         		S 544.3 545 10.3 1
    14-6 
    Figure US20190345133A1-20191114-C01486
         		S 560.2 561.3 11.76 1
    14-7 
    Figure US20190345133A1-20191114-C01487
         		S 580.2 581.3 11.24 1
    14-8 
    Figure US20190345133A1-20191114-C01488
         		S 580.2 581 11.91 1
    14-9 
    Figure US20190345133A1-20191114-C01489
         		S 564.2 565.4 10.92 1
    14-10
    Figure US20190345133A1-20191114-C01490
         		S 560.2 561.1 11.3 1
    14-11
    Figure US20190345133A1-20191114-C01491
         		S 580.2 581 11.8 1
    14-12
    Figure US20190345133A1-20191114-C01492
         		S 614.2 615 12.14 1
    14-13
    Figure US20190345133A1-20191114-C01493
         		S 594.3 595 11.69 1
    14-14
    Figure US20190345133A1-20191114-C01494
         		S 614.2 615 11.93 1
    14-15
    Figure US20190345133A1-20191114-C01495
         		S 580.2 581 11.34 1
    14-16
    Figure US20190345133A1-20191114-C01496
         		S 614.2 615 11.73 1
    14-17
    Figure US20190345133A1-20191114-C01497
         		S 594.3 595 11.7 1
    14-18
    Figure US20190345133A1-20191114-C01498
         		S 585.2 586 11.64 1
    14-19
    Figure US20190345133A1-20191114-C01499
         		S 551.3 552.4 10.88 1
    14-20
    Figure US20190345133A1-20191114-C01500
         		S 551.3 552 10.83 1
    14-21
    Figure US20190345133A1-20191114-C01501
         		S 608.2 609 12.82 1
    14-23
    Figure US20190345133A1-20191114-C01502
         		S 630.2 631.3 12.49 1
    14-24
    Figure US20190345133A1-20191114-C01503
         		S 644.2 645.2 12.5 1
    14-25
    Figure US20190345133A1-20191114-C01504
         		S 610.2 611.3 11.94 1
    14-26
    Figure US20190345133A1-20191114-C01505
         		S 605.2 606 4.27 5
    14-27
    Figure US20190345133A1-20191114-C01506
         		S 610.2 613.1 12.36 1
    14-28
    Figure US20190345133A1-20191114-C01507
         		S 624.3 625.1 12.13 1
    14-29
    Figure US20190345133A1-20191114-C01508
         		R 598.2 600.9 6.66 3
  • Figure US20190345133A1-20191114-C01509
    • Example 15 Synthesis of (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-(4,4-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 15-1)
  • Figure US20190345133A1-20191114-C01510
    • Step 15A. Synthesis of tert-butyl (S)-3-(((S)-4-azido-1-((3,4-dichloro-2-fluorophenyl) amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 15A)
  • Figure US20190345133A1-20191114-C01511
  • Into a solution of (S)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (500 mg, 1.8 mmol) and (S)-2-amino-4-azido-N-(3,4-dichloro-2-fluorophenyl)butanamide (600 mg, 1.98 mmol) in DMF (3 mL) and THF (8 mL) at to 0° C. was added DIEA (0.79 mL, 4.5 mmol), followed by HATU (0.69 g, 1.8 mmol). After 5h, the reaction was diluted with EA and washed with H2O (3×), and NaHCO3, then dried (MgSO4), concentrated and purified by column chromatography to provide 660 mg (65%) of Intermediate 15A. LCMS [m/z] calculated for C25H27Cl2FN6O4: 564.2; found 564.4 [M+H]+, tR=6.1 min (Method 1).
    • Step 15B. Synthesis of (S)—N—((S)-4-azido-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Intermediate 15B)
  • Figure US20190345133A1-20191114-C01512
  • Into a solution of Intermediate 15A (2.1 g, 3.7 mmol) in DCM (8 mL) was added 4N HCl in dioxane (2.79 mL, 11.17 mmol). After 5h, the reaction was concentrated and purified by prep-HPLC to provide 1.5 g (87%) of Intermediate 15B. LCMS [m/z] calculated for C20H19Cl2FN6O2: 464.1; found 465.1 [M+H]+, tR=4.3 min (Method 1).
    • Step 15C. Synthesis of 4-((S)-3-(((S)-4-azido-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl) carbamoyl)-3,4-dihydroisoquinolin-2 (1H)-yl)-4-oxobutanoic acid (Intermediate 15C)
  • Figure US20190345133A1-20191114-C01513
  • Into a solution of Intermediate 15B (1.5 g, 3.2 mmol) in DCM (10 mL) were added NEt3 (0.45 mL, 3.2 mmol) and succinic anhydride (0.32 g, 3.2 mmol) After 18 h, the reaction was concentrated and purified by column chromatography (MeOH/DCM) to provide 1.5 g (83%) of Intermediate 15C. LCMS [m/z] calculated for C24H23Cl2FN6O5: 564.1; found 565.2 [M+H]+, tR=6.08 min (Method 1).
    • Step 15D. Synthesis of (S)—N—((S)-4-azido-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-(4,4-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Intermediate 15D)
  • Figure US20190345133A1-20191114-C01514
  • Into a solution of Intermediate 15C (0.2 g, 0.35 mmol) in DMF (2 mL) at 0° C. were added DIEA (0.22 mL, 1.2 mmol), 4,4-dimethylpiperidine (52 mg, 0.35 mmol) and HATU (0.14 g, 0.37 mmol) After 2 h, the reaction was diluted with EA and washed with NaHCO3. The organic layer was dried (Na2SO4), concentrated and purified by column chromatography (EA/hexane) to provide 0.2 g (86%) of Intermediate 15D. LCMS [m/z] calculated for C31H36Cl2FN7O4: 659.2; found 660.1 [M+H]+, tR=6.04 min (Method 1).
    • Step 15E. Synthesis of (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-(4,4-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydro iso quinoline-3-carboxamide (Compound 15-1)
  • Figure US20190345133A1-20191114-C01515
  • Into a solution of Intermediate 15D (92 mg, 0.14 mmol) in THF (5 mL) were added H2O (0.1 mL) and PS-PPH3 resin (210 mg, 0.42 mmol equivalents). After shaking for 24 h, the resin was removed via filtration through celite. The resulting solution was concentrated and purified by RP-Column Chromatography (MeOH/H2O) to afford 10.4 mg (12%) Compound 15-1. LCMS [m/z] calculated for C31H38Cl2FN5O4: 633.2; found 634.2 [M+H]+, tR=4.75 min (Method 1).
  • Following the procedures as set forth in Example 15 above, the compounds of the following Table 15 were prepared using the appropriate NR8 and NR9 reagents.
  • TABLE 15
    Figure US20190345133A1-20191114-C01516
    Compound Number R10 R1
    Figure US20190345133A1-20191114-C01517
         		MS Calc MS (MH)+ LCMS Retention (min) Purity Method
    15-1  H
    Figure US20190345133A1-20191114-C01518
    Figure US20190345133A1-20191114-C01519
         		633.2 634 12.63 1
    15-2  H
    Figure US20190345133A1-20191114-C01520
    Figure US20190345133A1-20191114-C01521
         		619.2 620 12.19 1
    15-3  H
    Figure US20190345133A1-20191114-C01522
    Figure US20190345133A1-20191114-C01523
         		633.2 634.3 12.69 1
    15-4  H
    Figure US20190345133A1-20191114-C01524
    Figure US20190345133A1-20191114-C01525
         		619.2 620.5 12.43 1
    15-5  H
    Figure US20190345133A1-20191114-C01526
    Figure US20190345133A1-20191114-C01527
         		634.2 635 10.25 1
    15-6  H
    Figure US20190345133A1-20191114-C01528
    Figure US20190345133A1-20191114-C01529
         		633.2 634 12.65 1
    15-7  H
    Figure US20190345133A1-20191114-C01530
    Figure US20190345133A1-20191114-C01531
         		645.2 647 7.14 3
    15-8  H
    Figure US20190345133A1-20191114-C01532
    Figure US20190345133A1-20191114-C01533
         		653.2 655.8 6.56 3
    15-9  H
    Figure US20190345133A1-20191114-C01534
    Figure US20190345133A1-20191114-C01535
         		633.2 635 6.93 3
    15-10 H
    Figure US20190345133A1-20191114-C01536
    Figure US20190345133A1-20191114-C01537
         		633.2 635 6.83 3
    15-11 H
    Figure US20190345133A1-20191114-C01538
    Figure US20190345133A1-20191114-C01539
         		635.2 637.9 5.49 3
    15-12 H
    Figure US20190345133A1-20191114-C01540
    Figure US20190345133A1-20191114-C01541
         		647.2 648 3.61 5
    15-13 H
    Figure US20190345133A1-20191114-C01542
    Figure US20190345133A1-20191114-C01543
         		683.2 683.9 3.42 5
    15-14 H
    Figure US20190345133A1-20191114-C01544
    Figure US20190345133A1-20191114-C01545
         		675.3 676 5.8 5
    15-15 H
    Figure US20190345133A1-20191114-C01546
    Figure US20190345133A1-20191114-C01547
         		619.2 620 4.47 5
    15-16 H
    Figure US20190345133A1-20191114-C01548
    Figure US20190345133A1-20191114-C01549
         		649.2 650 4.37 5
    15-17 H
    Figure US20190345133A1-20191114-C01550
    Figure US20190345133A1-20191114-C01551
         		662.3 663 2.75 5
    15-18 H
    Figure US20190345133A1-20191114-C01552
    Figure US20190345133A1-20191114-C01553
         		635.2 636 3.76 5
    15-19 H
    Figure US20190345133A1-20191114-C01554
    Figure US20190345133A1-20191114-C01555
         		635.2 636 3.8 5
    15-20 H
    Figure US20190345133A1-20191114-C01556
    Figure US20190345133A1-20191114-C01557
         		661.3 662 5.57 5
    15-21 H
    Figure US20190345133A1-20191114-C01558
    Figure US20190345133A1-20191114-C01559
         		647.2 648 5.05 5
    15-22 H
    Figure US20190345133A1-20191114-C01560
    Figure US20190345133A1-20191114-C01561
         		659.2 660 5.12 5
    15-23 H
    Figure US20190345133A1-20191114-C01562
    Figure US20190345133A1-20191114-C01563
         		675.3 676 5.54 5
    15-24 H
    Figure US20190345133A1-20191114-C01564
    Figure US20190345133A1-20191114-C01565
         		681.2 682 4.38 5
    15-25 H
    Figure US20190345133A1-20191114-C01566
    Figure US20190345133A1-20191114-C01567
         		637.2 638 3.91 5
    15-26 H
    Figure US20190345133A1-20191114-C01568
    Figure US20190345133A1-20191114-C01569
         		635.2 636 3.67 5
    15-27 H
    Figure US20190345133A1-20191114-C01570
    Figure US20190345133A1-20191114-C01571
         		635.2 636 3.56 5
    15-28 H
    Figure US20190345133A1-20191114-C01572
    Figure US20190345133A1-20191114-C01573
         		622.2 623 2.08 5
    15-29 H
    Figure US20190345133A1-20191114-C01574
    Figure US20190345133A1-20191114-C01575
         		619.2 620 4.04 5
    15-30 H
    Figure US20190345133A1-20191114-C01576
    Figure US20190345133A1-20191114-C01577
         		634.2 635.3 4.32 5
    15-31 H
    Figure US20190345133A1-20191114-C01578
    Figure US20190345133A1-20191114-C01579
         		634.2 635.2 4.51 5
    15-32 H
    Figure US20190345133A1-20191114-C01580
    Figure US20190345133A1-20191114-C01581
         		661.3 683 5.64 5
    15-33 H
    Figure US20190345133A1-20191114-C01582
    Figure US20190345133A1-20191114-C01583
         		631.2 632 4.92 5
    15-34 H
    Figure US20190345133A1-20191114-C01584
    Figure US20190345133A1-20191114-C01585
         		647.2 648 5.37 5
    15-35 H
    Figure US20190345133A1-20191114-C01586
    Figure US20190345133A1-20191114-C01587
         		621.2 622.3 4.78 5
    15-36 H
    Figure US20190345133A1-20191114-C01588
    Figure US20190345133A1-20191114-C01589
         		619.2 620.3 4.61 5
    15-37 H
    Figure US20190345133A1-20191114-C01590
    Figure US20190345133A1-20191114-C01591
         		605.2 606.3 4.33 5
    15-38 H
    Figure US20190345133A1-20191114-C01592
    Figure US20190345133A1-20191114-C01593
         		645.2 646.3 4.79 5
    15-39 H
    Figure US20190345133A1-20191114-C01594
    Figure US20190345133A1-20191114-C01595
         		621.2 622.3 4.67 5
    15-40 H
    Figure US20190345133A1-20191114-C01596
    Figure US20190345133A1-20191114-C01597
         		635.2 636.3 4.92 5
    15-41 H
    Figure US20190345133A1-20191114-C01598
    Figure US20190345133A1-20191114-C01599
         		591.2 592.2 3.85 5
    15-42 H
    Figure US20190345133A1-20191114-C01600
    Figure US20190345133A1-20191114-C01601
         		593.2 594.3 3.97 5
    15-43 H
    Figure US20190345133A1-20191114-C01602
    Figure US20190345133A1-20191114-C01603
         		621.2 622.3 4.61 5
    15-44 H
    Figure US20190345133A1-20191114-C01604
    Figure US20190345133A1-20191114-C01605
         		635.2 636.3 4.98 5
    15-45 H
    Figure US20190345133A1-20191114-C01606
    Figure US20190345133A1-20191114-C01607
         		620.2 621.2 3.09 5
    15-46 H
    Figure US20190345133A1-20191114-C01608
    Figure US20190345133A1-20191114-C01609
         		617.2 618.3 4.16 5
    15-47 H
    Figure US20190345133A1-20191114-C01610
    Figure US20190345133A1-20191114-C01611
         		659.2 660.2 4.29 5
    15-48 H
    Figure US20190345133A1-20191114-C01612
    Figure US20190345133A1-20191114-C01613
         		627.2 629 5.25 3
    15-49 H
    Figure US20190345133A1-20191114-C01614
    Figure US20190345133A1-20191114-C01615
         		646.2 647.3 2.27 5
    15-50 H
    Figure US20190345133A1-20191114-C01616
    Figure US20190345133A1-20191114-C01617
         		629.3 632 5.98 3
    15-51 H
    Figure US20190345133A1-20191114-C01618
    Figure US20190345133A1-20191114-C01619
         		641.3 643 6.43 3
    15-52 H
    Figure US20190345133A1-20191114-C01620
    Figure US20190345133A1-20191114-C01621
         		629.3 632 6.22 3
    15-53 H
    Figure US20190345133A1-20191114-C01622
    Figure US20190345133A1-20191114-C01623
         		607.2 608.3 3.8 5
    15-54 H
    Figure US20190345133A1-20191114-C01624
    Figure US20190345133A1-20191114-C01625
         		645.2 646.3 4.52 5
    15-55 H
    Figure US20190345133A1-20191114-C01626
    Figure US20190345133A1-20191114-C01627
         		663.2 664.3 4.31 5
    15-56 H
    Figure US20190345133A1-20191114-C01628
    Figure US20190345133A1-20191114-C01629
         		655.2 656.3 4.49 5
    15-57 F
    Figure US20190345133A1-20191114-C01630
    Figure US20190345133A1-20191114-C01631
         		651.2 652.3 4.7 5
    15-58 F
    Figure US20190345133A1-20191114-C01632
    Figure US20190345133A1-20191114-C01633
         		663.2 664.3 5.06 5
    15-59 F
    Figure US20190345133A1-20191114-C01634
    Figure US20190345133A1-20191114-C01635
         		649.2 650.3 4.71 5
    15-60 F
    Figure US20190345133A1-20191114-C01636
    Figure US20190345133A1-20191114-C01637
         		651.2 652.3 4.77 5
    15-61 F
    Figure US20190345133A1-20191114-C01638
    Figure US20190345133A1-20191114-C01639
         		637.2 638.3 4.39 5
    15-62 F
    Figure US20190345133A1-20191114-C01640
    Figure US20190345133A1-20191114-C01641
         		651.2 652 4.89 5
    15-63 H
    Figure US20190345133A1-20191114-C01642
    Figure US20190345133A1-20191114-C01643
         		634.2 653.3 10.46 1
  • Figure US20190345133A1-20191114-C01644
    • Example 16 Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(cyclopropylamino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 16-1)
  • Figure US20190345133A1-20191114-C01645
    • Step 16A. Synthesis of tert-butyl (S)-(4-(benzyloxy)-1-((4-chloro-3-methylphenyl) amino)-1-oxobutan-2-yl) carbamate (Intermediate 16A)
  • Figure US20190345133A1-20191114-C01646
  • DIEA (5.63 mL, 32.3 mmol) was added to a solution of O-benzyl-N-(tert-butoxycarbonyl)-L-homoserine (2.5 g, 8.1 mmol) and 4-chloro-3-methylaniline (1.3 g, 8.9 mmol) in DCM (15 mL) at 0° C., followed by HATU (6.2 g, 16.6 mmol). After 2 h, the reaction was partitioned between DCM (50 mL) and H2O (40 mL). The layers were separated using a phase separator and the aqueous layer was re-extracted with DCM (50 mL). The combined organic layers were concentrated and purified by column chromatography (EA/isohexane) to provide 3.2 g (87%) of Intermediate 16A as a foaming white solid. LCMS [m/z] calculated for C23H29ClN2O4: 432.2; found 455.2 [M+Na]+, tR=2.79 min (Method 4). 1H NMR (400 MHz, DMSO-d6) δ 10.05 (br s, 1H), 7.60 (d, J=2.5 Hz, 1H), 7.46 (dd, J=8.6, 2.5 Hz, 1H), 7.37-7.20 (m, 6H), 7.09 (d, J=7.8 Hz, 1H), 4.45 (q, J=12.0 Hz, 2H), 4.28-4.15 (m, 1H), 3.59-3.44 (m, 2H), 2.29 (s, 3H), 2.04-1.90 (m, 1H), 1.90-1.75 (m, 1H), 1.39 (s, 9H).
    • Step 16B. Synthesis of tert-butyl (S)-(1-((4-chloro-3-methylphenyl)amino)-4-hydroxy-1-oxobutan-2-yl)carbamate (Intermediate 16B)
  • Figure US20190345133A1-20191114-C01647
  • Palladium (10%) on carbon (280 mg, 2.6 mmol) was added to a solution of Intermediate 16A (2.8 g, 6.4 mmol) in EtOH (105 mL). The solution was purged with N2 (3×) and H2 (3×), then was stirred under hydrogen (1 bar) for 40 min. The reaction mixture was filtered through a glass microfiber filter, rinsing with EtOH. The solution was concentrated in vacuo to afford an yellow oil (1.8 g) which was purified by RP-C18 flash chromatography (MeCN/H2O with 0.1% formic acid) to provide 1.4 g (64%) of Intermediate 16B as a white solid. LCMS [m/z] calculated for C16H23ClN2O4: 342.1; found 365.1 [M+Na]+, tR=2.08 min (Method 4).
    • Step 16C. Synthesis of tert-butyl (S)-(1-((4-chloro-3-methylphenyl)amino)-1,4-dioxo butan-2-yl) carbamate (Intermediate 16C)
  • Figure US20190345133A1-20191114-C01648
  • Oxalyl dichloride (199 μL, 2.35 mmol) was added dropwise to a solution of DMSO (332 μL, 4.67 mmol) in DCM (6 mL) at −78° C. After 15 min, a solution of Intermediate 16B (450 mg, 1.313 mmol) in DCM (4 mL) was added slowly. After 45 min at −78° C., NEt3 (951 μL, 6.83 mmol) was added dropwise. After 1 h, the mixture was warmed to 0° C. then quenched with NaHCO3 (20 mL), split through a hydrophobic frit, and washed with DCM. The solvent was removed to afford 447 mg (100%, assumed) of Intermediate 16C as a white solid which was used without further purification or analysis.
    • Step 16D. Synthesis of tert-butyl (S)-(1-((4-chloro-3-methylphenyl)amino)-4-(cyclopropylamino)-1-oxobutan-2-yl)carbamate (Intermediate 16D)
  • Figure US20190345133A1-20191114-C01649
  • To a solution of Intermediate 16C (220 mg, 0.65 mmol) in DCE (5 mL) was added AcOH (94 μl, 1.64 mmol) and cyclopropanamine (136 mL, 1.96 mmol). The reaction mixture was stirred for 30 min before sodium triacetoxyborohydride (350 mg, 1.64 mmol) was added. After stirring overnight, additional cyclopropanamine (140 μl, 1.96 mmol), AcOH (94 μl, 1.64 mmol) and sodium triacetoxyborohydride (347 mg, 1.636 mmol) were added. After 2 h, further cyclopropanamine (136 μl, 1.96 mmol) was added and the reaction mixture was stirred for 3 h. The reaction mixture was quenched with NaHCO3 (10 mL) and stirred for 5 min. DCM (20 mL) was added and the layers were separated using a phase sep-cartridge. The aqueous layer was re-extracted with DCM (15 mL). The combined organic phases were concentrated. The crude product was purified by chromatography ((MeOH+NH3)/DCM) to afford 76 mg (30%) of Intermediate 16D as a colourless oil. LCMS [m/z] calculated for C19H28ClN3O3: 381.2; found 382.1 [M+H]+, tR=1.57 min (Method 4).
    • Step 16E. Synthesis (S)-2-amino-N-(4-chloro-3-methylphenyl)-4-(cyclopropylamino) butanamide (Intermediate 16E)
  • Figure US20190345133A1-20191114-C01650
  • A solution of Intermediate 16D (77 mg, 0.2 mmol) in DCM (6 mL) was treated with TFA (1 ml, 12.9 mmol), stirred for 1 h, then concentrated and coevaporated with toluene. The crude product was partitioned between DCM (5 mL) and NaHCO3 (5 mL). The layers were separated using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (2×5 mL). The solvent was removed to afford 28 mg (68%) of Intermediate 16E as a colourless oil, which was used without further purification. LCMS [m/z] calculated for C14H20ClN3O: 281.1; found 282.1 [M+H]+, tR=0.33 min (Method 4).
    • Step 16F: Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(cyclopropylamino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 16-1)
  • Figure US20190345133A1-20191114-C01651
  • A solution of Intermediate 1B (40.2 mg, 0.12 mmol) and Intermediate 16E (28 mg, 0.1 mmol) in DMF (4 mL) was treated with DIEA (52 μl, 0.3 mmol) and HATU (76 mg, 0.2 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 2 h, then partitioned between DCM (5 mL) and a NaHCO3 (5 mL). The layers were separated and re-extracted with DCM (5 mL). The combined organic layers were concentrated. The crude product was purified by chromatography (MeOH (with 1% NH3)/DCM)) to afford 13 mg (21%) of Compound 16 as a white solid. LCMS [m/z] calculated for C34H37ClN4O4: 600.2; found 601.3 [M+H]+, tR=4.83 min (Method 5). 1H NMR (400 MHz, DMSO-d6, 363 K) δ 7.76-7.63 (m, 2H), 7.43-7.35 (m, 1H), 7.30-7.22 (m, 3H), 7.14 (dd, J=8.6, 2.6 Hz, 1H), 7.07-6.97 (m, 5H), 4.82-4.42 (m, 3H), 3.11 (br s, 2H), 2.96 (br s, 2H), 2.71-2.54 (m, 2H), 2.23-2.14 (m, 1H), 2.02 (s, 3H), 1.87-1.75 (m, 1H), 1.61 (dd, J=13.9, 7.5 Hz, 1H), 1.51-1.42 (m, 1H), 0.97-0.84 (m, 2H), 0.13 (d, J=6.5 Hz, 2H), 0.03-0.02 (m, 2H), 3×NH not observed.
  • Figure US20190345133A1-20191114-C01652
    • Example 17 Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-hydroxypteridin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 17-1)
  • Figure US20190345133A1-20191114-C01653
    • Step 17A: Synthesis of tert-butyl (S)-3-((((9H-fluoren-9-yl)methoxy) carbonyl)amino)-4-((4-chloro-3-methylphenyl)amino)-4-oxobutanoate (Compound 17A)
  • Figure US20190345133A1-20191114-C01654
  • A solution of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-4-oxobutanoic acid (10 g, 24.30 mmol) and 4-chloro-3-methylaniline (5.16 g, 36.5 mmol) in DCM (150 mL) at 0° C. was treated with DIEA (16.93 ml, 97 mmol) and cooled to ° C. After 10 min, HATU (18.48 g, 48.6 mmol) was added portionwise. The reaction mixture was stirred at 0° C. for 1 h and the reaction mixture was partitioned between EA (50 mL) and an aqueous 1 M HCl solution (200 mL). The layers were separated and the organic layer was re-washed with an aqueous 1 M HCl solution (2×200 mL) and brine (200 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated to 18.7 g (101%) of Intermediate 17A as a beige solid. LCMS [m/z] calculated for C30H31ClN2O5: 534.2; found 557.2 [M+Na]+, tR=3.01 min (Method 4). 1H NMR (400 MHz, DMSO-d6) δ 10.17 (s, 1H), 7.98-7.78 (m, 3H), 7.78-7.57 (m, 3H), 7.57-7.29 (m, 6H), 4.50 (td, J=8.4, 5.9 Hz, 1H), 4.43-4.15 (m, 3H), 2.71 (dd, J=15.9, 5.9 Hz, 1H), 2.55 (dd, J=16.0, 8.7 Hz, 1H), 2.29 (s, 3H), 1.37 (s, 9H).
    • Step 17B: Synthesis of tert-butyl (S)-3-amino-4-((4-chloro-3-methylphenyl) amino)-4-oxobutanoate (Compound 17B)
  • Figure US20190345133A1-20191114-C01655
  • Diethylamine (25.1 mL, 243 mmol) was added to a solution of Intermediate 17A (13 g, 24.3 mmol) in DCM (25 mL, 24.3 mmol) and the reaction mixture was stirred at rt for 1 h. The reaction mixture was concentrated, redissolved in toluene/DCM and concentrated (2×). The crude product was dissolved in DCM and washed with H2O (100 mL) then redissolved in EA (100 mL) and washed with water (2×50 mL). The organic phase was dried (MgSO4), filtered, and concentrated to afford 13 g (103%) of Intermediate 17B as a brown oil which crystallized upon standing. LCMS [m/z] calculated for C15H21ClN2O3: 312.1; found 257 [M+H-tBu]+, tR=1.46 min (Method 4), 60% purity, used without further purification.
    • Step 17C: Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-4-(tert-butoxy)-1-((4-chloro-3-methylphenyl) amino)-1,4-dioxobutan-2-yl) carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17C)
  • Figure US20190345133A1-20191114-C01656
  • A solution of (S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (10.5 g, 26.2 mmol) and Intermediate 17B (13 g, 24.9 mmol) in DCM (100 mL) at 0° C. was treated with DIEA (17.4 ml, 100 mmol) and, after 10 min, HATU (18.96 g, 49.9 mmol) was added portionwise at 0° C. The reaction mixture was stirred at 0° C. for 3 h. The reaction mixture was partitioned between DCM (200 mL) and an aqueous 1 M HCl solution (200 mL). The layers were separated and the organic layer was washed an aqueous 1 M HCl solution (2×200 mL) and brine (200 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated. The resulting crude material was purified by chromatography (EA/isohexane) to afford 13.6 g (65%) of Intermediate 17C as a white foam. LCMS [m/z] calculated for C40H40ClN3O6: 693.3; found 716 [M+Na]+, tR=3.13 min (Method 4).
    • Step 17D: Synthesis of (S)-3-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-((4-chloro-3-methylphenyl)amino)-4-oxobutanoic acid (Compound 17D)
  • Figure US20190345133A1-20191114-C01657
  • A solution of Intermediate 17C (13.6 g, 19.6 mmol) in DCM (30 mL) was treated with TFA (20 mL, 260 mmol) and stirred for 3.5 h. The reaction mixture was concentrated, redissolved in toluene and re-concentrated (2×). The crude product was purified by chromatography (EA(+1% AcOH)/isohexane) to afford 9.6 g (73%) of Intermediate 17D as a white solid. LCMS [m/z] calculated for C36H32ClN3O6: 637.2; found 638 [M+H]+, tR=2.78 min (Method 4).
    • Step 17E: Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-hydroxy-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17E)
  • Figure US20190345133A1-20191114-C01658
  • Intermediate 17D (9.5 g, 14.9 mmol) was dissolved in THF (200 mL). N-Methylmorpholine (1.64 mL, 14.9 mmol) was added and the resulting mixture was cooled to −5° C. using an ice/salt bath. Ethyl chloroformate (1.43 mL, 14.9 mmol) was added and, after 1 h, the formed precipitate was filtered off using a phase sep cartridge. The filtrate was cooled (−5° C.) and a solution of sodium borohydride (0.73 g, 19.4 mmol) in 30 mL of H2O/THF (1/1) was added. The resulting mixture was stirred at −5° C. and then allowed to warm to rt overnight. The solvent was evaporated and the residue dissolved in EA (100 mL) and washed with 1 M HCl solution (100 mL), NaHCO3 (100 mL), H2O (30 mL) and brine (30 mL). The organic phase was dried (MgSO4). Filtration and evaporation gave a crude product that was purified by chromatography (EA/isohexane) to provide 5 g (51.1%) of Intermediate 17E as a white solid. LCMS [m/z] calculated for C36H34ClN3O5: 623.2; found 624 [M+H]+, tR=2.76 min (Method 4).
    • Step 17F: Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-hydroxy-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17F)
  • Figure US20190345133A1-20191114-C01659
  • A stirred solution of DMSO (0.73 mL, 10.3 mmol) in DCM (12 mL) at −78° C. was treated dropwise with oxalyl dichloride (0.44 mL, 5.2 mmol). After 15 min at −78° C., a solution of Intermediate 17E (2.0 g, 3.2 mmol) in DCM (20 mL) was added slowly. After 45 min at −78° C., Hunig's base (2.96 mL, 16.0 mmol) was added slowly. The reaction mixture was stirred at −70° C. overnight. The mixture was quenched with NaHCO3 (20 mL), then passed through a hydrophobic frit, and washed with DCM. The solution was concentrated and the resulting crude product was purified by chromatography (EA/isohexane) to provide 1.6 g (84%) of Intermediate 17F as a white solid. LCMS [m/z] calculated for C36H32ClN3O5: 621.2; found 622 [M+H]+, tR=2.7 min (Method 4).
    • Step 17G: Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17G)
  • Figure US20190345133A1-20191114-C01660
  • To a solution of Intermediate 17F (320 mg, 0.51 mmol) in DCM (6 mL) was added piperidin-4-ol (175 mg, 1.73 mmol) and acetic acid (138 μl, 2.41 mmol). The reaction mixtures were stirred at rt for 15 min. Sodium triacetoxyborohydride (382 mg, 1.8 mmol) was added and the reaction mixture was stirred at overnight. Additional piperidin-4-ol (2 equiv), AcOH (138 μl, 2.4 mmol), sodium triacetoxyborohydride (382 mg, 1.8 mmol), and THF (2 mL) were added. The reaction mixture was heated to 45° C. over 4 h and overnight at 45° C. The reaction mixture was partitioned between DCM (10 mL) and 1 M aqueous HCl (10 mL) using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (10 mL). The combined organic phases were concentrated. The crude product was purified by chromatography (0.7 M NH3/MeOH)/DCM) to afford 220 mg (61%) of Intermediate 17G as a white solid. LCMS [m/z] calculated for C41H43ClN4O5: 706.3; found 707.0 [M+H]+, tR=2.12 min (Method 4).
    • Step 17H: Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Compound 17H)
  • Figure US20190345133A1-20191114-C01661
  • Diethylamine (0.32 mL, 3.1 mmol) was added to a solution of Intermediate 17G in DCM (5 ml) and the mixture was stirred at rt for 1 h. The reaction mixture was concentrated, dissolved in toluene and re-concentrated. The resulting crude product was purified by chromatography (MeOH (+1% NH3)/DCM) to afford 130 mg (72%) of Intermediate 17H. LCMS [m/z] calculated for C26H33ClN4O3: 484.2; found 485.3 [M+H]+, tR=1.7 min (Method 4).
    • Step 171: Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 17-1)
  • Figure US20190345133A1-20191114-C01662
  • A solution of Intermediate 17H (130 mg, 0.27 mmol) and 4-oxo-4-phenylbutanoic acid (71.6 mg, 0.40 mmol) in DCM (10 mL) was treated with DIEA (280 μl, 1.61 mmol). After 10 min, HATU (153 mg, 0.40 mmol) was added. The reaction mixture was stirred for 5 h and additional 4-oxo-4-phenylbutanoic acid (71.6 mg, 0.40 mmol), DIEA (280 μl, 1.61 mmol) and HATU (153 mg, 0.40 mmol) were added. The reaction mixture was stirred for 3 h, then partitioned between DCM (10 mL) and 1 M aqueous solution of HCl (10 mL). The layers were separated using a phase separating-cartridge and the aqueous layer was re-extracted with DCM (10 mL). The combined organic phases were concentrated. The crude product was purified by chromatography (MeOH/DCM) to afford 25 mg (14%) of Compound 17-1. LCMS [m/z] calculated for C36H41ClN4O5: 644.3; found 645.2[M+H]+, tR=2.5 min (Method 4). 1H NMR (400 MHz, DMSO-d6, 363 K) δ 9.87 (br s, 1H), 9.45 (br s, 1H), 8.03-7.76 (m, 3H), 7.66-7.59 (m, 1H), 7.56-7.47 (m, 3H), 7.42 (dd, J=8.7, 2.6 Hz, 1H), 7.35-7.14 (m, 5H), 4.91 (br s, 1H), 4.82-4.79 (m, 2H), 4.59 (br s, 1H), 4.44 (br s, 1H), 3.67 (br s, 1H), 3.38-3.28 (m, 2H), 3.20 (br s, 3H), 3.05-2.87 (m, 3H), 2.77-2.54 (m, 2H), 2.46 (s, 1H), 2.27 (s, 3H), 2.17 (br s, 1H), 1.90 (br s, 3H), 1.63 (br s, 2H).
  • Following the procedures as set forth in Scheme 17 above, the compounds of the following Table 17 were prepared using the appropriate R3a and R3b reagents.
  • TABLE 17
    Figure US20190345133A1-20191114-C01663
    *2 R3a/R3b LCMS
    Compound Stereo- MS MS Obs Retention Purity
    Number R 3a R 3b chem. Calc (MH)+ (min) Method
    17-1
    Figure US20190345133A1-20191114-C01664
    Figure US20190345133A1-20191114-C01665
         		S 644.3 645 4.59 5
    17-2
    Figure US20190345133A1-20191114-C01666
    Figure US20190345133A1-20191114-C01667
         		S 728.3 730.1 5.65 5
    17-3
    Figure US20190345133A1-20191114-C01668
    Figure US20190345133A1-20191114-C01669
         		S 643.3 644.1 4.76 5
    17-4
    Figure US20190345133A1-20191114-C01670
    Figure US20190345133A1-20191114-C01671
         		S 664.3 665.1 4.84 5
  • Figure US20190345133A1-20191114-C01672
    • Example 18 Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-2-cyano-5-methylphenyl)amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 18-1)
  • Figure US20190345133A1-20191114-C01673
    • Step 18A: Synthesis of (S)-4-(3-(tert-butoxycarbonyl)-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Compound 18A)
  • Figure US20190345133A1-20191114-C01674
  • NEt3 (3 mL, 21.4 mmol) was added to a solution of tert-butyl (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (5.0 g, 21.4 mmol) in DCM (10 mL). After 5 min, a solution of succinic anhydride (3.21 g, 32.2 mmol) in DCM (2 mL) was added dropwise. After 2 days, additional succinic anhydride (1.1 g, 10.7 mmol) was added. After 2 h, the reaction mixture was concentrated and purified by chromatography (MeOH/DCM) to afford 5 g (70%) of Intermediate 18A. LCMS [m/z] calculated for C18H23NO5: 333.2; found 334.3[M+H]+, tR=4.41 (Method 2).
    • Step 18B: Synthesis of tert-butyl (S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Compound 18B)
  • Figure US20190345133A1-20191114-C01675
  • HATU (855 mg, 2.25 mmol) was added to a solution of Intermediate 18A (500 mg, 1.5 mmol), 2,2-dimethylpiperidine, HCl (224 mg, 1.5 mmol), and DIEA (0.92 mL, 5.25 mmol) in DMF (3 mL) at 0° C. After 3 h, the mixture was concentrated and diluted with EA and washed with NaHCO3 (sat). The organic layer was dried (Na2SO4) and purified by chromatography (EA/hex) to afford 620 mg (96%) of Intermediate 18B. LCMS [m/z] calculated for C25H36N2O4: 428.3; found 429.7[M+H]+, tR=5.75 (Method 2).
    • Step 18C: Synthesis of (S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Compound 18C)
  • Figure US20190345133A1-20191114-C01676
  • TFA (1 mL) was added to a solution of Intermediate 18B (620 mg, 1.45 mmol), in DCM (4 mL). After 16 h, the mixture was diluted with EA and washed with NaHCO3 (sat). The organic layer was dried (Na2SO4) and concentrated to afford 232 mg (43%) of Intermediate 18C. LCMS [m/z] calculated for C21H28N2O4: 372.2; found 373.4[M+H]+, tR=4.79 (Method 2).
    • Step 18D: Synthesis of (S)—N—((S)-4-azido-1-((4-chloro-2-iodo-5-methylphenyl) amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 18D)
  • Figure US20190345133A1-20191114-C01677
  • HATU (356 mg, 0.93 mmol) was added to a solution of Intermediate 18C (232 mg, 0.62 mmol), (S)-2-amino-4-azido-N-(4-chloro- 2-iodo- 5-methyl phenyl) butanamide (245 mg, 0.62 mmol, prepared as shown in Scheme 14, step B), and DIEA (0.22 mL, 1.3 mmol) in DMF (5 mL). After 3 h, the mixture was concentrated and diluted with EA and washed with NaHCO3 (sat). The organic layer was dried (Na2SO4) and purified by chromatography (EA/hex) to afford 466 mg (43%) of Intermediate 18D. LCMS [m/z] calculated for C32H39ClIN7O4: 747.2; found 748 [M+H]+, tR=6.31 (Method 2).
    • Step 18E: Synthesis of (S)—N—((S)-4-azido-1-((4-chloro-2-cyano-5-methyl phenyl) amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethyl piperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 18E)
  • Figure US20190345133A1-20191114-C01678
  • A flask containing 18D (201 mg, 0.27 mmol) and Zn(CN)2 (33 mg, 0.28 mmol) in DMF(8 mL) was degassed by N2 purging for 2 min, after which Pd(PPh3)4 was added. After further degassing (1 min), the reaction mixture was heated at 90° C. for 2 h, then diluted with EA and washed with 50% NH4OH/H2O. The organic layer was concentrated and purified by chromatography (EA/hexane) to afford 46.2 mg (27%) of Compound 18E. LCMS [m/z] calculated for C33H39ClN8O4: 646.3; found 647.2[M+H]+, tR=5.81 (Method 2).
    • Step 18F: Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-2-cyano-5-methyl phenyl) amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethyl piperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 18-1)
  • Figure US20190345133A1-20191114-C01679
  • Into a solution of Intermediate 18E (46.2 mg, 0.07 mmol) in THF (3 mL) were added water (0.5 mL) and PS-PPH3 resin (135 mg, 0.3 mmol equiv). After shaking for 24 h, the resin was removed via filtration through celite. The resulting solution was concentrated and purified by RP-HPLC (MeOH/H2O) to afford 3.6 mg (8%) of Compound 18-1. LCMS [m/z] calculated for C33H41ClN6O4: 620.3; found 621.6 [M+H]+, tR=12.47 min (Method 1).
  • Figure US20190345133A1-20191114-C01680
    • Example 19 Synthesis of (S)—N—((S)-4-(4-acetylpiperazin-1-yl)-1-((4-chloro-3-methylphenyl) amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 19-1)
  • Figure US20190345133A1-20191114-C01681
  • Figure US20190345133A1-20191114-C01682
    • Step 19A: Synthesis of (S)-4-(3-(tert-butoxycarbonyl)-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Compound 19-1)
  • Figure US20190345133A1-20191114-C01683
  • To (S)—N—((S)-1-((4-chloro-3-methyl phenyl) amino)-1-oxo-4-(piperazin-1-yl) butan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide, HCl (57 mg, 0.09 mmol, made via Scheme 17) in CH3CN (2 mL) was added DIEA (0.07 mL, 0.43 mmol) followed by acetic anhydride (0.03 mL, 0.34 mmol). After 1 h, reaction mixture was concentrated and the residue was partitioned between DCM (5 mL) and NaHCO3 (sat) (5 mL). The layers were separated using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (5 mL). The combined organic phases were concentrated and the crude product was purified by chromatography (MeOH/DCM) to afford 20 mg (33%) of Compound 19-1 as a white solid. LCMS [m/z] calculated for C37H42ClN5O5: 671.3; found 672.1[M+H]+, tR=4.48 min (Method 2).
  • Figure US20190345133A1-20191114-C01684
    • Example 20 Synthesis of (S)—N-(4-((4-chloro-3-methylphenyl) carbamoyl)-1-(2-hydroxyethyl) piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 20-1)
  • Figure US20190345133A1-20191114-C01685
    • Step 20A: Synthesis of (S)—N-(1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-((4-chloro-3-methyl phenyl) carbamoyl)piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydro isoquinoline-3-carboxamide (Compound 20A)
  • Figure US20190345133A1-20191114-C01686
  • To Compound 4-12 (50 mg, 0.09 mmol) in CH3CN (2.5 mL) were added K2CO3 (23.5 mg, 0.17 mmol) and 2-bromoethoxy-tert-butyldimethylsilane (54 mg, 0.26 mmol). The mixture was heated to 40° C. After 18 h, the reaction mixture was diluted with EA (100 mL) and washed with NaHCO3 (sat) (100 mL). The organic layer was dried (Na2SO4), concentrated and purified by chromatography (EA/hexane) to afford 30.3 mg (48%) of Intermediate 20A as a white solid. LCMS [m/z] calculated for C41H53ClN4O5Si: 744.4; found 746.1[M+H]+, tR=4.61 min (Method 4).
    • Step 20B: Synthesis of (S)—N-(4-((4-chloro-3-methyl phenyl) carbamoyl)-1-(2-hydroxyethyl) piperidin-4-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydro isoquinoline-3-carboxamide (Compound 20-1)
  • Figure US20190345133A1-20191114-C01687
  • A solution of 1M TBAF in THF (51 μL) was added to a solution of Intermediate 20A (30 mg, 0.05 mmol) in THF (2.5 mL). After 2 h, the reaction mixture was concentrated and purified by RP-HPLC to afford 13.6 mg (43%) of Compound 20-1. LCMS [m/z] calculated for C35H39ClN4O5: 630.3; found 632 [M+H]+, tR=7.04 min (Method 3).
  • Figure US20190345133A1-20191114-C01688
    • Example 21 Synthesis of (3S)—N-(1-((4-chloro-3-methylphenyl)amino)-4-(3-(dimethylamino)oxetan-3-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 21-1)
  • Figure US20190345133A1-20191114-C01689
    • Step 21A: Synthesis of methyl (E)-2-((tert-butoxycarbonyl)amino)-4-(3-(dimethylamino)oxetan-3-yl)but-2-enoate (Intermediate 21A)
  • Figure US20190345133A1-20191114-C01690
  • To a solution of a catalytic amount of DBU (0.046 mL, 0.31 mmol) in dry THF (5 mL, 3.1 mmol) dimethylamine (1.84 mL, 3.7 mmol) was added dimethylamine (1.84 mL, 3.7 mmol) followed by a solution of 2-(oxetan-3-ylidene)acetaldehyde (500 mg, 3.1 mmol) in dry THF (3 mL) at −15° C. After 50 min at −15° C., the solution was added to another solution of methyl 2-((tert-butoxy carbonyl) amino)-2-(dimethoxyphosphoryl) acetate (1091 mg, 3.7 mmol) in dry THF (50 mL) and DBU (0.46 ml, 3.1 mmol) at 0° C. After 30 min, the mixture was warmed to 60° C. for 30 min, then was then left stirring at rt overnight. The mixture was quenched with 1 M HCl (10 mL) and the volatiles removed by concentration. Toluene was added and the mixture was extracted with DCM (3×50 mL). The organic phases were washed with 1 M HCl (50 mL), brine (50 mL) and the organics were dried (MgSO4), concentrated, and the resulting material was loaded onto a column of SCX (5 g) in MeOH. The column was washed (3×10 ml MeOH) and then the product was eluted with MeOH (0.7 M NH3). The resultant mixture was concentrated to afford 400 mg (35%) of Intermediate 21A as a colourless oil. LCMS [m/z] calculated for C15H26N2O5: 314.2; found 315.1 [M+H]+, tR=0.7 min (Method 4).
    • Step 21B: Synthesis of methyl 2-((tert-butoxycarbonyl)amino)-4-(3-(dimethylamino) oxetan-3-yl)butanoate (Intermediate 21B)
  • Figure US20190345133A1-20191114-C01691
  • Intermediate 21A (400 mg, 1.3 mmol) was dissolved in MeOH (20 mL) and AcOH (1 mL) was added. The reaction mixture was hydrogenated in an H-Cube (10% Pd/C, 30×4 mm, Full hydrogen, 60° C., 1 mL/min). The solvent was evaporated to afford 176 mg (44%) of Intermediate 21B as a colourless oil. LCMS [m/z] calculated for C15H28N2O5: 316.2; found 317.1 [M+H]+, tR=1.54 min (Method 4).
    • Step 21C: Synthesis of 2-((tert-butoxycarbonyl)amino)-4-(3-(dimethylamino) oxetan-3-yl) butanoic acid (Intermediate 21C)
  • Figure US20190345133A1-20191114-C01692
  • Lithium hydroxide (8.48 mg, 0.35 mmol) was added to a solution of Intermediate 21B (56 mg, 0.18 mmol) in MeOH (2 mL, 49.4 mmol) and the reaction stirred at rt for 1.5 h. The solvent was removed to provide 54 mg (99%) of Intermediate 21C, which was used without further purification. LCMS [m/z] calculated for C14H25N2O5: 302.2; found 303.1 [M+H]+, tR=0.84 min (Method 4).
    • Step 21D: Synthesis of tert-butyl (1-((4-chloro-3-methylphenyl)amino)-4-(3-(dimethylamino)oxetan-3-yl)-1-oxobutan-2-yl)carbamate (Intermediate 21D)
  • Figure US20190345133A1-20191114-C01693
  • Intermediate 21C (54 mg, 0.18 mmol) was dissolved in DCM (3 mL, 0.18 mmol). 4-chloro-3-methylaniline (27.2 mg, 0.19 mmol) and DIEA (0.091 mL, 0.52 mmol) were added, followed by HATU (100 mg, 0.26 mmol) and DMF (1 mL) to help solubility of the reagents. After stirring overnight, the mixture was diluted DCM (20 mL) and the reaction quenched with 10% citric acid (20 mL). The phases were separated and the organic phase washed with NaHCO3 and brine and the volatiles were evaporated. The crude product was purified by chromatography [MeOH (0.7 N NH3/DCM to afford 38.9 mg (47%) of Intermediate 21D as an orange oily solid. LCMS [m/z] calculated for C21H32ClN3O4: 425.2; found 426.1 [M+H]+, tR=1.49 min (Method 4).
    • Step 21E: Synthesis of 2-amino-N-(4-chloro-3-methyl phenyl)-4-(3-(dimethyl amino) oxetan-3-yl) butanamide (Intermediate 21E)
  • Figure US20190345133A1-20191114-C01694
  • TFA (0.2 mL, 2.6 mmol) was added to a solution of Intermediate 21E (37 mg, 0.09 mmol) in DCM (1 mL). After 4h, additional TFA (0.2 mL, 2.6 mmol) was added. After stirring overnight, the volatile solvents were removed to afford Intermediate 21E (assuming 100%), which was used without further purification. LCMS [m/z] calculated for C16H24ClN3O4: 325.2; found 326.1 [M+H]+, tR=1.59 min (Method 4).
    • Step 21F: Synthesis of (3S)—N-(1-((4-chloro-3-methylphenyl)amino)-4-(3-(dimethylamino)oxetan-3-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 21-1)
  • Figure US20190345133A1-20191114-C01695
  • DIEA (75 μL, 0.43 mmol) was added to a solution of Intermediate 21E (28.3 mg, 0.09 mmol) and Intermediate 1B (32.2 mg, 0.1 mmol) in DCM (3 mL). HATU (50 mg, 0.13 mmol) was added. After 1 h, the solution was diluted with DCM (10 mL) and washed with NaHCO3 (10 mL). The organics were dried (MgSO4), filtered, concentrated, and purified by chromatography (MeOH (0.7 N NH3)/DCM) to afford 25 mg (42%) of Compound 21-1 as a white solid. LCMS [m/z] calculated for C36H41ClN4O5: 644.3; found 645.1 [M+H]+, tR=4.85 min (Method 4).
  • Figure US20190345133A1-20191114-C01696
    • Example 22 Synthesis of ((S)—N—((S)-3-(3-aminobicyclo[1.1.1]pentan-1-yl)-1-((4-chloro-3-methyl phenyl) amino)-1-oxopropan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydro isoquinoline-3-carboxamide (Compound 22-1) and (S)—N—((R)-3-(3-amino bicycle [1.1.1] pentan-1-yl)-1-((4-chloro-3-methylphenyl)amino)-1-oxopropan-2-yl)-2-(4-oxo-4-phenyl butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 22-2)
  • Figure US20190345133A1-20191114-C01697
    • Step 22A: Synthesis of (E)-methyl 2-(((benzyloxy)carbonyl)amino)-3-(3-((tert-butoxycarbonyl)amino)bicycle[1.1.1]pentan-1-yl)acrylate (Intermediate 22A)
  • Figure US20190345133A1-20191114-C01698
  • DBU (102 μL, 0.68 mmol) was added to a solution of tert-butyl (3-formyl bicycle [1.1.1] pentan-1-yl)carbamate (110 mg, 0.52 mmol) and methyl 2-(((benzyloxy) carbonyl)amino)-2-(dimethoxyphosphoryl)acetate (224 mg, 0.68 mmol) in DCM (3 mL) at 0° C. After stirring at rt overnight, the reaction mixture was quenched with 1 M HCl, and the two phases separated by sept cartridge. The organic layer was concentrated and the resulting crude material was purified by chromatography (EA/isohexane) to provide 144 mg (60%) Intermediate 22A. LCMS [m/z] calculated for C22H28N2O6: 416.2; found 417.3 [M+H]+, tR=2.31 min (Method 4).
    • Step 22B: Synthesis of methyl 2-amino-3-(3-((tert-butoxycarbonyl) amino) bicyclo[1.1.1]pentan-1-yl) propanoate (Intermediate 22B)
  • Figure US20190345133A1-20191114-C01699
  • Intermediate 22A (144 mg, 0.35 mmol) was dissolved in MeOH (1 mL) and the solution was degassed with N2. Pd-C(36.8 mg, 0.35 mmol) was added and the mixture was shaken under 5 atm of H2 overnight. The mixture was filtered through celite and concentrated to provide 85 mg (74%) of Intermediate 22B, which was used without further purification. LCMS [m/z] calculated for C14H42N2O4: 284.2; found 197.3 [M+H-tBu]+, tR=0.19 min (Method 4).
    • Step 22C: Synthesis of (3-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)propanoic acid (Intermediate 22C)
  • Figure US20190345133A1-20191114-C01700
  • DIEA (300 μL, 1.7 mmol) was added to a solution of Intermediate 22B (98 mg, 0.35 mmol) and Intermediate 1B (128 mg, 0.38 mmol) in DCM (5 mL). HATU (157 mg, 0.41 mmol) was added. After 2 h, the reaction was diluted with 1M HCl (3 mL) and the two phases were separated with a sep-cartridge. The organic layer was concentrated and the resulting crude material was purified by chromatography (EA/isohexane) to provide 60 mg (27%) of Intermediate 22C. LCMS [m/z] calculated for C34H41N3O7: 603.3; found 604.3 [M+H]+, tR=2.65 min (Method 4).
    • Step 22D: Synthesis of 3-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-1)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) propanoic acid (Intermediate 22D)
  • Figure US20190345133A1-20191114-C01701
  • LiOH (39.7 mg, 1.7 mmol) was added to a solution of Intermediate 22C (100 mg, 0.17 mmol) in THF (2.5 mL) and MeOH (2.5 mL). After 3h, the solvent was removed and the resulting crude material was partitioned between aq. 1 M HCl (10 mL) and DCM (20 mL). The organic phase was dried (MgSO4), filtered and concentrated to give 102 mg (99%) of Intermediate 22D that was used in the next step without further purification LCMS [m/z] calculated for C33H39N3O7: 589.3; found 590.3 [M+H]+, tR=1.69 min (Method 4).
    • Step 22E: Synthesis of tert-butyl (3-(3-((4-chloro-3-methylphenyl)amino)-3-oxo-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,34-tetrahydroisoquinoline-3-carboxamido)propyl)bicyclo[1.1.1]pentan-1-yl)carbamate (Intermediate 22E)
  • Figure US20190345133A1-20191114-C01702
  • DIEA (0.12 mL, 0.67 mmol) and HATU (82 mg, 0.22 mmol) were added to a solution of Intermediate 22D (98 mg, 0.17 mmol) in DCM (30 ml). The reaction mixture was cooled to 0° C. and 4-chloro-3-methylaniline (28.2 mg, 0.2 mmol) was added. After 2 h, the reaction was diluted with THF and washed with H2O. The organic layers were dried (MgSO4), filtered, concentrated, and purified by chromatography (EA/isohexane) to give 110 mg (85%) of Intermediate 22E. LCMS [m/z] calculated for C40H45ClN4O6: 712.3; found 713 [M+H]+, tR=1.97 min (Method 4).
    • Step 22F: Synthesis of (S)—N—((S)-3-(3-aminobicyclo[1.1.1]pentan-1-yl)-1-((4-chloro-3-methylphenyl)amino)-1-oxopropan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 22-1) and (S)—N—((R)-3-(3-aminobicyclo[1.1.1]pentan-1-yl)-1-((4-chloro-3-methylphenyl)amino)-1-oxopropan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 22-2)
  • Figure US20190345133A1-20191114-C01703
  • A solution of Intermediate 22E (100 mg, 0.14 mmol) in DCM (2 ml) was treated with TFA (0.1 mL). After 3h, the reaction mixture was concentrated and the resulting crude material was partitioned between DCM (10 mL) and 1 M HCl (10 mL). The organic layer was dried (MgSO4), filtered, concentrated and purified by chromatography (MeOH (0.7 M NH3)/DCM) to give 15 mg (17%) of Compound 22-1 and 12 mg (13%) of Compound 22-2. Compound 22-1: LCMS [m/z] calculated for C35H37ClN4O4: 612.3; found 613.1 [M+H]+, tR=4.51 min (Method 5). Compound 22-2: LCMS [m/z] calculated for C35H37ClN4O4: 612.3; found 613.1 [M+H]+, tR=4.67 min (Method 5).
  • Following the procedures as set forth in Scheme 22 above, the compounds of the following Table 2 were prepared using the appropriate R1, R3a and R3b reagents.
  • TABLE 22
    Figure US20190345133A1-20191114-C01704
    R3a/R3b LCMS
    Cmpd. Stereo- MS MS Retention Purity
    # R1 R3a R3b chemistry Calc (MH)+ Time(min) Method
    22-1
    Figure US20190345133A1-20191114-C01705
         		H
    Figure US20190345133A1-20191114-C01706
         		S 612.3 613.1 4.51 5
    22-2
    Figure US20190345133A1-20191114-C01707
         		H
    Figure US20190345133A1-20191114-C01708
         		R 612.3 613.1 4.67 5
    22-3
    Figure US20190345133A1-20191114-C01709
         		H
    Figure US20190345133A1-20191114-C01710
         		racemic 650.2 651 6.08 5
  • Figure US20190345133A1-20191114-C01711
    • Example 23 Synthesis of N-(1-((2,3-dihydro-1H-inden-5-yl)amino)-4-(4-fluoropiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 23-1)
  • Figure US20190345133A1-20191114-C01712
    • Step 23A: Synthesis of tert-butyl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-homoserinate (Intermediate 23A)
  • Figure US20190345133A1-20191114-C01713
  • To a stirred solution of (S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-4-oxobutanoic acid (6.7 g, 16.3 mmol) in THF (65.1 mL, 16.3 mmol) was added N-methylmorpholine (1.8 mL, 16.3 mmol). The reaction was cooled to 0° C. followed by the slow addition of ethyl chloroformate (1.6 mL, 16.3 mmol). A colourless precipitate began to form immediately. The reaction was warmed to rt and stirred for 1 h. The formed precipitate was filtered off using a phase sep cartridge, rinsing with THF (10 mL). The filtrate was cooled again to 0° C. and a solution of sodium borohydride (0.8 g, 21.2 mmol) in 21 mL of H2O/THF (1:1) was added. The resulting mixture was stirred at 0° C., followed by slow warming to rt over 1 h. The reaction mixture was then concentrated under reduced pressure and the residue was dissolved in EA (120 mL), washed with 1 M HCl (2×50 mL) and dried (MgSO4). The solvent was removed in vacuo to afford 7.3 g (104%) of Intermediate 22A as a colorless oil. LCMS [m/z] calculated for C23H27NO5: 397.2; found 420.0 [M+Na]+, tR=2.55 min (Method 4).
    • Step 23B: Synthesis of tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-oxobutanoate (Intermediate 23B)
  • Figure US20190345133A1-20191114-C01714
  • To a round bottom flask containing Intermediate 23A (7.3 g, 16.9 mmol) in DCM (70 mL, 17.5 mmol) at 0° C. was added DMP (7.8 g, 18.4 mmol). The reaction was warmed to rt. The solution was washed with NaHCO3 (3×75 mL). The organic phase was dried (MgSO4) and the solvent was removed in vacuo. The residue was purified by column chromatography (EA/isohexane) to afford Intermediate 23B (4.4 g, 9.9 mmol, 57% yield) as a thick colourless oil. LCMS [m/z] calculated for C23H25NO5: 395.2; found 418.1 [M+Na]+, tR=2.54 min (Method 4).
    • Step 23C: Synthesis of tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-fluoropiperidin-1-yl)butanoate (Intermediate 23C)
  • Figure US20190345133A1-20191114-C01715
  • To a round bottom flask containing Intermediate 23B (500 mg, 1.3 mmol) in DCM (1.8 mL) and THF (6.3 mL) was added 4-fluoropiperidine, HCl (194 mg, 1.4 mmol) followed by acetic acid (80 μl, 1.4 mmol). The reaction was stirred at rt under N2 for 15 min, then cooled to 0° C. and sodium triacetoxyborohydride (670 mg, 3.2 mmol) was added to the reaction mixture portionwise. The reaction was then allowed to warm to rt overnight. The reaction mixture was diluted with DCM (30 mL) and washed with a NaHCO3 (2×30 mL) before being passed through a hydrophobic frit. The solvent was removed in vacuo to afford Intermediate 23C (695 mg, 1.3 mmol, 100% yield) as a colourless oil. LCMS [m/z] calculated for C28H35FN2O4: 482.3; found 483.1 [M+H]+, tR=1.8 min (Method 4).
    • Step 23D: Synthesis of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-fluoropiperidin-1-yl)butanoic acid (Intermediate 23D)
  • Figure US20190345133A1-20191114-C01716
  • Intermediate 23C (675 mg, 1.4 mmol) was dissolved in DCM (3 mL). TFA (1 ml, 12.9 mmol) was added and the reaction mixture was stirred at rt for 2 h. Additional TFA (1 mL) was added. After 1.5 h, the solvent was removed in vacuo and chased with toluene (2×5 mL) before DCM (3 mL) was added and the mixtures were stood at rt overnight. Isohexane (10 mL) was added to the resultant oil and the mixture was sonicated before the solvent was removed in vacuo to afford Intermediate 23D (662 mg, 1.4 mmol, 100% yield) as a white solid. LCMS [m/z] calculated for C24H27FN2O4: 426.2; found 427.0 [M+H]+, tR=1.54 min (Method 4).
    • Step 23E: Synthesis of (9H-fluoren-9-yl)methyl (S)-(1-((2,3-dihydro-1H-inden-5-yl)amino)-4-(4-fluoropiperidin-1-yl)-1-oxobutan-2-yl)carbamate (Intermediate 23E)
  • Figure US20190345133A1-20191114-C01717
  • To a vial containing 2,3-dihydro-1H-inden-5-amine (68.3 mg, 0.51 mmol) was added Intermediate 23D (182 mg, 0.43 mmol) in DCM (2 mL). The reaction mixture was cooled to 0° C., followed by the addition of DIEA (0.22 mL, 1.28 mmol) and HATU (244 mg, 0.64 mmol). The reaction mixture was stirred at 0° C. for 10 min and then warmed to rt. Additional DCM (3 mL) was added. After 1.5 h, the reaction mixture was diluted with DCM (10 mL) and sat. aq. NH4Cl (10 mL) and the mixture was transferred to a separating funnel. The layers were partitioned and the aqueous layer was further extracted with DCM (2×10 mL). The combined organics were dried (MgSO4), filtered, and the solvent was removed in vacuo. The material was purified by chromatography (MeOH (0.7 M NH3)/DCM), to provide 191 mg (74%) of Intermediate 23E as a clear colourless oil. LCMS [m/z] calculated for C33H36FN3O3: 541.3; found 542.1 [M+H]+, tR=1.95 min (Method 4).
    • Step 23F: Synthesis of (S)-2-amino-N-(2,3-dihydro-1H-inden-5-yl)-4-(4-fluoropiperidin-1-yl)butanamide (Intermediate 23F)
  • Figure US20190345133A1-20191114-C01718
  • Intermediate 23E (191 mg, 0.32 mmol) was dissolved in DCM (4 mL). Diethylamine (1 mL) was added and the mixture was stirred for 2.5 h, then concentrated under vacuum, co-evaporating with DCM/PhMe (×2) to afford 29 mg (28%) of the crude Intermediate 23F as a clear, orange oil. LCMS [m/z] calculated for C18H26FN3O: 319.2; found 320.1 [M+H]+, tR=0.45 min (Method 4).
    • Step 23G: Synthesis of N-(1-((2,3-dihydro-1H-inden-5-yl)amino)-4-(4-fluoropiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 23-1)
  • Figure US20190345133A1-20191114-C01719
  • To a vial were combined Intermediate 1B (35.7 mg, 0.11 mmol) and Intermediate 23F (29 mg, 0.09 mmol) in DCM (0.9 mL). The mixture was cooled to 0° C., followed by the addition of DIEA (0.08 mL, 0.44 mmol). After stirring at 0° C. for 10 min, HATU (67.1 mg, 0.18 mmol) was added and the reaction was stirred at 0° C. under an atmosphere of N2. After stirring for 1.5 h, the reaction mixture was diluted with DCM (10 mL) and sat. aq. NH4Cl (10 mL). The layers were partitioned and the aqueous phase was further extracted with DCM (5 mL). The combined organic extracts were filtered through a phase sep cartridge and the solvent was removed in vacuo. The crude material was purified by column chromatography (MeOH (0.7 M NH3) in DCM) to afford 5 mg (9%) of Compound 23-1 as a mixture of diastereomers. LCMS [m/z] calculated for C38H43FN4O4: 638.3; found 639.1 [M+H]+, tR=4.79 min (Method 4).
  • Following the procedures as set forth in Scheme 23 above, the compounds of the following Table 23 were prepared using the appropriate R1, R3a and R3b reagents.
  • TABLE 23
    Figure US20190345133A1-20191114-C01720
    R3a/R3b LCMS
    Cmpd. Stereo- MS MS Retention Purity
    # R1 R3a R3b chemistry Calc (MH)+ Time (min) Method
    23-1
    Figure US20190345133A1-20191114-C01721
         		H
    Figure US20190345133A1-20191114-C01722
         		racemic 638.3 639.1 4.79 5
    23-2
    Figure US20190345133A1-20191114-C01723
         		H
    Figure US20190345133A1-20191114-C01724
         		S 702.2 702.9 5.16 5
    23-3
    Figure US20190345133A1-20191114-C01725
         		H
    Figure US20190345133A1-20191114-C01726
         		racemic 684.2 685 4.92 5
    23-4
    Figure US20190345133A1-20191114-C01727
         		H
    Figure US20190345133A1-20191114-C01728
         		S 688.2 690.9 5.43 5
    23-5
    Figure US20190345133A1-20191114-C01729
         		H
    Figure US20190345133A1-20191114-C01730
         		S 702.2 704.9 5.43 5
    23-6
    Figure US20190345133A1-20191114-C01731
         		H
    Figure US20190345133A1-20191114-C01732
         		S 628.3 629.1 5.26 5
    23-7
    Figure US20190345133A1-20191114-C01733
         		H
    Figure US20190345133A1-20191114-C01734
         		S 642.3 643.1 5.11 5
    23-8
    Figure US20190345133A1-20191114-C01735
         		H
    Figure US20190345133A1-20191114-C01736
         		S 656.3 657.1 5.13 5
    23-9
    Figure US20190345133A1-20191114-C01737
         		H
    Figure US20190345133A1-20191114-C01738
         		S 670.3 671.1 6.01 5
  • Figure US20190345133A1-20191114-C01739
    • Example 24 (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-methoxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 24-1)
  • Figure US20190345133A1-20191114-C01740
    • Step 24A: Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-1-((4-chloro-3-methylphenyl)amino)-4-iodo-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 24A)
  • Figure US20190345133A1-20191114-C01741
  • Iodine (89 mg, 0.35 mmol) was added to a solution of triphenylphospine (92 mg, 0.35 mmol) in DCM (5 mL) at 0° C. After 1 min, imidazole (28.4 mg, 0.42 mmol) was added. The mixture was stirred 10 min. Intermediate 17E (200 mg, 0.32 mmol) was added and the reaction mixture was warmed to rt and stirred overnight. Water (5 mL) was added and the layers were separated using a phase sep-cartridge. The organic phase was concentrated in vacuo. The crude product was purified by chromatography (EA/isohexane) to afford 125 mg (48%) of Intermediate 24A as a yellow oil. LCMS [m/z] calculated for C36H33ClIN3O4: 733.1; found 756.1 [M+Na]+, tR=3.14 min (Method 4).
    • Step 24B: Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-methoxypiperidin-1-yl)-1-oxobutan-2-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Intermediate 24B)
  • Figure US20190345133A1-20191114-C01742
  • To a solution of Intermediate 24A (98 mg, 0.13 mmol) in dioxane (2 mL) was added 4-methoxypiperidine (76.0 mg, 0.67 mmol). The reaction was stirred at 50° C. overnight. The reaction was diluted with NaHCO3 (5 mL) and extracted with EA (2×5 mL). The combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo to afford 67 mg (99%) of Intermediate 24B. LCMS [m/z] calculated for C27H35ClN4O3: 498.2; found 499.3 [M+H]+, tR=1.17 min (Method 4).
    • Step 24C: Synthesis of (S)—N—((S)-1-((4-chloro-3-methylphenyl)amino)-4-(4-methoxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Intermediate 24-1)
  • Figure US20190345133A1-20191114-C01743
  • A solution of Intermediate 24B (67 mg, 0.13 mmol) and 4-oxo-4-phenylbutanoic acid (59.8 mg, 0.34 mmol) in DCM (2 mL) was treated with N-ethyl-N-isopropylpropan-2-amine (117 μl, 0.67 mmol) and HATU (153 mg, 0.40 mmol). The reaction mixture was stirred at rt for 2 h. The reaction mixture was partitioned between DCM (5 mL) and aq NH4Cl solution (5 mL). The layers were separated using a phase sep-cartridge then re-extracted with DCM (5 mL). The combined organic layers were concentrated in vacuo. The crude product was purified by chromatography (0.7 M Ammonia/MeOH)/DCM) to afford 26 mg (28%) of Compound 24-1 as a white solid. LCMS [m/z] calculated for C37H43ClN4O5: 658.3; found 659.1 [M+H]+, tR=4.81 min (Method 5).
  • Following the procedures as set forth in Scheme 24 above, the compounds of the following Table 24 were prepared using the appropriate R1, R3a and R3b reagents.
  • TABLE 24
    Figure US20190345133A1-20191114-C01744
    R3a/R3b LCMS
    Cmpd. Stereo- MS MS Retention Purity
    # R1 R3a R3b chemistry Calc (MH)+ Time (min) Method
    24-1
    Figure US20190345133A1-20191114-C01745
         		H
    Figure US20190345133A1-20191114-C01746
         		S 658.3 659.1 4.81 5
    24-2
    Figure US20190345133A1-20191114-C01747
         		H
    Figure US20190345133A1-20191114-C01748
         		S 635.3 636.1 4.28 5
  • Figure US20190345133A1-20191114-C01749
    • Example 25 (3S)—N-(1-((2,4-dichloro-3-methylphenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 25-1)
  • Figure US20190345133A1-20191114-C01750
    • Step 25A: Synthesis of (9H-fluoren-9-yl)methyl (3S)-3-((1-(tert-butoxy)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 25A)
  • Figure US20190345133A1-20191114-C01751
  • Crude tert-butyl 2-amino-4-(4-hydroxypiperidin-1-yl)butanoate (1.3 g, 5.2 mmol) (per scheme 23) was dissolved in DCM (52.2 mL). Into that flask were added N-ethyl-N-isopropylpropan-2-amine (3.64 mL, 20.9 mmol) and (S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (2.5 g, 6.3 mmol) and the mixture was cooled to 0° C. HATU was added (3.97 g, 10.4 mmol) portionwise. After 3 h, additional DCM (50 mL) was added and the organic layer was washed with 2M HCl (2×100 mL), dried (MgSO4) and concentrated under reduced pressure. The residue was purified by flash column chromatography (MeOH/DCM) to provide 1.45 g (40%) of Intermediate 25A as a white solid. LCMS [m/z] calculated for C38H45N3O6: 639.3; found 640.6 [M+H]+, tR=1.65 min (Method 4).
    • Step 25B: Synthesis of (9H-fluoren-9-yl)methyl (3S)-3-((4-(4-acetoxypiperidin-1-yl)-1-(tert-butoxy)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 25B)
  • Figure US20190345133A1-20191114-C01752
  • Acetic anhydride (0.56 mL, 5.9 mmol) was added dropwise to a solution of Intermediate 25A (3.16 g, 4.9 mmol) and pyridine (0.64 mL, 7.9 mmol) in DCM (24.7 mL, 4.9 mmol). After 1 h, the reaction mixture was diluted with DCM (100 mL), then washed with 1M HCl (2×50 mL), dried (MgSO4) then concentrated under reduced pressure. Crude intermediate 25B (3.42 g, 96% yield) was used without further purification. LCMS [m/z] calculated for C40H47N3O7: 681.3; found 682.6 [M+H]+, tR=1.89 min (Method 4).
    • Step 25C: Synthesis of tert-butyl 4-(4-acetoxypiperidin-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoate (Intermediate 25C)
  • Figure US20190345133A1-20191114-C01753
  • Diethylamine (15.49 mL, 148 mmol) was added to a solution of Intermediate 25B (3.37 g, 4.9 mmol) in DCM (10 mL). After 1 h, toluene (100 mL) was added and the mixture was concentrated under reduced pressure to remove excess diethylamine. The crude material was redissolved in DCM (25 mL) and DIEA (3.45 mL, 19.8 mmol) was added. The mixture was cooled to 0° C. and 4-oxo-4-phenylbutanoic acid (1.06 g, 5.9 mmol) was added, followed by HATU (3.76 g, 9.9 mmol). After stirring for 2 h at rt, additional 4-oxo-4-phenylbutanoic acid (0.5 g, 2.9 mmol) and HATU (1 g, 2.6 mmol) were added. After 6 h, the mixture was diluted with DCM (70 mL) and washed with 1M HCl (2×50 mL), dried (MgSO4), then concentrated under reduced pressure.
  • The crude material was purified chromatography (MeOH/DCM/Hexanes) to provide 813 mg, (19%) of Intermediate 25C as a yellow oil. LCMS [m/z] calculated for C35H45N3O7: 619.3; found 620.1 [M+H]+, tR=1.6 min (Method 4).
    • Step 25D: Synthesis of 4-(4-acetoxypiperidin-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoic acid (Intermediate 25D)
  • Figure US20190345133A1-20191114-C01754
  • Intermediate 25C (800 mg, 1.291 mmol) was suspended in DCM (3 mL) and TFA (1.3 mL). After 6 h, the mixture was diluted with toluene (20 mL) and concentrated under reduced pressure to obtain 770 mg (85%) of Intermediate 25D as a pale yellow solid. LCMS [m/z] calculated for C31H37N3O7: 563.3; found 564.4 [M+H]+, tR=0.98 min (Method 4).
    • Step 25E: Synthesis of 1-(4-((2,4-dichloro-3-methylphenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)piperidin-4-yl acetate (Compound 25-E)
  • Figure US20190345133A1-20191114-C01755
  • Intermediate 25D (100 mg, 0.18 mmol) was suspended in DCM (0.8 mL) and 1-chloro-N, N, 2-trimethylprop-1-en-1-amine (47.4 mg, 0.355 mmol) in DCM (0.7 mL) was added dropwise After 20 min, 2,4-dichloro-3-methylaniline (46.8 mg, 0.27 mmol) in pyridine (0.5 mL, 0.177 mmol) was added dropwise. After 2 days, the mixture was diluted with DCM (4 mL), washed with 1 M HCl (3×3 mL), dried (MgSO4) and concentrated under reduced pressure to provide 153 mg (36%) of Intermediate 25E. LCMS [m/z] calculated for C38H42Cl2N4O6: 720.3; found 720.3 [M]+, tR=1.7 min (Method 4).
    • Step 25F: Synthesis of (3S)—N-(1-((2,4-dichloro-3-methylphenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 25-1)
  • Figure US20190345133A1-20191114-C01756
  • Intermediate 25E (153.3 mg, 0.212 mmol) was dissolved in MeOH (8 mL). Potassium carbonate (117 mg, 0.85 mmol) was added. After 3 h, the mixture was diluted with DCM (4 mL), washed with brine (3×4 mL), dried (MgSO4) then concentrated under reduced pressure. The crude material was purified by chromatography (MeOH/DCM/0.7M NH3) to obtain 18 mg (12%) of Compound 25-1. LCMS [m/z] calculated for C36H40Cl2N4O5: 678.2; found 679.0 [M+H]+, tR=4.49 min (Method 5).
  • Following the procedures as set forth in Scheme 25 above, the compounds of the following Table 25 were prepared using the appropriate R1, R3a and R3b reagents.
  • TABLE 25
    Figure US20190345133A1-20191114-C01757
    R3a/R3b LCMS
    Cmpd. Stereo- MS MS Retention Purity
    # R1 R3a R3b chemistry Calc (MH)+ Time (min) Method
    25-1
    Figure US20190345133A1-20191114-C01758
         		H
    Figure US20190345133A1-20191114-C01759
         		racemic 678.2 679 4.49 5
    25-2
    Figure US20190345133A1-20191114-C01760
         		H
    Figure US20190345133A1-20191114-C01761
         		racemic 662.3 663 4.18 5
    25-3
    Figure US20190345133A1-20191114-C01762
         		H
    Figure US20190345133A1-20191114-C01763
         		racemic 644.3 645.1 3.88 5
  • Figure US20190345133A1-20191114-C01764
    • Example 26 (S)—N—((S)-1-((3,4-dichloro-2-fluorophenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 26-1)
  • Figure US20190345133A1-20191114-C01765
    • Step 26A: Synthesis of tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-acetoxypiperidin-1-yl)butanoate (Intermediate 26A)
  • Figure US20190345133A1-20191114-C01766
  • To a round bottom flask containing tert-butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-hydroxypiperidin-1-yl)butanoate (prepared via Scheme 23, 4.95 g, 10.3 mmol) was added DCM (51.5 mL)) and pyridine (1.3 mL, 16.5 mmol). Acetic anhydride (1.17 mL, 12.4 mmol) was then added to the reaction mixture dropwise and the reaction was allowed to stir at rt overnight, under an atmosphere of N2. Additional portions of pyridine (1.3 mL, 16.5 mmol) and acetic anhydride (1.17 mL, 12.4 mmol) were added. After 3 h, DMAP (0.13 g, 1.03 mmol) was added and, after stirring for 2 h, the reaction mixture was then diluted with DCM (70 mL) and transferred to a separating funnel and washed with 1 M aqueous HCl (2×70 mL). The organic phase was then dried (Mg2SO4) and the solvent was removed in vacuo to afford 5.64 g, (94%) of Intermediate 26A as a thick yellow oil. LCMS [m/z] calculated for C30H38N2O6: 522.3; found 523.2 [M+H]+, tR=1.81 min (Method 4).
    • Step 26B: Synthesis of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(4-acetoxypiperidin-1-yl)butanoic acid (Intermediate 26B)
  • Figure US20190345133A1-20191114-C01767
  • To a round bottom flask containing Intermediate 26B (5.64 g, 10.8 mmol) in DCM (32.2 mL) was added TFA (21.5 mL, 280 mmol). The reaction was stirred under an atmosphere of N2. After stirring for 3.5 h, the solvent was removed under vacuum and the resulting material was coevaporated with toluene/DCM (×3) and EA (×1). The crude material was then slurried with iso-hexane to afford a pale yellow solid which was collected by filtration, and dried in the vacuum oven at 40° C. for 2 h. The material was re-suspended in DCM/toluene and concentrated under vacuum to afford a thick yellow oil. The material was then dissolved in minimum DCM and iso-hexane (approx. 100 mL) was added to aid precipitation and the pale yellow solid was collected by filtration and dried in a vacuum oven at 40° C. to afford 1.91 g (32%) of Intermediate 26B. LCMS [m/z] calculated for C26H30N2O6: 466.2; found 467.2 [M+H]+, tR=1.60 min (Method 4).
    • Step 26C: Synthesis of (S)-1-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((3,4-dichloro-2-fluorophenyl)amino)-4-oxobutyl)piperidin-4-yl acetate (Intermediate 26C)
  • Figure US20190345133A1-20191114-C01768
  • To an oven dried round bottom flask was combined Intermediate 26B (16.4 mL, 4.1 mmol). 1-chloro-N,N,2-trimethylprop-1-en-1-amine (1.083 mL, 8.19 mmol) was added to the reaction mixture, which was stirred for 10 min under an atmosphere of N2. 3,4-dichloro-2-fluoroaniline (1.47 g, 8.2 mmol) was then added to the reaction mixture as a solution in pyridine (1.61 ml, 20 mmol). Upon complete addition the reaction mixture was stirred under an atmosphere of N2 for 2 h, then was diluted with DCM (70 mL) and transferred to a separating funnel where it was washed with 1 M HCl (aq.). The organic phase was dried (Mg2SO4) and the solvent was removed in vacuo to afford the crude product as a yellow oil. The material was purified by column chromatography (MeOH (w/0.7 M NH3)/DCM), to afford 1.36 g (51%) of Intermediate 26C. LCMS tR=1.59 min (Method 4).
    • Step 26D: Synthesis of (S)-1-(3-amino-4-((3,4-dichloro-2-fluorophenyl)amino)-4-oxobutyl)piperidin-4-yl acetate (Intermediate 26D)
  • Figure US20190345133A1-20191114-C01769
  • Into a flask was added Intermediate 26C (1.36 g, 2.16 mmol) and DCM (10 mL). Diethylamine (2 mL, 19.1 mmol) was added and the reaction mixture was stirred for 4 h, concentrated in vacuo (co-evaporating with DCM/toluene) to afford the crude product. The material was used directly in the next step without further purification nor analysis, assuming 100% yield and 100% purity. LCMS tR=1.59 min (Method 4).
    • Step 26E: Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-4-(4-acetoxypiperidin-1-yl)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 26E)
  • Figure US20190345133A1-20191114-C01770
  • To a round bottom flask was combined Intermediate 26D (879 mg, 2.16 mmol) and DCM (21.6 mL). DIEA (1.13 mL, 6.5 mmol) was added to the mixture and the reaction was cooled to 0° C. using an ice/water bath. HATU (1232 mg, 3.24 mmol) was added portionwise. Upon complete addition, the reaction was stirred at 0° C. for 5 minutes before warming to rt and stirring under an atmosphere of N2. After 1 h of stirring at rt, the reaction mixture was diluted with DCM (50 mL) and 1M HCl (aq.) (50 mL) and the mixture was transferred to a separating funnel. The layers were partitioned and the aqueous layer was further extracted with DCM (50 mL). The combined organics were then washed with a saturated aqueous solutions of NaHCO3 (50 mL) and brine (50 mL) and dried (MgSO4) and the solvent was removed in vacuo to afford the crude product as a thick clear yellow oil. The crude material was purified by column chromatography (MeOH (0.7M NH3)/DCM), to provide 929 mg (48%) of Intermediate 26E. LCMS [m/z] calculated for C42H41Cl2FN4O6: 786.2; found 787.2 [M+H]+, tR=2.24 min (Method 4).
    • Step 26F: Synthesis of 1-((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-4-oxo-3-((S)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)piperidin-4-yl acetate (Intermediate 26F)
  • Figure US20190345133A1-20191114-C01771
  • To a round bottom flask was combined Intermediate 26E (929 mg, 1.18 mmol) and DCM (8 mL). Diethylamine (4 mL, 38.3 mmol) was added and the reaction mixture was stirred at rt under an atmosphere of N2 overnight. The reaction mixture was concentrated under reduced pressure (co-evaporating with DCM/toluene) to afford the crude product as a thick orange oil. The crude material was purified by column chromatography (MeOH (0.7 M NH3)/DCM) to afford 417 mg (62%) Intermediate 26F as a sticky off-white solid. LCMS [m/z] calculated for C27H31Cl2FN4O4: 564.2; found 565.2 [M+H]+, tR=2.5 min (Method 4).
    • Step 26G: Synthesis of 4-((S)-3-(((S)-4-(4-acetoxypiperidin-1-yl)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Intermediate 26G)
  • Figure US20190345133A1-20191114-C01772
  • Into a round bottom flask were combined Intermediate 26F (417 mg, 0.74 mmol), DCM (9.8 mL) and THF (1 mL). Dihydrofuran-2,5-dione (77 mg, 0.77 mmol) was added. After stirring at rt overnight, under N2, the reaction was concentrated in vacuo, and used directly without further purification. LCMS [m/z] calculated for C31H35Cl2FN4O7: 664.2; found 665.2 [M+H]+, tR=1.59 min (Method 4).
    • Step 26H: Synthesis of 1-((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-3-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)piperidin-4-yl acetate (Intermediate 26H)
  • Figure US20190345133A1-20191114-C01773
  • Into a vial were combined 2,2-dimethylpiperidine (22.12 mg, 0.195 mmol) and Intermediate 26A (100 mg, 0.15 mmol) in DCM (1.5 mL). DIPEA (0.079 mL, 0.45 mmol) was added and the mixture was cooled to 0° C. HATU (86 mg, 0.23 mmol) was then added and the reaction mixture was stirred at 0° C. for 10 min, then warmed to rt. After stirring at rt for 1.5 h, the mixture was diluted with DCM (10 mL) and 1 M HCl (aq.) (10 mL) and the mixture was transferred to a separating funnel. The layers were partitioned and the aqueous layer was further extracted with DCM (10 mL). The combined organics were then washed with a saturated aqueous solution of NaHCO3 (10 mL), brine (10 mL) and dried (MgSO4) and the solvent was removed in vacuo to afford 114 mg (100%) of Intermediate 26H as an orange oil.
    • Step 261: Synthesis of (S)—N—((S)-1-((3,4-dichloro-2-fluorophenyl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 26-1)
  • Figure US20190345133A1-20191114-C01774
  • Into a round bottom flask were added Intermediate 26H (114 mg, 0.15 mmol) and MeOH (1.5 mL) and K2CO3 (83 mg, 0.6 mmol) under an atmosphere of N2. After stirring at rt for 2 h, the mixture was concentrated, followed by dissolving in DCM (20 mL) and brine (10 mL). The mixture was transferred to a separating funnel and the layers were partitioned. The organic phase was further washed with brine (10 mL), dried (MgSO4) and the solvent was removed in vacuo to afford the crude material as a clear orange oil. The crude material was purified by chromatography (MeOH (0.7 M NH3) in DCM), to afford 21.5 mg (19%) of Compound 26-1. (LCMS [m/z] calculated for C36H46Cl2FN5O5: 717.3; found 718.1 [M+H]+, tR=4.72 min (Method 5).
  • Following the procedures as set forth in Scheme 26 above, the compounds of the following Table 26 were prepared using the appropriate R1, R3a and R3b reagents.
  • TABLE 26
    Figure US20190345133A1-20191114-C01775
    Cmpd. # R3a R3b R3a/R3b Stereo- chemistry
    Figure US20190345133A1-20191114-C01776
         		MS Calc MS (MH)+ LCMS Retention Time (min) Purity Method
    26-1 H
    Figure US20190345133A1-20191114-C01777
         		S
    Figure US20190345133A1-20191114-C01778
         		717.3 718.1 4.72 5
    26-2 H
    Figure US20190345133A1-20191114-C01779
         		R
    Figure US20190345133A1-20191114-C01780
         		717.3 718.1 4.98 5
    26-3 H
    Figure US20190345133A1-20191114-C01781
         		S
    Figure US20190345133A1-20191114-C01782
         		717.3 718.1 4.69 5
  • Figure US20190345133A1-20191114-C01783
    • Example 27 (S)—N—((S)-4-amino-1-((4-chloro-5-methylpyridin-2-yl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 27-1)
  • Figure US20190345133A1-20191114-C01784
    • Step 27A: Synthesis of tert-butyl ((S)-4-((4-chloro-5-methylpyridin-2-yl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)carbamate (Intermediate 27A)
  • Figure US20190345133A1-20191114-C01785
  • tert-butyl ((S)-4-((4-chloro-5-methylpyridin-2-yl)amino)-4-oxo-3-((S)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)carbamate (made per Scheme 10, 60 mg, 0.12 mmol) and 4-oxo-4-phenylbutanoic acid (42.6 mg, 0.24 mmol) were dissolved in DCM (3 mL). DIEA (0.1 mL, 0.6 mmol) was added. After 10 min, HATU (136 mg, 0.36 mmol) was added. After 1 h, the reaction mixture was partitioned between DCM (5 mL) and sat aqueous solution of NaHCO3 (5 mL). The layers were separated using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (5 mL). The combined organic phases were concentrated in vacuo. The crude material was purified by chromatography (MeOH/DCM) 80 mg, (99%) of Intermediate 27A as a white solid. LCMS [m/z] calculated for C35H40ClN5O6: 661.3; found 662.1 [M+H]+, tR=2.57 min (Method 4).
    • Step 27B: Synthesis of (S)—N—((S)-4-amino-1-((4-chloro-5-methylpyridin-2-yl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,34-tetrahydroisoquinoline-3-carboxamide (Compound 27-1)
  • Figure US20190345133A1-20191114-C01786
  • Into a solution of Intermediate 27A (80 mg, 0.12 mmol) in DCM (5 mL) was added TFA (1 mL). After 30 min, the solvent was evaporated and the crude product was purified by chromatography ((0.7 M Ammonia/MeOH)/DCM) to afford an off-white solid. The product was partitioned between DCM (5 mL) and sat aq NaHCO3 solution (5 mL). The layers were separated using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (5 mL). The combined organic phases were concentrated in vacuo to provide 47 mg, (66.5%) of Compound 27-1 as a white solid. LCMS [m/z] calculated for C30H32ClN5O4: 561.2; found 562.0 [M+H]+, tR=3.74 min (Method 5).
  • Following the procedures as set forth in Scheme 27 above, the compounds of the following Table 27 were prepared using the appropriate R1 and R10 reagents.
  • TABLE 27
    Figure US20190345133A1-20191114-C01787
    LCMS
    Com- Retention
    pound MS MS Time Purity
    Number R1 R10 Calc (MH)+ (min) Method
    27-1
    Figure US20190345133A1-20191114-C01788
         		H 561.2 562 7.74 5
    27-2
    Figure US20190345133A1-20191114-C01789
         		H 598.2 599 4.69 5
    27-3
    Figure US20190345133A1-20191114-C01790
         		H 594.2 595 4.89 5
    27-4
    Figure US20190345133A1-20191114-C01791
         		H 537.2 538.1 3.2 5
    27-5
    Figure US20190345133A1-20191114-C01792
         		H 562.2 563.1 4.44 5
    27-6
    Figure US20190345133A1-20191114-C01793
         		H 598.2 599 5.11 5
    27-7
    Figure US20190345133A1-20191114-C01794
         		F 616.1 617.2 4.59 5
  • Figure US20190345133A1-20191114-C01795
    • Example 28 (S)—N—((S)-1-((2,3-dihydro-1H-inden-5-yl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 28-1)
  • Figure US20190345133A1-20191114-C01796
    • Step 28A: Synthesis of tert-butyl (S)-4-(4-hydroxypiperidin-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoate (Intermediate 28A)
  • Figure US20190345133A1-20191114-C01797
  • Diethylamine (4.85 mL, 46.9 mmol) was added to a solution of (S)-(9H-fluoren-9-yl)methyl 3-(((S)-1-(tert-butoxy)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl) carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (made per scheme 25) (1 g, 1.56 mmol) in DCM (5 mL). After 16 h, toluene (2×50 mL) was added and the mixture concentrated under reduced pressure to remove any excess diethylamine. The resulting residue was dissolved in DCM (40 mL). DIEA (1.09 mL, 6.3 mmol) and 4-oxo-4-phenylbutanoic acid (0.33 g, 1.88 mmol) were added. The mixture was cooled to 0° C. and HATU (1.19 g, 3.1 mmol) was added. After 4 h, the reaction mixture was washed with 1M HCl (2×50 mL) then dried (MgSO4) and concentrated under reduced pressure. Purification by chromatography (EA/hexanes) provided 431 mg (46%) of Intermediate 28A as a colorless solid. LCMS [m/z] calculated for C33H43N3O6: 577.3; found 578.5 [M+H]+, tR=1.28 min (Method 4).
    • Step 28B: Synthesis of (S)-4-(4-hydroxypiperidin-1-yl)-2-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butanoic acid (Intermediate 28B)
  • Figure US20190345133A1-20191114-C01798
  • Into a solution of Intermediate 28A (331 mg, 0.57 mmol) in DCM (1 mL) was added 2,2,2-trifluoroacetic acid (570 μl, 7.5 mmol). After 3 h the mixture was diluted with toluene and concentrated under reduced pressure to obtain 348 mg (99%) of Intermediate 28B. LCMS [m/z] calculated for C29H35N3O6: 521.3; found 522.3 [M+H]+, tR=1.29 min (Method 4).
    • Step 28C: Synthesis of (S)—N—((S)-1-((2,3-dihydro-1H-inden-5-yl)amino)-4-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 28-1)
  • Figure US20190345133A1-20191114-C01799
  • To a solution of Intermediate 28B (100 mg, 0.19 mmol), 2,3-dihydro-1H-inden-5-amine (30.6 mg, 0.23 mmol) and DIEA (167 μl, 0.96 mmol) in DCM (2 mL) was added HATU (87 mg, 0.23 mmol). After 3 h, 1 M aq solution HCl (2 mL) was added and the layers were separated using a sep. cartridge. The aqueous layer was re-extracted with DCM (3 mL). The combined organic layers were concentrated in vacuo and the crude product was purified by chromatography (MeOH/DCM). Further purification by preparative HPLC provided 13 mg, (10%) of Compound 28-1. LCMS [m/z] calculated for C38H44N4O5: 636.3; found 637.1 [M+H]+, tR=4.24 min (Method 5).
  • Following the procedures as set forth in Scheme 28 above, the compounds of the following Table 28 were prepared using the appropriate R1 reagents.
  • TABLE 28
    Figure US20190345133A1-20191114-C01800
    LCMS
    Compound MS MS Retention Purity
    Number R1 Calc (MH)+ Time Method
    28-1
    Figure US20190345133A1-20191114-C01801
         		636.3 637.1 4.24 5
    28-2
    Figure US20190345133A1-20191114-C01802
         		628.3 629.1 3.79 5
    28-3
    Figure US20190345133A1-20191114-C01803
         		628.3 629.1 3.78 5
    • Example 29 (S)-3-(((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl methanesulfonate (Compound 29-1)
  • Figure US20190345133A1-20191114-C01804
    • Step 29A: Synthesis of (S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-2-(4-oxo-4-phenylbutanol)-1,2,3,4-tetrahydroisoquinolin-7-yl methanesulfonate (Intermediate 29A)
  • Figure US20190345133A1-20191114-C01805
  • A solution of methane sulfonyl-C1 (2 M in DCM) (0.038 ml, 0.077 mmol) was added to a solution of tert-butyl ((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-3-((S)-7-hydroxy-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)carbamate (prepared via Scheme 4, 0.05 g, 0.07 mmol) and DIEA (0.018 mL, 0.105 mmol) in DCM (0.7 mL) at rt. The mixture was stirred overnight, diluted with DCM (10 mL) and quenched with H2O (10 mL). The layers were separated and the organic layer was concentrated in vacuo. Purification by chromatography (MeOH/DCM) afforded 0.041 g (73%) of Intermediate as a white solid. LCMS [m/z] calculated for C36H39ClFN4O9S: 792.2; found 793.3 [M+H]+, tR=2.63 min (Method 4).
    • Step 29B: Synthesis of (S)-3-(((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl methanesulfonate (Compound 29-1)
  • Figure US20190345133A1-20191114-C01806
  • Intermediate 29A (0.041 g, 0.052 mmol) was stirred in DCM (1 mL) and TFA (0.5 mL) for 1.5 h. The volatiles were removed in vacuo and the residue was dissolved in MeOH and transferred onto an SCX column. The column was washed with MeOH (12 mL). The product was eluted with 0.7 M NH3 in MeOH (12 mL) to afford 0.030 g, (80%) of Compound 29-1 as a white solid. LCMS [m/z] calculated for C31H31Cl2FN407S: 692.1; found 693.2 [M+H]+, tR=4.42 min (Method 5).
    • Example 30 (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-7-cyano-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 30-1)
  • Figure US20190345133A1-20191114-C01807
    • Step 30A: Synthesis of tert-butyl ((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-7-((trifluoromethyl)sulfonyl)-1,2,3,4-tetra hydro isoquinoline-3-carboxamido)butyl)carbamate (Intermediate 30A)
  • Figure US20190345133A1-20191114-C01808
  • tert-butyl ((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-3-((S)-7-hydroxy-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)carbamate (prepared via Scheme 4, 0.13 g, 0.18 mmol), DIEA (0.041 mL, 0.24 mmol) and 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl) sulfonyl) methanesulfonamide (0.078 g, 0.22 mmol) were stirred in DCM (1.5 mL) at rt overnight. The reaction mixture was diluted with DCM (10 mL) and washed with 10% citric acid solution (5 mL), sat. NaHCO3 solution (5 mL) and brine (5 mL). After drying (MgSO4) the solvent was removed in vacuo. Purification via chromatography (MeOH/DCM) afforded 0.133 g (86%) of Intermediate 30A as a white solid. LCMS [m/z] calculated for C36H36Cl2F4N4O9S: 846.2; found 847.2 [M+H]+, tR=2.97 min (Method 4).
    • Step 30B: Synthesis of tert-butyl ((S)-3-((S)-7-cyano-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-((3,4-dichloro-2-fluorophenyl) amino)-4-oxobutyl)carbamate (Intermediate 30B)
  • Figure US20190345133A1-20191114-C01809
  • Pd(Ph3P)4 (8.86 mg, 7.7 μmol) was added to a solution of Intermediate 30A (0.065 g, 0.08 mmol) and Zinc cyanide (0.012 g, 0.1 mmol) in degassed DMF (0.7 mL). The reaction mixture was degassed for another 10 min and heated to 80° C. for 2.5 h under N2. Additional Pd(Ph3P)4 (8.86 mg, 7.7 μmol) was added and the temperature increased to 120° C. and stirred for 6 h. The reaction mixture was cooled to rt, diluted with EA (5 mL), washed with NaHCO3 solution (2×3 mL) and brine (3 mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo. Chromatography (EA/iHex) afforded 0.013 g, (23.2%) of Intermediate 30B as a colourless oil. LCMS [m/z] calculated for C36H36Cl2FN5O6: 723.2; found 746.2 [M+Na]+, tR=2.67 min (Method 4).
    • Step 30C: Synthesis of (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-7-cyano-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 30-1)
  • Figure US20190345133A1-20191114-C01810
  • Intermediate 30B (0.013 g, 0.018 mmol) was stirred in DCM (1 mL) and TFA (0.5 mL) for 1 h. The volatiles were removed in vacuo and the residue was dissolved in MeOH and transferred onto an SCX column. The resin was washed with MeOH (15 mL) and the product was eluted with 0.7 M NH3 in MeOH (13 mL) to afford 0.009 g, (76%) of Compound 30-1 as a beige solid. LCMS [m/z] calculated for C31H28Cl2FN5O4: 623.2; found 624.2 [M+Na]+, tR=4.55 min (Method 5).
    • Example 31 (S)—N—((S)-4-(2-aminoacetamido)-1-((4-chloro-3-methylphenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl)butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 31-1)
  • Figure US20190345133A1-20191114-C01811
    • Step 31A: Synthesis of tert-butyl (2-(((S)-4-((4-chloro-3-methylphenyl)amino)-4-oxo-3-((S)-2-(4-oxo-4-(piperidin-1-yl) butanoyl)-1,2,3,4 tetrahydroisoquinoline-3-carboxamido) butyl)amino)-2-oxoethyl)carbamate (Intermediate 31A)
  • Figure US20190345133A1-20191114-C01812
  • A solution of Compound 10-1 (120 mg, 0.21 mmol) and 2-((tert-butoxycarbonyl)amino)acetic acid (55.5 mg, 0.32 mmol) in DCM (4 mL) was treated with DIPEA (184 μl, 1.06 mmol) and HATU (161 mg, 0.42 mmol). The reaction mixture was stirred at rt for 2 h. The reaction mixture was partitioned between DCM (5 mL) and 1 M aq HCl solution (5 mL). The organic layer was washed with sat. aq. NaHCO3 (10 mL) and brine (10 mL) before the pooled aqueous layers were extracted with DCM (20 mL). The pooled organics were passed through a phase separator. The product was purified by chromatography (MeOH/DCM) to afford the product as a sticky, yellow oil. The solvent was removed in vacuo and the sticky yellow oil was dried in the dessicator at 40° C. overnight. To the product was added MTBE (2 mL) and this was sonicated for 30 sec. The filtrate was decanted and the process repeated 4 times. The residual solvent was removed in vacuo to afford 36 mg (22%) of Intermediate 31A as white, fluffy solid. LCMS [m/z] calculated for C37H49ClN6O7: 724.3; found 725.1 [M+H]+, tR=6.83 min (Method 5).
    • Step 31B: Synthesis of (S)—N—((S)-4-(2-aminoacetamido)-1-((4-chloro-3-methylphenyl) amino)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl) butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 31-1)
  • Figure US20190345133A1-20191114-C01813
  • Intermediate 31A (30 mg, 0.04 mmol) was dissolved in DCM (3 mL) and TFA (0.3 mL). After stirring at rt for 2 h, the solvent was removed in vacuo and dissolved in toluene and re-concentrated (2×10 mL). The residue was taken up in DCM (10 mL) and sat. aq. NaHCO3 (10 mL) was added before the layers were separated. The organic layer was washed with sat. aq. NaHCO3 (10 mL). The pooled aqueous layers were extracted with DCM (10 mL) and the organics were passed through a phase separator and the solvent was removed in vacuo. The crude product was purified by chromatography (0.7 M NH3/MeOH)/DCM) to afford 4 mg, (15%) of Compound 31-1 as a white solid. LCMS [m/z] calculated for C32H41ClN6O5: 624.3; found 625.1 [M+H]+, tR=4.12 min (Method 5).
  • Figure US20190345133A1-20191114-C01814
    • Example 32 (S)—N—((S)-1-((3,4-dichloro-2-fluorophenyl)amino)-4-(methyl sulfonamido)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl)butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 32-1)
  • Figure US20190345133A1-20191114-C01815
    • Step 32A: Synthesis of (S)—N—((S)-1-((3,4-dichloro-2-fluorophenyl)amino)-4-(methylsulfonamido)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl)butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 32-1)
  • Figure US20190345133A1-20191114-C01816
  • Methane sulfonyl chloride (14.04 μl, 0.18 mmol) was added dropwise to a solution of (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-(piperidin-1-yl)butanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (prepared via Scheme 15, 110 mg, 0.18 mmol) and DIEA (63.2 μl, 0.36 mmol) in DCM (1.8 mL). After 2 h, added DCM (4 mL), washed with 1M hydrochloric acid (2×5 mL), dried (MgSO4) and concentrated under reduced pressure. Purification by flash column chromatography (MeOH/DCM) afforded a colourless solid that was further purified by reverse phase flash column chromatography using (ammonium carbonate/acetonitrile) to afford 29 mg, (23%) of Compound 32-1 as a colourless solid. LCMS [m/z] calculated for C30H36Cl2FN5O6S: 683.2; found 683.9 [M+H]+, tR=6.47 min (Method 5).
  • Following the procedures as set forth in Scheme 32 above, the compounds of the following Table 32 were prepared using the appropriate R1 reagents.
  • TABLE 32
    Figure US20190345133A1-20191114-C01817
    LCMS
    Compound MS MS Retention Purity
    Number R1 Calc (MH)+ Time Method
    32-1
    Figure US20190345133A1-20191114-C01818
         		683.2 683.9 6.47 5
    32-2
    Figure US20190345133A1-20191114-C01819
         		645.2 646 6.27 5
    • Example 33 (3 S)—N-(3-(3-aminobicyclo[1.1.1]pentan-1-yl)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxopropan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 33-1)
  • Figure US20190345133A1-20191114-C01820
    • Step 33A: Synthesis of methyl 3-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1] pentan-1-yl)-2-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetra hydro isoquinoline-3-carboxamido) propanoate (Intermediate 33A)
  • Figure US20190345133A1-20191114-C01821
  • Into a flask containing Intermediate 18C (0.24 g, 0.56 mmol), Intermediate 22B (0.18 g, 0.63 mmol) and DIPEA (0.30 mL, 1.73 mmol) in DCM (11.5 mL, 0.56 mmol) at 0° C. was added HATU (0.656 g, 1.73 mmol). After 1.5 h at 0° C., 1M HCl (50 mL) was added and the mixture stirred for 30 min, then passed through a phase separator. The aqueous layer was further washed with DCM (20 mL), the organics were combined, concentrated and purified by chromatography (EA/hexanes) to provide 0.362 g (94%) of Intermediate 33A as an off-white solid. LCMS [m/z] calculated for C35H50N4O7: 638.4; found 639.4 [M+H]+, tR=2.56 min (Method 4).
    • Step 33B: Synthesis of 3-(3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)-2-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)propanoic acid (Intermediate 33-B)
  • Figure US20190345133A1-20191114-C01822
  • To a solution of Intermediate 33A (0.362 g, 0.57 mmol) in a mixture of THF (3.8 mL) and water (1.4 mL) was added LiOH (0.02 g, 0.85 mmol). After stirring for 2 h at 0° C., the solvent was removed in vacuo and the crude material was partitioned between aq. 1 M HCl (5 mL) and DCM (5 mL). The layers were separated using a phase sep-cartridge and the aqueous layer was re-extracted with DCM (10 mL). The combined organic layers were concentrated in vacuo to give the desired compound which was used for the next step without further purification. LCMS [m/z] calculated for C34H48N4O7: 624.4; found 625.6 [M+H]+, tR=1.54 min (Method 4).
    • Step 33C: Synthesis of tert-butyl (3-(3-((3,4-dichloro-2-fluorophenyl)amino)-2-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-3-oxopropyl)bicyclo[1.1.1]pentan-1-yl)carbamate (Intermediate 33-C)
  • Figure US20190345133A1-20191114-C01823
  • Into vial containing Intermediate 33B (0.354 g, 0.57 mmol), 3,4-dichloro-2-fluoroaniline (0.122 g, 0.68 mmol) and DIEA (0.297 mL, 1.7 mmol) in DCM (11.33 mL) at 0° C. was added HATU (0.646 g, 1.7 mmol). After 1.5 h at 0° C., 1M HCl (10 mL) was added and the mixture was passed through a phase separator. The organics were collected, concentrated and purified by chromatography (EA/hexanes) to provide 0.315 g, (68.5%) of Intermediate 33C as an off-white solid. LCMS [m/z] calculated for C40H50Cl2FN5O6: 785.3; found 786.3 [M+H]+, tR=3.03 min (Method 4).
    • Step 33D: Synthesis of (3S)—N-(3-(3-aminobicyclo[1.1.1]pentan-1-yl)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxopropan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 33-1)
  • Figure US20190345133A1-20191114-C01824
  • A solution of Intermediate 33C (0.315, 0.40 mmol) in DCM (2 mL, 31.1 mmol) was treated with TFA (0.308 mL, 4.0 mmol). After 2 h, the reaction mixture was concentrated in vacuo and the crude was partitioned between DCM (10 mL) and NaHCO3 (10 mL). The mixture was passed through a phase separator and the organics were concentrated and purified by chromatography (MeOH (1% NH3)/DCM) to provide 0.09 g (31%) of Compound 33-1 as an off-white solid. LCMS [m/z] calculated for C35H42Cl2FN5O4: 685.3; found 686 [M+H]+, tR=6.76 min (Method 5).
  • Figure US20190345133A1-20191114-C01825
    • Example 34 (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 34-1)
  • Figure US20190345133A1-20191114-C01826
    • Step 34A: Synthesis of (S)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 34A)
  • Figure US20190345133A1-20191114-C01827
  • Into a suspension of (S)-2-amino-3-(3-fluorophenyl)propanoic acid, HCl (250 mg, 1.14 mmol) in conc HCl (2500 μl, 82 mmol) was added formaldehyde in water (1000 μl, 13.4 mmol). The mixture was heated at 90° C. for 1 h, then was left to stand at rt for 2 d. The solvent was removed under vacuum and the solid was triturated with MTBE and filtered to afford 261 mg, (94% yield) of Intermediate 34A as a yellow solid. LCMS [m/z] calculated for C10H10FNO2: 195.1; found 196.1 [M+H]+, tR=0.41 min (Method 4).
    • Step 34B: Synthesis of (S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Intermediate 34B)
  • Figure US20190345133A1-20191114-C01828
  • Into a solution of Intermediate 34A (261 mg, 1.13 mmol) and NaHCO3 (2250 l, 4.51 mmol) in THF (3 mL) and water (2 mL) was added (9H-fluoren-9-yl)methyl carbonochloridate (350 mg, 1.35 mmol). After 2 h, the reaction was diluted with a 1 M aqueous solution of HCl (20 mL) and extracted with EA (2×20 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo to afford a 501 mg of crude material that was purified by chromatography (EA/isohexane) to afford 260 mg (48%) of Intermediate 34B as a colourless oil. LCMS [m/z] calculated for C25H20FNO4: 417.1; found 418.1 [M+H]+, tR=2.59 min (Method 4).
    • Step 34C: Synthesis of (9H-fluoren-9-yl)methyl (S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-6-fluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 34C)
  • Figure US20190345133A1-20191114-C01829
  • Intermediate 34B (0.135 g, 0.32 mmol) was dissolved in DCM (3 mL). Into this solution were added (S)-tert-butyl (3-amino-4-((3,4-dichloro-2-fluorophenyl)amino)-4-oxobutyl)carbamate (prepared via Scheme 4, 0.123 g, 0.32 mmol), DIEA (0.169 mL, 0.97 mmol) and HATU (0.135 g, 0.36 mmol) at 0° C. The mixture was stirred at 0° C. for 2 h and at rt overnight. The mixture was then diluted with DCM (3 mL) and quenched with water (3 mL). The layers were separated and the organics concentrated in vacuo and purified by chromatography (EA/hexanes) to provide 0.17 g, (64%) of Intermediate 34C as a white solid. LCMS [m/z] calculated for C40H38Cl2F2N4O4: 778.2; found 800.9 [M+Na]+, tR=3.10 min (Method 4).
    • Step 34D: Synthesis of tert-butyl ((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-3-((S)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)carbamate (Intermediate 34D)
  • Figure US20190345133A1-20191114-C01830
  • Intermediate 34C (0.170 g, 0.22 mmol) was stirred in DCM (2 mL) and diethylamine (1 mL, 9.6 mmol) at rt for 5 h. The volatiles were removed in vacuo and the residue azeotroped with toluene (5 mL). Chromatography of the resulting residue (MeOH (0.7 M NH3)/DCM) afforded 0.060 g (44.6%) of Intermediate 34D as a beige solid. LCMS [m/z] calculated for C25H28Cl2F2N4O4: 556.2; found 557.1 [M+Na]+, tR=1.87 min (Method 4).
    • Step 34E: Synthesis of 4-((S)-3-(((S)-4-((tert-butoxycarbonyl)amino)-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)carbamoyl)-6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-4-oxobutanoic acid (Intermediate 34E)
  • Figure US20190345133A1-20191114-C01831
  • Succinic anhydride (11 mg, 0.11 mmol) was added to a solution of Intermediate 34D (60 mg, 0.11 mmol) and DIEA (0.056 mL, 0.32 mmol) in DCM (2 mL) at rt. After stirring overnight, the mixture was diluted with DCM (2 mL) and washed with 1 M aq. HCl (3 mL). The organic phase was concentrated in vacuo and purified by chromatography (EA/isohexane) to provide 56 mg (76%) of Intermediate 34E as a white solid. LCMS [m/z] calculated for C29H32Cl2F2N4O7: 656.2; found 678.9 [M+Na]+, tR=2.35 min (Method 4).
    • Step 34F: Synthesis of tert-butyl ((S)-4-((3,4-dichloro-2-fluorophenyl)amino)-3-((S)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)-4-oxobutyl)carbamate (Intermediate 34F)
  • Figure US20190345133A1-20191114-C01832
  • HATU (42 mg, 0.11 mmol) was added to a solution of 2,2-dimethylpiperidine (15 μl, 0.11 mmol), Intermediate 34E (56 mg, 0.09 mmol) and DIEA (45 μl, 0.26 mmol) in DCM (1.5 mL) at rt. The mixture was stirred for 2 h, diluted with DCM (3 mL) and washed with 1 M aq. HCl (3 mL). The organic phase was concentrated in vacuo to afford 64 mg (100%) of Intermediate 34F as a yellow oil that was carried forward without further purification or analysis. LCMS [m/z] calculated for C36H45Cl2F2N5O6: 751.3; found 752 [M+H]+, tR=2.35 min (Method 4).
    • Step 34G: Synthesis of (S)—N—((S)-4-amino-1-((3,4-dichloro-2-fluorophenyl)amino)-1-oxobutan-2-yl)-2-(4-(2,2-dimethylpiperidin-1-yl)-4-oxobutanoyl)-6-fluoro-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 34-1)
  • Figure US20190345133A1-20191114-C01833
  • Intermediate 34F (61 mg, 0.09 mmol) was stirred in DCM (2 mL) and TFA (1 mL) at rt for 2 h. Volatiles were removed in vacuo and the residue azeotroped with toluene (4 mL). Chromatography of the resulting residue (MeOH (0.7 M NH3)/DCM) afforded 7 mg (13%) of Compound 34-1 as a white solid. LCMS [m/z] calculated for C31H37Cl2F2N5O4: 651.2; found 652.0 [M+H]+, tR=4.79 min (Method 5).
  • Figure US20190345133A1-20191114-C01834
    • Example 35 (S)—N—((S)-4-amino-1-((4-cyano-2,3-dihydro-1H-inden-5-yl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 35-1)
  • Figure US20190345133A1-20191114-C01835
    • Step 35A: Synthesis of tert-butyl ((S)-4-((4-cyano-2,3-dihydro-1H-inden-5-yl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido) butyl)carbamate (Intermediate 35A)
  • Figure US20190345133A1-20191114-C01836
  • To a stirred solution of tert-butyl ((S)-4-((4-bromo-2,3-dihydro-1H-inden-5-yl)amino)-4-oxo-3-((S)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamido)butyl)carbamate (prepared via Scheme 4 using 4-bromo-2,3-dihydro-1H-inden-5-amine, 200 mg, 0.27 mmol) in DMF, was added CuCN (29 mg, 0.33 mmol) under N2. The reaction was heated to 140° C., stirred overnight, allowed to cool to rt, diluted with H2O and extracted with DCM. The organic phase was washed with H2O, separated, and then dried (NaSO4), filtered, and the solvent was removed. The resulting residue was purified by chromatography (EA/hexanes) to provide 123 mg (66%) of Intermediate 35A. LCMS [m/z] calculated for C39H43N5O6: 677.3; found 678.3 [M+H]+, tR=5.35 min (Method 4).
    • Step 35B: Synthesis of (S)—N—((S)-4-amino-1-((4-cyano-2,3-dihydro-1H-inden-5-yl)amino)-1-oxobutan-2-yl)-2-(4-oxo-4-phenylbutanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (Compound 35-1)
  • Figure US20190345133A1-20191114-C01837
  • Into a solution of Intermediate 35 A (100 mg (0.15 mmol) in DCM (2 mL) was added TFA (2 mL). After 20 min, the solvents were removed and the residue was purified by prep-HPLC. Fractions were combined, concentrated, and lyophilized from MeOH/H2O to provide 34 mg (44%) of Compound 35-1. LCMS [m/z] calculated for C34H35N5O4: 577.3; found 578.3 [M+H]+, tR=5.31 min (Method 4).
  • Following the procedures as set forth in Scheme 35 above, the compounds of the following Table 35 were prepared using the appropriate R1 reagents.
  • TABLE 35
    Figure US20190345133A1-20191114-C01838
    LCMS
    Compound MS MS Retention Purity
    Number R1 Calc (MH)+ Time Method
    35-1
    Figure US20190345133A1-20191114-C01839
         		577.3 578.3 11.35 1
    35-2
    Figure US20190345133A1-20191114-C01840
         		585.2 586.3 4.18 5
    • Example 36 4-methoxy-2,3-dihydro-1H-inden-5-amine (Intermediate 36-1)
  • Figure US20190345133A1-20191114-C01841
    • Step 36A: Synthesis of 7-bromo-2,3-dihydro-1H-inden-4-ol (Intermediate 36A)
  • Figure US20190345133A1-20191114-C01842
  • A 2M solution of Br2 (519 mg, 3.3 mmol) in CCl4 (1.5 mL) was added to a solution of 2,3-dihydro-1H-inden-4-ol (400 mg, 3.0 mmol) in DCM (11 mL). After 1 hr, the reaction mixture was concentrated and purified by chromatography to provide 200 mg (31%) of Intermediate 36A. LCMS [m/z] calculated for C9H9BrO: 212.0; found 213.3 [M+H]+, tR=5.14 min (Method 4).
    • Step 36B: Synthesis of 7-bromo-5-nitro-2,3-dihydro-1H-inden-4-ol (Intermediate 36B)
  • Figure US20190345133A1-20191114-C01843
  • Intermediate 36A (1.64 g, 7.7 mmol) was dissolved in AcOH (2.3 mL) and H2O (0.46 mL). After cooling at 5° C., fuming HNO3 (0.13 mL) in AcOH (0.9 mL) of was added dropwise. The mixture was stirred 15 min at 5° C., diluted with H2O, extracted with DCM, washed with water, dried (Na2SO4), concentrated and purified by chromatography (EA/hexane) to provide 400 mg (20%) of Intermediate 36B. LCMS [m/z] calculated for C9HBrNO3: 257.0; found 258.3 [M+H]+, tR=5.13 min (Method 4).
    • Step 36C: Synthesis of 7-bromo-4-methoxy-5-nitro-2,3-dihydro-1H-indenene (Intermediate 36C)
  • Figure US20190345133A1-20191114-C01844
  • To Intermediate 36B (350 mg, 1.4 mmol) in DMF (5 mL) was added K2CO3 (375 mg, 2.7 mmol) and CH3I (290 mg, 2 mmol). After stirring overnight, the solvent was removed in vacuo and the residue was dissolved in DCM, washed with H2O, dried (Na2SO4), concentrated and purified by chromatography (EA/hexanes) to provide 200 mg (54%) of Intermediate 36C. LCMS [m/z] calculated for C10H10BrNO3: 271; found 272.2 [M+H]+, tR=5.73 min (Method 4).
    • Step 36D: Synthesis of 4-methoxy-2,3-dihydro-1H-inden-5-amine (Intermediate 36-1)
  • Figure US20190345133A1-20191114-C01845
  • Intermediate 36B (200 mg, 0.74 mmol) was dissolved in a mixture of MeOH (2 mL) and THF (2 mL) and 10% Pd/C (200 mg) was added. The reaction mixture was purged with H2 and stirred under H2 for 24 h. After filtration and evaporation in vacuo, a solid was obtained which was recrystallized in ether to afford 70 mg (58%) of Intermediate 36-1 as a gray solid. LCMS [m/z] calculated for C10H13NO: 163.1; found 164 [M+H]+, tR=2.45 min (Method 4).
    • Example 37 2-methoxy-3,4-dimethylaniline (Intermediate 37-1)
  • Figure US20190345133A1-20191114-C01846
    • Step 37A: Synthesis of 2,3-dimethylphenol (Intermediate 37A)
  • Figure US20190345133A1-20191114-C01847
  • K2CO3 (11 g 79.7 mmol) and CH3I (8.7 g, 61.4 mmol) were added to a solution of 2,3-dimethylphenol (5 g, 41 mmol) in DMF (20 mL) After stirring overnight, the reaction mixture was diluted with DCM, washed with H2O, dried (Na2SO4), concentrated and purified by chromatography (EA/hexanes) to provide 4.1 g (74%) of Intermediate 37A. No analytical data were obtained.
    • Step 37B: Synthesis of 1-bromo-4-methoxy-2,3-dimethylbenzene (Intermediate 37B)
  • Figure US20190345133A1-20191114-C01848
  • A solution of Br2 (5.3 g, 33.2 mmol) in CCl4 (15 mL) was added to a solution of Intermediate 37B (4.1 g, 30.2 mmol) in DCM (100 mL) and the resulting solution was stirred for 1 h. The reaction mixture was concentrated and purified by chromatography to provide 1.7 g (26%) of Intermediate 37B. 1HNMR (DMSO-d6): 7.33 (d, J=8 Hz, 1H), 6.58 (d, J=8 Hz, 1H), 3.78 (s, 3H), 2.36 (s, 3H), 2.19 (s, 3H).
    • Step 37C: Synthesis of 1-bromo-4-methoxy-2,3-dimethylbenzene (Intermediate 37C)
  • Figure US20190345133A1-20191114-C01849
  • Intermediate 37B (1.5 g, 7 mmol) was dissolved in AcOH (9.2 mL) and H2O (1.6 mL). After cooling at 5° C., fuming HNO3 (0.49 mL) in AcOH (3.6 mL) was added dropwise. The mixture was stirred 15 min at 5° C., H2O was added, and the mixture was extracted with DCM. The organic layer was washed with H2O, dried (Na2SO4), concentrated, and purified by chromatography (EA/hexanes) to provide 1.2 g (66%) of Intermediate 37C. LCMS [m/z] calculated for C9H10BrNO3: 259.0; found 261.1 [M+H]+, tR=5.60 min (Method 4).
    • Step 37D: Synthesis of 2-methoxy-3,4-dimethylaniline (Intermediate 37-1)
  • Figure US20190345133A1-20191114-C01850
  • Intermediate 37C (1.0 g, 3.9 mmol) was dissolved in a mixture of MeOH (2 mL) and THF (2 mL). 10% Pd/C (0.2 g) was added and the mixture was flushed with H2 and stirred for 24 h under an atmosphere of H2. The mixture was filtered and concentrated in vacuo, to provide a solid that was crystallized from diethyl ether to afford 0.2 g (34%) of Intermediate 37-1 as a gray solid. LCMS [m/z] calculated for C9H13NO: 151.0; found 152 [M+H]+, tR=2.31 min (Method 4).
    • Example 38 1-methoxy-5,6,7,8-tetrahydronaphthalen-2-amine (Intermediate 38-1)
  • Figure US20190345133A1-20191114-C01851
    • Step 38A: Synthesis of 5-methoxy-1,2,3,4-tetrahydronaphthalene (Intermediate 38A)
  • Figure US20190345133A1-20191114-C01852
  • Into a solution of 5-methoxy-3,4-dihydronaphthalen-1(2H)-one (3 g, 1.7 mmol) in MeOH (60 mL) and THF (16 mL) was added 20% Pd(OH)2/C (0.5 g). The solution was degassed with N2, then stirred under H2 (1 atm) for 24 h. The mixture was filtered through celite and the filtrate was concentrated to give crude product which was purified by chromatography to provide 1.5 g (54%) of Intermediate 38A. LCMS [m/z] calculated for C11H14O: 162.1; no m/z observed; tR=6.14 min (Method 4).
    • Step 38B: Synthesis of 5-bromo-8-methoxy-1,2,3,4-tetrahydronaphthalene (Intermediate 38B)
  • Figure US20190345133A1-20191114-C01853
  • A solution of Br2 (1.6 g, 10.2 mmol) in CCl4 (3 mL) was added to a solution of Intermediate 38A (1.5 g, 9.3 mmol) in DCM (20 mL) and the resulting solution was stirred for 1 h. The reaction mixture was concentrated and purified by chromatography to provide 1.2 g (54%) of Intermediate 38B. LCMS [m/z] calculated for C11H13BrO: 240.1; found 241.3 [M+H]+, tR=6.5 min (Method 4).
    • Step 38C: Synthesis of 8-bromo-5-methoxy-6-nitro-1,2,3,4-tetrahydronaphthalene (Intermediate 38C)
  • Figure US20190345133A1-20191114-C01854
  • Intermediate 38B (1.2 g, 5.0 mmol) was dissolved in AcOH (5 mL) and cooled to 5° C. Fuming HNO3 (0.41 mL) in AcOH (1 mL) was added. The mixture was stirred for 15 min at 5° C., and then H2O was added. The solution was extracted with DCM, washed with H2O, dried (Na2SO4), concentrated, and purified by chromatography (EA/hexane) to provide 0.85 g (60%) of Intermediate 38C. LCMS [m/z] calculated for C11H12BrNO3: 285.0; found 286.0 [M+H]+, tR=5.42 min (Method 4).
    • Step 38D: Synthesis of 1-methoxy-5,6,7,8-tetrahydronaphthalen-2-amine (Intermediate 38-1)
  • Figure US20190345133A1-20191114-C01855
  • Intermediate 38C (0.85 g, 2.97 mmol) was dissolved in a mixture of MeOH (2 mL) and THF (2 mL). 10% Pd/C (200 mg) was added and the mixture was flushed with H2 and stirred for 24 h under an atmosphere of H2. After filtration and evaporation in vacuo, a solid was obtained that was crystallized from diethyl ether to afford 200 mg (38%) of Intermediate 38-1 as gray solid. LCMS [m/z] calculated for C11H15NO: 177.1; found 178.4 [M+H]+, tR=2.8 min (Method 4).
    • Example 39 5-fluoro-2-methoxy-4-methylaniline (Intermediate 39-1)
  • Figure US20190345133A1-20191114-C01856
    • Step 39A: Synthesis of 1-fluoro-4-methoxy-2-methyl-5-nitrobenzene (Intermediate 39A)
  • Figure US20190345133A1-20191114-C01857
  • To a suspension of NaH (200 mg, 5 mmol) in THF (10 mL) was added MeOH (203 μL, 5 mmol) dropwise and the mixture was stirred for 30 min. 1,4-Difluoro-2-methyl-5-nitrobenzene (865 mg, 5 mmol) was added and the mixture was heated to 60° C. for 12 h. The contents were poured into H2O and extracted with EA. The organic phase was washed with diluted NaOH, then H2O, and brine. The organic phase was dried (Na2SO4), filtered, and the solvent was removed in vacuo. The resulting residue was purified by chromatography (EA/hexanes) to provide 640 mg (68%) of Intermediate 39A. LCMS [m/z] calculated for C8H8FNO: 185.1; found 186.4 [M+H]+, tR=4.2 min (Method 4).
    • Step 39B: Synthesis of 1-fluoro-4-methoxy-2-methyl-5-nitrobenzene (Intermediate 39-1)
  • Figure US20190345133A1-20191114-C01858
  • Into a solution of Fe (1290 mg, 23 mmol), AcOH (0.4 mL), THF (2.4 mL) and H2O was added Intermediate 39A (425 mg, 2.3 mmol). The mixture was heated to 100° C. for 6 h and then was cooled to rt. The solid was collected and diluted with EA. The mixture was filtered through a pad of celite. The organic phase was washed with H2O, dried, filtered, and the solvent removed in vacuo to provide 294 mg (83%) of Intermediate 39-1. LCMS [m/z] calculated for C8H10FNO: 155.1; found 156.2 [M+H]+, tR=2.26 min (Method 4).
    • Example 40 1,1-dimethyl-2,3-dihydro-1H-inden-5-amine (Intermediate 40A)
  • Figure US20190345133A1-20191114-C01859
    • Step 40A: Synthesis of 1,1-dimethyl-2,3-dihydro-1H-inden-5-amine (Intermediate 40-1)
  • Figure US20190345133A1-20191114-C01860
  • 3,3-dimethyl-6-nitro-2,3-dihydro-1H-inden-1-one (600 mg, 2.93 mmol) was dissolved in MeOH (5 mL), and Pd/C (20% weight, 0.2 eq) and CH3SO3H (0.37 mL, 3.8 mmol) were added. The reaction mixture was purged with H2, and the mixture was stirred for 24 h under an atmosphere of H2. The mixture was filtered, concentrated in vacuo, and purified by chromatography to provide 200 mg (42%) of Intermediate 40-1. LCMS [m/z] calculated for C11H15N: 161.1; found 162.4 [M+H]+, tR=3.11 min (Method 4).
    • Example 41 2,2-dimethyl-2,3-dihydro-1H-inden-5-amine (Intermediate 41-1)
  • Figure US20190345133A1-20191114-C01861
    • Step 41A: Synthesis of 2,2-dimethyl-2,3-dihydro-1H-inden-5-amine (Intermediate 41A)
  • Figure US20190345133A1-20191114-C01862
  • To a cooled (0° C.) solution of NaH (1.9 g, 47 mmol) in DMF (15 mL) was added 2,3-dihydro-1H-inden-1-one (2.5 g, 19 mmol). The mixture was stirred for 20 min before MeI (3.5 mL, 57 mmol) was added dropwise. The mixture was stirred for 2 h, then was quenched with MeOH and H2O and extracted with EA. The organic layer was collected, dried over (Na2SO4), filtered and the solvent was removed in vacuo. The resulting residue was purified by chromatography (EA/hexanes) to provide 2.8 g (90%) of Intermediate 41A. LCMS [m/z] calculated for C11H12O: 160.1; found 161.4 [M+H]+, tR=4.3 min (Method 4).
    • Step 41B: Synthesis of 2,2-dimethyl-6-nitro-2,3-dihydro-1H-inden-1-one (Intermediate 41B)
  • Figure US20190345133A1-20191114-C01863
  • Into a solution of Intermediate 41A (600 mg, 3.8 mmol) in H2SO4 (5 mL) at 0° C. was added KNO3 in H2SO4 (2 mL). The mixture was stirred for 1 h at 0° C. then warmed to rt and stirred overnight. The reaction was quenched with ice, extracted with EA, then washed with H2O, dried (Na2SO4), and concentrated in vacuo. The crude product was purified by chromatography (EA/hexane) to provide 680 mg (88%) of Intermediate 41B. LCMS [m/z] calculated for C11H11NO3: 205.1; found 206.5 [M+H]+, tR=4.2 min (Method 4).
    • Step 41C: Synthesis of 2,2-dimethyl-2,3-dihydro-1H-inden-5-amine (Intermediate 41-1)
  • Figure US20190345133A1-20191114-C01864
  • Intermediate 41B (680 mg, 3.3 mmol) was dissolved in a mixture of MeOH (6 mL) and THF (1 mL). 10% Pd/C (800 mg, 3.32 mmol) and methanesulfonic acid (280 μL, 4.3 mmol) were added. The mixture was flushed with N2 and purged, then was stirred at rt for 24 h under an atmosphere of H2. The mixture was filtered, concentrated in vacuo, and purified by chromatography (EA/Hexanes). The resulting material was dissolved in EA, washed with H2O, dried (Na2SO4), and concentrated in vacuo. The resulting material was re-chromatographed (MeOH/DCM) to provide 400 mg (75%) of Intermediate 41-1. LCMS [m/z] calculated for C11H15N: 161.1 found 162.4 [M+H]+, tR=3.61 min (Method 4).
    • Example 42 3-ethyl-2-methoxyaniline (Intermediate 42-1)
  • Figure US20190345133A1-20191114-C01865
    • Step 42A: Synthesis of 2-methoxy-1-nitro-3-vinylbenzene (Intermediate 42A)
  • Figure US20190345133A1-20191114-C01866
  • To a 50 mL flask were added 1-bromo-2-methoxy-3-nitrobenzene (1 g, 4.31 mmol), tributyl(vinyl)stannane (1.26 mL, 4.31 mmol), and toluene (8 mL). The mixture was degassed for 1 min by N2 bubbling. Pd(PPh3)4 (104 mg, 0.22 mmol) was added to the mixture, which was again purged by N2 bubbling for 1 min. The reaction mixture was stirred at 110° C. under N2 for 18 h. The mixture was allowed to cool to rt and quenched with 1M KF (aq), then extracted with EA. The organic layer was washed with brine, dried (MgSO4), filtered and concentrated. The crude product was purified by chromatography (EA/Hexane) to give 500 mg (65%) of Intermediate 42A, which was used without further analytical evaluation.
    • Step 42B: Synthesis of 3-ethyl-2-methoxyaniline (Intermediate 42-1)
  • Figure US20190345133A1-20191114-C01867
  • To a flask containing Intermediate 42A (500 mg, 2.8 mmol) was added Pd/C (10%, 500 mg, 0.28 mmol), and MeOH (8 mL). The flask was placed under vacuum for 1 min, then a H2 balloon was attached and the reaction was stirred at rt overnight.
  • The reaction was filtered and concentrated to provide 420 mg (99%) of Intermediate 42-1 which was used without further purification. LCMS [m/z] calculated for C9H13NO: 151.1 found 152.2 [M+H]+, tR=2.9 min (Method 4).
    • Example 43 3,4-dichloro-2-methoxyaniline (Intermediate 43-1)
  • Figure US20190345133A1-20191114-C01868
    • Step 43A: Synthesis of tert-butyl (3,4-dichloro-2-hydroxyphenyl)carbamate (Intermediate 43A)
  • Figure US20190345133A1-20191114-C01869
  • To a solution of 6-amino-2,3-dichlorophenol (100 mg, 0.57 mmol) in DCM (5 mL) were added Boc2O (370 mg (1.7 mmol) and ZnCl2 (77 mg, 0.57 mmol). The reaction mixture was stirred overnight, diluted with EA and washed with H2O and brine. The organic layer was collected, dried (Na2SO4), filtered and concentrated. The residue was purified by chromatography (EA/Hexanes) to provide 116 mg (74%) of Intermediate 43A. LCMS [m/z] calculated for C11H13Cl2NO3: 277.0 found 278.2 [M+H]+, tR=5.33 min (Method 4).
    • Step 43B: Synthesis of tert-butyl (3,4-dichloro-2-methoxyphenyl)carbamate (Intermediate 43B)
  • Figure US20190345133A1-20191114-C01870
  • To a stirring solution of Intermediate 43A (173 mg, 0.62 mmol) in DMF (5 mL) was added K2CO3 (129 mg, 0.93 mmol). MeI (58 μL, 0.93 mmol) was added after 5 min. The reaction mixture was stirred at rt for 16 h under an atmosphere of N2. The mixture was diluted with EA and washed with H2O. The organic layer was collected, dried (Na2SO4) and concentrated. The residue was purified by chromatography (EA/hexanes) to provide 95 mg (52%) of Intermediate 43B. LCMS [m/z] calculated for C12H15Cl2NO3: 291.0, found 294.2 [M+H]+, tR=5.81 min (Method 4).
    • Step 43C: Synthesis of 3,4-dichloro-2-methoxyaniline (Intermediate 43-1)
  • Figure US20190345133A1-20191114-C01871
  • To a solution of Intermediate 43B (95 mg, 0.32 mmol) in DCM (4 mL) was added TFA (1 mL). The reaction mixture was stirred for 20 min then was diluted with DCM and concentrated multiple times to remove residual TFA to provide 51 mg (62%) of Intermediate 43-1. LCMS [m/z] calculated for C7H7Cl2NO: 191.0, found 192.3 [M+H]+, tR=4.18 min (Method 4).
    • Example 44 4,5-dimethyl-2-(trifluoromethoxy)aniline (Intermediate 43-1)
  • Figure US20190345133A1-20191114-C01872
    • Step 44A: Synthesis of 5-methyl-2-(trifluoromethoxy)aniline (Intermediate 44A)
  • Figure US20190345133A1-20191114-C01873
  • A mixture of 5-bromo-2-(trifluoromethoxy)aniline (2 g, 7.8 mmol), K2CO3 (2.7 g, 19.5 mmol), and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (50% in THF, 4.4 mL, 15.6 mmol) in dioxane (60 mL) was degassed for 20 min with N2. PdCl2(dppf)-CH2Cl2 (319 mg, 0.39 mmol) was added and the mixture was further degassed for 10 min then heated to 100° C. for 1 h. The reaction mixture was cooled to rt, filtered through a pad of celite, concentrated, and purified by chromatography (EA/hexane) to provide 1.49 g (74%) of Intermediate 44A. LCMS [m/z] calculated for C8H8F3NO: 191.1 found 192.2[M+H]+, tR=4.22 min (Method 4).
    • Step 44B: Synthesis of 4-bromo-5-methyl-2-(trifluoromethoxy)aniline (Intermediate 44B)
  • Figure US20190345133A1-20191114-C01874
  • Intermediate 44A (1.11 g, 5.8 mmol) was dissolved in DCM (20 mL). A solution of Br2 (330 μL, 6.4 mmol) in CCl4 (6 mL) was added. The reaction was stirred at rt for 1 h then was concentrated and the residual solid was filtered and washed with hexane. The washed solid was then dissolved in DCM and washed with NaHCO3 (aq) to provide 1.31 g (83.8%) of Intermediate 44B. LCMS [m/z] calculated for C8H7BrF3NO: 269.0 found 270.4 [M+H]+, tR=5.18 min (Method 4).
    • Step 44C: Synthesis of 4,5-dimethyl-2-(trifluoromethoxy)aniline (Intermediate 44-1)
  • Figure US20190345133A1-20191114-C01875
  • A mixture of Intermediate 44B (1.3 g, 4.9 mmol), K2CO3 (1.7 g, 12.2 mmol), and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (50% in THF, 2.7 mL, 9.7 mmol) in dioxane (60 mL) was degassed for 20 min with N2 bubbling. PdCl2(dppf)-CH2Cl2 (197 mg, 0.24 mmol) was added and the mixture was further degassed for 10 min. The reaction mixture was heated to at 100° C. for 1 h, then was cooled to rt, filtered through a pad of celite and concentrated. The resulting residue was purified by chromatography (EA/Hexane) to provide 602 mg (60%) of Intermediate 44-1. LCMS [m/z] calculated for C9H10F3NO: 205.1 found 206.3 [M+H]+, tR=4.16 min (Method 4).
    • Example 45 6-fluoro-2,3-dihydro-1H-inden-5-amine (Intermediate 45-1)
  • Figure US20190345133A1-20191114-C01876
    • Step 45A: Synthesis of 5-fluoro-6-nitro-2,3-dihydro-1H-inden-1-one (Intermediate 45A)
  • Figure US20190345133A1-20191114-C01877
  • Fuming HNO3 (31.3 mmol) was added dropwise to 5-fluoro-2,3-dihydro-1H-inden-1-one (4.7 g, 31.3 mmol) at 0° C. The reaction mixture was stirred for 1.5 h. The reaction mixture was quenched with the addition of H2O (50 mL). The precipitated solid was collected by filtration and washed with H2O. The resulting crude residue (2 g, 33%) was dried under high vac and used without further purification. LCMS [m/z] calculated for C9H6FNO3: 195.0 found 196.2 [M+H]+, tR=3.15 min (Method 4).
    • Step 45B: Synthesis of 6-fluoro-2,3-dihydro-1H-inden-5-amine (Intermediate 45-1)
  • Figure US20190345133A1-20191114-C01878
  • To a solution of Intermediate 45A (1.3 g, 6.7 mmol) in MeOH (20 mL) and THF (10 mL) was added MeSO3H (0.83 g, 8.66 mmol) followed by Pd/C (10%, 650 mg). The reaction mixture was evacuated and filled with H2. The mixture was stirred overnight under an atmosphere of H2. The reaction mixture was filtered through a pad of Celite and washed with MeOH. The solvents were removed in vacuo and the resulting crude residue was purified by chromatography (EA/hexanes) to provide 614 mg (61%) of Intermediate 45-1. LCMS [m/z] calculated for C9H10FN: 151.1 found 152.3 [M+H]+, tR=7.83 min (Method 5).
    • Example 46 4-chloro-2,3-dihydro-1H-inden-5-amine (Intermediate 46-1)
  • Figure US20190345133A1-20191114-C01879
    • Step 46A: Synthesis of 4,6-dibromo-2,3-dihydro-1H-inden-5-amine (Intermediate 46A)
  • Figure US20190345133A1-20191114-C01880
  • To a solution of 2,3-dihydro-1H-inden-5-amine (2.5 g, 18.8 mmol) in AcOH (100 mL) was added Br2 (3.0 g, 18.8 mmol). After 1 h, the reaction mixture was concentrated to −20 mL. DCM and H2O were added. The mixture was neutralized to pH-5 with NaHCO3 (sat). The DCM was separated and concentrated. The resulting crude material was purified by chromatography to provide 5.5 g (55%) of Intermediate 46A. LCMS [m/z] calculated for C9H9Br2N: 288.9 found 289.9 [M+H]+, tR=6.08 min (Method 4).
    • Step 46B: Synthesis of 4-bromo-2,3-dihydro-1H-inden-5-amine (Intermediate 46B)
  • Figure US20190345133A1-20191114-C01881
  • To a solution of Intermediate 46A (6.4 g, 22.2 mmol) in AcOH (30 mL) and HCl (conc) (24 mL) was added tin chloride (6 g, 26.6 mmol). The reaction mixture was stirred at 120° C. for 30 min then cooled to rt. The solvents were removed en vacuo, diluted with DCM and neutralized with NaOH. The organic layer was collected, dried (Na2SO4), filtered, and concentrated in vacuo to provide 3.76 g (81%) of Intermediate 46B. LCMS [m/z] calculated for C9H10BrN: 211.0 found 212.1 [M+H]+, tR=30.81 min (Method 4).
    • Step 46C: Synthesis of 4-chloro-2,3-dihydro-1H-inden-5-amine (Intermediate 46-1) H2N H2
  • Figure US20190345133A1-20191114-C01882
  • To a sealed tube, was added Cu2O (70 mg, 0.5 mmol), Bu4NCl (2.62 g, 9.4 mmol) Intermediate 46B (1.0 g, 4.7 mmol), proline (100 mg, 0.94 mmol) and EtOH (3 mL). The mixture was heated at 110° C. for 24 h. The reaction mixture was diluted with EA and washed consecutively with sat. NaHCO3, H2O, and brine then concentrated. The resulting crude residue was purified by chromatography (EA/hexanes) to provide 103 mg (13%) of Intermediate 46-1. LCMS [m/z] calculated for C9H10ClN: 167.1 found 167.4 [M+H]+, tR=3.42 min (Method 4).
    • Example 47 2-methoxy-5-methyl-4-(trifluoromethyl)aniline (Intermediate 47-1)
  • Figure US20190345133A1-20191114-C01883
    • Step 47A: Synthesis of 1-bromo-4-methoxy-5-nitro-2-(trifluoromethyl)benzene (Intermediate 47A)
  • Figure US20190345133A1-20191114-C01884
  • To 1-bromo-4-methoxy-2-(trifluoromethyl)benzene (2.0 g, 7.88 mmol) in H2SO4 (6 mL) at 0° C. was added KNO3 (0.53 mL, 7.88 mmol) in H2SO4 (2 mL). The mixture was stirred or 1 h at 0° C. then warmed to rt and stirred overnight. The reaction was quenched with ice and extracted with EA. The organic layer was washed with H2O, dried, and concentrated in vacuo. The crude product was purified by chromatography (EA/hexane) to provide 500 mg (22%) of Intermediate 47A. LCMS [m/z] calculated for C8H5BrF3NO3: 298.9 found 300.2 [M+H]+, tR=5.01 min (Method 4).
    • Step 47B: Synthesis of 1-methoxy-4-methyl-2-nitro-5-(trifluoromethyl)benzene (Intermediate 47B)
  • Figure US20190345133A1-20191114-C01885
  • A mixture of Intermediate 47A (500 mg, 1.67 mmol), K2CO3 (691 mg, 5 mmol) and 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (420 mg, 3.34 mmol) in dioxane (30 mL) was degassed for 20 min with N2. PdCl2(pddf)-CH2Cl2 (70 mg, 0.08 mmol) was added and the mixture was further degassed for 10 min. The mixture was heated at 80° C. for 2 h under N2. The mixture was filtered through a pad of celite, concentrated, and the resulting crude material was purified by chromatography (EA/hexane) to provide 250 mg (63%) of Intermediate 47B. LCMS [m/z] calculated for C9HF3NO3: 235.1 found 236.3 [M+H]+, tR=4.81 min (Method 4).
    • Step 47C: Synthesis of 2-methoxy-5-methyl-4-(trifluoromethyl)aniline (Intermediate 47-1)
  • Figure US20190345133A1-20191114-C01886
  • To a solution of Fe (596 mg, 10.6 mmol), AcOH (0.092 mL), THF (1.5 mL) and H2O (1.5 mL) was added Intermediate 47B (250 mg, 1.1 mmol). The mixture was heated to 100° C. for 2 h then cooled to rt. The solid was collected, diluted with EA, and then filtered through a pad of celite. The organic phase was washed with H2O, dried, filtered, and the solvent was removed in vacuo to provide 148 mg (68%) of Intermediate 47-1. LCMS [m/z] calculated for C9H10F3NO: 205.1 found 206.3 [M+H]+, tR=4.06 min (Method 4).
    • Example 48 Biological Assays
  • CXCR3 cAMP Assay
  • The cAMP Hunter™ CHOK1 CXCR3 Gi cell line was purchased from DiscoveRx. Cells were seeded into a 96-well white assay plate at 50,000 cells/well/94 μl assay buffer (Hank's Buffered Saline Solution, 10 mM HEPES, 0.1% fatty acid-free BSA, pH 7.4) and immediately assayed in suspension. Forskolin was added to 20 μM (5 μl of 400 μM stock) simultaneously with a 12-point dose response curve of compound at 0-10 μM (1 μl of 100× stock in 100% DMSO), and cells were incubated for 30 minutes. A cAMP standard curve is run as an assay control. A CXCL11 dose response was included to determine maximum efficacy. Direct detection of cAMP was carried out using the DiscoveRx HitHunter cAMP kit according to manufacturer's instructions, and luminescence was read using a SpectraMax M5 plate reader.
    • CXCR3 Activity
  • Activity data for representative CXCR3 agonists are displayed in Table 36. The CXCR3 cAMP agonist assay compound EC50 is denoted as follows: + denotes activity <0.050 μM, ++ denotes activity between 0.050 and 0.25 μM, +++ denotes activity between 0.25 and 0.5 μM, and ++++ denotes activity >0.5 μM.
  • TABLE 36
    CXCR3 ACTIVITY
    Compound
    Number Activity
    1-1 ++
    1-2 +++
    1-3 ++
    1-5 ++++
    1-6 +++
    1-7 ++++
    1-8 ++++
    1-9 ++
     1-10 ++
     1-11 +++
     1-12 +++
     1-13 ++
     1-14 +
     1-15 +++
     1-16 ++
     1-17 ++
     1-18 +
     1-19 +++
     1-20 ++
     1-21 ++++
     1-22 +++
     1-23 ++
     1-24 ++
     1-25 +
     1-26 +
     1-27 +
     1-28 ++
     1-29 +
     1-30 +
     1-31 +++
     1-32 +
     1-33 +
     1-34 +
     1-35 +++
     1-36 +
     1-37 ++
     1-38 +
     1-39 +
    2-1 ++
    2-2 +
    2-3 +
    2-4 ++
    2-5 +
    2-6 ++
    2-7 +
    2-8 ++++
    2-9 ++
     2-10 +++
     2-11 +++
     2-12 +++
     2-13 ++++
     2-14 +
     2-15 +
     2-16 +
     2-17 ++
     2-18 +
     2-19 +
     2-20 ++
     2-21 +
     2-22 +
     2-23 +
     2-24 +
     2-25 +
     2-26 +
     2-27 ++
     2-28 +
     2-29 +++
     2-30 ++
     2-31 ++
     2-32 +
     2-33 +
     2-34 +
     2-35 ++
     2-36 +++
     2-37 ++
     2-38 +
     2-39 +
     2-40 +
     2-41 ++
     2-42 ++++
     2-43 ++
     2-44 +
     2-45 +++
     2-46 +
     2-47 +
     2-48 ++
     2-49 +
     2-50 +++
     2-51 ++
     2-52 ++
     2-53 ++
     2-54 ++++
     2-55 +
     2-56 +++
     2-57 +
     2-58 ++
     2-59 +++
     2-60 ++
     2-61 ++++
     2-62 ++
     2-63 ++
     2-64 +++
     2-65 ++
     2-66 +
     2-67 +
     2-68 ++
     2-69 ++++
     2-70 +++
     2-71 ++
     2-72 +
     2-73 +
     2-74 ++
     2-75 ++
     2-76 ++
     2-77 ++
     2-78 +
     2-79 +
     2-80 +++
     2-81 ++
     2-82 +
    3-1 ++
    3-2 +
    3-3 +++
    3-4 ++
    3-5 ++
    3-6 +++
    3-7 +
    3-8 +
    3-9 +
     3-10 ++
     3-11 +++
     3-12 ++
     3-13 ++
     3-14 +++
    4-2 +++
    4-3 +
    4-4 +
    4-5 ++++
    4-6 +
    4-7 ++++
    4-8 +
    4-9 ++
     4-10 ++
     4-11 ++
     4-12 ++
     4-13 ++
     4-14 +
     4-15 +++
     4-16 +
     4-17 ++++
     4-18 ++
     4-19 +
     4-20 +
    5-1 +
    5-2 ++
    5-3 ++
    5-4 ++
    6-1 ++
    6-2 ++
    6-3 ++
    6-4 ++
    6-5 ++
    6-6 +
    6-7 ++
    7-1 ++
    7-2 ++
    7-3 ++
    7-4 +++
    7-5 ++++
    7-6 ++
    7-7 ++
    7-8 +
    7-9 ++++
    8-1 +
    8-2 +
    8-3 +
    8-4 +
    8-5 +
    8-6 ++
    8-7 +
    9-1 +
    10-1  +
    10-2  ++
    10-3  +
    10-4  +
    10-5  +
    10-6  +
    10-7  +
    10-8  +
    10-9  +
    10-10 +
    10-11 +
    10-12 +
    11-1  ++++
    11-2  +++
    11-3  +
    11-4  ++
    11-5  ++++
    11-6  +
    12-1  ++
    12-2  +
    12-3  ++
    12-4  +
    12-5  +
    12-6  ++
    12-7  +
    12-8  ++
    12-9  ++++
    12-10 ++
    12-11 +
    12-12 ++++
    12-13 +
    12-14 ++
    12-15 ++
    12-16 ++++
    12-17 ++
    12-18 ++++
    12-19 +++
    12-20 +
    12-21 +
    12-22 +
    12-23 +
    12-24 +++
    12-25 +
    12-26 +
    12-27 ++
    12-28 +
    12-29 +
    12-30 ++
    12-31 +
    12-32 +
    12-33 ++
    12-34 ++
    12-35 +
    12-36 +
    12-37 ++
    12-38 +++
    12-39 +
    12-40 +
    12-41 +
    12-42 +
    12-43 +
    12-44 +
    12-45 +
    12-46 +
    12-47 +
    12-48 ++
    12-49 +
    12-50 +
    12-51 +
    12-52 +
    12-53 +
    12-54 ++
    12-55 +
    12-56 +
    12-57 +
    12-58 +
    12-59 +
    12-60 +
    12-61 +
    12-62 +
    12-63 +
    12-64 +
    12-65 +
    12-66 +
    12-67 +
    12-68 +
    12-69 +
    12-70 ++
    12-71 +
    12-72 +
    12-73 +
    12-74 +
    12-75 +
    12-76 +
    12-77 +
    12-78 +
    12-79 +
    12-80 +
    12-81 +
    12-82 +++
    12-83 ++
    12-84 +
    12-85 ++++
    12-86 +++
    12-87 +
    12-88 +
    12-89 ++++
    12-90 ++
    12-91 +
    12-92 ++
    12-93 +
    12-94 +
    12-95 +
    12-96 +
    12-97 +
    12-98 +
    12-99 ++
     12-100 +
     12-101 ++++
     12-102 ++
     12-103 +
     12-104 +
     12-105 ++++
     12-106 +++
     12-107 ++
     12-108 ++
     12-109 +++
     12-110 +
     12-111 +
     12-112 +
     12-113 +++
     12-114 +
     12-115 ++++
     12-116 ++
     12-117 ++
     12-118 +
     12-119 +++
     12-120 +
     12-121 +
     12-122 +
     12-123 +
     12-124 +++
     12-125 ++
     12-126 ++
     12-127 ++
     12-128 +
     12-129 +++
     12-130 +
     12-131 +
     12-132 ++
     12-133 ++
     12-134 ++
     12-135 +
     12-136 +
     12-137 ++
     12-138 +
     12-139 +
     12-140 +
     12-141 +
     12-142 +
     12-143 +
     12-144 +
     12-145 +
     12-146 ++++
     12-147 +
     12-148 +++
     12-149 +
     12-150 +
     12-151 +
     12-152 +
     12-153 +
     12-154 +
     12-155 +
     12-156 +
     12-157 +
     12-158 +
     12-159 +
    13-1  +
    13-2  ++
    13-3  ++
    13-4  ++
    13-5  ++
    13-6  ++++
    13-7  ++
    14-1  +++
    14-2  +
    14-3  +
    14-4  +
    14-5  +++
    14-6  +
    14-7  ++++
    14-8  +
    14-9  +++
    14-10 ++++
    14-11 ++
    14-12 ++
    14-13 +++
    14-14 ++
    14-15 +++
    14-16 +++
    14-17 +
    14-18 +
    14-19 ++
    14-20 +++
    14-21 ++
    14-22 +++
    14-23 ++
    14-24 +
    14-25 +
    14-26 ++
    14-27 ++++
    14-28 +
    14-29 +++
    15-1  +
    15-2  +
    15-3  +
    15-4  +
    15-5  +
    15-6  +
    15-7  +
    15-8  +
    15-9  +
    15-10 +
    15-11 +
    15-12 +++
    15-13 ++++
    15-14 ++
    15-15 +
    15-16 +
    15-17 ++++
    15-18 +
    15-19 ++
    15-20 +
    15-21 ++
    15-22 +
    15-23 ++
    15-24 +++
    15-25 +
    15-26 +
    15-27 +
    15-28 ++++
    15-29 +
    15-30 ++
    15-31 +
    15-32 +++
    15-33 +
    15-34 +
    15-35 +
    15-36 +
    15-37 ++
    15-38 +
    15-39 +++
    15-40 ++
    15-41 ++++
    15-42 +++
    15-43 +
    15-44 +
    15-45 +++
    15-46 +
    15-47 +
    15-48 +
    15-49 +
    15-50 +
    15-51 +
    15-52 +
    15-53 ++
    15-54 +
    15-55 +
    15-56 +
    15-57 +
    15-58 +
    15-59 +
    15-60 +
    15-61 +
    15-62 +
    15-63 +
    15-64 ++
    16-1  +
    17-1  +
    17-2  +++
    17-3  ++
    17-4  ++
    18-1  +
    19-1  +++
    20-1  ++
    21-1  ++
    22-1  +
    22-2  +++
    22-3  +
    23-1  ++++
    23-2  ++
    23-3  +
    23-4  ++
    23-5  +++
    23-6  ++
    23-7  +++
    23-8  +++
    23-9  ++
    24-1  ++
    24-2  ++
    25-1  ++
    25-2  ++
    25-3  +++
    26-1  +
    26-2  +
    26-3  +
    27-1  +
    27-2  +++
    27-3  +
    27-4  +
    27-5  +
    27-6  ++
    27-7  +
    28-1  +
    28-2  +
    28-3  +++
    29-1  ++
    30-1  ++
    31-1  +
    32-1  ++
    32-2  +
    33-1  +
    34-1  +
    35-1  +
    35-2  +
    • Example 49 DMPK Assays Formulation and Dosing
  • Compounds were formulated in 5% DMSO/5% Tween20 in H2O, sonicated, vortexed, and put on stir plate overnight at a dose volume of 10 mL/kg. Balb/C (Jackson laboratories) or C57bl/6 (Taconic Biosciences) mice (8-9 weeks old) were acclimated to the colony for 3 days prior to dosing. Water and food were provided ab libitum. Compounds were administered by oral gavage. Groups of six animals received 3 to 4 bleeds per day with one terminal bleed. The time points were 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h. Plasma was collected via centrifugation and analyzed for drug concentrations.
    • Preparation of Study Samples and Standards for Analysis by LC-MS/MS
  • 50 μL of plasma was aliquoted into a 96 well deep-well polypropylene plate (2 mL) to which 5 μL of DMSO was added. For standards, 5 μl of test compound in DMSO at 10× the standard concentration was added to 50 μL of blank matrix in a 96 well deep-well polypropylene plate. For example, for a 300 nM standard, the 10×DMSO concentration was 3 M. Study samples that require dilution are diluted with the appropriate blank matrix. For example, for a 10× dilution, 5 μL of study sample is added to 45 μL of blank matrix. Protein was precipitated from study samples and standards with the addition of 150 μL of acetonitrile. After a clean plate map was placed firmly over the top of the 96-well plate, a bench top shaker was used for 1 min to ensure complete precipitation of protein. The precipitated protein was pelleted by centrifuging for 3,000 rpm for 10 min at 20° C. and then the clear supernatant was transferred to a clean 96-well plate and spun again under the same conditions in order to pellet any solid material that may have been transferred.
  • Analysis of Study Samples and Standards with LCMS with MRM Detection
  • An Agilent 1200 HPLC with binary pump and a Leap CTC with fast wash autosampler were used to introduce samples to the mass spectrometer. The reversed phase chromatography method was as shown in the following Table 37.
  • TABLE 37
    Time % A: 0.1% % B: 0.1% Flow
    (min) Formic Acid in water Formic Acid in Acetonitrile (uL/min)
    0 95 5 1000
    0.5 95 5 1000
    1.25 0 100 1000
    2.5 0 100 1000
    3 95 5 1000
    4 95 5 1000
  • The column used was a Phenomenex Luna C8 30×2 mm 5 m with a security guard. Mass detection was performed by an Applied Biosystems 4000 Qtrap in MRM mode and ionization was achieved by positive electrospray with a source temperature of 500° C. The ion transitions, depolarizing potential and collision energies were dependent on the specific analyte.
  • Prepared samples were usually analyzed in reverse chronological order with bracketing standard curves. Typically at least 6 standards were used for quantification with a percent accuracy of +/−15% for all standards except at the LLOQ where a percent accuracy of +/−20% was allowed. The concentration time profile was fit using a one compartment model for the applicable mode of dosing using Phoenix WinNonLin 6.4.
  • The results of these assays are presented in the following Tables 38, 39 and 40.
  • TABLE 38
    PHARMACOKINETIC PROPERTIES
    BALB/C, 10 MG/KG, PO, MALE MICE
    Compound Cmax AUC0-24
    Number Clearance (mL/min/kg) (mM) (mM * hr)
    A BQL 0.004 BLQ
    B BQL 0.007 BLQ
    1-20 527 0.23 0.53
    1-25 782 0.07 0.34
    1-26 41000 0.003 0.006
    2-1 66 1.8 4.3
    2-2 — 3.5 —
    2-3 403 0.4 0.8
    2-5 389 0.5 0.8
    2-7 86 1.9 3.3
    2-18 47 2.9 6.2
    2-19 59 1.3 4.9
    2-21 65 0.9 4.3
    2-22 10 4.2 27
    2-24 23 3.3 12.3
    2-26 76 0.9 3.8
    4-3 4627 0.03 0.06
    4-4 10709 0.02 0.03
    4-6 158 1.2 1.7
    8-3 56 0.8 4.9
    BQL: Below limit of quantification (limit amount)
  • TABLE 39
    Pharmacokinetic Properties
    C57BL/6, 10 mg/kg, PO, Male Mice
    Compound Cmax AUC0-24
    Number Clearance (mL/min/kg) (mM) (mM * hr)
    A BQL 0.002 BQL
    B 9000 0.03 0.029
    1-14 27000 0.006 0.011
    2-2 176 0.9 1.7
    2-15 37 0.97 7.5
    2-22 19 2.9 15.1
    2-24 38 1 7
    4-6 2346 0.07 0.11
    4-12 32 3.3 9
    6-4 33 0.81 8.3
    8-2 112 0.71 2.3
    8-3 246 0.33 1.2
    BQL: Below limit of quantification (limit amount)
    ND: Not determined
  • TABLE 40
    Pharmacokinetic Properties
    C57BL/6, 60 mg/kg, PO
    Compound Cmax AUC0-24
    Number Mice Gender Clearance (mL/min/kg) (mM) (mM * hr)
     2-2 Male 266 2.7 6.7
     2-23 Male 88 3.9 19
     2-24 Male 58 3 29
     2-47 Female 66 7.6 27.5
     2-49 Female 131 7.1 14.1
     2-55 Female 176 3 9.9
     2-57 Female 393 1.5 4.4
     4-14 Female 16 5.2 99
    10-8 Female 431 1.5 3.9
    10-9 Female 132 4.3 12.4
    12-88 Female 280 3.1 6
    12-100 Female ND 0.37 BQL
    12-114 Female 823 0.6 2.1
    12-138 Female 851 0.5 1.8
    12-152 Female 190 2.8 8.3
    14-17 Female 22 22 78
    14-18 Female 222 3.2 7.7
    14-28 Female 47 5.2 33.8
    15-2 Female 347 1.8 4.6
    15-3 Female 666 0.6 2.4
    15-6 Female 90 5.7 17.6
    15-48 Female 98 6.7 16.3
    15-62 Female 1100 0.6 1.4
    18-1 Female 565 1.2 2.9
    22-1 Female 34 7.3 48
    27-3 Female 143 5.1 11.7
    27-7 Female 92 4.3 17.6
    BQL: Below limit of quantification (limit amount)
    ND: Not determined
  • All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to in this specification, and/or listed in the Application Data Sheet, including U.S. Provisional Patent Application No. 62/383,202 filed on Sep. 2, 2016, and 62/478,496 filed on Mar. 29, 2017 are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications, and publications to provide yet further embodiments.
  • While specific embodiments of the invention have been illustrated and described, it will be readily appreciated that the various embodiments described above can be combined to provide further embodiments, and that various changes can be made therein without departing from the spirit and scope of the invention. These and other changes can be made to the embodiments in light of the above-detailed description.
  • In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

Claims (39)

1. A compound having the structure of Formula I:
Figure US20190345133A1-20191114-C01887
or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof, wherein:
R is hydrogen, hydroxy, cyano, halo or —OS(═O)2R6;
R1 is aryl or heteroaryl and substituted with 0-4 R4 groups;
R2 is aryl or heteroaryl and substituted with 0-3 R5 groups,
or R2 is —NR8R9;
R3a is hydrogen or alkyl and R3b is a nitrogen- or amine-containing moiety of carbon, at least one nitrogen atom and hydrogen,
or R3a and R3b taken together with the carbon to which they are attached form a cyclic nitrogen- or amine-containing moiety of carbon, at least one nitrogen atom and hydrogen;
R4 and R5 are, at each occurrence, cyano, halo, alkyl, haloalkyl, aminoalkyl, hydroxyalkyl, hydroxy, alkoxy, phenyl, heterocyclyl, —S(═O)2R6, —C(═O)R6, —C(═O)OR6, —C(═O)NR6N7 or —NR6R7;
R6 and R7 are, at each occurrence, hydrogen or alkyl; and
R8 is hydrogen or alkyl and R9 is alkyl or aryl substituted with 0-4 R4 groups,
or R8 and R9 taken together with the nitrogen atom to which they are attached form a heterocyclyl substituted with 0-4 R4 groups and optionally substituted with oxo (═O) or thioxo (═S).
2. The compound of claim 1, wherein R1 is aryl substituted with 0-4 R4 groups.
3. The compound of claim 1, wherein R1 is heteroaryl substituted with 0-4 R4 groups.
4. The compound of claim 1, wherein R2 is aryl substituted with 0-3 R5 groups.
5. The compound of claim 1, wherein R2 is heteroaryl substituted with 0-3 R5 groups.
6. The compound of claim 1, wherein R1 and R2 are phenyl, and the compound has the structure of Formula II, or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof:
Figure US20190345133A1-20191114-C01888
7. The compound of claim 1, wherein R1 is substituted with at least two R4 groups.
8. The compound of claim 1, wherein R1 is substituted with at least three R4 groups.
9. The compound of claim 1, wherein R1 is substituted with at least three R4 groups individually selected from halo and alkyl.
10. The compound of claim 1, wherein R2 is substituted with zero R5 groups.
11. The compound of claim 1, wherein R1 and R2 are phenyl, R3a is hydrogen, and the compound has the structure of Formula III, or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof:
Figure US20190345133A1-20191114-C01889
12. The compound of claim 1, wherein R1 and R2 are phenyl, R3a is hydrogen, and the compound has the structure of Formula IV, or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof:
Figure US20190345133A1-20191114-C01890
13. The compound of claim 1, wherein R2 is —NR8R9 and the compound has the structure of Formula V, or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof:
Figure US20190345133A1-20191114-C01891
14. The compound of claim 13, wherein R8 is hydrogen or alkyl and R9 is alkyl or aryl substituted with 0-4 R4 groups.
15. The compound of claim 13, wherein R8 and R9 taken together with the nitrogen atom to which they are attached form a heterocyclyl substituted with 0-4 R4 groups and optionally substituted with oxo (═O) or thioxo (═S).
16. The compound of claim 1, wherein R2 is —NR8R9 and R8 and R9 taken together with the nitrogen atom to which they are attached form a heterocyclyl, and the compound has the structure of Formula VI, or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof:
Figure US20190345133A1-20191114-C01892
17. The compound of claim 1, wherein R2 is —NR8R9 and R8 and R9 taken together with the nitrogen atom to which they are attached form a heterocyclyl, and the compound has the structure of Formula VII, or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof:
Figure US20190345133A1-20191114-C01893
18. The compound of claim 1, wherein R2 is —NR8R9 and R8 and R9 taken together with the nitrogen atom to which they are attached form a heterocyclyl, and the compound has the structure of Formula VIII, or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof:
Figure US20190345133A1-20191114-C01894
19. The compound of claim 1, wherein R2 is —NR8R9 and R8 and R9 taken together with the nitrogen atom to which they are attached form a heterocyclyl, and the compound has the structure of Formula IX, or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof:
Figure US20190345133A1-20191114-C01895
20. The compound of claim 1, wherein R2 is —NR8R9 and R8 and R9 taken together with the nitrogen atom to which they are attached form a heterocyclyl, and the compound has the structure of Formula X, or a stereoisomer, hydrate, solvate, isotope or pharmaceutically acceptable salt thereof:
Figure US20190345133A1-20191114-C01896
wherein R14 is H or R4.
21. The compound of claim 1, wherein R3a is hydrogen and R3b is a nitrogen- or amine-containing moiety of carbon, at least one nitrogen atom and hydrogen.
22. The compound of claim 21, wherein R3b is a nitrogen-containing heterocyclyl substituted with 0-4 R4 groups, or wherein R3b is alkyl substituted with —NR10R11, —N+R10R11R12, —NR12C(═O)NR10R11, —C(═O)NR10R11, —NR12C(═O)CH2NR10R11, —NR12N(═NR12NR13)NR10R11, —NR10SO2R11, or a nitrogen-containing heterocyclyl substituted with 0-4 R4 groups, and wherein R10, R11, R12 and R13 are independently hydrogen, alkyl or haloalkyl.
23. The compound of claim 22, wherein R3b is alkyl substituted with —NR10R11 or —N+R10R11R12.
24. The compound of claim 23, wherein R3b is —(CH2)2-4NH2.
25. The compound of claim 22, wherein R3b is alkyl substituted with —NR12N(═NR13)NR10R11.
26. The compound of claim 22, wherein R3b is alkyl substituted with —C(═O)NR10R11, —NR12C(═O)NR10R11 or —NR12C(═O)CH2NR10R11.
27. The compound of claim 22, wherein R3b is alkyl substituted with a nitrogen-containing heterocyclyl substituted with 0-4 R4 groups.
28. The compound of claim 1, wherein R3a and R3b taken together with the carbon to which they are attached form a cyclic nitrogen- or amine-containing moiety of carbon, at least one nitrogen atom and hydrogen.
29. The compound of claim 28, wherein R3a and R3b taken together with the carbon to which they are attached form a nitrogen-containing heterocyclyl substituted with 0-4 R4 groups.
30. The compound of claim 1, wherein the compound is a compound of Table A.
31. The compound of claim 1, wherein the compound is a compound of Table B.
32. The compound of claim 1, wherein R3a is H and the compound of claim 1 is a stereoisomer having the structure of Formula XI:
Figure US20190345133A1-20191114-C01897
or a hydrate, solvate, isotope or pharmaceutically acceptable salt thereof.
33. The compound of claim 1, wherein R3a and R3b taken together with the carbon to which they are attached form a cyclic nitrogen- or amine-containing moiety of carbon, at least one nitrogen atom and hydrogen, and the compound of claim 1 is a stereoisomer having the structure of Formula XII:
Figure US20190345133A1-20191114-C01898
34. The compound of claim 1 wherein R is hydrogen.
35. A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.
36. A method for agonizing a chemokine receptor of a cell comprising contacting the cell with a compound of claim 1.
37. The method of claim 36, wherein the chemokine receptor is CXCR3.
38. A method for treating a disease or condition in a subject for which activation of a CXCR3 receptor is medically indicated, comprising administering to the subject a therapeutically acceptable amount of a compound of claim 1.
39. A method for treating rheumatoid arthritis, multiple sclerosis or inflammatory bowel disease in a subject in need thereof, comprising administering to the subject a therapeutically acceptable amount of a compound of claim 1.
US16/335,641 2016-09-02 2017-08-31 Cxcr3 receptor agonists Abandoned US20190345133A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/335,641 US20190345133A1 (en) 2016-09-02 2017-08-31 Cxcr3 receptor agonists
US16/872,161 US11040954B1 (en) 2016-09-02 2020-05-11 CXCR3 receptor agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662383202P 2016-09-02 2016-09-02
US201762478496P 2017-03-29 2017-03-29
US16/335,641 US20190345133A1 (en) 2016-09-02 2017-08-31 Cxcr3 receptor agonists
PCT/US2017/049768 WO2018045246A1 (en) 2016-09-02 2017-08-31 Cxcr3 receptor agonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/049768 A-371-Of-International WO2018045246A1 (en) 2016-09-02 2017-08-31 Cxcr3 receptor agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/872,161 Continuation US11040954B1 (en) 2016-09-02 2020-05-11 CXCR3 receptor agonists

Publications (1)

Publication Number Publication Date
US20190345133A1 true US20190345133A1 (en) 2019-11-14

Family

ID=59846729

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/335,641 Abandoned US20190345133A1 (en) 2016-09-02 2017-08-31 Cxcr3 receptor agonists
US16/872,161 Active US11040954B1 (en) 2016-09-02 2020-05-11 CXCR3 receptor agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/872,161 Active US11040954B1 (en) 2016-09-02 2020-05-11 CXCR3 receptor agonists

Country Status (8)

Country Link
US (2) US20190345133A1 (en)
EP (1) EP3507275B1 (en)
JP (1) JP7181857B2 (en)
AU (1) AU2017318674B2 (en)
CA (1) CA3034108A1 (en)
ES (1) ES2950560T3 (en)
MX (1) MX380217B (en)
WO (1) WO2018045246A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230181691A1 (en) 2020-02-12 2023-06-15 The Regents Of The University Of California Platelet factors and cognitive improvement
CN111943823A (en) * 2020-09-16 2020-11-17 安徽工业大学 A kind of preparation method of benzophenone
CN116178383B (en) * 2022-12-26 2025-04-22 南方科技大学 Alkaloid and method for synthesizing alkaloid by catalysis of trivalent ferrous porphyrin

Also Published As

Publication number Publication date
US11040954B1 (en) 2021-06-22
MX2019002166A (en) 2019-06-12
AU2017318674A1 (en) 2019-03-28
MX380217B (en) 2025-03-12
ES2950560T3 (en) 2023-10-11
WO2018045246A1 (en) 2018-03-08
AU2017318674B2 (en) 2020-11-12
CA3034108A1 (en) 2018-03-08
EP3507275A1 (en) 2019-07-10
JP2019533639A (en) 2019-11-21
JP7181857B2 (en) 2022-12-01
EP3507275B1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
US11639353B2 (en) Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
US11912686B2 (en) LPA receptor antagonists and uses thereof
US11673886B2 (en) 5-membered and bicyclic heterocyclic amides as inhibitors of ROCK
CN111278825B (en) Diazaspiro ROCK Inhibitor
ES2715682T3 (en) Autotaxin Inhibitors
JP7177825B2 (en) Spirocyclic compounds and methods of making and using the same
US11572374B2 (en) N-cyano-7-azanorbornane derivatives and uses thereof
US11040954B1 (en) CXCR3 receptor agonists
ES2864349T3 (en) New GLP-1 receptor modulators
JP7042804B2 (en) Piperazine carbamate, and how to make and use it
US11440913B2 (en) Aminoimidazopyridazines as kinase inhibitors
KR20200020978A (en) Compounds and methods for the targeted degradation of androgen receptor
JP7157771B2 (en) pyrazole MAGL inhibitor
ES2719713T3 (en) Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors
MX2014006622A (en) Carboxylic acid derivatives comprising four cycles acting as glp-1 receptor modulators for therapy of diseases such as diabetes.
TW202346289A (en) Compounds as glp-1r agonists
EP3137168A1 (en) Substituted 4-phenylpiperidines, their preparaiton and use
ES2844573T3 (en) GLP-1 receptor modulators
EP2976077A1 (en) Substituted benzimidazoles as nociceptin receptor modulators
JP5369000B2 (en) Novel catechol derivatives, pharmaceutical compositions containing them, and uses thereof
JP2025503945A (en) Compounds and methods for YAP/TEAD modulation and their indications
WO2025170939A1 (en) Proteasome inhibitors for the treatment of malaria
HK40102628A (en) Btk inhibitors
EA047826B1 (en) PYRAZOLE BASED MAGL INHIBITORS

Legal Events

Date Code Title Description
AS Assignment

Owner name: CELGENE INTERNATIONAL II SARL, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YEAGER, ADAM;TURNBULL, PHILIP;TAMIYA, JUNKO;AND OTHERS;SIGNING DATES FROM 20170828 TO 20170830;REEL/FRAME:049323/0005

Owner name: CELGENE INTERNATIONAL II SARL, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SYGNATURE DISCOVERY LIMITED;REEL/FRAME:049322/0980

Effective date: 20171214

Owner name: SYGNATURE DISCOVERY LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FOWLER, TOM;BENELKEBIR, HANAE;PASCERI, RAFFAELE;AND OTHERS;SIGNING DATES FROM 20170901 TO 20170907;REEL/FRAME:049322/0920

Owner name: CELGENE INTERNATIONAL II SARL, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TRAN, YANG;ZHANG, LIN;FAN, JUNHUA;REEL/FRAME:049322/0983

Effective date: 20170831

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: RECEPTOS LLC, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CELGENE INTERNATIONAL II SARL;REEL/FRAME:055192/0805

Effective date: 20200622